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With advances in medical, surgical and intensive care interventions, more individuals 
with congenital heart disease (CHD) are surviving infancy. However, long-term 
survival is not well researched. Given that UK paediatric cardiovascular services are 
undergoing reforms to ensure there are adequate health-care provisions, further 
information is required on CHD prevalence and survival. 
An analysis of data from six British Isles Network of Congenital Anomaly Registers 
(BINOCARs), showed no overall trend in CHD prevalence between 1991 and 2010. 
However, there was an increasing trend in the prevalence of tetralogy of Fallot, equating 
to a yearly excess of 16 cases in England and Wales. There was an increased risk of 
CHD in twins, particularly monochorionic (MC) twins. The prevalence of CHD in MC 
twins increased over time, equating to a yearly excess of seven cases in England and 
Wales. 
Using a systematic review and meta-analysis, pooled five and 10-year survival was 
85.4% and 81.4%, respectively. Year of delivery, preterm delivery, extra-cardiac 
anomalies (ECAs) and birth weight were associated with mortality. 
In an analysis of data from one BINOCAR linked to death registrations, one-year 
survival was 89.1%, decreasing to 85.2% at 20 years. Less recent year of delivery, 
lower gestational age, low birth weight, prenatal diagnosis and the presence of ECAs 
increased the risk of mortality. 
The predicted 20-year survival of individuals born with isolated CHD in 2015 was 
98.7%. The predicted prevalence of CHD was 74.0 and 68.8 per 10,000 live births in 
2015 and 2020, respectively. Using ONS data to extrapolate, this equates to 
approximately 296,000 cases of CHD being born between 2012-2017 in the UK. 
Given that infants with CHD require complex surgeries, the predicted prevalence and 
survival estimates described in this thesis are important for health service planning and 




























Firstly, I would like to express my gratitude to my supervisor, Prof Judith Rankin, who 
secured the funding for this PhD, and who constantly supported and encouraged me 
throughout. Thanks are also due to my second supervisor, Prof Steve Rushton who 
provided valuable statistical guidance during my studies. I would also like to thank my 
clinical colleagues Angela McBrien and Matt Thomas, and my assessors Martin Ward-
Platt and Deborah Stocken for their expert input during my PhD. Thank-you to Svetlana 
Glinianaia for her helpful advice on twinning, and to Fiona Matthews for her 
suggestions on my systematic review. I would like to acknowledge the IT staff at the 
Institute of Health & Society, particularly Mark Warwick, who helped me with 
countless forms required for ethics. Also, a big thank-you to Anita Tibbs for keeping me 
organised. 
Thanks to the register staff at the BINOCAR for supplying data, particularly Nic Miller 
who went above and beyond to seek out data for me. Thank-you to all the clinical and 
administrative staff who routinely provide data for the BINOCAR. 
I really appreciated the moral support from my family and friends, particularly my 
partner Sean and my wonderful friends, Sarah and Nicola. Thank-you also to my fellow 
level two-ers, the support (and the cake) really spurred me on. 
Lastly, I would like to acknowledge my funders, the British Heart Foundation, who 













List of Figures ........................................................................................................................ VIII 
List of Tables ............................................................................................................................. X 
Chapter 1. Background ........................................................................................................... 1 
Congenital anomalies .............................................................................................................. 1 
1.1.1 Definition and prevalence ..................................................................................... 1 
1.1.2 Public health ......................................................................................................... 1 
1.1.3 Classification ........................................................................................................ 2 
1.2 Congenital heart disease .............................................................................................. 3 
1.2.1 Definition, prevalence and survival ...................................................................... 3 
1.2.2 Public health ......................................................................................................... 3 
1.2.3 Classification ........................................................................................................ 4 
1.2.4 Pathology .............................................................................................................. 5 
1.2.5 Aetiology ............................................................................................................ 13 
1.2.6 Care pathway ...................................................................................................... 13 
Chapter 2. Aim and objectives ............................................................................................. 20 
Chapter 3. The birth prevalence of congenital heart disease: a literature review ................ 21 
3.1 Introduction ................................................................................................................ 21 
3.1.1 Aim ..................................................................................................................... 21 
3.2 Methods ..................................................................................................................... 22 
3.2.1 Definitions .......................................................................................................... 22 
3.2.2 Inclusion criteria ................................................................................................. 22 
3.2.3 Exclusion criteria ................................................................................................ 22 
3.2.4 Search strategy .................................................................................................... 23 
3.2.5 Data extraction .................................................................................................... 23 
3.2.6 Statistical analysis .............................................................................................. 23 
3.3 Results ........................................................................................................................ 26 
3.3.1 Description of studies ......................................................................................... 26 
II 
3.3.2 Prevalence .......................................................................................................... 41 
3.3.3 Trends in prevalence .......................................................................................... 49 
3.3.4 Heterogeneity in prevalence between studies .................................................... 50 
3.3.5 Risk factors and characteristics .......................................................................... 55 
3.4 Discussion ................................................................................................................. 60 
3.4.1 Summary ............................................................................................................ 60 
3.4.2 Strengths............................................................................................................. 60 
3.4.3 Limitations ......................................................................................................... 61 
3.4.4 Comparison to previous reviews ........................................................................ 62 
Chapter 4. Data sources and case classification ................................................................... 63 
4.1 Data sources .............................................................................................................. 63 
4.1.1 British Isles Network of Congenital Anomaly Registers ................................... 63 
4.1.2 ONS annual births .............................................................................................. 71 
4.1.3 The Northern Survey of Twin and Multiple Pregnancies .................................. 71 
4.1.4 The Northern Perinatal Morbidity and Mortality Survey .................................. 71 
4.1.5 ONS death registrations ..................................................................................... 71 
4.2 Case inclusion............................................................................................................ 72 
4.3 Case classification ..................................................................................................... 72 
4.3.1 Subtypes ............................................................................................................. 72 
4.3.2 Severity categories ............................................................................................. 72 
4.3.3 Extra-cardiac anomalies ..................................................................................... 74 
Chapter 5. Epidemiology of congenital heart disease in singletons in the UK .................... 75 
5.1 Introduction ............................................................................................................... 75 
5.1.1 Aim..................................................................................................................... 75 
5.2 Methods ..................................................................................................................... 77 
5.2.1 Case inclusion .................................................................................................... 77 
5.2.2 Case classification .............................................................................................. 77 
5.2.3 Data .................................................................................................................... 77 
III 
5.2.4 Statistical analysis .............................................................................................. 80 
5.3 Results ........................................................................................................................ 83 
5.3.1 CHD severity categories ..................................................................................... 83 
5.3.2 CHD subtypes ..................................................................................................... 83 
5.3.3 ECAs occurring with total birth cases of CHD .................................................. 84 
5.3.4 ECAs occurring with live birth cases of CHD ................................................... 92 
5.3.5 Sex distribution in total birth cases of CHD ....................................................... 99 
5.3.6 Gestational age at delivery in live born cases of CHD ..................................... 102 
5.3.7 Gestational age at delivery according to prenatal diagnosis............................. 106 
5.3.8 Standardised birth weight in live births ............................................................ 108 
5.3.9 Total birth prevalence ....................................................................................... 111 
5.3.10 Trends in total birth prevalence ........................................................................ 112 
5.3.11 Heterogeneity in total birth prevalence between registers................................ 114 
5.3.12 Heterogeneity in trends in total birth prevalence.............................................. 117 
5.3.13 Live birth prevalence ........................................................................................ 121 
5.3.14 Trends in live birth prevalence ......................................................................... 122 
5.3.15 Heterogeneity in live birth prevalence between registers ................................. 124 
5.3.16 Heterogeneity in trends in live birth prevalence between registers .................. 127 
5.3.17 Prenatal diagnosis ............................................................................................. 130 
5.3.18 Trends in prenatal diagnosis ............................................................................. 131 
5.3.19 Heterogeneity in prenatal diagnosis between registers..................................... 131 
5.3.20 Heterogeneity in trends in prenatal diagnosis between registers ...................... 131 
5.3.21 Association between prenatal diagnosis and maternal age ............................... 133 
5.3.22 Pregnancy outcomes ......................................................................................... 134 
5.3.23 Termination of pregnancy for fetal anomaly .................................................... 137 
5.3.24 Trends in termination rates ............................................................................... 140 
5.3.25 Trends in terminations in prenatally diagnosed cases only .............................. 141 
5.3.26 Heterogeneity in termination rates between registers....................................... 143 
IV 
5.3.27 Association between maternal age and total birth prevalence ......................... 143 
5.4 Discussion ............................................................................................................... 150 
5.4.1 Strengths........................................................................................................... 150 
5.4.2 Limitations ....................................................................................................... 151 
5.4.3 Summary and comparison to other studies ...................................................... 153 
Chapter 6. Congenital heart disease in twins: what are the risks? ...................................... 162 
6.1 Introduction ............................................................................................................. 162 
6.1.1 Aim................................................................................................................... 162 
6.2 Methods ................................................................................................................... 164 
6.2.1 Case inclusion .................................................................................................. 164 
6.2.2 Case coding ...................................................................................................... 164 
6.2.3 Data .................................................................................................................. 164 
6.2.4 Statistical analysis ............................................................................................ 167 
6.3 Results ..................................................................................................................... 168 
6.3.1 Extra-cardiac anomalies ................................................................................... 168 
6.3.2 CHD severity and concordance ........................................................................ 168 
6.3.3 Pregnancy outcomes ........................................................................................ 169 
6.3.4 Gestational age at delivery ............................................................................... 169 
6.3.5 Standardised birthweight.................................................................................. 170 
6.3.6 Prenatal diagnosis ............................................................................................ 171 
6.3.7 Birth prevalence and pregnancy risk ................................................................ 171 
6.3.8 Maternal age ..................................................................................................... 172 
6.3.9 Temporal trends ............................................................................................... 174 
6.3.10 Relative risk of CHD in twins compared to singletons .................................... 174 
6.4 Discussion ............................................................................................................... 177 
Chapter 7. Long-term survival and risk factors for mortality among individuals with 
congenital heart disease: A systematic review and meta-analysis .......................................... 181 
7.1 Introduction ............................................................................................................. 181 
V 
7.1.1 Aim ................................................................................................................... 181 
7.2 Methods ................................................................................................................... 182 
7.2.1 Inclusion criteria ............................................................................................... 182 
7.2.2 Exclusion criteria .............................................................................................. 182 
7.2.3 Search strategy .................................................................................................. 182 
7.2.4 Data extraction .................................................................................................. 184 
7.2.5 Statistical analysis ............................................................................................ 184 
7.2.6 Quality assessment ........................................................................................... 185 
7.3 Results ...................................................................................................................... 191 
7.3.1 Study characteristics ......................................................................................... 191 
7.3.2 Survival estimates ............................................................................................. 192 
7.3.3 Quality assessment ........................................................................................... 204 
7.3.4 Risk factors for mortality .................................................................................. 207 
7.4 Discussion ................................................................................................................ 217 
Chapter 8. Survival and risk factors for mortality among individuals with congenital heart 
disease: a data-linkage study .................................................................................................. 221 
8.1 Introduction .............................................................................................................. 221 
8.1.1 Aim ................................................................................................................... 221 
8.2 Methods ................................................................................................................... 223 
8.2.1 Case inclusion ................................................................................................... 223 
8.2.2 Data ................................................................................................................... 223 
Statistical analysis ........................................................................................................... 224 
8.3 Results ...................................................................................................................... 227 
8.3.1 Survival estimates and mortality rates .............................................................. 228 
8.3.2 Risk factors for mortality .................................................................................. 233 
8.3.3 Sensitivity analysis ........................................................................................... 256 
8.3.4 Predicting survival ............................................................................................ 267 
8.4 Discussion ................................................................................................................ 272 
VI 
8.4.1 Summary .......................................................................................................... 272 
8.4.2 Strengths........................................................................................................... 273 
8.4.3 Limitations ....................................................................................................... 274 
8.4.4 Comparison to previous studies ....................................................................... 276 
8.4.5 Potential mechanisms ....................................................................................... 280 
Chapter 9. Future prevalence of CHD ................................................................................ 283 
9.1 Introduction ............................................................................................................. 283 
9.2 Methods ................................................................................................................... 284 
9.2.1 Case inclusion and data .................................................................................... 284 
9.2.2 Statistical analysis ............................................................................................ 284 
9.2.3 Wavelet analysis .............................................................................................. 284 
9.2.4 Harmonic regression ........................................................................................ 285 
9.3 Results ..................................................................................................................... 286 
9.3.1 Live births ........................................................................................................ 286 
9.3.2 Birth prevalence of CHD ................................................................................. 288 
9.4 Discussion ............................................................................................................... 300 
9.4.1 Summary .......................................................................................................... 300 
9.4.2 Strengths........................................................................................................... 300 
9.4.3 Limitations ....................................................................................................... 300 
9.4.4 Comparison to previous studies ....................................................................... 301 
Chapter 10. Discussion ..................................................................................................... 302 
10.1 Summary and context of findings ........................................................................... 302 
10.2 Strengths of the thesis.............................................................................................. 305 
10.3 Limitations of the thesis .......................................................................................... 306 
10.4 Implications for practice .......................................................................................... 308 
10.5 Further research ....................................................................................................... 309 
Appendix A) Chapter 6 publication ........................................................................................ 302 
Appendix B) CAG and REC approval .................................................................................... 319 
VII 
Appendix C) Data extraction form ......................................................................................... 321 
Appendix D) Published abstracts ........................................................................................... 325 
References .............................................................................................................................. 326 
VIII 
List of Figures 
Figure 1.1 Diagram of fetal heart looping .................................................................................. 7 
Figure 1.2 Fetal circulation ........................................................................................................ 9 
Figure 1.3 Neonatal circulation ................................................................................................ 10 
Figure 1.4 Prenatal care pathway for CHD .............................................................................. 15 
Figure 1.5 Criteria for "high-risk" pregnancy for CHD ........................................................... 16 
Figure 3.1: PRISMA diagram showing flow of articles through the review ........................... 28 
Figure 3.2: Prevalence of CHD per 10,000 live and total births, by country .......................... 53 
Figure 4.1 Map showing the regions covered by the six BINOCARs ..................................... 65 
Figure 4.2 Categorisation of CHD subtypes into severity categories ...................................... 73 
Figure 5.1 Percentage of male (total birth) cases of CHD, by CHD subtype and ECAs ....... 100 
Figure 5.2 Gestational age at delivery in live births, by CHD subtype and ECAs ................ 104 
Figure 5.3 Standardised birth weight in live births, by CHD subtype and ECAs .................. 109 
Figure 5.4 Percentage of total birth prevalence accounted for by each register .................... 115 
Figure 5.5 Total birth prevalence of CHD over time, by register and subtype ...................... 118 
Figure 5.6 Percentage of prevalence contributed by each register, by CHD subtype ............ 125 
Figure 5.7 Live birth prevalence of CHD over time, by register and subtype ....................... 128 
Figure 5.8 Graph showing percentage of prenatally diagnosed cases of isolated CHD over 
time, by register and CHD severity ........................................................................................ 132 
Figure 5.9 Pregnancy outcome for All CHD, by CHD subtype ............................................ 135 
Figure 5.10 Gestational age at TOPFA, by CHD subtype and ECAs .................................... 138 
Figure 6.1 Pregnancy outcomes in cases of CHD, by plurality ............................................. 169 
Figure 6.2 Gestational age at delivery in live born cases of CHD, by plurality .................... 170 
Figure 6.3 Standardised birth weight in live born cases of CHD, by plurality ...................... 171 
Figure 7.1 PRISMA flowchart ............................................................................................... 191 
Figure 7.2 Forest plot for all CHD at ages one, five and 10 .................................................. 194 
Figure 7.3 Bubble plot of survival estimates for all CHD at ages one to 25 ......................... 195 
Figure 7.4 Bubble plots showing the association between study period and survival for all 
CHD ....................................................................................................................................... 196 
Figure 8.1 Smoothed hazard functions for cases of CHD up to age five, by CHD subtype* 231 
Figure 8.2 Log-log plot of survival for all CHD subtypes combined .................................... 257 
Figure 8.3 Margins for year of delivery according to presence of ECAs .............................. 257 
Figure 8.4 Margins for prenatal diagnosis according to the presence of ECAs ..................... 258 
Figure 8.5 Margins depicting the interaction between year of delivery and gestational age at 
delivery, for all CHD ............................................................................................................. 259 
IX 
Figure 8.6 Margins depicting the interaction between year of delivery and prenatal diagnosis
 ................................................................................................................................................ 259 
Figure 8.7 Schoenfield residuals plotted against age for univariable models ........................ 262 
Figure 8.8 Log-log plot of survival according to standardised birth weight .......................... 262 
Figure 8.9 Cox Snell residuals plotted against the cumulative hazard, by CHD subtype ...... 263 
Figure 8.10 Martingale residuals for maternal age at delivery for all CHD ........................... 264 
Figure 8.11 Martingale residuals for maternal age at delivery, by CHD subtype .................. 265 
Figure 8.12 Martingale residuals for year of delivery, by CHD subtype ............................... 265 
Figure 8.13 Martingale residuals for year of delivery, for all CHD ....................................... 266 
Figure 8.14 Martingale residuals for gestational age at delivery, by CHD subtype ............... 266 
Figure 8.15 Martingale residuals for gestational age at delivery, for all CHD ...................... 267 
Figure 8.16 Extrapolated 30 year survival and Kaplan-Meier curves for isolated CHD ....... 270 
Figure 9.1 Number of live births over time, actual and modelled .......................................... 287 
Figure 9.2 Wavelet power spectrum to detect seasonality in live births ................................ 287 
Figure 9.3 Actual and predicted live birth prevalence of CHD over time, by subtype .......... 289 
Figure 9.4 Wavelet power spectrum of prevalence per 10,000 live births, by CHD subtype 292 
Figure 9.5 Predicted number of live born cases ..................................................................... 296 
X 
List of Tables 
Table 1.1 Descriptions of the most common CHD subtypes ................................................... 11 
Table 1.2 Treatment for CHD according to NHS Choices ...................................................... 18 
Table 3.1: Medline, Embase and Scopus search terms ............................................................ 25 
Table 3.2: Description of studies included in the literature review ......................................... 29 
Table 3.3 Prevalence of CHD per 10,000 live births ............................................................... 42 
Table 3.4 Prevalence (95% CI) of individual CHD subtypes per 10,000 live births ............... 43 
Table 3.5 Prevalence of CHD per 10,000 total births .............................................................. 45 
Table 3.6 Prevalence of individual CHD subtypes per 10,000 total births .............................. 47 
Table 3.7 Heterogeneity in prevalence between studies .......................................................... 51 
Table 4.1 Population statistics in the populations covered by the six BINOCARs ................. 68 
Table 5.1 Description of variables used in analysis and frequency of missing data................ 78 
Table 5.2 Proportion of cases with missing maternal age data ................................................ 81 
Table 5.3 Proportion of cases with missing prenatal diagnosis data by register ..................... 82 
Table 5.4 Frequency and percentages of CHD severity categories ......................................... 83 
Table 5.5 Frequency and percentage of CHD subtypes ........................................................... 84 
Table 5.6 Type of ECA in CHD total births according to CHD subtypes ............................... 86 
Table 5.7 Chromosomal/ genetic ECAs in total births, by CHD severity ............................... 87 
Table 5.8 Associations, sequences and syndromes in total births, by CHD severity .............. 89 
Table 5.9 Structural ECAs in total birth cases of CHD, by CHD severity .............................. 90 
Table 5.10 Type of ECA in CHD live births according to CHD subtypes .............................. 93 
Table 5.11 Chromosomal\ genetic ECA in live births, by CHD severity ................................ 94 
Table 5.12 Associations, sequences and syndromes in live births, by CHD severity ............. 96 
Table 5.13 Structural ECAs in live births, by CHD severity ................................................... 97 
Table 5.14 Preterm birth according to prenatal diagnosis among isolated cases of CHD, by 
CHD subtype* ........................................................................................................................ 107 
Table 5.15 Total birth prevalence (95% CI) of CHD, by CHD subtype and ECAs .............. 111 
Table 5.16 Trends in the total birth prevalence of CHD over time, by CHD subtype ........... 112 
Table 5.17 Unadjusted trends in total birth prevalence according to presence of ECAs ....... 113 
Table 5.18 Total birth prevalence by register ........................................................................ 114 
Table 5.19 Live birth prevalence of CHD, by CHD subtype and ECAs ............................... 121 
Table 5.20 Trends in the live birth prevalence of CHD over time, by CHD subtype ............ 122 
Table 5.21 Trends in live birth prevalence according to the presence of ECAs .................... 123 
Table 5.22 Live birth prevalence by register ......................................................................... 124 
Table 5.23 Prenatal diagnosis of (all birth) isolated cases of CHD, by CHD subtype .......... 130 
XI 
Table 5.24 Association between maternal age category and prenatal diagnosis of CHD, by 
CHD severity† ........................................................................................................................ 133 
Table 5.25 Pregnancy outcomes for CHD cases, by CHD subtype and ECAs ...................... 136 
Table 5.26 RRs of TOPFA per year’s increase in year of delivery, adjusted for ECAs ........ 140 
Table 5.27 Trends in TOPFA rates over time in isolated cases of CHD, by prenatal diagnosis
 ................................................................................................................................................ 142 
Table 5.28 Prevalence and RR of CHD according to maternal age, by CHD subtype .......... 144 
Table 5.29 RR of CHD according to maternal age, by CHD subtype and presence of ECAs
 ................................................................................................................................................ 149 
Table 5.30 Total birth prevalence in the current study and previous population-based studies 
(as discussed in Chapter 3) ..................................................................................................... 156 
Table 5.31 Live birth prevalence in the current study and previous population-based studies 
(as discussed in Chapter 3) ..................................................................................................... 158 
Table 6.1 Description of variables used in analysis ............................................................... 166 
Table 6.2 Prevalence of CHD in twins and singletons, according to CHD severity and 
chorionicity ............................................................................................................................. 172 
Table 6.3 Relative risk of CHD according to maternal age and year of delivery .................. 174 
Table 6.4 Relative risk of CHD in twins versus singletons, according to CHD severity and 
chorionicity ............................................................................................................................. 176 
Table 7.1 Medline, Embase and Scopus search terms ............................................................ 183 
Table 7.2 Study descriptions .................................................................................................. 186 
Table 7.3 Survival estimates at age one to 25 ........................................................................ 197 
Table 7.4 Quality assessment ................................................................................................. 205 
Table 7.5 Risk factors for mortality........................................................................................ 210 
Table 8.1 Description of variables used in analysis ............................................................... 224 
Table 8.2 CHD subtypes in live births according to presence of ECAs, 1985-2003 ............. 227 
Table 8.3 Survival estimates up to age 20, by CHD subtype ................................................. 229 
Table 8.4 Kaplan-Meier survival estimates, by CHD subtype and the presence of ECAs .... 234 
Table 8.5 Hazard ratios of the presence of ECAs, according to CHD subtype ...................... 237 
Table 8.6 Hazard ratios for year of delivery, by CHD subtype* ............................................ 239 
Table 8.7 Hazard ratios for gestational age at delivery, by CHD subtype* ........................... 241 
Table 8.8 Hazard ratios for standardised birth weight, by CHD subtype ............................... 243 
Table 8.9 Hazard ratios for maternal age at delivery, by CHD subtype................................. 246 
Table 8.10 Hazard ratios for male versus female, by CHD subtype ...................................... 248 
XII 
Table 8.11 HRs for moderate and least deprived compared to most deprived, by CHD subtype
 ................................................................................................................................................ 250 
Table 8.12 Hazard ratios for prenatal diagnosis compared to postnatal diagnosis, by CHD 
subtype ................................................................................................................................... 253 
Table 8.13 Hazard ratios for cases from multiple compared to singleton pregnancies, by CHD 
subtype ................................................................................................................................... 254 
Table 8.14 Hazard ratios for annual TOPFA rate, by CHD subtype ..................................... 255 
Table 8.15 Univariable models that did not satisfy the proportional hazard assumption at the 
p<0.05 level ............................................................................................................................ 261 
Table 8.16 Test of proportional hazards assumption for all multivariable models, by CHD 
subtype ................................................................................................................................... 261 
Table 8.17 Predicted survival to age 20 for cases born in 2003 and 2010............................. 268 
Table 8.18 Predicted 30 year survival of isolated CHD, by CHD subtype ............................ 269 
Table 9.1 Harmonic regression models of CHD live birth prevalence, by CHD subtype ..... 295 
Table 9.2 Yearly projected number of cases (95% CI) in the North of England, born 2016-
2020 ........................................................................................................................................ 299 
 
1 
 Chapter 1. Background 
Congenital anomalies 
1.1.1 Definition and prevalence 
Congenital anomalies are structural, chromosomal or genetic abnormalities that develop 
before birth. The consequences of congenital anomalies to the individual vary according to 
the type of abnormality. However, many of those affected are burdened with lifelong physical 
or mental disability. 
In the UK, congenital anomalies affect approximately 2% of children [1, 2]. Despite the 
increased availability of prenatal screening and therefore the opportunity for pregnancy 
termination, the live birth prevalence of congenital anomalies has not declined over the last 20 
years. This is partly due to the increased proportion of women entering pregnancy at 
“advanced” maternal age, the increased uptake of assisted reproductive technologies (ART), 
the increased prevalence of maternal obesity (and diabetes), all of which are risk factors for 
congenital anomalies [3-6]. 
1.1.2 Public health 
Congenital anomalies are a significant public health concern for a variety of reasons. Firstly, 
the static prevalence means that congenital anomalies continue to be a leading cause of fetal 
and infant death, both in the UK and internationally [7, 8]. Secondly, congenital anomalies are 
a major cause of morbidity and disability with some requiring surgery in childhood [9]. 
Therefore, those affected will require considerable medical and health care provision, 
including specialist surgeries, procedures and medications, which (in the UK) come at a 
significant cost to the National Health Service (NHS) [9]. Similarly, educational and social 
care provisions are sometimes required to support the affected individuals and their families 
[9]. The accuracy and uptake of prenatal screening is also a public health concern. The Fetal 
Anomaly Screening Programme (FASP) was instigated in England with the aim of setting 
national prenatal screening standards and overseeing their implementation [10]. Specifically, 
the FASP states that all women should be offered two prenatal ultrasound scans, a dating scan 
at eight weeks and an anomaly scan at 18+0 to 20+6 weeks gestation [11]. Additionally, FASP 
set targets for 11 congenital anomalies that should be screened for prenatally, including: 
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anencephaly, spina bifida, cleft lip and/or palate, diaphragmatic hernia, gastroschisis, 
omphalocele, severe congenital heart disease (CHD), bilateral agenesis, lethal skeletal 
dysplasias, trisomy 13 (Patau syndrome) and trisomy 18 (Edward’s syndrome), with different 
target detection rates for each [12]. The implementation of FASP requires resources both for 
the screening process and for the follow-up of affected women. 
1.1.3 Classification 
Around 76% of cases with a congenital anomaly have only one structural anomaly affecting 
one organ system [13]. These are known as isolated anomalies, thought to have multifactorial 
aetiologies involving both environmental and genetic factors. Conversely, around 24% of 
cases with congenital anomalies have multiple structural anomalies affecting one or more 
organ system [13]. The majority of these have a recognised pattern of structural anomalies 
and in most (70% of cases with multiple anomalies) the pattern is caused by a single known 
chromosomal anomaly or genetic syndrome [13, 14]. Other patterns of congenital anomalies 
may not have a genetic aetiology and may occur as part of a sequence, association or 
syndrome. Sequences are a set of anomalies that arise consecutively during fetal development 
as a consequence of one original anomaly or mechanical issue [15]. Associations are a distinct 
formation of anomalies, with unknown cause, which arise during blastogenesis [14]. 
Syndromes encompass all other recognised patterns of anomalies with as yet unknown 
aetiology, which may or may not be genetic. Finally, cases with several structural anomalies 
with no distinct pattern are classified as having “multiple structural anomalies”. These 
anomalies may occur together by chance and have separate aetiologies, although this has not 
been confirmed. 
Generally, congenital anomalies are classed as occurring in isolation, occurring with other 
structural congenital anomalies (excluding cases occurring with chromosomal/ genetic 
congenital anomalies) or occurring with chromosomal/genetic congenital anomalies. Cases 
occurring with sequences, associations or non-genetic syndromes are commonly classed as 
occurring with structural anomalies, but this varies by study. Cases with more than one 
congenital anomaly may sometimes be classed as isolated if all the anomalies are directly 
related to a single anomaly, for example congenital diaphragmatic hernia occurring with lung 
hypoplasia may be classed as isolated diaphragmatic hernia because the hypoplasia is a 
consequence of the hernia. 
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1.2 Congenital heart disease 
1.2.1 Definition, prevalence and survival 
CHD is a diverse group of structural congenital anomalies that affect the cardiovascular 
system. According to Mitchell’s definition, CHD is, “a gross structural abnormality of the 
heart or intrathoracic great vessels that is actually or potentially of functional significance” 
[16]. CHD is the largest group of congenital anomalies, accounting for a third of congenital 
anomaly cases [12]. In the UK, the birth prevalence of CHD between 2005-2010 was 
estimated to be 68 per 10,000 live and stillbirths [17]. However, the prevalence of CHD varies 
regionally and over time [18, 19]. As a group, CHD is not the most lethal type of congenital 
anomaly, with survival to age 15 reaching 72% in the UK (for births between 1992-1995) 
[20]. Despite improvements in surgical interventions, intensive care technologies, anaesthetics 
and medical therapies, survival for certain CHD subtypes is as low as 21% at age 12 [20]. 
1.2.2 Public health 
Babies born with CHD require highly specialised health care, which may involve multiple, 
complex and often life-saving surgeries, normally within the first year of life [9, 21]. 
Adequate paediatric cardiology services are required to treat these children. After reports that 
post-operative paediatric cardiac mortality at the Bristol Royal Infirmary was higher than in 
other UK centres between 1984-1995, an independent public inquiry began in 2001, entitled 
the “Bristol enquiry” [22]. However, the validity of the inquiry was challenged [23] and the 
outcomes of paediatric cardiology surgeries remained under scrutiny. A subsequent NHS 
review, “Safe and Sustainable”, was undertaken between 2008-2012 to consider the 
configuration of paediatric cardiology services [24]. The review controversially recommended 
that paediatric cardiac surgery should be restricted to seven of the original 11 units [24]. The 
intention was to have fewer, larger units which would have greater expertise due to the 
increased number of children being treated. However, the reformation has been halted since 
the Secretary for Health reported that the analysis that formed the basis of the review, was 
flawed. A new review established by the NHS commenced in 2013, entitled the “New 
Congenital Heart Disease Review”. The aim of this review was to: “agree a model of care and 
service standards”, to “note the analysis of the required service capacity” and to “agree the 
proposals for commissioning the service” [25].  
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CHD cases that survive infancy require ongoing medical surveillance, reinvestigation and 
subsequent operations. UK hospital admission rates have therefore risen as survival has 
improved [26]. Individuals with CHD are at increased risk of developmental disorders [27]. It 
is therefore important that adequate services are in place to provide health care for the 
children and adults affected. However, prevalence and trends in prevalence of individual 
CHD subtypes in the UK have not been thoroughly researched. Similarly, there is a paucity of 
research on long-term survival estimates. Therefore, it is difficult to anticipate the expected 
number of cases in the future and hence the health care provisions required. 
Another public health concern is the prenatal diagnosis of CHD, which became possible in the 
early 1980s. CHD is difficult to diagnose prenatally with only 36% of UK cases being 
prenatally diagnosed between 2012-2013 [28]. However, the proportion of prenatally 
diagnosed cases varies by region in the UK, perhaps due to differences in screening programs 
and uptake [28]. To improve the prenatal diagnosis of CHD, visualisation of the four heart 
chambers has become a routine part of the second trimester scan. In 2003, the FASP 
guidelines altered to state that women should expect to be screened for “severe” CHD during 
pregnancy [11]. The exact definition of severe CHD has altered over time, but in 2015 the 
FASP defines it as: transposition of the great vessels (TGV, excluding congenitally corrected 
TGV), atrioventricular septal defect (AVSD), tetralogy of Fallot (ToF) and hypoplastic left 
heart (HLH). The FASP standards currently state that severe CHD should have a detection 
rate of ≥ 50% between 18+0 to 20+6 weeks gestation, with evidence suggesting that this is 
being met in most regions [12, 29]. 
1.2.3 Classification 
CHD can occur in isolation, with structural extra-cardiac anomalies (ECAs, excluding those 
with chromosomal/ genetic ECAs but sometimes including cases with sequences, associations 
or non-genetic syndromes), or with chromosomal/genetic ECAs. 
CHD can be further categorised into CHD subtypes; the most common of which are described 
in Table 1.1 (and will hereon be referred to as the abbreviations listed). However, there are 
several coding systems used to code CHD subtypes. Epidemiologists generally use the World 
Health Organisation’s (WHO) International Classification of Disease (ICD) codes [30]. 
Congenital anomalies of the circulatory system correspond to ICD version nine codes: 745-
747, or the ICD version 10 codes: Q20-Q28. The ICD nine codes correspond to anomalies of: 
the cardiac septal closure (745), the heart (746), and the circulatory system (747) [30]. The 
ICD 10 codes correspond to anomalies of: the cardiac chambers and connections (Q20), the 
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cardiac septa (Q21), the pulmonary and tricuspid valves (Q22), the aortic and mitral valves 
(Q23), the heart (Q24), the great arteries (Q25) and the great veins (Q26), the peripheral 
vascular system (Q27) and the circulatory system (Q28). In line with Mitchell’s definition, 
congenital anomalies of the peripheral vascular and circulatory system (ICD 10: Q27-28), and 
minor CHD which are functionless or have little impact on health or wellbeing (such as heart 
block or patent ductus arteriosus (PDA) in preterm infants) are not generally classed as CHD. 
This definition of CHD is not universally adopted, but it is used by one of the largest 
networks of congenital anomalies registers, the European Surveillance of CARs 
(EUROCAT), which classifies ICD 9: 745, 746, 7470-7474 and ICD 10: Q20-26 as CHD. 
Clinicians tend to use a different coding system for CHD, known as the International 
Cardiology Society (ISC) coding system or more recently, the Association for European 
Paediatric and Congenital Cardiology (AEPC) coding system [31]. Similar to the ICD coding 
system, the ISC/AEPC provides separate codes for each CHD subtype. However, the subtypes 
are further broken down according to the surgeries used to treat the CHD subtype, the exact 
location of the CHD subtype and the severity of the CHD subtype. 
It is common practice to assign cases with multiple CHD subtypes to one subtype. A CHD 
hierarchy is therefore required, but currently there is little consensus on this. Several 
hierarchies have been utilised in previous research, which are ordered based on: clinical 
outcomes (‘favouring’ subtypes with the lowest survival), physiology (favouring the subtype 
that first necessitated intervention) and embryology (favouring the subtype that occurs first 
during fetal development). These hierarchies may cause heterogeneity within subtypes and an 
under-representation of some subtypes lower down the hierarchy [32]. To address this, Wren 
et al used a two-dimensional classification system, where cases were categorised by the main 
CHD subtype (using the clinical hierarchy) and further categorised by the CHD which 
triggered the diagnosis of CHD [32]. While clinically this is intuitive, the frequency of cases 
in each sub-group can be unmanageable statistically. 
1.2.4 Pathology 
1.2.4.1 Fetal heart development 
Four weeks into pregnancy, the heart forms as a vascular tube which gradually elongates [33]. 
As the tube grows longer, primitive chambers called the truncus atreriosus, the bulbus cordis, 
the primitive ventricle and the primitive atrium form (see Figure 1.1 A) [33]. The chambered 
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tube loops into an S-shape (see Figure 1.1 B), continuing until the atrium is above and 
beneath the truncus arteriosus, the ventricle and the bulbus cordis (see Figure 1.1 C) [33, 34].  
Septation, the separation of the heart into four chambers, occurs at approximately four weeks 
gestation [33]. The left and right atria form when a ridge of tissue, called the septum primum, 
grows downwards to fuse with the endocardial cushions [33, 34]. A small gap called the 
foramen ovale remains [35]. The septum primum regresses and forms a temporary valve over 
the foramen ovale [35]. Simultaneously, a septum in the primative ventricle grows upwards to 
fuse with the endocardial cushion above, to form the left and right ventricles [33] [35]. 
Cells from the top of the truncus arteriosus and the bottom of the bulbus cordis grow 
downwards and upwards, respectively [35]. Once these cells meet, they entwine to form a 
helix structure. The helix divides to form the aorta and the pulmonary artery, which are 
crossed over each other (Figure 1.1 D). In utero, the pulmonary artery remains connected to 
the aorta via a small gap called the patent ductus.  
At the entrance and exit of each ventricle, one-way valves form [33]. The atrioventricular 
(tricuspid and mitral) valves form between the atria and the entrance to the ventricles and the 
semilunar (pulmonic and aortic) valves form between the ventricles and the entrance to the 
arteries [33, 36].
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Figure 1.1 Diagram of fetal heart looping 
 
A. Growth of the fetal heart tube B. S-shaped looping C. Fetal heart looping, D. the developed fetal heart. Abbreviations: TA: Truncus Arteriosus, BC: Bulbus cordis, PV: 
Primitive ventricle, PA: Primitive atrium, RV: Right ventricle, LV: Left ventricle, RA: Right atrium, LA: Left atrium. 
Figure drawn by Kate Best, adapted from “Anatomy of the Human Body” [37] 
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1.2.4.2 Fetal circulation 
Blood oxygenated by the placenta passes through the fetal liver and the umbilical artery into 
the right atrium [35]. Most of the oxygenated blood is then shunted through the formaen 
ovale, into the left atrium and then the aorta (Figure 1.2). The remainder of the oxygenated 
blood from the umbilical artery mixes with deoxygenated blood coming from the superior 
vena cava and passes through the right ventricle into the pulmonary artery [35]. By shunting 
through the patent ductus, the majority of this mixed blood then combines with the 
oxygenated blood passing through the aorta. The mixed and oxygenated blood is then pumped 
around the fetus before returning as deoxygenated blood to the right atrium via the superior 
vena cava, effectively bypassing the lungs [35]. 
1.2.4.3 Neonatal circulation 
After birth, the lungs take in air, causing increased blood flow to the lungs and therefore back 
to the heart. The pressure in the left atrium increases and thus causes the foramen ovale to 
close after around five days of life [35]. Similarly, the shift in pressure also causes the patent 
ductus to shut. As a result, circulation shifts from a shared to a series circuit, the lungs are no 
longer bypassed and the right side of the heart becomes more dominant than the left [35] 
(Figure 1.2). This shift explains why babies with CHD remain healthy in utero but become 
symptomatic after birth or when the ductus closes [38]. 
When the newborn heart beats, muscles in both ventricle walls contract in unison, causing 
pressure in the ventricles to increase [36]. When this pressure becomes greater than the 
pressure in the arteries, the semilunar valves open and the blood is ejected into the arteries. 
Here, oxygenated blood travels from the left ventricle into the aorta and around the body, 
while simultaneously, the deoxygenated blood travels from the right ventricle into the 
superior vena cava and to the lungs to be oxygenated (Figure 1.2). After the blood is released 
from the ventricles, the ventricle muscles relax and the pressure drops. The semilunar valves 
close in response to the pressure gradient between the ventricles and arteries [36]. In unison, 
oxygenated blood flows back from the lungs to the left atrium and deoxygenated blood 
returns from the body to the right atrium. The blood levels in the atria cause the pressure to 
increase. When the pressure becomes greater in the atria than the ventricles, the 
atrioventricular valves open and blood flows into the ventricles. The heart contracts again and 
the cycle continues.
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Figure 1.2 Fetal circulation 
 
Figure drawn by Kate Best, adapted from [39] 
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Figure 1.3 Neonatal circulation 
 













Table 1.1 Descriptions of the most common CHD subtypes 
CHD subtype  ICD 9  ICD 10 Description 
Common arterial 
truncus (CAT) 
74500 Q200 One large artery leaving the heart instead of two; 
usually occurs with a VSD [41]. 
Transposition of the 
great vessels (TGV) 
74510 Q203 A switch over of the pulmonary artery and the aorta, 
meaning they are connected to opposite ventricles 
[42]. This causes deoxygenated blood to be sent into 
the right ventricle and through the aorta without being 
oxygenated in the lungs [33]. Similarly, oxygenated 
blood is sent through the pulmonary artery meaning 




7453 Q204 Only one ventricle, resulting in blood passing from 
both atria into the same ventricle [41]. 
Ventricular septal 
defect (VSD) 
7454 Q210 A gap in the ventricular septum [33]. 





Q230  Blockage or narrowing of the aortic valve. 
Atrial septal defect 
(ASD) 




7456 Q212 A common atrioventricular canal and just one 
atrioventricular valve bridging the canal [41, 42]. 
Tetralogy of Fallot 
(ToF) 
7452 Q213 A combination of four defects: sub-pulmonary 




7461 Q224 The lack of an opening between the right atria and 
ventricle, usually caused by the tricuspid valve failing 
to form. This means that blood is not able to pass 
from the atria to the ventricle and into the lungs. The 
blood must alternatively pass from the right to left 
atria. Stenosis occurs when the passage exists but is 
very small. This usually occurs with a VSD. 
Ebstein’s anomaly 
(EA) 
7462 Q225 EA occurs when the tricuspid valve is located lower 
than it should be, towards the right ventricle, resulting 








74600 Q220 The failure of the pulmonary valve to form. 
Hypoplastic left 
heart (HLH) 
7467 Q234 A small or non-existent left ventricle. 
Hypoplastic right 
heart (HRH) 
No code Q226 A small or non-existent right ventricle. 
Coarctation of aorta 
(CoA) 




74742 Q262 Incorrect positioning of the pulmonary vein and the 
superior vena cava, resulting in oxygenated blood 
entering the right chambers instead of the left. There 
must be an ASD or patent foramen ovale so that 
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CHD subtype  ICD 9  ICD 10 Description 
blood can pass to the correct chamber, without these 
the child will die. 
Mitral valve 
anomalies (MVA) 
7465 Q232 Underdevelopment of the mitral valve, usually 
prolapse, atresia, regurgitation of the mitral valve. 
Interrupted aortic 
arch (IAA) 
74711 Q252 An undeveloped aorta usually characterised by a gap 
or a discontinuation in the aortic arch. 
Double outlet right 
ventricle (DORV) 




The aetiology of CHD is hypothesised to be both environmental and genetic [43-45]. A 
review of non-inherited risk reported strong evidence that maternal illnesses such as 
phenylketonuria, diabetes, febrile illnesses, influenza, rubella and epilepsy were associated 
with CHD [43]. There was also strong evidence that maternal exposure to vitamin A, 
anticonvulsants, indomethacin, ibuprofen, Sulfasalazine, thalidomide and trimethoprim/ 
sulfonamides was associated with CHD [43]. 
Aneuploidies and microdeletions account for approximately 20% of CHDs [45]. For example, 
80% of children with Trisomy 13, 40-50% of children with Trisomy 21 (Down syndrome) 
and 90-100% of children with Trisomy 18 occur with CHD [45]. However, single gene 
mutations also account for a small proportion of CHDs. Some of these single gene disorders 
cause a syndrome such as Noonan Syndrome or Holt-Oram syndrome, which are linked with 
CHD [46]. However other single gene mutations, such as in NKX2.5 or GATA4 are 
hypothesised to cause CHD directly and do not occur as part of a syndrome [46]. Lastly, 
Pierpont et al state that a proportion of CHDs are the result of multiple gene mutations, which 
make the fetus more vulnerable to CHD, particularly upon interaction with environmental 
exposures [46]. 
Although the genetic aetiology of CHD is an important area of research, the focus of my 
thesis is on the birth prevalence and survival of CHD. Therefore, I will not be further 
investigating the role of genetics in CHD in this thesis.  
1.2.6 Care pathway 
1.2.6.1 Prenatal diagnosis 
For cases of CHD prenatally diagnosed in the UK, there is a structured care pathway outlined 
by the British Congenital Cardiac Association [47]. Most prenatally diagnosed cases are 
initially suspected during the 18+0 to 20+6 routine fetal anomaly scan. These cases are referred 
to a fetal cardiology service, perhaps after a re-scan at a local hospital, where fetal 
echocardiography is performed to confirm the diagnosis. At this point, further prenatal tests 
such as amniocentesis or karyotyping are offered. If the pregnancy continues, local and 
specialist multidisciplinary teams plan active treatment or palliative care. After birth, there 
will be a cardiac assessment and treatment. “High-risk” pregnancies (defined as shown in 
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Figure 1.5), will be referred to fetal cardiology services regardless of whether an anomaly was 
identified at the routine fetal anomaly scan. 
1.2.6.2 Postnatal diagnosis 
For babies that were not diagnosed prenatally or at birth, newborn screening checks within 72 
hours of birth are in place to diagnose CHD (among other things) before hospital discharge 
[48]. There is an additional health check at around 6-8 weeks with the baby’s GP [48]. These 
checks involve listening to the heart with a stethoscope with the aim of picking up heart 
murmurs, which can be indicative of AVA/S, PVS, ToF, PDA, MVA, VSD or ASD. Babies 
with PDA, VSD, ASD and CAT may present with breathlessness that has developed 
gradually and with difficulty feeding. Babies with cyanotic CHD (such as ToF, TAPVR, 
HLH, TGV, TA, IAA and PVA) are sometimes diagnosed before hospital discharge due to 
their “blue-ish” colouring and difficulty with breathing [49]. While symptoms occur quickly 
after birth in most babies with PVA, SV, TA and HLH, this is not true for all types of 
cyanotic CHD. Babies with duct dependent CHD may develop symptoms at around five days 
of age, when the patent ductus closes [49]. These babies can often go into shock or critical 
cyanosis, meaning they present as emergencies. 
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Figure 1.4 Prenatal care pathway for CHD 
 
Figure taken from: 
http://www.bcs.com/documents/Fetal_Cardiology_Standards_Final_Version_March_2010.pdf
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Figure 1.5 Criteria for "high-risk" pregnancy for CHD 
 





Interventions vary considerably according to CHD subtype. The most common treatments are 
shown in Table 1.2. To summarise, SV, TA, HLH, ToF, TGV, CAT, AVSD, PVA-VSD cases 
require open heart surgery to survive. For SV, TA and HLH cases, surgical intervention is 
required within the first few days of life. For AVSD, PVA-VSD, CAT and TGV, surgical 
intervention needs to occur within the first few weeks of life. Individuals with AVA/S and CoA 
generally require catheterisation of the heart, with the timing dependent on severity.
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Table 1.2 Treatment for CHD according to NHS Choices 




AVA/S Balloon valvuloplasty  






Depends on severity, 




CoA Inserting a catheter and using a 
balloon to enlarge the tube or 
using a metal stent. 
Or (for more severe CoA) 
Removing the narrow section/ 







First few days of life 
for severe CoA 
EA Mild EA doesn’t require 
treatment.  
 









PDA Medicine prescribed to close the 
duct.  
Or (if unsuccessful) 
The duct may be sealed with a 










PVS Mild PVS requires no treatment. 
 
Severe PVS requires balloon 









VSD, ASD  Small septal defects do not 
require treatment.  
 
Larger septal defects can be 
closed with a catheter. 
 












SV, TA, HLH Prostaglandin prescribed after 
birth to prevent the closure of the 
ductus. These subtypes are then 
palliated surgically in three stages 
1) Norwood procedure: A 
shunt is created between 
the heart and lungs 
2) Glenn operation: The 
superior vena cava is 







Stage 1 performed in 
first few days of life 
Stage 2 4-6 months 








3) Fonatan operation: the 
inferior vena cave is 
connected to the 
pulmonary artery. 
ToF Shunt operation sometimes 
required soon after birth. 
Then 
The hole in the heart is closed and 







Severe ToF treated 
soon after birth.  
 
Less severe ToF 
treated at 3-6 
months 
TAPVR The abnormally positioned veins 
are repositioned in the correct 
position in the left atrium. 
Open heart 
surgery 
If the pulmonary 
vein is obstructed 
repair is at birth. If 
not surgery occurs at 
a few weeks or 
months 
TGV Prostaglandin prescribed at birth 
(a catheter may also be used to 




Later the arterial switch operation 
is performed to reattach the 










performed in the 
first month 
CAT The common truncus is split into 
two and repositioned. 
Open heart 
surgery 
A few weeks after 
birth 





PVA-VSD Prostaglandin at birth 
Arterial shunt then possible major 






First few weeks and 
then later in life 




 Chapter 2. Aim and objectives 
The aim of this PhD is to describe and predict the prevalence and survival of individuals with 
CHD, overall and by subtype. 
The specific objectives are to: 
1. Conduct a literature review of CHD birth prevalence, risk factors for CHD and birth 
characteristics of children with CHD, in population-based studies (Chapter 3). 
2. Describe the epidemiology of CHD in singletons including: prevalence, trends in prevalence 
and CHD risk factors in the UK, using data obtained from the British Isles Network of 
Congenital Anomaly Registers (BINOCARs) (Chapter 5). 
3. Describe the epidemiology of CHD in multiple births, and estimate the relative risk of CHD 
in twins compared to singletons using data from the Northern Congenital Abnormality Survey 
(NorCAS) linked to data from the Northern Survey of Twins and Multiple Pregnancies 
(NorSTAMP) (Chapter 6). 
4. Conduct a systematic review on population-based studies that have reported the long-term 
survival and risk factors for mortality for children born with CHD (Chapter 7). 
5. Analyse survival and risk factors for mortality in individuals with CHD in the UK using data 
obtained from the NorCAS linked to death registrations. Using this data, to estimate the 
future survival associated with CHD (Chapter 8). 
6. Predict the future prevalence of CHD using data from the NorCAS (Chapter 9).
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 Chapter 3.  The birth prevalence of congenital heart disease: a literature 
review 
3.1 Introduction 
Worldwide, many studies have been published on the epidemiology of CHD. Recently, two 
systematic reviews on the global prevalence of CHD have been published, reporting 
prevalence rates of between 50-70 per 10,000 live births [18, 19]. However, both reviews did 
not account for cases occurring in terminations of pregnancy for fetal anomaly (TOPFAs) or 
fetal deaths. Additionally, these reviews consisted of hospital-based studies, meaning cases 
were included only if they presented in hospital. Population-based studies include cases born 
in (or to mothers residing in) a pre-defined area, defined by geo-political boundaries [50]. 
A literature review that solely includes population-based studies will provide more reliable 
estimates of CHD birth prevalence. 
3.1.1 Aim  
The primary aim of this literature review is to identify and appraise the relevant international 
literature on the birth prevalence of CHD. 
3.1.1.1 Objectives 
1) To identify all population-based studies that have reported the prevalence of CHD, 
using a systematic search strategy. 
2) To critically appraise the studies and identify possible sources of heterogeneity. 






Total birth prevalence (per 10,000) was defined as: 
 
No of cases of CHD in live births, stillbirths, l𝑎𝑡𝑒 𝑚𝑖𝑠𝑐𝑎𝑟𝑟𝑖𝑎𝑔𝑒𝑠, 𝑇𝑂𝑃𝐹𝐴𝑠
No of live births and stillbirths in the population
 x 10,000 
Ideally, total birth prevalence of CHD is calculated using the number of cases occurring in 
late miscarriages and TOPFAs. However, this is not always possible and so sometimes the 
numerator consists only of live and stillbirths. 
Live birth prevalence (per 10,000) was defined as: 
No of cases of CHD in live births
No of live births in the population
 x 10,000 
3.2.2 Inclusion criteria 
Population-based studies that reported the live or total birth prevalence (or frequency of cases 
and study population) of CHD were included. Studies that reported the prevalence of: a) all 
cases of CHD; b) cases of CHD excluding cases with CHD and chromosomal/ genetic ECAs; 
or c) isolated cases of CHD, were included. Only full, original articles available from the 
British library or internet, written in the English language and reporting on CHDs in humans 
were eligible for inclusion. There was no restriction based on year of publication. 
3.2.3  Exclusion criteria 
Case-series, case-control, hospital-based studies and “population-based” studies featuring 
cases ascertained from a single hospital were excluded. Studies that reported the prevalence of 
single CHD subtypes, studies requiring parental consent for case inclusion and studies that did 
not report birth prevalence were also excluded. Studies that included the same set or subset of 
data as a larger or more recent study were excluded. 
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3.2.4 Search strategy 
Medline, Embase and Scopus were searched systematically from their inceptions (1946, 1974 
and 1996, respectively) to October 2014 inclusive. MeSH-terms and key word searches were 
entered systematically into the databases (Table 3.1). After systematic searches of each 
database, the citations were extracted and titles and abstracts were screened according to the 
inclusion criteria and full articles were retrieved for all relevant citations. Reference lists of 
included articles were searched and key journals such as “Congenital Heart Disease”, “Birth 
Defects Research”, “Circulation”, “Heart” and “Cardiology in the Young” were searched 
using keywords. 
The citations were searched and extracted by one reviewer only, meaning this literature 
review cannot be considered as a systematic review. 
3.2.5 Data extraction 
Study characteristics including study period, study region and case definition were extracted. 
Study quality characteristics including: method of ascertainment, methods of diagnosis, 
maximum age at diagnosis and case definition were extracted. The frequency of cases and 
denominators were extracted from all included studies. Where possible, case numbers were 
extracted separately for: a) all cases of CHD; b) cases of CHD excluding cases with structural 
ECAs; or c) cases of CHD excluding cases with chromosomal/genetic ECAs. Where possible, 
case numbers were also extracted for the following CHD subtypes: SV, HLH, HRH, EA, TA, 
PVA, CAT, AVSD, AVA/S, TGV, ToF, TAPVR, IAA, CoA, DORV, MVA, VSD, ASD, 
PVS and PDA. This was completed for all cases of CHD only (as opposed isolated cases, as 
few studies reported subtype specific prevalence for these cases). 
Information on trends in CHD prevalence over time was extracted where available. 
Information on maternal age, maternal ethnicity, infant sex, timing of diagnosis, percentage 
diagnosed postnatally, birth weight and gestational age at delivery were extracted from the 
identified studies, where possible. 
3.2.6 Statistical analysis 
Using the extracted case numbers and denominators, the prevalence of CHD and 95% 
(binomial) confidence intervals per 10,000 births were calculated. A meta-analysis was not 
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performed due to the high degree of variation between studies. However, χ2 tests were applied 
to test for heterogeneity and Cochrane’s Q test was used to quantify heterogeneity between 
studies, where I2 >50% was considered as significant heterogeneity [51]. 
Analyses were performed in Stata version 13 (StataCorp, College Station, Texas) and p<0.05 
was considered statistically significant. 
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Table 3.1: Medline, Embase and Scopus search terms 
Medline Embase Scopus 
1 Heart Defects, 
Congenital/ or ((cardi$ 
adj1 anomal$) or 
(cardi$ adj1 
abnormalit$) or (cardi$ 
adj1 malformation$) or 
(cardi$ adj1 defect$) or 
(heart adj1 anomal$) or 
(heart adj1 
abnormalit$) or (heart 
adj1 malformation$) or 
(heart adj1 defect$) or 
(congenital adj1 heart 
adj1 disease$)).ti,ab. 
1 Congenital heart 
malformation/ or 
congenital heart 
disease/ or ((cardi$ adj1 
anomal$) or (cardi$ 
adj1 abnormalit$) or 
(cardi$ adj1 
malformation$) or 
(cardi$ adj1 defect$) or 
(heart adj1 anomal$) or 
(heart adj1 abnormalit$) 
or (heart adj1 
malformation$) or 
(heart adj1 defect$) or 
(congenital adj1 heart 
adj1 disease$)).ti,ab.  
1 (TITLE-ABS-
KEY((cardi$ anomal$) 
OR (cardi$ abnormalit$) 
OR (cardi$ 
malformation$) OR 
(cardi$ defect$) OR 
(heart anomal$) OR 
(heart abnormalit$) OR 
(heart malformation$) 




mortality OR incidence 
OR prevalence OR 
epidemiology OR (risk 
factor$) OR (predict$)) 
AND ALL(epidemiology 
OR epidemiological) 
AND NOT ALL(animal$ 
OR rat OR rats OR cat 
OR cats OR bovine OR 
sheep)) AND 






2 Survival Analysis/ or 
survival.ti,ab. Or (exp 
Mortality/ not (Poult 
Enteritis Mortaliy 
Syndrome/ or Maternal 
Mortality/)) or 
mortality.ti,ab. 
2 Survival.ti,ab. or 
survival/ Or mortality/ 
or mortality.ti,ab. 




predict$.ti,ab. Or exp 
Risk/ or Epidemiology 
or epidemiology.ti,ab. 







4 Exp Epidemiological 
Studies/ 
4 Exp epidemiology/ or 
epidemiology.mp or 
epidemiological.mp 
5 1 and (2 or 3) and 4 5 1 and (2 or 3) and 4 
6 Limit 5 to (English 
language and humans) 
6 Limit 5 to (english 
language and humans) 
7 6 not (case study.mp or 
exp Case Reports/ or 
exp Clinical Trials as 
Topic/ or clinical 
trial.mp) 
7 6 not (case study.mp or 
exp Case Report/ or exp 
controlled clinical trials 




Figure 3.1 shows a PRISMA diagram for the flow of articles through the review. Of 18,280 
identified articles, 35 met the inclusion criteria. 
3.3.1 Description of studies 
Study descriptions are shown in Table 3.2. Of the 35 included articles, two reported data from 
more than one study. Knoshnood et al presented data from 27 different registers across 
Europe (data from two registers were excluded due to overlapping data with other included 
articles) and Pradat et al reported data from a French, a Swedish and an American register 
[52, 53]. 
Three articles studied populations in Asia [54-56], 21 in Europe [1, 52, 53, 57-74], eight in 
North America [53, 75-83], two in Oceania [84, 85] and one in South America [77]. Six 
articles (10 studies) reported the prevalence of CHD in the UK, three in the North of England, 
three in Liverpool, one each in Wales, Thames Valley, Wessex and the East Midlands [52, 60, 
61, 63, 64, 69]. 
The oldest study period began in 1960 [64], and the most recent in 2007 [56]. The longest 
study period spanned 37 years [80] and the shortest spanned one year [56, 66, 68, 71, 85]. 
The majority of articles (n=19) used ICD versions eight, nine, or 10 to code CHD [1, 52, 54, 
55, 57-60, 62, 63, 65, 67, 68, 72, 74, 76, 79-81]. However, seven of these did not state which 
ICD codes were classed as CHD [55, 58, 59, 62, 68, 79, 81]. Six of the articles using the ICD 
coding system included cases according to the EUROCAT inclusion criteria [1, 52, 60, 65, 
67, 72] and six used a more inclusive set of ICD codes to define CHD [54, 62, 63, 74, 76, 80]. 
Three articles (five studies) stated that ISC coding was used but provided no further 
information [53, 70, 82]. One article used the “Anatomical and Clinical Criteria” (ACC) 
coding [73]. Four articles did not specify codes but defined CHD according to Mitchell’s 
definition (Chapter 1 section 1.2.1) [56, 66, 69, 71]. Two articles used an adapted version of 
Mitchell’s definition (“a structural anomaly of the great vessels”) [77, 84]. The six remaining 
articles provided no definition of CHD [61, 64, 75, 78, 85, 86]. 
CHD was diagnosed using echocardiography, cardiac catheterisation and post mortem in the 
majority of articles (n=19) [52, 53, 56, 57, 59-63, 65, 69, 74-77, 80-82, 84]. The method of 
diagnosis was not stated in nine articles [53-55, 58, 64, 66, 68, 78, 79]. 
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The maximum age at diagnosis ranged from five days to 16 years [57, 60]. There was no 
maximum age of diagnosis in eight articles, but as none of the eight were register-based 
studies, cases identified throughout the study periods, regardless of age, were probably 
included [55, 62-64, 70, 77, 80, 83]. 
Twenty-one articles ascertained cases using CARs [1, 52-58, 60, 61, 63-65, 68, 69, 72, 76, 80, 
82, 84, 85] and five used CHD registers or databases [53, 59, 62, 66, 73, 81]. Hospital 
records, admissions/referrals and health systems were used in four articles [55, 70, 77, 79]. 
The remaining sources were an insurance database [55], patient registry data [67], a birth 
cohort [71], a birth register [74] and “Crippled children’s services” [78].
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CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 








, diagnosed by 
paediatric 
cardiologists 
None stated 18 
months 
156 live births 
 
None stated 
15,949 Live births 
 
Live births from all 
hospitals in the area 
Borman, 
et al [85] 
1978 New Zealand, 
Oceania 
None stated None stated None stated 1 year 181 live births 
 
National CAR  
517,77 live births 
 
Births notified to the 
register 
Bourdial, 






ICD 10: Q20-26 Pathology, 
medical genetics, 
cardiology units 
PDA 1 year 424 live births. 512 total 
births (live births, fetal 
deaths, terminations). 448 





88,025 total births 
(live births and 
stillbirths), 
 













anomaly of the 
heart or the 
great vessels, 












peripheral veins or 
arteries. PDA if not 
present after 3 
months in term births 
and after 6 months if 
preterm 
6 years 1,787 live births. 1635 
live births excl. 
chromosomal cases. 1337 
isolated live births 
 
Western Australia Birth 
Defects Registry 
233,502  total births 









CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 
Calzolari, 








CHD codes not 
stated 
Echocardiography
, surgery, post 
mortem 
PDA< 37 weeks 
gestational age 
≤5 days 1,549 total births (live 
births and stillbirths. 1397 
total births excl. 
chromosomal cases. 1149 









Source not stated 
Cambra 







ICD 10: Q20-26 Sonography, 
genetic test, 
pathology 
None stated 1 year 962 live births, fetal 
deaths (>22 weeks), 
termination for fetal 
anomaly. 873 live births 
 
Population registry of 
Neonatal Screening and 
Congenital Anomalies 
191,171 total births 
(live and stillbirth) 
 
Registry of Newborns 









ICD 9: specific 
CHD codes not 
stated 
None stated CAT 2 years 13,036 live births 
 
New York Congenital 
malformation register 











ICD codes uses, 
not specific 








PDA associated with 
prematurity and birth 
weight <2500g. 
 
Cases occurring in a 
multiple pregnancy 
1 year 8,947 live births excl. 
chromosomal cases. 5338 
isolated live births 
 
Swedish medical birth 
registries, child 
770,355 total births 












CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 




medical records  
 
Dadvand, 













PDA associated with 
prematurity, 






5,715 total births 
(livebirths, stillbirths (≥28 
weeks until 1992, 24 
weeks after), late 
miscarriages and 
terminations for fetal 
anomaly (at any 
gestational age)). 5050 
total births excl. 
chromosomal cases. 4382 





665,377 total births 
(livebirths, stillbirths 
(≥28 weeks until 1992, 

























5/6 years  884 live births 
 
Liverpool Registry of 
Congenital Malformations  
160,480 live births 
 
Office of Population 









ICD 9: 745-747 








PDA associated with 
prematurity, PFO 
with the tiny left-to-
right shunt in the first 
year of life, partial 




1,480 total births (live 
births, still births, late 
fetal deaths following 
prenatal diagnoses). 1296 
total births excl. 
205,051 live births 
 








CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 






pericardium and AV 
fistule, aortic arch 
branch anomaly, and 
vascular ring. Minor 
EUROCAT 
anomalies. 
chromosomal cases. 1265 
isolated total births 
 






















None stated 1 year 5,010 total births (live 
births, fetal deaths, 
elective terminations 
of all gestational ages) 
 
Hawaii Birth defects 
program 
282,900 total births 




Department of Health 
Office of Health Status 
Monitoring as derived 











anomaly of the 
heart or the 
great vessels, 









PDA only included if 
present >10 days 
(normal weight at 
birth) or >3 months 
when gestational age 





441 live births, 390 live 
births excl. chromosomal 
cases. 337 isolated live 
births 
 
Hospital records  












CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 




“all types” None stated Heart murmurs 1 year 233 total births (live 
births and fetal deaths 
(>20 weeks)) 
 
Iowa hospitals and 
crippled children's 
services, hospital data, 
birth and death 
certificates. 
58,686 total births 
(live births, 
terminations and fetal 
deaths (>20 weeks)) 
 
Hospital births in 
Louisiana 
Jackson, 















1,543 live births 
 
Liverpool registry of 
Congenital Malformations 
203,880 live births 
 
Office of Population 










ICD 9: specific 
CHD codes not 
stated. 
None stated PDA associated with 
prematurity 
1 year 8,012 total births (live 
births and stillbirths) 
 
Hospital admissions and 
discharges  
593,042 total births 
(live births and 
stillbirths), 
 









None stated None stated None stated Study 
period (3-
12 years) 
1,081 total births (No 
further description). 856 
total births  
 
Liverpool registry of 
Congenital 
Malformations, paediatric 
cardiology clinic records.  
163,692 total births 











CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 
Khoshno















PDA and PFO 1 year Live births, fetal deaths 
and terminations for fetal 
anomaly. 
 
The EPICARD register 













ICD 9: 745, 
746, 7470-7474 
ICD 10: Q20-26 
 
Varies by register EUROCAT 
exclusions including: 





Total births (live births, 
fetal deaths (> 20 weeks), 
and terminations for fetal 
anomaly) excl. 
chromosomal cases 
Hainut 1637, Odense 806, 
Paris 3954,Tuscany 3229,  
Dublin 1682, N 
Netherlands  1956, Emilia 
Romagna 2434, 
Strasbourg 1851, Vaud 
1573, Zagreb 503, Malta  
944, Antwerp 1246, 
Basque Country 1218, 
Saxony-Anhalt 2074,  
Mainz 530, Barcelona 
1088, Styria 1747, Cork 
& Kerry 517,  Sicily 
1440, Wales 3305, 
Norway 3774, Ukraine 
568, La Reunion 391, 
Wielkopolska 2776, 
Thames Valley 493, 
Total births (live births 
and fetal deaths (>20 
weeks)), 
Hainut 225381, 
Odense 101028, Paris 
619098, Tuscany 
443981,  Dublin 




Vaud 135154, Zagreb 




Anhalt 234610,  Mainz 
59403, Barcelona 
196160, Styria 
188454, Cork & Kerry 










CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 
Wessex 1210, East 
midlands (UK) 2139, 
Northern England (UK) 
2149, South East Ireland  
 
EUROCAT registers 
Ukraine 83446, La 
Reunion 73023, 
Wielkopolska 278536, 
Thames Valley (UK) 
169919, Wessex (UK) 
370122, East midlands 
(UK) 622064, N 
England 247091 , SE 
Ireland  61821, Total  
729911629 
 











ICD 9: 745, 
746, 7470-7474 









cardiac murmurs  
1 year 204 isolated total births 
(live births, stillbirths  
(≥28 weeks until 1992 
and  ≥24 weeks after 
1992), 
late miscarriages (≥20 
weeks), TOPFA).  
 
Pleven, Bulgaria CAR 
47,622 total births 



























5,249 Live births excl. 
chromosomal cases 
 
860,492 live births 
 








CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 



























newborn infants less 
than 6 weeks of age. 
None 
stated 
8,277 total births (live 
births and stillbirths) excl. 
chromosomal cases. 5289 

















None stated PFO not requiring 
closure, rhythm 
disturbances, mild 
PVS, PDA not 
requiring closure, 





malpositioning of the 
heart 
5 years 922 total births (live 




111,225 total births 
(live births and 
stillbirths (≥26 weeks)) 
 









CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 
Source of denominator 
Nuutinen, 
et al [71] 








mortem, ECG , X-
ray 
Arrhythmia, PDA if 
patent after neonatal 
period 
1 year 50 live births 
 
Birth Cohort, hospital 
admissions, 1 year public 
health questionnaire filled 
out by nurses, death 
certificates.  
12,058 live births 
 







ICD 8: 746-747 




PDA <37 weeks 
gestational age 
1 year 6,646 live births. 5191 
isolated live births 
 
Danish Patient registry 
data  












ICD Q20-28 Echocardiography 
(from the late 
1990s), post 
mortem 
None stated Not stated  1,029 live births and 
stillbirths (>28 weeks) 
 
The Kola birth register 
28,511 total births 












ISC coding, no 
specific codes 
stated 
Not stated Positional anomalies 








1 year 2,749 total births (Live 






951,211 total births 
(live births and 
stillbirths) 
 








CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 

























1 year 3,171 total births (live 
births and stillbirths (≥ 
28 weeks)) excl 
chromosomal cases.  
 
Cardiology clinics and a 
CAR 
1,268,400 total births 
(live births and 
stillbirths) 
 


























1 year 7,012 total births (live 
births and stillbirths (≥ 20 
weeks)) excl 
chromosomal cases.  
 
Californian Birth Defects 
Research (register) 
 
2,218,987 total births 
(live births and 
stillbirths) 
 
Source not stated 
Samanek, 

















None stated None 
stated 
5,030 live births 
 
Hospital records 
816,569 live births 
 









CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 











ICD 9: specific 






Cases occurring with 




chromosome 21), 13 
and 18 
1 year 319 live births 
 
Hospital records 
143,896 live births 
 
Office of Public 
Health Vital Records 
Database of the State 
of Louisiana 
Tagliabue





ICD 9 codes 
used, no 
specific codes 
for CHD stated 
None stated None stated 1 year 109 live births 
 
Lombardy Birth Defect 
Registry 
12,008 live births 
 
Social Security List 






ICD 9 745-747  None stated PDA <37 weeks 
gestational age or 









Singapore National Birth 
Defects Register  
329,093 total births 
(live births and 
stillbirths) 
 
Birth and death 
registrations 
Wilson, 

















None stated 1year 2,217 isolated live births 
 
Subset of the Baltimore 
Washington Infant study:  
619,367 live births 
 
























676,927 live births 
 








CHD definition Methods of 
Diagnosis 




Source of cases 
Denominator 
population, 






bicuspid aortic valve 
with no stenosis, 






prematurity and ASD 






ICD 9: specific 
CHD codes not 
stated 
None stated Small VSD, PDA, 
ASD, and mild PVS, 
if they didn’t have a 
CHD specific 





(Frequencies not stated) 
live births 
 




(prevalence: 13.08 per 
1000) 
 










, case records, 
post mortem  
ASDs <5 mm, PFO, 
arrhythmias, PDA 
which was patent 
throughout the first 
14 days of life  
28 days 686 total births (live 
births, stillbirths (>20 
weeks), termination of 
pregnancy (>20 weeks)). 
556 live births 
 
Beijing Congenital 
Malformations Registry  
84,062 total births 
(live births and 
stillbirths). 
83929 live births 
 
Source not stated 
PDA=Patent Ductus Arteriosus, ASD= Atrial septal defect, PFO = Patent Foramen Ovale, PVS= Pulmonary valve stenosis, EUROCAT= European Surveillance of CARs, TAPVR= 
Total anomalous pulmonary venous return, AV= Atrial ventricular, Excl= Excluding, TOPFA= Termination of pregnancy for fetal anomaly 




3.3.2.1 Live birth prevalence 
Twenty articles reported the live birth prevalence of CHD, which ranged from 22.1 per 10,000 
to 130.7 per 10,000 live births (Table 3.3). The prevalence of individual CHD subtypes was 
reported by 16 studies, with VSD, ASD and PVS having the greatest prevalence in all of the 
studies (Table 3.4).  
Seven articles reported the live birth prevalence of CHD excluding cases with chromosomal/ 
genetic ECAs (Table 3.3). The live birth prevalence ranged from 34.9 to 70.2 per 10,000 live 
births.  
Seven articles reported the live birth prevalence of isolated CHD, which ranged from 28.8 to 
61.6 per 10,000 total births (Table 3.3).  
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Table 3.3 Prevalence of CHD per 10,000 live births 
 
Setting/ Study period Prevalence per 








Louisiana, USA 1988-1989 [81] 22.1 (19.8-24.7) 
Monchegorsk, Russia, 1973-2006 [74] 25.4 (19.9-32.1) 
Denmark 1977-2006 [67] 37.0 (36.1-37.8) 
Emilia Romagna, Italy,1980-94 [57] 46.9 (44.6-49.3) 
La Reunion, France, 2002-07 [1] 48.1 (43.7-52.9) 
Oulu & Lapland, Finland, 1966 [71] 41.4 (30.7-54.6) 
Londrina, Brazil, 1989-98 [77] 54.9 (49.9-60.2) 
Liverpool, UK, 1960-69 [61] 55.0 (51.5-58.8) 
Bohemiam Czech Republic, 1980-90 [86] 61.6 (59.9-63.3) 
New York, USA, 1992-2006 [58] 63.7 (62.6-64.8) 
Beijing, China, 2007 [56] 66.2 (60.8-71.9) 
N England, 1987-06 [69] 65.5 (63.6-67.4) 
Croatia, 2002-05 [62] 72.1 (68.5-75.9) 
Paris, France, 2005-09 [73] 74.7 (71.7-77.8) 
Liverpool, UK, 1979-88 [63] 75.6 (71.9-79.5) 
Western Australia, 1980-89 [84] 76.5 (73.0-80.1) 
N England, 1985-2003 [60] 79.6 (77.5-81.8) 
Lombardy, Italy, 1999 [68] 90.7 (74.5-109.) 
Tennessee, USA, 1992-93 [75] 97.8 (83.1-114.3) 



























s New Zealand 1978 [85] 34.9 (30.0-40.4) 
Emilia Romagna, Italy, 1980-94 [57] 42.3 (40.1-44.6) 
Londrina, Brazil, 1989-98 [77] 48.5 (43.8-53.6) 
Denmark 1963-1973 [70] 60.9 (59.3-62.6) 
Croatia, 2002-06 [62] 63.2 (59.8-66.7) 
Western Australia, 1980-1989 [84] 70.0 (66.6-73.4) 










Denmark 1977-2006 [67] 28.8 (28.1-29.6) 
Emilia Romagna 1980-1994 [57] 34.8 (32.8-36.8) 
Maryland & Columbia, USA 1981-1988 
[82] 
35.7 (34.3-37.3) 
Londrina, Brazil 1989-1998 [77] 41.9 (37.6-46.7) 
Western Australia 1980-1989 [84] 57.2 (54.2-60.4) 
Paris, France 2005-2013 [73] 60.1 (57.5-62.9) 
Croatia 2002-2007 [62] 61.6 (58.3-65.1) 
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   0.8  
(0.7-1.0) 





































  2.1  
(1.8-2.4) 




      0.6 
(0.1-1.9) 
    0.2  
(0-0.8) 















          0.3  
(0.2-0.4) 








  0.6 
(0.2-1.4) 














       1.0 
(0.4-1.9) 
    0.2  
(0-0.8) 






  1.3  
(1.1-1.6) 




   0.8  
(0.7-0.9) 
  1.0 
(0.4-1.9) 


































































































































































































































































































































































































































   1.1  
(0.9-1.2) 


















       0.1 
(0-0.7) 
  1.4 
(1.0-2.0) 
        0.8  
(0.5-1.3) 
  0.2  
(0.1-0.4) 














































                     1.5 
(1-2.1) 



























































































  3.6 
(2.8-4.5) 











  3.6  
(3.2-4) 


























  0.9 
(0.6-1.3) 
In Columbia 1981-88 [82] the prevalence of VSD= 11.6 (10.8-12.5) and PVS= 4.3 (3.8-4.9) 
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3.3.2.2 Total birth prevalence 
Twelve articles reported the total birth prevalence of CHD, with the prevalence ranging 
between 30.1 to 213.4 per 10,000 total births (Table 3.5). Eight articles (10 studies) reported 
the prevalence for individual CHD subtypes (Table 3.6). 
Seven articles of 33 studies reported the total birth prevalence of CHD excluding cases with 
chromosomal/ genetic ECAs (Table 3.5). The prevalence ranged between 25.0 to 161.4 per 
10,000 live births. 
Six articles reported the total birth prevalence of isolated cases of CHD. Which ranged 
between 42.8 and 69.2 per 10,000 (Table 3.5). 
Table 3.5 Prevalence of CHD per 10,000 total births 
 Setting/ Study period Prevalence per 10,000 live 







Monchegorsk 1973-2005 [74] 30.1 (24.1-37.2) 
Iowa, USA, 1963 [78] 39.7 (34.7-45.1) 
La Reunion, France 2002-07 [1] 58.1 (53.2-63.4) 
Liverpool, UK, 1960-69 [64] 66.0 (62.1-70.0) 
Belgium, 2002 [66] 82.8 (77.6-88.3) 
N England, 1985-2003 [60] 85.8 (83.6-88.1) 
Paris, France, 2005-08 [73] 90.2 (87.0-93.3) 
Singapore, 1994-2000 [54] 90.4 (87.2-93.7) 
Beijing, China, 2007 [56] 81.6 (75.6-87.9) 
Canada 1979-93 [79] 135.1 (132.1-138.0) 
Hawaii, USA, 1986-99 [76] 177.0 (172.2-182.0) 




























La Reunion, France, 2002-07 [1] 50.8 (46.3-55.8) 
Basque Country, Spain, 1999-2008 [72] 161.6 (156.0-167.3) 
N England, 1985-2003 [60] 75.8 (73.8-78.0) 
N Netherlands 1990-2007 [52] 55.8 (53.4-58.3) 
Norway, 1990-2005 [52] 92.7 (89.8-95.7) 
East Midlands & South Yorkshire, UK 
[52] 
34.3 (32.9-35.8) 
Saxony Anhalt, 1990-2007 [52] 88.4 (84.6-92.2) 
Sicily, Italy, 1991-2004 [52] 56.0 (53.1-59.0) 
Zagreb, Croatia, 1990-2007 [52] 45.2 (41.4-49.4) 
Dublin, Ireland 1990-2007 [52] 44.7 (42.6-46.9) 
Paris, France, 1990-2006 [52] 63.8 (61.8-65.8) 
Emilia Romagna, Italy, 1990-2006 [52] 51.6 (49.6-53.7) 
Hainut, Belgium, 1990-2007 [52] 72.6 (69.1-76.2) 




 Setting/ Study period Prevalence per 10,000 live 




























Sweden, 1981-92 [53] 25 (24.1-25.8) 
Central Eastern France, 1983-92 [53] 28.9 (27.8-29.9) 
Thames Valley, UK, 1991-2007 [52] 29.0 (26.5-31.6) 
California, USA 1985-92 [53] 31.6 (30.8-32.3) 
Wessex, UK, 1994-2007 [52] 32.6 (30.8-34.5) 
SE Ireland, 1997-2007 [52] 44.3 (39.2-49.8) 
Antwerp, Belgium, 1990-2007 [52] 48.5 (45.8-51.2) 
La Reunion, France, 2002-06 [52] 53.5 (48.3-59.1) 
Barcelona, Spain, 1992-2006 [52] 55.4 (52.2-58.8) 
Miller, et al. 2011 [80] 63.6 (62.2-64.9) 
Ukraine, 2005-2007 [52] 68.0 (62.6-73.8) 
Cork & Kerry, Ireland, 1996-2004 [52] 72.1 (66.1-78.6) 
Paris, France, 2005-08 [73] 77.8 (74.7-80.9) 
Odense, Denmark, 1990-2007 [52] 79.7 (74.3-85.4) 
N England, 2000-07 [52] 86.9 (83.3-90.7) 
Mainz, Germany, 1990-2006 [52] 89.2 (81.8-97.1) 
Styria, Austria, 1990-2005 [52] 92.7 (88.4-97.1) 
Strasbourg, France, 1990-2004 [52] 96.7 (92.3-101.1) 
Wielkopolska, Poland, 1999-2006 [52] 99.6 (96.0-103.4) 
Wales, UK, 1998-2007 [52] 102.1 (98.7-105.7) 
Vaud, Switzerland, 1990-2007 [52] 116.3 (110.7-122.2) 










Metropolitan Atlanta, USA, 1968-2005 [80] 40.6 (39.5-41.7) 
Pleven region, Bulgaria, 1988-06 [65] 42.8 (37.1-49.1) 
Liverpool, UK, 1960-69 [64] 52.2 (48.8-55.9) 
Paris, France, 2005-08 [73] 64.1 (61.3-66.9) 
N England, 1985-2003 [60] 65.8 (63.9-67.8) 




Table 3.6 Prevalence of individual CHD subtypes per 10,000 total births 
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(5.3-7.8)   
15.7 




3.3.3 Trends in prevalence 
Six studies examined trends in CHD live birth prevalence [55, 57, 60, 62, 70, 82]. Wu et al 
reported a decrease in the live birth prevalence of CHD over time in Taiwan (2000-06). This 
decrease was apparent for cases of ToF, HLH, AVSD, AVA/S, VSD and ASD, but no other 
subtypes [55]. However, there was no maximum age of inclusion, suggesting that there was 
lower case ascertainment in the tail end of the study period. Additionally, decreases in live 
birth prevalence may be related to increases in TOPFA rates. Dilber et al and Wilson et al 
reported no evidence of trends in the live birth prevalence of CHD in Croatia (2002-07; 
205,051 live births) and Colombia (1981-88; 619,367 live births) [62, 82]. Dilber et al 
reported an increasing trend in the live birth prevalence of CoA, but suggested this was due to 
the “continuous improvement of early diagnosis” [62]. Three studies reported increasing 
trends in the live birth prevalence of CHD [57, 60, 70]. Dadvand et al reported an increase 
between 1985-2003 in the North of England (659,2344 live births); Calzolari et al reported an 
increasing trend between 1980-94 in Italy (330,017 live births) and Laursen et al reported an 
increase between 1963-1973 in Denmark (860,492 live births) [57, 60, 70]. Calzolari et al 
reported that the increasing trend was restricted to cases of VSD and ASD between 1980-94 
in Italy (330,017 live births). Dadvand et al similarly reported that the trends were restricted 
to cases of VSD, ASD, ToF and AVSD in England between 1985-2003 (665,377 total births). 
Therefore, it is likely that the trends were mostly related to improvements in ascertain of 
septal defects over the study period. 
Nine studies analysed trends in the total birth prevalence of CHD [52, 53, 60, 64, 72, 74, 76, 
79, 80]. Three studies reported no evidence of trends in prevalence rates in Russia (1973-88; 
28,511 total births), in Italy (1999-2008; 191,171 total births) and in the UK (1960-69; 
163,692 total births), although these were smaller, shorter studies with lower statistical power 
[64, 72, 74]. Miller et al reported an increasing trend in the total birth prevalence of CHD in 
the USA (1968-2005; 1,301,143 total births), Johnson et al reported an increasing trend in 
Canada (1979-93; 593,042 total births), Dadvand et al reported an increasing trend in the 
North of England (1985-2003; 665,377 total births) and Khoshnood et al reported an increase 
in Europe until 2000 (7,299,116 total births), and a decrease thereafter [52, 60, 79, 80]. 
Dadvand et al, Miller et al and Khoshnood et al did not examine trends in individual CHD 
subtypes [52, 60, 80], but Khoshnood et al did report that their increasing trend was observed 
amongst moderate (PVA, CAT, AVSD, AVA/S, TGV, ToF, TGV and TAPVR) and mild 
(VSD, PVS) severity CHD, but not amongst severe CHD (SV, HLH, HRH, EA and TA). 
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Johnson et al reported increasing trends in the prevalence of ToF, VSD, ASD, PDA, other 
(unspecified) CHD and HLH, a decreasing trend in AVSD, and no trends in the other CHD 
subtypes [79]. In Hawaii between 1986-99 (282,900 total births), Forrester et al reported an 
increasing trend in the total birth prevalence of TGV and EA, a decreasing trend in the 
prevalence of ToF and no evidence of trends in any other subtypes [76]. In France, California 
and Sweden, Pradat el al reported an increasing trend in the total birth prevalence of ASD, 
VSD, ToF and AVSD between 1983-92 (4,438,598 total births). 
Increasing trends may be real and perhaps related to the increase in older mothers that has 
been seen in Europe [88]. Or, as a result of the increasing obese population [89], which is a 
risk factor for certain CHD subtypes [4]. However, the trends could merely reflect improved 
ascertainment as data sources have become more established over the study periods. 
Increasing trends might also reflect improvement in CHD diagnosis due to the development 
of fetal echocardiography, more accurate ultrasonography and improved prenatal screening 
programmes [90, 91]. Technological improvements in pulse oximetry and colour Doppler 
echocardiography may also have increased postnatal diagnosis, although these are not 
routinely offered to low risk babies [92, 93]. 
Khoshnood et al suggest that their decreasing trend between 2004-2007 corresponds to 
increased uptake of folic acid, which has been shown to reduce the risk of a pregnancy 
associated with a CHD [94, 95]. However, the decreasing trend at the tail end of the study is 
more likely due to under-ascertainment given that cases born between 2004-2007 had a 
smaller window for diagnosis. 
3.3.4 Heterogeneity in prevalence between studies 
As shown in Table 3.7, there was significant heterogeneity in live and total birth prevalence 
between registers. This heterogenity between studies can be attributed to a number of factors, 
including: study period, study location, study design and case ascertainment.
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Table 3.7 Heterogeneity in prevalence between studies 
Case inclusion Live/total 
births 
Cochrane’s Q test and Chi2 test for 
heterogeneity 
Isolated CHD Live birth I2=99.4%, p<0.001 
Total birth I2=96.7%, p<0.001 
Isolated CHD and CHD 
with structural ECAs 
Live birth I2=99.0%, p<0.001 
Total birth I2=99.8%, p<0.001 
Isolated CHD with 
chromosomal/genetic 
ECAs 
Live birth I2=99.7%, p<0.001 
Total birth I2=99.7%, p<0.001 
 
3.3.4.1 CHD definition 
Prevalence rates for each study are dependent on the definition of CHD applied. The studies 
using the EUROCAT, the ISC and Mitchell’s definition had similar inclusion and exclusion 
criteria. All three criteria excluded anomalies of the circulatory system and minor functionless 
anomalies. The adapted version of Mitchell’s definition includes some minor CHDs (e.g. 
heart block) that EUROCAT, ISC and Mitchell’s full definition would exclude. Therefore, 
studies using this criterion may have a higher CHD prevalence. Dilber et al and Miller et al 
defined CHD as ICD 10: Q20-28, which includes anomalies of the peripheral vascular system 
and the circulatory system as well as cardiovascular anomalies. Circulatory system anomalies 
are rare and so the impact on prevalence would have been low [62]. 
3.3.4.2 Study period 
Variation in study period may have caused variation in prevalence between articles. While 
there was no obvious pattern in prevalence with increasingly recent study periods, articles 
could not be accurately ranked by study period as the years spanned varied between articles. 
Nevertheless, the more recent articles may have reported greater prevalence rates due to 
increases over time in the proportion of pregnant women who are obese, have diabetes and 
who enter pregnancy at advanced maternal age, which are suggested risk factors for certain 
CHD subtypes [4, 5, 80]. Alternatively, increases in prevalence over time might be related to 
case ascertainment given that improvements have been made in prenatal diagnosis over time 
(see section 1.3.3). 
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3.3.4.3 Study location 
It is possible that geographical location is a source of heterogeneity in prevalence. Figure 3.2 
shows that average prevalence varies substantially according to the country the study was 
performed in. Geographical differences in prevalence could be “real” and related to variation 
in exposures between countries (such as maternal smoking, maternal age or ethnicity, which 
may be risk factors for CHD [4, 96, 97] but may also be related to geographical variation in 
ascetainment perhaps due to differences in health care systems and policies. 
TOPFA rates reportedly vary by country, perhaps due to cultural beliefs, difference in TOPFA 
laws (such as different maximum gestational age at TOPFA) or disparities in prenatal 
diagnosis rates [98]. This may have contributed to the variation in live birth prevalence 
between studies. However, even in Brazil where TOPFA is illegal, the live birth prevalence 
was low compared to the average prevalence of the other countries (Figure 3.2). 
Even studies based on data from the same country showed substantial variation in prevalence. 
This suggests that although some heterogeneity may be attributed to study location, variation 
is most likely caused by differences between studies caused by other factors, such as case 
ascertainment, CHD definition and inclusion criteria.
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Figure 3.2: Prevalence of CHD per 10,000 live and total births, by country 
 
A= live births, all cases, B= live births, excluding cases with chromosomal/ genetic ECAs, C= live births, isolated cases, D= total births, all 
cases, E= total births, excluding cases with chromosomal/ genetic ECAs, F= total births, isolated cases. 
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3.3.4.4 Ascertainment of VSDs 
Isolated VSDs are rarely diagnosed prenatally (<1%) and up to 83% are undiagnosed before 
hospital discharge with 35% still undiagnosed within three months [99]. Indeed, smaller VSDs 
are often symptomless and can close spontaneously [100]. Given that VSDs are the most 
common CHD subtype, the prevalence of CHD in each study is likely to be highly influenced by 
the ascertainment of VSDs. 
The proportion of CHD cases that were VSD varied by study, ranging between 11-64%. Articles 
with a lower proportion of VSDs tended to have earlier study periods [63, 78, 85] and articles 
with a high proportion of VSDs (>45%) tended to have more recent study periods and the data 
source was more commonly a CAR [1, 60, 68, 73]. Studies with a higher maximum age at 
diagnosis also reported a greater proportion of VSD cases [60, 75]. Potentially, under-
ascertainment of other difficult to diagnose subtypes (e.g. ASD and PVS) may also be driving 
some of the heterogeneity. 
3.3.4.5 Maximum age at diagnosis 
Maximum age at diagnosis may influence ascertainment and therefore cause heterogeneity. The 
study with the lowest cut-off (five days) yielded the second lowest live birth prevalence [57]. A 
Chinese study that also used a short cut-off (28 days) reported prevalence only just below 
average, but compared to the other Asian studies, the prevalence was lower [56]. This suggestion 
of lower ascertainment complies with existing evidence that just 54% of babies diagnosed with 
CHD in their first year are diagnosed by six weeks, and 69% are diagnosed by 12 weeks [101]. 
Studies with higher cut-offs on the other hand, yielded prevalence not too dissimilar to those 
using a one year cut-off [58, 60, 61, 64, 66, 70, 84, 102, 103]. Approximately 82-97% of CHD 
cases are diagnosed by age one, so this is not surprising [104]. 
3.3.4.6 Study design 
Koshnood et al reported significant heterogeniety in prevalence between 29 EUROCAT registers 
[52]. While each EUROCAT register abides by the same inclusion and exclusion criteria, as well 
as the same coding system, heterogenity still may be caused by variation in ascertainment. For 
example, some registers have been longer established and are therefore more practiced at 
ascertaining cases. Other registers may have better links with cardiology departments, which 
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influences ascertainment. It is possible however, that there is real variation between the regions 
under surveillance, due to difference in study populations or exposures. 
3.3.5 Risk factors and characteristics 
3.3.5.1 Associated anomalies 
According to eight studies, 9-14% of all cases occurred with chromosomal anomalies, the 
majority of which were Trisomy 21 (41-89%) [1, 57, 60, 62, 73, 77, 84, 103]. Trisomy 18 and 13 
were the second and third most commonly reported chromosomal anomalies, accounting for 4-
15% and 4-6% of chromosomal cases, respectively [57, 60, 77, 84]. A further 2-17% of all cases 
occurred with (non-chromosomal) structural anomalies, according to five studies [57, 60, 62, 73, 
77, 84]. Calzolari et al reported that genital/urinary system (combined) and musculoskeletal 
anomalies were the most commonly associated with CHD, accounting for 23% and 25% of 
structural anomalies, respectively [57]. However, the types of associated anomalies were 
dependent on the CHD subtype, for example CNS anomalies were more common in cases of 
AVSD [57]. Between 71-85% of CHD cases occurred in isolation [57, 60, 62, 73, 77, 84]. 
Variation in the proportion of associated anomalies may be related to maternal age distributions, 
which impact the prevalence of congenital anomalies [105]. Additionally, studies that did not use 
congenital anomaly registers (CARs) as their data source may have under-ascertained co-
occurring congenital anomalies, if the main focus was to collect data on CHDs. The classification 
of multiple CHDs also varied between studies, with some studies excluding these cases, some 
counting each CHD as opposed to each case and some articles classing them as a specific isolated 
CHD (with the subtype being dependent on the chosen hierarchy). There was also variation 
between studies in the anomalies classed as minor congenital anomalies for exclusion. 
3.3.5.2 Maternal age 
The association between CHD and maternal age was examined in eight articles (nine studies). 
Pradat et al (USA), Miller et al and Hay, described an increased risk of CHD with ‘advanced’ 
maternal age (defined by all three articles as ≥35) [53, 78, 80]. Pradat et al (USA), Miller et al 
and Hay reported that women of advanced maternal age were at 10, 20 and 30% increased risk of 
a pregnancy associated with any CHD, respectively [53, 78, 80]. Hay’s higher relative risk (RR) 
likely resulted from the inclusion of cases with chromosomal ECAs, due to the known association 
between genetic disorders and advanced maternal age [78]. Furthermore, Hay reported the crude 
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risk whereas Pradat et al (USA) stratified by register, race, year of delivery and parity and Miller 
et al adjusted for sex, year of birth and ethnicity, which are likely to have reduced the effect size 
[53, 78, 80]. 
Miller et al reported that women of advanced maternal age were at significant increased risk of a 
child with (non-chromosomal) TGV, CoA, VSD and ASD [80]. Pradat et al reported an increased 
risk of a child with “less severe” CHD ( SD, ASD, corrected TG , CoA, A A/S and P S) but 
no significant association amongst non-chromosomal cases of severe CHD (HLH, SV, TA, CAT, 
IAA. PVA, TGV, DORV, AVSD, TAPVR, ToF, EA) [53]. Forrester and Merz reported that the 
association with advanced maternal age varied by CHD subtype, with increased risks of 25%, 
29%, 196%, 221% and 392% for non-chromosomal VSD, ASD, AVSD, HLH and IAA, but for 
no other CHD subtypes. Miller et al compared the risk of CHD in women of advanced maternal 
age to women aged 25-29. Pradat et al (USA), Hay and Forrester and Merz controversially used 
mothers aged <35 as their reference category, meaning the effect could be diluted or biased. 
Importantly, none of the risks were adjusted for maternal obesity, which is a risk factor for 
certain CHD subtypes and is therefore a potential confounder given the correlation between 
obesity and age [4]. Similarly, none of the studies adjusted for maternal diabetes, which may also 
have been a confounder since diabetes becomes more prevalent with increasing age [106]. 
Kenna et al, Cedergren and Kallen, Pradat et al (Sweden) and Posteov et al reported no 
association between CHD and advanced maternal age [53, 59, 64]. However, Cedergren and 
Kallen reported a similar distribution of maternal age in case mothers compared to all delivered 
women, but did not actually calculate RRs [59]. My own calculation of the (unadjusted) RR 
actually showed a significant 10% increase in the risk of non-chromosomal CHD in women aged 
≥35 compared to women aged 25-29. This estimate was slightly lower than Miller et al’s, which 
could perhaps be explained by a different distribution of CHD subtypes [80]. Kenna et al 
performed the maternal age analysis in a nested case-control study which perhaps led to a lower 
power to detect an association [64]. Posteov et al did not identify an association but merely 
compared mean maternal age in cases versus non cases using a t-test [74]. In using a t-test, 
Posteov et al made the assumption that maternal age was normally distributed, which is not likely 
to have been the case. 
Cedergren and Kallen, Pradet et al, Miller et al and Hay also investigated the association with 
‘young’ maternal age (defined as <20), but none reported significant associations [53, 59, 64, 80]. 
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3.3.5.3 Ethnicity 
Four studies examined the association between CHD prevalence and ethnicity. Miller et al 
reported an 11% significant increased risk of non-chromosomal CHD (amongst total births) in 
White compared to non-Whites in the USA. Also in the USA, Wilson et al described a 4% 
increased risk of isolated CHD (amongst live births) in non-Whites compared to Whites, but this 
did not reach statistical significance. Neither study examined CHD subtypes separately, which 
may have different associations with ethnicity. For example, previous research from the USA 
suggests Whites are at increased risk of EA, AVA/S, PVA and AVSD, compared to Blacks, but 
at decreased risk of PVS [107]. Compared to Whites, Forrester and Merz reported significant 
increased risks of ToF (amongst total births) in Pacific Islanders and Filipinos, ASD in Pacific 
Islanders and Filipinos, PVS in Far East Asians, TA in Pacific Islanders, EA in Pacific Islanders, 
CoA in Far East Asians and Pacific Islanders and TAPVR in Far East Asians, Pacific Islanders 
and Filipinos. Bower and Ramsay found a 30% significant increased risks of CHD in Aboriginals 
compared to non-Aboriginals in Australia [80, 84, 96]. All of the studies reported only the crude 
risk of CHD associated with ethnicity, without adjustment for potential confounders. Potentially, 
ethnicity may be confounded by socioeconomic status, smoking status, BMI and maternal age, 
amongst other factors, which are all potential risk factors for CHD [4, 80, 96, 108, 109]. 
3.3.5.4 Sex distribution 
Considering all subtypes of CHD, there was little evidence of a male or female predominance. 
The proportions of cases in males ranged from 46% to 54% in 18 articles [68, 78, 110, 111]. 
However, Tennant et al’s recent meta-analysis of five population-based studies identified a 
significant 70% increased risk of CHD in males compared to females [112]. Both Tennant et al 
and Pradat et al reported that the association with sex varied according to CHD subtype. Tennant 
et al reported significant increased risks of TGV, HLH, AVA/S, and CoA in males compared to 
females and a significant decreased risk of AVSs in males compared to females [112]. Pradat et 
al (USA) reported an increased risk of HLH, PVA, TAPVR, CoA and AVA/S and a decreased 
risk of AVSD in males compared to females [53]. Bourdial et al also found that the proportion of 
male cases also decreased with decreasing CHD severity [1]. 
3.3.5.5 Preterm deliveries  
Cederegren and Kallen, and Miller et al reported that 11 and 18% of CHD cases were delivered 
preterm (<37 weeks), respectively [59, 80]. Variation in rates could be related to the proportion 
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of induced as opposed to spontaneous preterm births, which may vary by country. With a more 
pronounced risk of preterm CHD in women of advanced maternal age, the maternal age 
distributions of the studies may also have impacted on the rates [80]. Cederegren and Kallen 
uniquely compared the proportion of preterm deliveries in case to the proportion in the general 
population, identifying a significant increased risk of preterm delivery (RR=2.58), after adjusting 
for maternal age, parity, smoking, year of delivery and BMI [59]. The risk was slightly lower in 
isolated cases (RR=2.15) and cases of mild CHD (RR=2.27), and greater in cases of severe CHD 
(RR=2.58). Cedergren and Kallen’s study was also the only one to investigate the risk of post-
term delivery (>42 weeks), finding no significant association with CHD. Both articles delivery 
limited bias by excluding cases from multiple pregnancies, which are more likely to be delivered 
preterm [113, 114]. 
3.3.5.6 Birth weight 
After adjusting for maternal age, parity, maternal smoking, year of birth and maternal BMI, 
Cedergren and Kallen reported a significant 96% significant increased risk of small for 
gestational age (SGA) in children with CHD compared to the general population [59]. Excluding 
cases with structural ECAs, the risk decreased, but remained significant (RR=1.61). The effect 
size was greater in severe compared to mild severity CHD (RR=2.46 vs RR=1.47) [59]. No other 
studies examined SGA but Bower and Ramsay and Kenna et al both report an increased risk of 
low birth weight (<2500g) in CHD cases [64, 84]. Although these results are somewhat biased by 
the lack of adjustment for gestational age (among other confounders), the effect sizes are broadly 
similar and Bower and Ramsay still describe a pattern similar to that of Cedergren and Kallen’s 
in terms of isolated cases having a lower risk [84]. While Cedergren and Kallen describe an 
increased risk of large for gestation age (LGA) in cases of CHD, Bower and Ramsay did not find 
an association with higher birth weight [59, 84]. Cedergren and Kallen  also showed that when 
considering severe and mild severity CHD, the effect was confined to those with mild CHD 
(VSD, ASD, CoA, P S, corrected TG , PDA, “other” CHD) [59]. 
3.3.5.7 Diagnosis 
Evidence from four studies showed that prenatal detection of CHD is challenging, with Calzolari 
et al reporting a detection rate of 5.5%, Yang et al a rate of 22%, Khoshnood et al a rate of 23% 
and Bourdial et al 33% [1, 56, 57, 73]. However, the studies by Calzolari et al and Yang et al 
included cases diagnosed in the first 28 and five days of life respectively, meaning they may be 
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unrealistically high, if postnatally diagnosed cases are under-ascertained [56, 57]. The higher 
prenatal detection rates described by Yang et al, Bourdial et al and Khoshnood et al may also be 
attributed to their more recent study periods, with the study populations likely to have had access 
to more developed fetal diagnostic tools, including fetal echocardiography. Additionally, prenatal 
diagnosis will be strongly influenced by the frequency of different CHD subtypes. The study by 
Calzolari et al, for example, had a slightly higher prevalence of VSDs than the study by Yang et 




In this review of international population-based studies of CHD, the prevalence of CHD ranged 
between 30-213 cases per 10,000 total births and 22-131 cases per 10,000 live births. There was 
substantial heterogeneity in prevalence between studies, which may have arisen due to variation 
in: case definition, case ascertainment, study period, study location and study design. 
There were conflicting reports regarding trends in prevalence over time. The larger studies with 
longer study periods tended to report increasing trends in the prevalence of CHD over time [53, 
57, 60, 79, 80]. However, these trends were often driven by increases in the prevalence of septal 
defects, which have become easier to diagnose and therefore ascertain over time. Several studies 
reported increasing trends in the prevalence of ToF [53, 60, 79], although one smaller study 
reported a decreasing trend [76]. There was conflicting evidence on the direction of the trends in 
AVSD [53, 55, 60, 79, 115] and HLH [55, 79]. 
Several potential risk factors for CHD were identified including: advanced maternal age [53, 59, 
76, 78, 80], White ethnicity [80, 82] and maternal obesity [59]. Compared to the general 
population, children with CHD were more likely to: have chromosomal anomalies (particularly 
trisomy 21) [1, 57, 60, 62, 73, 77, 84, 103], be delivered preterm [59, 80] and to be SGA (with a 
stronger effect size in cases with severe CHD or structural ECAs) [59]. There was also some 
evidence that post-term delivery was more common in children with CHD compared to the 
general population [59]. Prenatal detection was shown to be challenging, although appeared to 
improve over time [1, 56, 57, 73]. 
3.4.2 Strengths 
This review has a number of strengths. Firstly, in order to increase the sensitivity of the search 
strategy, and thus the number of citations retrieved, three large literature databases were 
interrogated using a systematic search using keywords and MESH headings. Key journals and 
reference lists were also searched in order to be as inclusive as possible. 
Articles that reported total or live birth prevalence rates were included so that no relevant studies 
were excluded. Studies that reported the prevalence of isolated CHD or the prevalence of CHD in 
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the presence of ECAs were analysed separately in order to eliminate this as a source of 
heterogeneity. 
Bias caused by referral was limited by the inclusion of population-based studies only. Hospital-
based studies for example, may under-ascertain mild cases that do not require medical or surgical 
intervention. 
Many sources of heterogeneity were examined in order to better distinguish between real 
differences in prevalence and artificial variation caused by differences in ascertainment. 
However, with the sample sizes of all studies being large, and therefore the standard errors being 
relatively small, heterogeneity between studies was inevitable. 
Lastly, prevalence estimates were extracted for individual CHD subtypes. In previous systematic 
reviews of CHD prevalence, only the prevalence of the most common subtypes have been 
reported [18, 19]. This is problematic from a public health perspective as the rarer subtypes, such 
as those with HLH or SV, are those that require more complex medical interventions which need 
to be planned for [116, 117]. 
3.4.3 Limitations 
This review has a number of limitations. While the aim was to be geographically inclusive, few 
studies reported the prevalence of CHD in less developed countries. European and North 
American studies dominated the literature and only a few studies from Asia, South America and 
Oceania were identified. The restriction to articles published in the English language did not 
contributed to this disparity as I did not identify any articles that were not written in the English 
language. 
The majority of the included articles were comprised of cases diagnosed within the first year of 
life. CHD subtypes, such as VSD, ASD and PVS, are not always diagnosed infancy [104]. 
Therefore, the prevalence of CHD may actually be greater than reported. Arguably cases that are 
not diagnosed during infancy are less functionally significant and from a clinical perspective, 
should not be included in prevalence estimates. 
While I extracted the prevalence of individual CHD subtypes from each study, I restricted my 
search strategy to studies that reported the prevalence of all CHD subtypes combined. Expanding 
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the search strategy to include studies of single subtypes would have been more informative, but 
too time consuming. 
Because the primary aim of the review was to establish the international prevalence of CHD, only 
population-based studies that reported prevalence were included. Therefore, the review of 
specific risk factors is not inclusive of all relevant published papers regarding risk factors. For 
example, studies of case-control design were excluded. 
3.4.4 Comparison to previous reviews 
The range of live birth prevalence rates in my review (22-137 per 10,000 live births) 
encompasses the pooled prevalence estimate reported in  an der  inde et al’s (2011) recent 
systematic review (68 per 10,000 live births [19]). In Bernier et al’s (2010) systematic review, a 
pooled live birth prevalence is not reported, but most of their studies report a prevalence between 
50-70 per 10,000 live births [18]. Neither Van der Linde et al or Bernier et al appear to separate 
the prevalence of isolated or non-chromosomal CHD, which is important as these cases tend to 
have different aetiologies and epidemiology. Both reviews include all study designs, including 
hospital-based studies, which may conversely raise the prevalence. 
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 Chapter 4. Data sources and case classification 
In this chapter, the data sources and CHD classification used in chapters 5, 6, 8 and 9 will be 
described. The study design and statistical analyses are described in the respective chapters. 
4.1 Data sources 
Data from at least one British Isles Network of Congenital Anomaly Register (BINOCAR) 
was used in each analysis chapter. In several of the chapters this data was linked to another 
data source, including: ONS yearly births, the Northern Survey of Twins and Multiple 
Pregnancy (NorSTAMP), the Northern Perinatal Mortality Survey (PMS) and ONS death 
registrations. Each of these data sources is described in detail below. 
4.1.1 British Isles Network of Congenital Anomaly Registers 
The BINOCAR is a collaborative network of regional population-based CARs. Each register 
prospectively collects data on congenital anomalies occurring in the pregnancies of women 
residing in their specific region, which is geographically well-defined. Data are recorded on 
cases occurring in late miscarriages (20-23 weeks gestation), TOPFAs (any gestation), 
stillbirths (≥24 weeks gestation) or live births. 
The BINOCAR consists of six full member registers in England and Wales, covering 36% of 
the birth population in 2014 (Figure 4.1). The Northern Congenital Abnormality Survey 
(NorCAS), established in 1985, covers the North East of England and North Cumbria; the 
Wessex Antenatally Detected Anomalies Register (WANDA), established in 1994, covers 
Wessex (England); the East Midlands and South Yorkshire CAR (EMSYCAR), established in 
1997, covers the East Midlands and South Yorkshire; the CAR for Oxford, Berkshire and 
Buckinghamshire (CAROBB), established in 1991, covered Oxford between 1991-2004 and 
Oxford, Berkshire and Buckinghamshire from 2005 onwards; the South West CAR 
(SWCAR), established in 2002, covers South West England; and the CAR and Information 
Service (CARIS), established in 1998, covers the whole of Wales. 
Each BINOCAR allows between six and eight congenital anomalies to be recorded for each 
case and both prenatal and postnatal diagnoses are recorded (where applicable). Each anomaly 
is coded using the WHO ICD, consistent with EUROCAT guidelines [118]. The registers 
originally coded cases using ICD version nine, but began using version ten in the late 1990s. 
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The change-over was gradual and each register adopted the new coding system at different 
time points. All cases are now coded according to ICD version 10, with the congenital 
anomalies originally coded using ICD nine having been translated to ICD 10. To ensure high 
case ascertainment, congenital anomalies are notified to each register from a variety of 
sources including prenatal ultrasound departments, fetal medicine records, cytogenetic 
laboratories, regional cardiology centres, pathology departments and paediatric surgery 
departments. CHD diagnoses are confirmed by surgery, echocardiography, CT or MRI scans, 
cardiac catheterisation, or post mortem. For each case, data is recorded on: year of delivery, 
maternal age at delivery, pregnancy outcome, prenatal diagnosis, sex, birth weight and 
gestational age at delivery. 
Members of the BINOCAR have approval from the National Information Governance Board, 
subsequently the Confidentiality Advisory Group of the Health Research Authority (PIAG 2-
08(e)/2002), to hold data without consent and ethics committee approval (09/H0405/48) to 
undertake studies involving their data. 
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Figure 4.1 Map showing the regions covered by the six BINOCARs 
 
a CAROBB covered Oxford only (dark blue area) only between 1991- 2005 
Map taken from www.BINOCAR.org and subsequently modified
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Table 4.1 shows population statistics relating to the populations covered by each register, 
using data from the ONS, the Census, the General Household Survey (GHS), the General 
lifestyle survey (GLS) and the English Indices of Deprivation. Smoking data was taken from 
the GHS, which is completed by a random sample of households in the UK (7,960 in 2010, 
with a 72% response rate). Given that sampling bias may occur, care should be taken when 
interpreting these statistics. Calculated from post-codes, the indices of multiple deprivation 
(IMD) are a comparative measure of area-level socioeconomic deprivation. They are 
calculated based on seven domains including: income, employment, health, education, access 
to services, social environment, housing stress, living environment and crime [119, 120]. The 
IMD data does not correspond completely to the areas covered by the registers and thus 
should be used as a rough estimation of deprivation. 
EMSYCAR and SWCAR cover the largest populations (74,000 and 60,000 births per year, on 
average). The other four registers cover populations of between 31-35,000 births per year, on 
average. 
Maternal age distribution also varies by region. According to ONS data, the highest 
proportions of teenage pregnancies are observed in the areas covered by NorCAS, CARIS and 
EMSYCAR (10.0, 9.4 and 8.4% respectively between 1991-2010). The population covered by 
CAROBB has the highest proportion of births to mothers aged ≥40 and the largest proportion 
of births to mothers aged ≥30 (56%) compared to the other registers, followed by SWCAR 
and WANDA (50.2% and 47.6%, respectively). 
While the majority of each population is of White ethnicity, there is some variation by region. 
In 2011, the regions covered by CAROBB and EMSYCAR have the largest non-White 
populations (14.9% and 10.4%, respectively) and the highest Asian populations (9.2% and 
6.1%). 
According to the GLS, the proportion of the population who were current smokers between 
1998-2010 varied by region, with the area covered by the NorCAS having the highest 
proportion of all smokers and female smokers (25.8% and 26.5% respectively). The 
populations covered by CARIS and NorCAS had the lowest proportion of women claiming to 
have drunk alcohol in the previous week (64% and 68%, respectively). The area covered by 
SWCAR had the highest proportion of women who had drunk alcohol on at least five days in 
the previous week (21%). 
67 
 
Deprivation varied by region, with the area covered by the NorCAS and EMSYCAR having 
the largest proportions in the top 10% most deprived (9% and 6% respectively). 
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Table 4.1 Population statistics in the populations covered by the six BINOCARs 
Statistics Area covered by: 
CARIS CAROBB EMSYCAR NorCAS  SWCAR WANDA 
Annual births* (n) 35,000 31,000 74,000 33,000 60,000 31,000 
Maternal age distribution* 
(%) 
      
<20 9.4% 4.3% 8.4% 10.0% 6.3% 6.2% 
20-24 22.1% 14.1% 21.0% 23.6% 17.7% 17.7% 
25-29 27.6% 25.6% 27.9% 29.9% 25.8% 28.6% 
30-34 25.7% 32.8% 26.8% 24.4% 29.3% 29.8% 
35-39 12.6% 19.1% 13.3% 10.3% 17.2% 14.8% 
≥40 2.5% 4.1% 2.6% 1.8% 3.7% 3.0% 
Ethnicity† (%)       
White 95.6% 85.1% 89.6% 95.7% 95.4% 96.6% 
Mixed 1.0% 2.4% 1.8% 0.8% 1.4% 1.1% 
Asian 2.3% 9.2% 6.1% 2.6% 2.0% 1.8% 
Black 0.6% 2.6% 1.8% 0.5% 0.9% 0.4% 
Arab 0.3% 0.2% 0.3% 0.2% 0.1% 0.1% 
Other 0.2% 0.5% 0.4% 0.2% 0.2% 0.1% 
Smoking‡ (%)       
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Statistics Area covered by: 
CARIS CAROBB EMSYCAR NorCAS  SWCAR WANDA 
Current smokers (18+) 24.1% 22.0%† 23.1% 25.8% 22.8% 22.0%† 
Current smokers (women 
18+) 
23.7% 20.4%† 22.3% 26.5% 21.8% 20.4%† 
Drinking† (%)       
Drank last week (women 
16+) 
64% 72%† 70%* 68% 74% 72%† 
Drank on 5+ days last week 
(women 16+) 
17% 20%† 16%* 16% 21% 20%† 
Index of Multiple 
Deprivationф (%) 
      
1% most deprived N/A 2% 5% 12% 2% 2% 
5% most deprived N/A 2% 5% 10% 3% 2% 
10% most deprived N/A 3% 6% 9% 4% 3% 
20% most deprived N/A 4% 7% 8% 4% 4% 
*Average annual yearly births and maternal age distribution data came from the Office for National Statistics and represents the local areas covered by the registers for the respective 
years included in the study 
†Information on ethnicity, religion and drinking came from the 2011 Census and represents the local areas covered by the registers for the year 2011. 
‡Information on smoking came from the General Lifestyle Survey, Office for National Statistics and represents the following Government Office Regions, which do not exactly 
correspond to the areas covered by the registers: CARIS: Wales; CAROBB: South East; EMSYCAR: East Midlands; NorCAS: North East; SWCAR: South West; WANDA: South 
East. The General Lifestyle Survey represents 1998-2010 although the survey was not carried out in 1997/98 or 1999/2000. 
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фInformation on the Index of Multiple Deprivation came from the English Indices of Deprivation and represents the following Lower Super Output Areas, which do not exactly 
correspond to the areas covered by the registers: CAROBB: South East; EMSYCAR: East Midlands; NorCAS: North East; SWCAR: South West; WANDA: South East. The IMD 
was calculated based on data in 2010 only. The IMD is calculated for England only. 
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4.1.2 ONS annual births 
Denominator data consisting of the number of yearly live and stillbirths in each region was 
obtained from the ONS. Similarly, yearly denominator data (total births only) grouped by 
maternal age categories was obtained from the ONS. 
4.1.3 The Northern Survey of Twin and Multiple Pregnancies 
The Northern Survey of Twin and Multiple Pregnancies (NorSTAMP), established in 1998, 
collects data on all multiple pregnancies of mothers who reside in the North of England 
(Figure 4.1) [121]. Multiple pregnancies are ascertained from the prenatal dating scan, the 20 
week anomaly scan and at delivery. After gaining parental consent, data on multiple 
pregnancies are notified to NorSTAMP by midwives and ultra-sonographers. Data recorded 
includes: year of birth, number of fetuses, maternal age at delivery, and chorionicity 
(monochorionic (MC) and dichorionic (DC)). The final diagnosis of chorionicity for twins of 
the same sex is based on placental examination and histology. If there is no pathologic 
examination of the placenta, the diagnosis is made based on the prenatal ultrasound 
determination. Information on zygosity is not recorded. 
The NorSTAMP is held at the PHE Regional Maternity Survey Office in the North of 
England, along with the NorCAS and the PMS. NorSTAMP, PMS and NorCAS records are 
linked using unique maternal ID numbers. 
4.1.4 The Northern Perinatal Morbidity and Mortality Survey 
The PMS, established in 1981, collects data on all deaths before age one, in infants born to 
mothers who reside in the North of England (Figure 4.1). Deaths are derived from statutory 
death registrations. 
4.1.5 ONS death registrations 
The register of deaths is statutory and death records are derived from this via the ONS. The 
register holds death records for all individuals who die whilst resident in England. The record 
holds information on the person’s name (forename and surname), last known address, date of 
birth and sex. These data can be used to link death registrations to other data sources, with 
appropriate ethical approval. 
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4.2 Case inclusion 
In all chapters, cases with at least one postnatally confirmed CHD (ICD 10: Q20-26) notified 
to one of the BINOCAR were included; minor anomalies, such as heart murmurs, patent 
ductus arteriosus (PDA) occurring with a gestational age<37 weeks were excluded according 
to the EUROCAT guidelines [118, 122]. Cases with an isolated PDA born at an unknown 
gestational age were excluded. 
4.3 Case classification 
4.3.1 Subtypes 
Cases were categorised into one of the 17 EUROCAT CHD subtypes: SV, HLH, EA, HRH, 
CAT, AVSD, AVA/S, TGV, ToF, TAPVR, CoA, DORV, IAA, VSD, ASD, PVS, MVA 
(Figure 4.2). 
CHD subtypes with ICD 10 codes included in Q20-Q26 but that were not one of the 17 
EUROCAT subtypes were included in this study but classified as “Other” CHD. These 
included: atrial isomerism, corrected TGV, aortopulmonary window, tricuspid regurgitation, 
aortic regurgitation, dextrocardia, heart block, aortic stenosis, hypoplastic aorta, sinus venosus 
ASD. 
Cases with multiple CHD subtypes were coded as a single CHD subtype according to the 
subtype of the greatest aetiological severity. As described in Chapter 1 (section 1.1.1), there is 
no universally accepted CHD hierarchy, but several have been created. Cases were coded 
using an adapted version of Khoshnood et al’s (2012) aetiological hierarchy, used in a similar 
study of trends in CHD prevalence [52]. However, the groups are altered to include DORV 
and IAA and MVA, which are placed in the moderate category in line with the more recent 
EUROCAT guidelines [122]. The hierarchy is depicted in Figure 4.2. A case with CoA and 
VSD would here be categorised as CoA, for example. 
4.3.2 Severity categories 
Subtypes were also grouped as mild, moderate and severe severity, according to the functional 
implications of the CHD. These categories were created based on those used by Khoshnood et 
al (2012) [52]. Figure 4.2 shows the subtypes according to the three severity categories. Cases 
categorised as “Other” CHD were not assigned to a severity category.
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Figure 4.2 Categorisation of CHD subtypes into severity categories 
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4.3.3 Extra-cardiac anomalies 
Cases were further coded according to the presence of ECAs. Cases were coded as: a) isolated 
cases i.e. cases with no ECAs; b) cases occurring with structural ECAs (including those occurring 
with sequences, associations and non-genetic syndromes but excluding those with chromosomal/ 
genetic ECAs; and c) cases occurring with chromosomal/ genetic ECAs. Cases with multiple 
CHD subtypes but no ECAs were classed as isolated.
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 Chapter 5. Epidemiology of congenital heart disease in singletons in the 
UK 
5.1 Introduction 
In Chapter 3, a review of the existing literature showed that the global prevalence of CHD 
ranged between 30-213 per 10,000 total births. Several studies investigated trends in 
prevalence, but the direction of these were conflicting and varied by CHD subtype, which 
were rarely examined separately. The review showed that there is a paucity of information 
regarding the prevalence and trends in prevalence of CHD in the UK. Given that the UK’s 
paediatric cardiology services are currently undergoing reforms (Chapter 1), obtaining 
accurate information on CHD prevalence will aid health service planning. 
Information on prenatal diagnosis, and TOPFA have been previously described for CHD, but 
trends over time in these pregnancy outcomes have not been reported [1, 21, 56, 57]. This 
information influences prevalence and is therefore important for the interpretation of temporal 
trends. 
The association between CHD prevalence and maternal age has been researched to some 
extent, but generally not by CHD subtype (Chapter 3). Recent studies have shown an 
increased risk of TGV, CoA, VSD and ASD in pregnancies of mothers aged ≥35, despite 
excluding cases with chromosomal ECAs [76, 80]. It is possible that the changing maternal 
age distribution over time, due to women postponing childbearing in the UK, may contribute 
to the increasing trend in prevalence of some CHD subtypes [123]. Therefore, it is important 
to examine maternal age as a confounder for trends over time. 
5.1.1 Aim 
The aim of this chapter is to describe the epidemiology of CHD in the UK between 1991-
2010. 
5.1.1.1 Objectives 
To describe for all CHD subtypes combined and by subtype: 
 The frequency of ECAs 
 Sex distribution 
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 Average gestational age at delivery 
 Average (standardised) birth weight at delivery 
 Prenatal diagnosis rates and trends in prenatal diagnosis rates over time 
 Pregnancy outcomes and trends in TOPFA over time 
 The total birth prevalence of CHD and trends in the total birth prevalence over time 
 The live birth prevalence of CHD and trends in the live birth prevalence over time 
 The association between total birth prevalence of CHD and maternal age at delivery
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5.2 Methods 
5.2.1 Case inclusion 
All cases with a final diagnosis of CHD notified to six BINOCARs (CARIS and EMSYCAR 
between 1st January 1998-31st December 2010, NorCAS and CAROBB between 1st January 
1991-31st December 2010, SWCAR between 1st January 2003-31st December 2010 or 
WANDA between 1st January 1994-31st December 2010) were included in this study. Cases 
occurring in live births, stillbirths, late miscarriages and TOPFAs were included. Cases 
occurring in multiple pregnancies were excluded in this chapter and were considered 
separately in Chapter 6, due to the different aetiologies of these cases. Cases with missing 
data on plurality (n=571, 2.7%) were assumed to be singletons and included in the analysis of 
this chapter. 
5.2.2 Case classification 
According to the EUROCAT guidelines, HRH is a secondary CHD which occurs as a result 
of a primary CHD, namely TA or PVA. While ICD 10 has a specific code for HRH, ICD nine 
did not. This change in coding system may artificially produce an increasing trend in HRH 
over time. Ideally all cases with HRH would therefore be coded as the primary anomaly (TA 
and PVA) in this chapter. However, in some cases of HRH (n=65), the primary CHD was not 
recorded. Therefore, all cases of PVA, TA and HRH are coded simply as HRH. 
5.2.3 Data 
Table 5.1 shows the variables included in the analysis. Year of delivery, was considered as a 
continuous variable; gestational age at delivery, preterm delivery, gestational age at TOPFA, 
pregnancy outcome, TOPFA, fetal death, sex, maternal age at delivery, prenatal diagnosis and 
standardised birth weight were all considered as categorical variables. Birth weight at 40 
weeks, standardised for gestational age at delivery, sex and plurality, was estimated using 
Gardosi et al’s fetal growth formula with Tin et al’s regional birth weight reference [124, 
125]. Gardosi et al calculated the fetal growth curves of 38,000 babies born in Nottingham 
using the adjusted weight centiles [125]. 
Information on the exact timing of prenatal diagnosis was not available, so prenatal diagnosis 
was simply categorised as “diagnosed” or “not diagnosed”. In this chapter, prenatal diagnosis 
refers to the diagnosis of any congenital anomaly prenatally. Therefore, cases with, for 
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example, prenatally diagnosed trisomy 21 but an undiagnosed CHD would be coded as 
‘diagnosed’. Thus, analysis on prenatal diagnosis was restricted to cases of isolated CHD. 
Data on the number of live and stillbirths in the population were available from ONS, by year 
and maternal age category.  
Table 5.1 Description of variables used in analysis and frequency of missing data 
Variable Classification 
Year of delivery (years) Continuous variable 
Gestational age at delivery 
(weeks) 
Extreme preterm (20-27 weeks) 
Very preterm (28-31 weeks) 
Moderately preterm (32-36 weeks) 
Term (37-41 weeks) 
Post-term (≥41 weeks) 
Missing (n= 3,267, 15.9%) 
Preterm delivery Preterm (<37 weeks gestational age) 
Term (≥37 weeks gestational age) 
Missing (n= 3,267, 15.9%) 
Gestational age at TOPFA 
(weeks) 





Missing (n= 788, 33.8%) 
Pregnancy outcome Live birth 
Late miscarriage (20-23 weeks gestational age at delivery) 
Stillbirth (≥24 weeks gestational age at delivery) 
TOPFA (any gestational age at delivery) 
Fetal death Fetal death (late miscarriage or stillbirth) 
No fetal death 
Sex Male 
Female 
Missing (n=289, 1.4%) 
Maternal age at delivery (years) <20 
20-24 






Missing (n= 1,382, 6.7%) 







CHD with structural ECAs 
CHD with chromosomal/ genetic ECAs 
CHD with teratogenic syndromes 
Prenatal diagnosis Prenatally diagnosed (any anomaly) 
Not prenatally diagnosed (any anomaly) 
Missing (n=2,893, 14.0%) 
Standardised birth weight (SD 
from the mean) 
Low: SD< -1 
Average: -1 ≤ SD ≥1 
High: SD> 1 
Missing (n= 3,014, 14.6%) 
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5.2.4 Statistical analysis 
Most statistical analyses were performed separately for: a) all cases of CHD; b) isolated cases; 
c) cases occurring with structural ECAs; and d) cases occurring with chromosomal/genetic 
ECAs. The analysis was not carried out separately for cases of CHD with teratogenic 
syndromes because these cases occurred in low frequency and the teratogenic syndromes are 
likely to be under-ascertained by the registers. Most analyses were also carried out for all 
CHD subtypes combined and for each individual CHD subtype. Descriptive statistics were 
calculated for the variables listed in Table 5.1. 
5.2.4.1 Birth prevalence 
Total and live birth prevalence was defined as outlined in Chapter 3 (section 3.2.1). 
5.2.4.2 Modelling birth prevalence 
The total birth prevalence of CHD over time were modelled using multilevel Poisson 
regression models. The number of CHD cases were nested within register, an offset equal to 
log (yearly total births) and year of birth as a (continuous) explanatory variable. The models 
were also adjusted for ECAs. Each model estimated RRs representing the risk of CHD per 
year increase in year of birth. The significance of an interaction between ECAs and year of 
delivery was tested by incorporating a cross-product term in the models and performing a 
Wald test. Where the interaction was significant, this implied that trends over time varied 
according to whether CHD occurred in isolation, with structural ECAs or with chromosomal/ 
genetic ECAs. Therefore, trends were modelled separately for each of the three ECA groups. 
The prevalence models were refitted to include maternal age at delivery (categorised as shown 
in Table 5.1). Here the offset was equal to log (yearly number of total births, stratified by 
maternal age categories). All cases notified to WANDA and EMSYCAR, and cases notified 
to SWCAR in 2010, were excluded from this analysis due to incomplete maternal age data for 
>10% of cases (Table 5.2). Of the cases notified to the remaining registers, 0.2% of cases 
were excluded due to missing maternal age data. The adjusted and unadjusted RRs 
corresponding to year of delivery were then compared to examine whether changes in 
maternal age distribution confounded trends in CHD prevalence. These models were also used 
to estimate the association between CHD prevalence and maternal age at delivery, where the 
significance of the overall association was estimated using a Wald test. 
Trends in the live birth prevalence of CHD were similarly modelled with live born cases as 
the outcome and an offset equal to log (yearly live births). The association between live birth 
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prevalence and maternal age could not be examined as the maternal age denominator data 
were available for total births only. 
The multilevel models were fitted with random intercepts, to better account for variation 
between registers. The significance of the random intercept was tested using a likelihood ratio 
(LR) test, comparing the fixed effects model to the random intercept model. If the intercept 
improved the fit of the model, this indicated that there was significant heterogeneity in 
prevalence between registers. Where the intercept improved model fit, LR tests were used to 
compare random intercept models to random slope models. If the slope was significant, this 
implied that there was variation in time trends between registers. Additional variance terms 
were added to models to account for over-dispersion, where necessary. 
Table 5.2 Proportion of cases with missing maternal age data 
Register Missing data, N (%) 
CARIS 1 (0.0) 
CAROBB 46 (4.0) 
EMSYCAR 632 (16.6) 
NorCAS 148 (2.3) 
SWCAR 68 (3.2) 
WANDA 485 (25.1) 
 
5.2.4.3 Modelling prenatal diagnosis 
This analysis was restricted to isolated cases of CHD. As shown in Table 5.3, prenatal 
diagnosis data was missing disproportionately by register. The registers with >10% of 
prenatal diagnosis data missing (i.e. CAROBB, EMSYCAR and SWCAR) were excluded 
from all analysis of this variable. Of the remaining three registers, 0.8% of cases had missing 
prenatal diagnosis data and so these cases were excluded from analysis of prenatal diagnosis. 
Prenatal diagnosis is not possible (or highly unlikely) for cases of ASD, VSD, PVS and PDA 
[126] and these cases were therefore excluded from this analysis. RRs representing the “risk” 
of prenatal diagnosis per year increase in year of birth were estimated using multilevel 
Poisson regression models (as described in section 5.2.4.2). The number of diagnosed cases 
was used as the outcome and log (number of cases) as the offset. Models were also refitted, 
adjusting for maternal age at delivery. 
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Table 5.3 Proportion of cases with missing prenatal diagnosis data by register 
Register Missing data, N (%) 
CARIS 36 (0.7) 
CAROBB 278 (27.4) 
EMSYCAR 1,835 (55.9) 
NorCAS 79 (1.0) 
SWCAR 665 (29.6) 
WANDA 0 (0.0) 
 
5.2.4.4 Modelling TOPFA rates over time 
RRs representing the risk of TOPFA per years increase in year of delivery were estimated 
using multilevel Poisson models, with TOPFA cases nested within registers and modelled 
with an offset equal to log (number of cases), year of birth as a continuous predictor and 
ECAs as an explanatory variable. These models were refitted to cases that were prenatally 
diagnosed only in order to investigate whether trends in TOPFA were caused by improvement 
in prenatal diagnosis rates. These adjusted models were carried out on isolated cases only, 
with the same exclusions described in section 5.2.4.3. 
All statistical analyses were performed in Stata 13 (Stata Corp, Texas). As all analyses was 
conducted for each of the 20 subtypes, a Bonferroni adjustment to the nominal significance 
level was carried out. Therefore p<0.003 (i.e. 0.05/20) was considered statistically significant 
for all analyses. As this is arguably over-conservative, associations significant at the p<0.05 
level are also discussed and described as having “some evidence of an association”.
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5.3 Results 
There were 19,754 singleton cases notified to the six BINOCARs, among 3,040,952 total 
births. 
5.3.1 CHD severity categories 
The frequency and percentage of each CHD severity category is presented in Table 5.4. 
Severe CHD was rarest, followed by moderate CHD and mild CHD. There was a greater 
proportion of mild cases among live births. 
Table 5.4 Frequency and percentages of CHD severity categories 
Severity category* Total births 
N (% of 19,754) 
Live births 
N (% of 16,923) 
Severe 1,601 (8.1) 919 (5.4) 
Moderate 5,431 (27.5) 4,543 (26.9) 
Mild 9,911 (50.2) 9,251 (54.7) 
Unclassified 2,811 (14.2) 2,210 (13.1) 
All subtypes 19,754 (100) 16,923 (100) 
 
 
5.3.2 CHD subtypes 
The frequency and percentage of each CHD subtype is shown in Table 5.5. Septal defects 
occurred most frequently, and the subtypes with single ventricle physiology (SV, HLH, HRH) 
occurred less frequently. 
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Table 5.5 Frequency and percentage of CHD subtypes 
CHD subtype Total births 
N (% of 19,754) 
Live births 
N (% of 16,923) 
SV 147 (0.7) 93 (0.6) 
HLH 882 (4.5) 422 (2.5) 
EA 155 (0.8) 118 (0.7) 
HRH 573 (2.9) 405 (2.4) 
CAT 220 (1.1) 142 (0.8) 
AVSD 1,227 (6.2) 861 (5.1) 
AVA/S 495 (2.5) 461 (2.7) 
TGV 904 (4.6) 833 (4.9) 
ToF 1,027 (5.2) 871 (5.2) 
TAPVR 191 (1) 189 (1.1) 
IAA 108 (0.6) 87 (0.5) 
CoA 1,015 (5.1) 936 (5.5) 
DORV 244 (1.2) 163 (1.0) 
MVA 182 (0.9) 173 (1.0) 
VSD 6,741 (34.1) 6,251 (36.9) 
ASD 2,225 (11.3) 2,066 (12.2) 
PVS 944 (4.8) 933 (5.5) 
PDA 533 (2.7) 531 (3.1) 
Other 1,941 (9.8) 1,388 (8.2) 
All subtypes 19,754 (100) 16,923 (99.9) 
 
 
5.3.3 ECAs occurring with total birth cases of CHD 
Of 19,754 cases, 53 (0.3%) occurred with a teratogenic syndrome, 3,795 (19.2%) with 
chromosomal/ genetic ECAs, 2,390 (12.1%) with structural ECAs and 13,516 (68.4%) were 
isolated CHD. Of the isolated CHD, 3,751 (27.8%) had multiple CHD subtypes and 9,765 
(72.2%) occurred with a single subtype. The distribution of ECAs varied by CHD subtype 
(Table 5.6). For example, 28.4% of AVSD cases were isolated, whereas 88.9% of TGV cases 
were isolated. 
Of the 53 cases of CHD with teratogenic syndromes, 19 (35.9%) were fetal alcohol syndrome 
(35.9%), 10 (18.9%) were cytomegalic virus, seven (13.2%) were valproate syndrome and 16 
(30.2%) were other teratogens. Cases with teratogenic syndromes were most commonly VSD 
or ASD (Table 5.6). 
Excluding cases with teratogenic syndromes, chromosomal anomalies occurred in 14.7% of 
cases of CHD. Chromosomal anomalies occurred in 20% of cases with moderate CHD 
compared to 13.0% with mild severity CHD and 8.2% with severe severity CHD. The 
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majority (52.8%) of chromosomal ECAs were Trisomy 21. Trisomy 21 occurred in 12.6% of 
cases with moderate severity CHD, compared to 7.2% of cases with mild severity CHD and 
1.4% of severe severity CHD (Table 5.7). Trisomy 13, Trisomy 18, Turner syndrome, Cri-du-
chat syndrome and Wolff Hirschorn syndrome occurred in small numbers amongst cases of 
CHD, with little variation in whether they occurred with severe, moderate or mild severity 
CHD (Table 5.7). 
Genetic syndromes occurred in 4.6% of cases with CHD, occurring most commonly in cases 
of moderate severity CHD (6.7%), compared to cases of severe (5.6%) and mild CHD (2.8%). 
The most commonly occurring genetic syndromes were DiGeorge syndrome (1.3%), 
Isomerism (0.9%), Noonan syndrome (0.3%) and Williams syndrome (0.2%) (Table 5.7). 
DiGeorge syndrome occurred most commonly in cases with mild severity CHD whereas 
Isomerism occurred more commonly in cases with severe severity CHD (Table 5.7). 
Table 5.8 and Table 5.9 show the frequency of structural ECAs that occurred with cases of 
CHD. Discounting those cases with chromosomal/ genetic ECAs, CHD most commonly 
occurred with anomalies of the digestive system (3.9%), the urinary system (2.8%), the limbs 
(2.6%) and the nervous system (2.3%). There was little variation in the frequency of ECAs 
across the CHD severity categories. However, digestive system anomalies were more 
prevalent amongst cases with moderate and mild severity CHD (4.1% and 3.5%, respectively) 
compared to those of severe severity (2.9%). 
5.3.3.1 Summary 
While there was variation in the distribution of ECAs according to CHD subtype, the majority 
of cases occurred in isolation (68.4%). 
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N (% of CHD subtype) 
SV 105 (71.4) 22 (15) 20 (13.6) 0 (0) 147 (100.0) 
HLH 708 (80.3) 75 (8.5) 99 (11.2) 0 (0) 882 (100.0) 
EA 126 (81.3) 15 (9.7) 13 (8.4) 1 (0.6) 155 (100.0) 
HRH 396 (69.1) 73 (12.7) 102 (17.8) 2 (0.3) 573 (100.0) 
CAT 106 (48.2) 48 (21.8) 66 (30) 0 (0) 220 (100.0) 
AVSD 338 (27.5) 111 (9) 774 (63.1) 4 (0.3) 1,227 (100.0) 
AVA/S 414 (83.6) 33 (6.7) 47 (9.5) 1 (0.2) 495 (100.0) 
TGV 799 (88.4) 54 (6) 49 (5.4) 2 (0.2) 904 (100.0) 
ToF 602 (58.6) 182 (17.7) 241 (23.5) 2 (0.2) 1,027 (100.0) 
TAPVR 156 (81.7) 25 (13.1) 10 (5.2) 0 (0) 191 (100.0) 
IAA 50 (46.3) 10 (9.3) 48 (44.4) 0 (0) 108 (100.0) 
CoA 749 (73.8) 114 (11.2) 148 (14.6) 4 (0.4) 1,015 (100.0) 
DORV 134 (54.9) 44 (18) 65 (26.6) 1 (0.4) 244 (100.0) 
MVA 150 (82.4) 14 (7.7) 18 (9.9) 0 (0) 182 (100.0) 
VSD 5,067 (75.2) 611 (9.1) 1046 (15.5) 17 (0.3) 6,741 (100.0) 
ASD 1,361 (61.2) 407 (18.3) 447 (20.1) 10 (0.4) 2,225 (100.0) 
PVS 817 (86.5) 55 (5.8) 68 (7.2) 4 (0.4) 944 (100.0) 
PDA 370 (69.4) 95 (17.8) 67 (12.6) 1 (0.2) 533 (100.0) 



















N (% of 
1,599*) 
Moderate 
N (% of 
5,417*) 
Mild 





Chromosomal Anomalies 131 (8.2) 1,083 (20.0) 1,284 (13) 2,893 (14.7) 
Trisomy 21 23 (1.4) 681 (12.6) 713 (7.2) 1528 (7.8) 
Patau sydrome 22 (1.4) 64 (1.2) 75 (0.8) 209 (1.1) 
Trisomy 18 31 (1.9) 114 (2.1) 237 (2.4) 446 (2.3) 
Turner syndrome 22 (1.4) 67 (1.2) 25 (0.3) 202 (1.0) 
Klinefelter syndrome 0 (0) 8 (0.1) 8 (0.1) 17 (0.1) 
Cri-du-chat syndrome 0 (0) 0 (0) 10 (0.1) 11 (0.1) 
Wolff Hirschorn syndrome 0 (0) 1 (0) 17 (0.2) 20 (0.1) 
Other  33 (2.2) 151 (3.4) 218 (2.5) 485 (32.8) 
Genetic Syndromes 90 (5.6) 365 (6.7) 277 (2.8) 902 (4.6) 
Aarskog syndrome 1 (0.1) 1 (0) 13 (0.1) 17 (0.1) 
Alagille syndrome 0 (0) 2 (0) 5 (0.1) 10 (0.1) 
Angelman syndrome 0 (0) 1 (0) 0 (0) 2 (0) 
Apert syndrome 0 (0) 1 (0) 1 (0) 3 (0) 
Beckwith-Wiedemann 1 (0.1) 1 (0) 6 (0.1) 10 (0.1) 
CHARGE 1 (0.1) 9 (0.2) 1 (0) 11 (0.1) 
Chrondrodysplasia 0 (0) 0 (0) 2 (0) 2 (0) 
Cornelia de Lange syndrome 1 (0.1) 2 (0) 3 (0) 8 (0) 
Crouzon syndrome 0 (0) 0 (0) 2 (0) 2 (0) 
DiGeorge syndrome 16 (1) 156 (2.9) 64 (0.6) 253 (1.3) 
Ehlers-Danlos syndrome 0 (0) 1 (0) 1 (0) 2 (0) 
Ellis van Creveld 0 (0) 3 (0.1) 0 (0) 3 (0) 
Holt-Oram syndrome 2 (0.1) 3 (0.1) 7 (0.1) 16 (0.1) 
Incontinentia pigmenti 0 (0) 0 (0) 1 (0) 1 (0) 
Isomerism/ Ivemark 
Syndrome 42 (2.6) 86 (1.6) 17 (0.2) 180 (0.9) 
Jeune syndrome 0 (0) 1 (0) 1 (0) 5 (0) 
Klipped-Feil syndrome 0 (0) 0 (0) 1 (0) 1 (0) 
Marfan syndrome 1 (0.1) 0 (0) 3 (0) 16 (0.1) 
Moebius syndrome 0 (0) 0 (0) 1 (0) 2 (0) 
Exostosis 0 (0) 0 (0) 0 (0) 2 (0) 
Nail Patella syndrome 0 (0) 0 (0) 0 (0) 2 (0) 
Noonan syndrome 2 (0.1) 9 (0.2) 40 (0.4) 62 (0.3) 
Pena Shokeir syndrome 1 (0.1) 1 (0) 1 (0) 6 (0) 
Poland syndrome 0 (0) 0 (0) 0 (0) 2 (0) 
Prader Willi syndrome 0 (0) 0 (0) 1 (0) 1 (0) 
Rubinstein Taybi 0 (0) 4 (0.1) 2 (0) 8 (0) 
Seckel syndrome 0 (0) 0 (0) 1 (0) 1 (0) 
Silver 0 (0) 0 (0) 2 (0) 2 (0) 
Smith-Lemli-Opitz syndrome 1 (0.1) 3 (0.1) 3 (0) 9 (0) 
Sotos syndrome 0 (0) 0 (0) 3 (0) 4 (0) 





N (% of 
1,599*) 
Moderate 
N (% of 
5,417*) 
Mild 






syndrome 0 (0) 0 (0) 2 (0) 2 (0) 
Van der Woude syndrome 1 (0.1) 4 (0.1) 5 (0.1) 14 (0.1) 
Williams syndrome 0 (0) 13 (0.2) 14 (0.1) 43 (0.2) 
Zellweger syndrome 0 (0) 0 (0) 3 (0) 3 (0) 
*Cases with teratogenic syndromes were excluded 
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Table 5.8 Associations, sequences and syndromes in total births, by CHD severity 
Group 
     Subtype 
 
Severe  
N (% of 
1,378)* 
Moderate 
N (% of 
3,969)* 
Mild 
N (% of 
8,319)* 
All CHD 
N (% of 15,906)* 
Association 7 (0.5) 31 (0.8) 35 (0.4) 89 (0.6) 
VATER 5 (0.4) 27 (0.7) 30 (0.4) 74 (0.5) 
Goldenhar Syndrome 1 (0.1) 4 (0.1) 6 (0.1) 15 (0.1) 
MURCS 1 (0.1) 0 (0) 0 (0) 1 (0) 
Sequences 6 (0.4) 18 (0.5) 38 (0.5) 87 (0.6) 
Pierre Robin 2 (0.2) 2 (0.1) 18 (0.2) 25 (0.2) 
Body Stalk 1 (0.1) 4 (0.1) 2 (0) 18 (0.1) 
Prune Belly 1 (0.1) 0 (0) 3 (0) 5 (0) 
Sirenomelia 1 (0.1) 1 (0) 3 (0) 7 (0) 
Partial Urorectal Septum 
Malformation Sequence 0 (0.0) 3(0.1) 6 (0.1) 13 (0.1) 
Amniotic band sequence 1 (0.1) 5 (0.1) 3 (0) 18 (0.1) 
Caudal dysplasia 0 (0) 3 (0.1) 0 (0) 3 (0) 
Skeletal dysplasia 0 (0) 5 (0.1) 8 (0.1) 20 (0.1) 
Syndrome (Non-genetic) 
Blepharophimosis-ptosis Syndrome 2 (0.2) 2 (0.1) 6 (0.1) 12 (0.1) 
*Cases with teratogenic syndromes and chromosomal/ genetic ECAs were excluded  
†Cases with teratogenic syndromes, chromosomal/ genetic ECAs, associations, sequences, skeletal dysplasia and 
non-genetic syndromes were excluded 
VATER=co-occurrence of Vertebral anomalies, Anal atresia, CHD, tracheoesophageal fistula/ atresia, renal and 
radial anomalies and limb anomalies 
MURCS=co-occurrence of Mullerian agenesis, renal agenesis and cervicothoracic somite anomalies
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Table 5.9 Structural ECAs in total birth cases of CHD, by CHD severity 
Group 
     Subtype 
 
Severe 
N (% of 
1,363)† 
Moderate 
N (% of 
3,913) † 
Mild 
N (% of 
8,232) † 
All CHD N 
(% of 15,698) † 
Nervous system anomalies 32 (2.3) 87 (2.2) 159 (1.9) 358 (2.3) 
Neural tube defect 7 (0.5) 17 (0.4) 32 (0.4) 75 (0.5) 
Anencephaly 2 (0.1) 8 (0.2) 6 (0.1) 21 (0.1) 
Encephalocele 3 (0.2) 3 (0.1) 13 (0.2) 26 (0.2) 
Spina bifida 2 (0.1) 8 (0.2) 15 (0.2) 36 (0.2) 
    Spina bifida & hydrocephalus 2 (0.1) 3 (0.1) 12 (0.1) 22 (0.1) 
Hydrocephalus 15 (1.1) 36 (0.9) 52 (0.6) 135 (0.9) 
Microcephaly 1 (0.1) 18 (0.5) 24 (0.3) 54 (0.3) 
Holoprosencephaly 4 (0.3) 3 (0.1) 10 (0.1) 19 (0.1) 
Eye anomalies 8 (0.6) 31 (0.8) 46 (0.6) 112 (0.7) 
Micophalamos 1 (0.1) 7 (0.2) 9 (0.1) 20 (0.1) 
Phalmos 0 (0) 1 (0) 0 (0) 2 (0) 
Cateract 2 (0.1) 4 (0.1) 3 (0) 11 (0.1) 
Glaucoma 0 (0) 2 (0.1) 3 (0) 5 (0) 
Ear, face or neck anomalies 1 (0.1) 21 (0.5) 32 (0.4) 72 (0.5) 
Anotia 0 (0) 0 (0) 3 (0) 3 (0) 
Respiratory system anomalies 29 (2.1) 91 (2.3) 112 (1.4) 321 (2.0) 
Choanal atresia 5 (0.4) 18 (0.5) 19 (0.2) 51 (0.3) 
Cystic lung 2 (0.1) 10 (0.3) 8 (0.1) 32 (0.2) 
Orofacial anomalies 22 (1.6) 70 (1.8) 141 (1.7) 274 (1.7) 
Cleft lip 2 (0.1) 10 (0.3) 21 (0.3) 47 (0.3) 
Cleft lip & palate 13 (1) 29 (0.7) 48 (0.6) 102 (0.6) 
Cleft palate 7 (0.5) 28 (0.7) 70 (0.9) 119 (0.8) 
Digestive system anomalies 39 (2.9) 161 (4.1) 287 (3.5) 614 (3.9) 
Oesophageal atresia 10 (0.7) 35 (0.9) 55 (0.7) 119 (0.8) 
Duodenal atresia/ stenosis 3 (0.2) 14 (0.4) 23 (0.3) 45 (0.3) 
Small intestinal atresia/ stenosis 0 (0) 2 (0.1) 11 (0.1) 15 (0.1) 
Anorectal atresia/ stenosis 9 (0.7) 27 (0.7) 50 (0.6) 112 (0.7) 
Hirschsprung’s disease 0 (0) 5 (0.1) 5 (0.1) 15 (0.1) 
Bile atresia 0 (0) 2 (0.1) 6 (0.1) 8 (0.1) 
Diaphragmatic hernia 7 (0.5) 22 (0.6) 54 (0.7) 113 (0.7) 
Diaphragmatic event 1 (0.1) 2 (0.1) 3 (0) 8 (0.1) 
Abdominal anomalies 5 (0.4) 26 (0.7) 71 (0.9) 136 (0.9) 
Gastroschisis 1 (0.1) 3 (0.1) 18 (0.2) 30 (0.2) 
Omphalocele 4 (0.3) 23 (0.6) 54 (0.7) 107 (0.7) 
Urinary anomalies 38 (2.8) 120 (3.1) 179 (2.2) 445 (2.8) 
Renal agenesis 3 (0.2) 12 (0.3) 10 (0.1) 39 (0.2) 
Renal dysplasia 8 (0.6) 13 (0.3) 31 (0.4) 67 (0.4) 
Cystic kidney 0 (0) 4 (0.1) 5 (0.1) 19 (0.1) 
Hydronephrosis 7 (0.5) 28 (0.7) 51 (0.6) 108 (0.7) 
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Group 
     Subtype 
 
Severe 
N (% of 
1,363)† 
Moderate 
N (% of 
3,913) † 
Mild 
N (% of 
8,232) † 
All CHD N 
(% of 15,698) † 
Bladder extrophy 0 (0) 0 (0) 5 (0.1) 8 (0.1) 
Genital anomalies 14 (1) 79 (2) 110 (1.3) 250 (1.6) 
Hypospadias 6 (0.4) 48 (1.2) 71 (0.9) 152 (1) 
Sex indeterminate 1 (0.1) 5 (0.1) 7 (0.1) 22 (0.1) 
Limb anomalies 34 (2.5) 100 (2.6) 190 (2.3) 404 (2.6) 
Limb reduction 12 (0.9) 38 (1) 39 (0.5) 106 (0.7) 
    Upper limb reduction 11 (0.8) 36 (0.9) 29 (0.4) 87 (0.6) 
    Lower limb reduction 2 (0.1) 6 (0.2) 15 (0.2) 31 (0.2) 
Polydactyly 7 (0.5) 18 (0.5) 25 (0.3) 63 (0.4) 
Syndactyly 0 (0) 4 (0.1) 3 (0) 12 (0.1) 
Arthrogryposis 0 (0) 0 (0) 0 (0) 12 (0.1) 
Musculo-skelatal anomalies 23 (1.7) 61 (1.6) 81 (1) 214 (1.4) 
Thanatophoric dwarfism 0 (0) 0 (0) 0 (0) 214 (1.4) 
Craniosynostosis 0 (0) 4 (0.1) 9 (0.1) 16 (0.1) 
*Cases with teratogenic syndromes and chromosomal/ genetic ECAs were excluded  
†Cases with teratogenic syndromes, chromosomal/ genetic ECAs, associations, sequences, skeletal dysplasia and 
non-genetic syndromes were excluded
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5.3.4 ECAs occurring with live birth cases of CHD 
Of 16,923 live born cases, 42 (0.3%) occurred with a teratogenic syndrome, 2,488 (14.7%) 
with chromosomal/ genetic ECAs, 1,768 (10.5%) with structural ECAs and 12,625 (74.6%) 
were isolated CHD. Of the cases with isolated CHD, 9,160 (72.5%) had multiple CHD 
subtypes and 3,465 (27.4%) occurred with a single CHD subtype. The distribution of ECAs 
varied by CHD subtype (Table 5.10). For example, 57.8% of AVSD cases compared to 3.4% 
of TGV cases occurred with chromosomal/ genetic ECAs. 
Of the 42 live born cases with a teratogenic syndrome, 18 (42.9%) were fetal alcohol 
syndrome, 6 (14.3%) were cytomegalic virus, three (7.1%) were valproate syndrome and 15 
(35.7%) were other teratogenic syndromes. Cases with teratogenic syndromes were most 
commonly VSD or ASD. 
Excluding cases with teratogenic syndromes, chromosomal anomalies occurred in 10.4% of 
cases of CHD. Chromosomal anomalies occurred in 14.1% of cases with moderate severity 
CHD, compared to 9.9% of cases with mild severity CHD and just 4.6% of cases with severe 
severity CHD. The majority (66.9%) of chromosomal anomalies were Trisomy 21. Cases with 
moderate severity CHD occurred with Trisomy 21 in 10.3% of cases, compared to 6.6% of 
mild and 1.3% of severe severity cases (Table 5.11). Trisomy 13, Trisomy 18, Turner 
syndrome, Cri-du-chat syndrome and Wolff Hirschorn syndrome occurred in small numbers 
amongst cases of CHD, with little variation in whether they occurred with severe, moderate or 
mild CHD (Table 5.11). 
Genetic syndromes occurred in 4.4% of cases with CHD, with cases of moderate and severe 
severity CHD occurring with a genetic syndrome more commonly than cases of mild CHD 
(6.5%, 6.2% and 2.8%, respectively). The most commonly occurring genetic syndromes were 
DiGeorge syndrome, Isomerism, Noonan syndrome and William syndrome, which occurred 
in 1.3%, 0.6%, 0.4% and 0.3% of cases, respectively (Table 5.11). 
Table 5.12 and Table 5.13 show the frequency of structural ECAs that occurred with live born 
cases of CHD. Discounting those cases with chromosomal/ genetic ECAs, CHD in live borns 
most commonly occurred with anomalies of the digestive system (3.2%), the urinary system 
(1.9%), the limbs (2.0%) and the respiratory system (1.6%). There was little variation in the 
frequency of ECAs across the CHD severity categories. However, digestive system anomalies 
were slightly more prevalent amongst cases with moderate and mild severity CHD (3.4% and 
2.9%, respectively) compared to severe CHD (2.0%). 
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Table 5.10 Type of ECA in CHD live births according to CHD subtypes 
CHD 
Subtype* 










N (% of CHD subtype) 
SV 71 (76.3) 12 (12.9) 10 (10.8) 0 (0) 93 (100.0) 
HLH 367 (87) 28 (6.6) 27 (6.4) 0 (0) 422 (100.0) 
Eb 96 (81.4) 9 (7.6) 12 (10.2) 1 (0.8) 118 (100.0) 
HRH 308 (76) 33 (8.1) 62 (15.3) 2 (0.5) 405 (100.0) 
CAT 86 (60.6) 24 (16.9) 32 (22.5) 0 (0) 142 (100.0) 
AVSD 295 (34.3) 66 (7.7) 498 (57.8) 2 (0.2) 861 (100.0) 
AVA/S 400 (86.8) 26 (5.6) 35 (7.6) 0 (0) 461 (100.0) 
TGV 759 (91.1) 44 (5.3) 28 (3.4) 2 (0.2) 833 (100.0) 
ToF 562 (64.5) 135 (15.5) 172 (19.7) 2 (0.2) 871 (100.0) 
TAPVR 155 (82) 24 (12.7) 10 (5.3) 0 (0) 189 (100.0) 
IAA 46 (52.9) 9 (10.3) 32 (36.8) 0 (0) 87 (100.0) 
CoA 739 (79) 95 (10.1) 99 (10.6) 3 (0.3) 936 (100.0) 
DORV 106 (65) 28 (17.2) 28 (17.2) 1 (0.6) 163 (100.0) 
MVA 146 (84.4) 14 (8.1) 13 (7.5) 0 (0) 173 (100.0) 
VSD 5,020 (80.3) 504 (8.1) 712 (11.4) 15 (0.2) 6,251 (100.0) 
ASD 1,334 (64.6) 336 (16.3) 388 (18.8) 8 (0.4) 2,066 (100.0) 
PVS 811 (86.9) 51 (5.5) 68 (7.3) 3 (0.3) 933 (100.0) 
PDA 370 (69.7) 93 (17.5) 67 (12.6) 1 (0.2) 531 (100.0) 















Table 5.11 Chromosomal\ genetic ECA in live births, by CHD severity 
ECA Severe 
N (% of 
917*) 
Moderate 
N (% of 
4,533*) 
Mild 
N (% of 
9,225*) 
All CHD 
N (% of 
16,881*) 
Chromosomal Anomalies 42 (4.6) 641 (14.1) 914 (9.9) 1753 (10.4) 
Trisomy 21 12 (1.3) 468 (10.3) 610 (6.6) 1172 (6.9) 
Patau sydrome 4 (0.4) 14 (0.3) 23 (0.2) 50 (0.3) 
Trisomy 18 9 (1) 36 (0.8) 90 (1) 145 (0.9) 
Turner syndrome 6 (0.7) 25 (0.6) 16 (0.2) 56 (0.3) 
Klinefelter syndrome 0 (0) 6 (0.1) 6 (0.1) 12 (0.1) 
Cri-du-chat syndrome 0 (0) 0 (0) 10 (0.1) 11 (0.1) 
WolffHirschorn 0 (0) 1 (0) 17 (0.2) 19 (0.1) 
Genetic Syndromes 57 (6.2) 293 (6.5) 254 (2.8) 735 (4.4) 
Aarskog syndrome 0 (0) 1 (0) 13 (0.1) 16 (0.1) 
Alagille syndrome 0 (0) 2 (0) 5 (0.1) 10 (0.1) 
Angelman syndrome 0 (0) 1 (0) 0 (0) 2 (0) 
Apert syndrome 0 (0) 1 (0) 1 (0) 3 (0) 
Beckwith-Wiedemann 1 (0.1) 1 (0) 6 (0.1) 10 (0.1) 
CHARGE 1 (0.1) 9 (0.2) 1 (0) 11 (0.1) 
Chrondrodysplasia 0 (0) 0 (0) 2 (0) 2 (0) 
Cornelia de Lange 
syndrome 1 (0.1) 1 (0) 3 (0) 7 (0) 
Crouzon syndrome 0 (0) 0 (0) 2 (0) 2 (0) 
DiGeorge syndrome 14 (1.5) 140 (3.1) 58 (0.6) 227 (1.3) 
Ehlers-Danlos syndrome 0 (0) 1 (0) 1 (0) 2 (0) 
EllisvanCreveld 0 (0) 0 (0) 0 (0) 2 (0) 
Holt-Oram syndrome 2 (0.2) 2 (0) 6 (0.1) 12 (0.1) 
Incontinentia pigmenti 0 (0) 0 (0) 1 (0) 1 (0) 
Isomerism/ Ivemark 
Syndrome 22 (2.4) 51 (1.1) 11 (0.1) 99 (0.6) 
Jeune syndrome 0 (0) 1 (0) 0 (0) 2 (0) 
Klipped-Feil syndrome 0 (0) 0 (0) 1 (0) 1 (0) 
Marfan syndrome 1 (0.1) 0 (0) 2 (0) 15 (0.1) 
Moebius syndrome 0 (0) 0 (0) 1 (0) 2 (0) 
Exostosis 0 (0) 0 (0) 0 (0) 2 (0) 
Nail Patella syndtrome 0 (0) 0 (0) 0 (0) 2 (0) 
Noonan syndrome 1 (0.1) 9 (0.2) 40 (0.4) 61 (0.4) 
Pena Shokeir syndrome 0 (0) 0 (0) 1 (0) 3 (0) 
Poland syndrome 0 (0) 0 (0) 0 (0) 2 (0) 
Prader Willi syndrome 0 (0) 0 (0) 1 (0) 1 (0) 
Rubinstein Taybi 0 (0) 4 (0.1) 2 (0) 8 (0) 




N (% of 
917*) 
Moderate 
N (% of 
4,533*) 
Mild 
N (% of 
9,225*) 
All CHD 
N (% of 
16,881*) 
Smith-Lemli-Opitz 
syndrome 1 (0.1) 2 (0) 3 (0) 8 (0) 
Sotos syndrome 0 (0) 0 (0) 3 (0) 4 (0) 
Treacher Collins 
syndrome 0 (0) 0 (0) 1 (0) 1 (0) 
Tricho-rhino phalangeal 
syndrome 0 (0) 0 (0) 2 (0) 2 (0) 
Van der Woude 
syndrome 0 (0) 3 (0.1) 3 (0) 9 (0.1) 
Williams syndrome 0 (0) 13 (0.3) 14 (0.2) 43 (0.3) 
Zellweger syndrome 0 (0) 0 (0) 3 (0) 3 (0) 
*Cases with teratogenic syndromes were excluded
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Table 5.12 Associations, sequences and syndromes in live births, by CHD severity 
Group 
     Subtype 
 
Severe 
N (% of 
1,378*) 
Moderate 
N (% of 
3,969*) 
Mild 
N (% of 
8,319*) 
All CHD 
 N (% of  
15,906*) 
Association 3 (0.2) 21 (0.5) 25 (0.3) 60 (0.4) 
VATER 2 (0.1) 18 (0.5) 19 (0.2) 48 (0.3) 
Goldenhar Syndrome 1 (0.1) 3 (0.1) 6 (0.1) 12 (0.1) 
Sequences 1 (0.1) 7 (0.2) 29 (0.3) 46 (0.3) 
Pierre Robin 1 (0.1) 1 (0) 18 (0.2) 23 (0.1) 
Body Stalk 0 (0) 1 (0) 0 (0) 2 (0) 
Prune Belly 0 (0) 0 (0) 3 (0) 4 (0) 
Partial Urorectal Septum 
Malformation Sequence 0 (0) 2 (0.1) 4 (0) 10 (0.1) 
Amniotic band sequence (0) (0) 1 (0) (0) 
Caudal dysplasia 0 (0) 2 (0.1) 0 (0) 2 (0) 
Skeletal dysplasia 0 (0) 1 (0) 4 (0) 8 (0.1) 
Syndrome (Non-genetic) 
Blepharophimosis-ptosis Syndrome 2 (0.1) 2 (0.1) 6 (0.1) 12 (0.1) 
*Cases with teratogenic syndromes and chromosomal/ genetic ECAs were excluded  
† Cases with teratogenic syndromes, chromosomal/ genetic ECAs, associations, sequences, skeletal dysplasia 
and non-genetic syndromes were excluded 
VATER=co-occurrence of Vertebral anomalies, Anal atresia, CHD, tracheoesophageal fistula/ atresia, renal and 
radial anomalies and limb anomalies 
MURCS=co-occurrence of Mullerian agenesis, renal agenesis and cervicothoracic somite anomalies
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Table 5.13 Structural ECAs in live births, by CHD severity 
Group 
     Subtype 
 
Severe  
N (% of 
812†) 
Moderate  
N (% of 
3,568†) 
Mild  
N (% of 
7,993†) 
All CHD  
N (% of 
14,267†) 
Nervous system anomalies 8 (1) 51 (1.4) 96 (1.2) 190 (1.3) 
Neural tube defect 0 (0) 3 (0.1) 5 (0.1) 11 (0.1) 
Anencephaly 0 (0) 0 (0) 0 (0) 11 (0.1) 
Encephalocele 0 (0) 0 (0) 4 (0.1) 6 (0) 
Spina bifida 0 (0) 3 (0.1) 1 (0) 6 (0) 
    Spina bifida & hydrocephalus 0 (0) 1 (0) 1 (0) 4 (0) 
Hydrocephalus 3 (0.4) 23 (0.6) 27 (0.3) 68 (0.5) 
Microcephaly 1 (0.1) 14 (0.4) 23 (0.3) 48 (0.3) 
Holoprosencephaly 2 (0.2) 1 (0) 3 (0) 6 (0) 
Eye anomalies 6 (0.7) 30 (0.8) 44 (0.6) 100 (0.7) 
Micophalamos 1 (0.1) 7 (0.2) 9 (0.1) 19 (0.1) 
Phalmos 0 (0) 1 (0) 0 (0) 1 (0) 
Cateract 2 (0.2) 4 (0.1) 3 (0) 11 (0.1) 
Glaucoma 0 (0) 2 (0.1) 3 (0) 5 (0) 
Ear, face or neck anomalies 0 (0) 18 (0.5) 27 (0.3) 58 (0.4) 
Anotia 0 (0) 0 (0) 3 (0) 3 (0) 
Respiratory system anomalies 14 (1.7) 61 (1.7) 90 (1.1) 224 (1.6) 
Choanal atresia 5 (0.6) 16 (0.4) 18 (0.2) 47 (0.3) 
Cystic lung 0 (0) 4 (0.1) 7 (0.1) 23 (0.2) 
Orofacial anomalies 10 (1.2) 47 (1.3) 119 (1.5) 202 (1.4) 
Cleft lip 0 (0) 9 (0.3) 18 (0.2) 34 (0.2) 
Cleft lip & palate 6 (0.7) 20 (0.6) 39 (0.5) 73 (0.5) 
Cleft palate 4 (0.5) 16 (0.4) 60 (0.8) 90 (0.6) 
Digestive system anomalies 16 (2) 120 (3.4) 234 (2.9) 461 (3.2) 
Oesophageal atresia 4 (0.5) 30 (0.8) 53 (0.7) 103 (0.7) 
Duodenal atresia/ stenosis 3 (0.4) 11 (0.3) 19 (0.2) 38 (0.3) 
Small intestinal atresia/ stenosis 0 (0) 2 (0.1) 11 (0.1) 15 (0.1) 
Anorectal atresia/ stenosis 5 (0.6) 17 (0.5) 39 (0.5) 77 (0.5) 
Hirschsprung’s disease 0 (0) 5 (0.1) 5 (0.1) 15 (0.1) 
Bile atresia 0 (0) 2 (0.1) 6 (0.1) 8 (0.1) 
Diaphragmatic hernia 4 (0.5) 16 (0.4) 39 (0.5) 81 (0.6) 
Diaphragmatic event 0 (0) 2 (0.1) 3 (0) 6 (0) 
Abdominal anomalies 2 (0.2) 17 (0.5) 57 (0.7) 97 (0.7) 
Gastroschisis 0 (0) 2 (0.1) 18 (0.2) 26 (0.2) 
Omphalocele 2 (0.2) 15 (0.4) 40 (0.5) 72 (0.5) 
Urinary anomalies 13 (1.6) 75 (2.1) 130 (1.6) 273 (1.9) 
Renal agenesis 1 (0.1) 0 (0) 0 (0) 1 (0) 
Renal dysplasia 1 (0.1) 11 (0.3) 20 (0.3) 38 (0.3) 




     Subtype 
 
Severe  
N (% of 
812†) 
Moderate  
N (% of 
3,568†) 
Mild  
N (% of 
7,993†) 
All CHD  
N (% of 
14,267†) 
Hydronephrosis 4 (0.5) 23 (0.6) 45 (0.6) 87 (0.6) 
Bladder extrophy 0 (0) 0 (0) 4 (0.1) 6 (0) 
Genital anomalies 6 (0.7) 65 (1.8) 99 (1.2) 207 (1.5) 
Hypospadias 4 (0.5) 47 (1.3) 67 (0.8) 144 (1) 
Sex indeterminate 1 (0.1) 2 (0.1) 6 (0.1) 15 (0.1) 
Limb anomalies 10 (1.2) 69 (1.9) 142 (1.8) 280 (2.0) 
Limb reduction 2 (0.2) 25 (0.7) 22 (0.3) 63 (0.4) 
    Upper limb reduction 1 (0.1) 24 (0.7) 19 (0.2) 53 (0.4) 
    Lower limb reduction 1 (0.1) 2 (0.1) 5 (0.1) 14 (0.1) 
Polydactyly 2 (0.2) 14 (0.4) 22 (0.3) 49 (0.3) 
Syndactyly 0 (0) 4 (0.1) 2 (0) 10 (0.1) 
Arthrogryposis 0 (0) 0 (0) 0 (0) 0 (0) 
Musculo-skelatal anomalies 5 (0.6) 35 (1) 60 (0.8) 134 (0.9) 
Thanatophoric dwarfism 0 (0) 0 (0) 0 (0) 0 (0) 
Craniosynostosis 0 (0) 4 (0.1) 9 (0.1) 16 (0.1) 
*Cases with teratogenic syndromes and chromosomal/ genetic ECAs were excluded  
† Cases with teratogenic syndromes, chromosomal/ genetic ECAs, associations, sequences, skeletal dysplasia 
and non-genetic syndromes were excluded
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5.3.5 Sex distribution in total birth cases of CHD 
5.3.5.1 All CHD 
Among total birth cases, 51.4% of cases were male. However, sex distribution varied by CHD 
subtype (Figure 5.1 A). There was a male preponderance of SV, HLH, HRH, AVA/S, TGV, 
ToF, TAPVR, CoA and DORV and a female preponderance of AVSD, MVA, ASD, PVS and 
PDA. There was a significant difference in the sex distribution according to the presence of 
ECAs (χ2 test on all CHD subtypes combined: p<0.001). Specifically, cases with CHD and 
structural ECAs occurred most frequently in males, whereas cases with CHD and 
chromosomal/ genetic ECAs and CHD with teratogenic syndromes occurred more frequently 
in females. 
5.3.5.2 Isolated CHD 
Of the isolated cases of CHD, 52.1% were male. Amongst isolated cases there was a male 
preponderance of SV, HLH, HRH, AVA/S, TGV, ToF, TAPVR, IAA, CoA, DORV and 
“other” CHD subtypes (Figure 5.1 B). Cases of isolated AVSD, MVA, ASD, PVS and PDA 
were more common in females. 
5.3.5.3 CHD with structural ECAs 
Of the cases with structural ECAs, 56.8% of cases were male. There was a male 
preponderance of SV, HLH, HRH, AVA/S, TGV, ToF, CoA, DORV, MVA, VSD, PVS, PDA 
and “other” CHD subtypes (Figure 5.1 C). Cases with structural ECAs and EA, AVSD and 
IAA were more common in females. 
5.3.5.4 CHD with chromosomal/ genetic ECAs 
Of the cases with chromosomal/ genetic ECAs, 45.6% were male. As shown in Figure 5.1, 
there was a male preponderance of EA and TGV. Cases with chromosomal/ genetic ECAS 
and SV, HLH, HRH, CAT, AVSD, IAA, CoA, DORV, MVA, ASD and other CHD subtypes 
were more common in females (Figure 5.1 D). 
5.3.5.5 Summary 
Although sex distribution varied substantially by CHD subtype, there was a male 
preponderance of cases with CHD and structural ECAs and a female preponderance of cases 
with CHD and chromosomal/ genetic ECAs. 
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Figure 5.1 Percentage of male (total birth) cases of CHD, by CHD subtype and ECAs 
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Infant sex was missing in 185 (1.4%) isolated cases, 49 (2.1%) cases with structural ECAs, 42 (1.1%) with 
chromosomal/ genetic ECAs. 
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5.3.6 Gestational age at delivery in live born cases of CHD 
5.3.6.1 All CHD 
There were 14,553 live born cases of CHD with complete data for gestational age at delivery. 
Of these, 159 (1.1%) were extremely preterm, 421 (2.9%) were very preterm, 1,902 (13.1%) 
were moderately preterm, 11,563 were term (79.5%) and 508 (3.5%) were post-term 
deliveries. As shown in Figure 5.2 A, these proportions varied according to CHD subtype. 
Cases of TAPVR (87.1%), IAA (88.6%), CoA (85.0%) and MVA (84.9%) were the most 
likely CHD subtypes to be term deliveries. TAPVR (5.7%) and CAT (4.7%) were the most 
likely subtypes to be delivered post-term. ASD and HLH was the most likely subtype to be 
born extremely preterm (2.6% and 2.0%). The distribution of gestational age at delivery 
varied significantly according to the presence of ECAs (Kruskal-Wallis test: p<0.001). 
Specifically, isolated cases were more likely to be born at term compared to cases with CHD 
and structural ECAs or chromosomal/ genetic ECAs or teratogenic syndromes. Below, 
gestational age at delivery is described in more detail according to the presence of ECAs. 
5.3.6.2 Isolated CHD 
There were 10,634 live born cases of isolated CHD with complete data for gestational age at 
delivery. Of these, 112 (1.1%) were delivered extremely preterm, 266 (2.5%) were very 
preterm, 1,134 (10.7%) were moderately preterm, 8,774 (82.1%) were term and 388 (3.6%) 
were post-term. As shown in Figure 5.2 B, these proportions varied by CHD subtype. For 
example, cases of HLH and ASD were most likely to be born extremely preterm (2.0% and 
3.6%, respectively); cases of ASD, PVS and IAA were most likely to be born very preterm 
(4.6%, 4.2% and 4.8%, respectively); cases with TAPVR, PDA and MVA were more likely to 
be born term (91.7%, 95.4% and 87.5% respectively); cases of TAPVR and CAT were most 
likely to be born post-term (5.5% and 6.8%, respectively). 
5.3.6.3 CHD with structural ECAs 
There were 1,636 live born cases of CHD with structural ECAs and complete data for 
gestation age at delivery. Of these 29 (1.8%) were extremely preterm, 104 (6.4%) were very 
preterm, 336 (20.5%) were moderately preterm, 1,114 (68.1%) were term and 53 (3.2%) were 
post-term. Again these proportions varied by CHD subtype (Figure 5.2 C). For example, cases 
of PVS and MVA were most likely to be extremely preterm (11.4% and 7.7%, respectively); 
cases of M A were most likely to be very preterm (15.4%); cases with “Other” CHD 
subtypes were most likely to be born moderately preterm (28.8%), cases of MVA were most 
likely to be born post-term (7.7%). 
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5.3.6.4 CHD with chromosomal/ genetic ECAs 
There were 2,243 live or stillborn cases of CHD with chromosomal/ genetic ECAs with 
complete data for gestational age at delivery. Of these, 18 (0.8%) were extremely preterm, 50 
(2.2%) were very preterm, 421 (18.8%) were moderately preterm, 1,689 (75.3%) were term 
and 65 (2.9%) were post-term. Again these proportions varied by CHD subtype (Figure 5.2 
D). Cases with “Other” CHD subtypes were most likely to be born extremely preterm (2.9%); 
cases of CAT were most likely to be born very preterm (6.7%); cases of EA were most likely 
to be born moderately preterm (27.3%) and cases of PVS were most the most likely to be born 
post-term (14.1%). 
5.3.6.5 Summary 
Overall 1.1% of cases were extremely preterm, 2.9% were very preterm and 13.1% were 
moderately preterm. Cases of HLH, IAA, ASD and PVS were most likely to be born 
extremely or very preterm. Isolated cases of CHD were more likely to be born at term 
compared to cases with CHD and structural ECAs or chromosomal/ genetic ECAs.
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Figure 5.2 Gestational age at delivery in live births, by CHD subtype and ECAs 
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Gestational age at delivery was missing in 1,991 (15.8%) isolated cases, 132 (7.5%) cases with structural ECAs 
and 245 (9.9%) cases with chromosomal/ genetic ECAs. 
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5.3.7 Gestational age at delivery according to prenatal diagnosis 
5.3.7.1 Isolated CHD 
Considering all isolated CHD subtypes, 21.4% of prenatally diagnosed cases were delivered 
preterm compared to 14.5% of non-prenatally diagnosed cases. Prenatally diagnosed cases 
were significantly more likely to be delivered preterm (test of proportions: p=0.001). With the 
exception of ToF, all subtypes that were prenatally diagnosed were more likely to be 
delivered preterm, although this only reached statistical significance in cases with EA, 
A A/S,  SD and “Other” CHD subtypes (Table 5.14).
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Table 5.14 Preterm birth according to prenatal diagnosis among isolated cases of CHD, by CHD subtype* 











SV 0/ 17, 0 6/ 34, 17.6 0.065 
HLH 17/ 116, 14.7 38/ 230, 16.5 0.654 
EA 4/ 38, 10.5 16/ 40, 40 0.003 
HRH 15/ 91, 16.5 27/ 137, 19.7 0.539 
CAT 3/ 37, 8.1 8/ 23, 34.8 0.009 
AVSD 11/ 115, 9.6 18/ 86, 20.9 0.023 
AVA/S 27/ 228, 11.8 10/ 31, 32.3 0.002 
TGV 30/ 372, 8.1 17/ 132, 12.9 0.102 
ToF 34/ 251, 13.5 11/ 83, 13.3 0.946 
TAPVR 2/ 73, 2.7 0/ 8, 0 0.636 
IAA 3/ 26, 11.5 1/ 6, 16.7 0.732 
CoA 38/ 354, 10.7 11/ 96, 11.5 0.840 
DORV 6/ 38, 15.8 5/ 40, 12.5 0.677 
MVA 5/ 77, 6.5 2/ 10, 20 0.140 
VSD 418/ 2,751, 15.2 48/ 197, 24.4 0.001 
ASD 184/ 813, 22.6 17/ 57, 29.8 0.213 
PVS 90/ 487, 18.5 5/ 17, 29.4 0.257 
PDA 0/ 269, 0 0/ 14, 0 - 
Other 64/ 419, 15.3 58/ 151, 38.4 0.001 
All subtypes 951/ 6,572, 14.5 298/ 1,392, 21.4 0.001 
 
*Cases notified to CAROBB, EMSYCAR and SWCAR were excluded due to incomplete data on prenatal 
diagnosis. 1,895 (15.7%) cases were excluded due to either missing gestational age or missing prenatal diagnosis 
data. 
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5.3.8 Standardised birth weight in live births 
5.3.8.1 All CHD 
Standardised birth weight was calculated for 13,226 (78.2%) live born cases of CHD. Overall, 
3,434 (26.0%) were low birth weight, 7659 (57.9%) were average birth weight and 2,133 
(16.1%) were high birth weight. There was variation in standardised birth weight according to 
CHD subtype (Figure 5.3 A) and standardised birth weight varied significantly according to 
the presence of ECAs (Kruskal-Wallis test: p<0.001). 
5.3.8.2 Isolated CHD 
Standardised birth weight was calculated for 9,651 (76.4%) live born cases with isolated 
CHD. There were 2,021 (20.9%) cases with low birth weight, 5,902 (61.2%) with average 
birth weight and 1,728 (17.9%) with high birth weight, although this varied by CHD subtype 
(Figure 5.3 B). 
5.3.8.3 CHD with structural ECAs 
Standardised birth weight was calculated for 1,536 (86.9%) live born cases with CHD and 
structural ECAs. There were 543 (35.4%) cases with low birth weight, 799 (52.0%) with 
average birth weight and 194 (12.6%) with high birth weight, although this varied by CHD 
subtype (Figure 5.3 C). 
5.3.8.4 CHD with chromosomal/ genetic ECAs 
Standardised birth weight was calculated for 2,002 (80.5%) live born cases with CHD and 
chromosomal/ genetic ECAs. There were 848 (42.4%) cases with low birth weight, 944 
(47.2%) with average birth weight and 210 (10.5%) with high birth weight, although this 
varied by CHD subtype (Figure 5.3 D). 
5.3.8.5 Summary 
In total, 26% of cases were of low birth weight, although this varied by CHD subtype and the 
presence of ECAs. In general, cases with ECAs were more likely to have a low birth weight 
than isolated cases of CHD.
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Standardised birth weight was missing in 1,678 (13.3%) isolated cases, 143 (8.1%) cases with structural ECAs 
and 343 (13.8%) cases with chromosomal/ genetic ECAs.
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5.3.9 Total birth prevalence 
The total birth prevalence of CHD was 65.0 (95% CI: 64.1-65.9) per 10,000 total births. Table 
5.15 shows the total birth prevalence of each CHD subtype according to the presence of 
ECAs. 
Table 5.15 Total birth prevalence (95% CI) of CHD, by CHD subtype and ECAs 
CHD 
subtype 
Prevalence per 10,000 total births (95% CI) 







SV 0.3 (0.3-0.4) 0.1 (0-0.1) 0.1 (0-0.1) 0.5 (0.4-0.6) 
HLH 2.3 (2.2-2.5) 0.2 (0.2-0.3) 0.3 (0.3-0.4) 2.9 (2.7-3.1) 
EA 0.4 (0.3-0.5) 0 (0-0.1) 0 (0-0.1) 0.5 (0.4-0.6) 
HRH 1.3 (1.2-1.4) 0.2 (0.2-0.3) 0.3 (0.3-0.4) 1.9 (1.7-2) 
CAT 0.3 (0.3-0.4) 0.2 (0.1-0.2) 0.2 (0.2-0.3) 0.7 (0.6-0.8) 
AVSD 1.1 (1-1.2) 0.4 (0.3-0.4) 2.5 (2.4-2.7) 4.0 (3.8-4.3) 
AVA/S 1.4 (1.2-1.5) 0.1 (0.1-0.2) 0.2 (0.1-0.2) 1.6 (1.5-1.8) 
TGV 2.6 (2.4-2.8) 0.2 (0.1-0.2) 0.2 (0.1-0.2) 3 (2.8-3.2) 
ToF 2 (1.8-2.1) 0.6 (0.5-0.7) 0.8 (0.7-0.9) 3.4 (3.2-3.6) 
TAPVR 0.5 (0.4-0.6) 0.1 (0.1-0.1) 0 (0-0.1) 0.6 (0.5-0.7) 
IAA 0.2 (0.1-0.2) 0 (0-0.1) 0.2 (0.1-0.2) 0.4 (0.3-0.4) 
CoA 2.5 (2.3-2.6) 0.4 (0.3-0.5) 0.5 (0.4-0.6) 3.3 (3.1-3.5) 
DORV 0.4 (0.4-0.5) 0.1 (0.1-0.2) 0.2 (0.2-0.3) 0.8 (0.7-0.9) 
MVA 0.5 (0.4-0.6) 0 (0-0.1) 0.1 (0-0.1) 0.6 (0.5-0.7) 
VSD 16.7 (16.2-17.1) 2 (1.9-2.2) 3.4 (3.2-3.7) 22.2 (21.6-22.7) 
ASD 4.5 (4.2-4.7) 1.3 (1.2-1.5) 1.5 (1.3-1.6) 7.3 (7-7.6) 
PVS 2.7 (2.5-2.9) 0.2 (0.1-0.2) 0.2 (0.2-0.3) 3.1 (2.9-3.3) 
PDA 1.2 (1.1-1.3) 0.3 (0.3-0.4) 0.2 (0.2-0.3) 1.8 (1.6-1.9) 
Other 3.5 (3.3-3.7) 1.3 (1.2-1.5) 1.5 (1.4-1.7) 6.4 (6.1-6.7) 
All 
subtypes 44.4 (43.7-45.2) 7.9 (7.5-8.2) 12.5 (12.1-12.9) 65.0 (64.1-65.9) 
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5.3.10 Trends in total birth prevalence 
5.3.10.1 All CHD adjusted for the presence of ECAs 
Overall, there was no evidence of a trend in total birth prevalence over time (p=0.529) (Table 
5.16). However, the total birth prevalence of AVA/S decreased significantly by 3% per year 
(RR=0.97, 95% CI: 0.95-0.99; p=0.002), the total birth prevalence of CoA decreased 
significantly by 2% per year (RR=0.98, 95% CI: 0.96-0.99; p<0.001) and the total birth 
prevalence of ToF increased significantly by 3% per year (RR=1.03, 95% CI: 1.01-1.04; 
p=0.001). Adjusting for maternal age at delivery had little impact on the trends in CHD over 
time (Table 5.16). 
Table 5.16 Trends in the total birth prevalence of CHD over time, by CHD subtype 
Subtype 
RR of CHD per 
year* (95% CI) P-value 
Adjusted RR of 
CHD per year 
(95% CI)‡ P-value 
SV 0.97 (0.94-1.00) 0.082 0.95 (0.91-0.99) 0.028 
HLH 1.01 (1-1.02) 0.191 1.00 (0.98-1.02) 0.706 
EA 1.00 (0.97-1.03) 0.979 1.00 (0.96-1.04) 0.914 
HRH 0.99 (0.98-1.01) 0.540 0.98 (0.95-1.00) 0.026 
CAT 1.02 (0.99-1.05) 0.180 1.02 (0.99-1.06) 0.172 
AVSD 1.01 (0.99-1.02) 0.396 1.00 (0.98-1.01) 0.749 
AVA/S¥ 0.97 (0.95-0.99) 0.002 0.96 (0.94-0.98) <0.001 
TGV 1.00 (0.99-1.02) 0.902 1.01 (0.99-1.03) 0.296 
ToF 1.03 (1.01-1.04) <0.001 1.03 (1.01-1.05) <0.001 
TAPVR 0.99 (0.96-1.02) 0.515 1.00 (0.96-1.03) 0.946 
IAA 1.01 (0.97-1.05) 0.667 1.00 (0.96-1.05) 0.962 
CoA 0.98 (0.96-0.99) 0.001 0.98 (0.96-0.99) 0.006 
DORV 1.01 (0.98-1.04) 0.561 1.02 (0.99-1.06) 0.170 
MVA 0.98 (0.95-1.01) 0.202 0.96 (0.93-1.00) 0.034 
VSD† 1.02 (0.99-1.06) 0.186 1.04 (0.99-1.10) 0.147 
ASD† 1.00 (0.96-1.05) 0.925 0.99 (0.93-1.07) 0.857 
PVS† 1.00 (0.99-1.02) 0.585 1.01 (0.99-1.02) 0.221 
PDA† 1.08 (1.01-1.14) 0.014 1.09 (0.99-1.19) 0.080 
Other† 0.98 (0.96-1.01) 0.146 0.99 (0.97-1.02) 0.636 
All subtypes 1.00 (1.00-1.00) 0.529 1.02 (0.98-1.06) 0.402 
*Relative risks (RRs) were estimated using multilevel Poisson regression models with a random intercept (for 
register), adjusted for presence of structural and chromosomal extra-cardiac anomalies. 
†The RRs for these subtypes were estimated using Poisson regression with a random slope and random intercept 
¥ The RR for this subtype was estimated using Poisson regression with a random intercept and an overdispersion 
term 
‡ Adjusted for maternal age at delivery. This analysis excluded cases notified to CAROBB (all years), 
EMSYCAR (all years) and SWCAR for 2010.
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5.3.10.2 Interaction between year of delivery and the presence of ECAs 
Overall, there was a significant interaction between year of delivery and the presence of ECAs 
(p<0.001). Therefore, the prevalence models were fitted separately to isolated cases of CHD, 
CHD with structural ECAs and CHD with chromosomal/ genetic ECAs. The trends over time 
were slightly steeper among cases with structural ECAs and cases with chromosomal/ genetic 
ECAs compared to cases with CHD isolated CHD (Table 5.17). As shown in Table 5.17, 
trends over time were not significant. 
Of the individual subtypes, trends in total birth prevalence varied significantly according to 
the presence of ECAs for VSDs only (p=0.001). Trends over time in the total birth prevalence 
of VSD with chromosomal/ genetic ECAs were steeper than trends over time in isolated VSD, 
but none of the trends were statistically significant (Table 5.17). 
Table 5.17 Unadjusted trends in total birth prevalence according to presence of ECAs 
Subtype Isolated CHD CHD with structural 
ECAs 
CHD with chromosomal/ 
genetic CHDs 
RR (95% CI) P-
value 
RR (95% CI) P-
value 


















5.3.11 Heterogeneity in total birth prevalence between registers 
5.3.11.1 All CHD adjusted for the presence of ECAs 
Overall, there was significant heterogeneity in total birth prevalence between registers (LR 
test for random intercept: p<0.001), the total birth prevalence of CHD was greatest in CARIS, 
followed by NorCAS. CAROBB, EMSYCAR, SWCAR and WANDA had broadly similar 
total birth prevalence rates. There appeared to be slightly less variation in prevalence among 
cases with ECAs compared to those with isolated CHD. 
There was also significant heterogeneity in total birth prevalence between registers for every 
CHD subtype (LR tests: p<0.001 for all CHD subtypes). Figure 5.4 shows the percentage of 
the prevalence contributed by each register. Here, it appears that there is a greater degree of 
variation among the milder CHD subtypes than the more severe ones, particularly among 
isolated cases of CHD. For many subtypes, CARIS and NorCAS account for the largest 
proportions of cases. 
Table 5.18 Total birth prevalence by register 
Register Prevalence per 10,000 total births (95% CI) 






CARIS 75.9 (73.3-78.5) 17.4 (16.1-18.6) 18.9 (17.7-20.3) 112.6 (109.5-115.8) 
CAROBB 26.3 (24.4-28.4) 5.7 (4.8-6.6) 10.5 (9.3-11.8) 42.8 (40.3-45.4) 
EMSYCAR 29.8 (28.6-30.9) 5.7 (5.2-6.2) 8.0 (7.4-8.6) 43.6 (42.2-45) 
NorCAS 71.1 (69-73.1) 6.6 (6-7.2) 15.8 (14.8-16.8) 93.5 (91.2-95.9) 
SWCAR 33.7 (31.9-35.6) 8.1 (7.2-9) 11.7 (10.6-12.8) 53.7 (51.4-56) 
WANDA 22.9 (21.5-24.3) 5.8 (5.2-6.6) 11.7 (10.7-12.7) 40.6 (38.7-42.4) 
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5.3.12 Heterogeneity in trends in total birth prevalence 
5.3.12.1 All CHD adjusted for the presence of ECAs 
Overall, there was variation in trends in prevalence between registers (p<0.001). However, 
variation in trends over time between registers was observed in only the milder CHD 
subtypes:  SD, ASD, PDA and “other” CHD subtypes (all at p<0.001). As shown in Figure 
5.5 A, trends over time were similar in the areas covered by NorCAS, EMSYCAR, CAROBB 
and WANDA, all showing a slight increase in prevalence over time. Trends in CHD 
prevalence in the area covered by SWCAR also increased slightly over time, but with a 
steeper gradient. Alternatively, trends in total birth prevalence over time in the area covered 
by CARIS appeared to decrease. For cases of VSD, the trends in the registers mirrored those 
of trends in all CHD subtypes combined. For cases of ASD and PDA, all registers had similar 
(slightly increasing) trends in total birth prevalence over time, with the exception of CARIS, 
which showed a decreasing trend in total birth prevalence (Figure 5.5 C and D). For cases 
with “Other” CHD subtypes, the prevalence decreased slightly for all registers except 
SWCAR, where the prevalence appeared to increase slightly over time (Figure 5.5 E). 
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5.3.13 Live birth prevalence 
The live birth prevalence was 55.9 (95% CI: 55.1-56.7) per 10,000 live births. Table 5.19 
shows the live birth prevalence of each CHD subtype according to the presence of ECAs. 
Table 5.19 Live birth prevalence of CHD, by CHD subtype and ECAs 
CHD 
subtype 
Prevalence per 10,000 live births (95% CI) 







SV 0.2 (0.2-0.3) 0 (0-0.1) 0 (0-0.1) 0.3 (0.2-0.4) 
HLH 1.2 (1.1-1.3) 0.1 (0.1-0.1) 0.1 (0.1-0.1) 1.4 (1.3-1.5) 
EA 0.3 (0.3-0.4) 0 (0-0.1) 0 (0-0.1) 0.4 (0.3-0.5) 
HRH 1.0 (0.9-1.1) 0.1 (0.1-0.2) 0.2 (0.2-0.3) 1.3 (1.2-1.5) 
CAT 0.3 (0.2-0.4) 0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.5 (0.4-0.6) 
AVSD 1 (0.9-1.1) 0.2 (0.2-0.3) 1.6 (1.5-1.8) 2.8 (2.7-3) 
AVA/S 1.3 (1.2-1.5) 0.1 (0.1-0.1) 0.1 (0.1-0.2) 1.5 (1.4-1.7) 
TGV 2.5 (2.3-2.7) 0.1 (0.1-0.2) 0.1 (0.1-0.1) 2.8 (2.6-2.9) 
ToF 1.9 (1.7-2) 0.4 (0.4-0.5) 0.6 (0.5-0.7) 2.9 (2.7-3.1) 
TAPVR 0.5 (0.4-0.6) 0.1 (0.1-0.1) 0 (0-0.1) 0.6 (0.5-0.7) 
IAA 0.2 (0.1-0.2) 0 (0-0.1) 0.1 (0.1-0.1) 0.3 (0.2-0.4) 
CoA 2.4 (2.3-2.6) 0.3 (0.3-0.4) 0.3 (0.3-0.4) 3.1 (2.9-3.3) 
DORV 0.4 (0.3-0.4) 0.1 (0.1-0.1) 0.1 (0.1-0.1) 0.5 (0.5-0.6) 
MVA 0.5 (0.4-0.6) 0 (0-0.1) 0 (0-0.1) 0.6 (0.5-0.7) 
VSD 16.6 (16.1-17) 1.7 (1.5-1.8) 2.4 (2.2-2.5) 20.6 (20.1-21.2) 
ASD 4.4 (4.2-4.6) 1.1 (1-1.2) 1.3 (1.2-1.4) 6.8 (6.5-7.1) 
PVS 2.7 (2.5-2.9) 0.2 (0.1-0.2) 0.2 (0.2-0.3) 3.1 (2.9-3.3) 
PDA 1.2 (1.1-1.4) 0.3 (0.2-0.4) 0.2 (0.2-0.3) 1.8 (1.6-1.9) 
Other 3.2 (3-3.4) 0.8 (0.7-0.9) 0.6 (0.6-0.7) 4.6 (4.3-4.8) 
All 
subtypes 41.7 (41-42.4) 5.8 (5.6-6.1) 8.2 (7.9-8.5) 55.9 (55.1-56.7) 
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5.3.14 Trends in live birth prevalence 
5.3.14.1 All CHD adjusted for the presence of ECAs 
Overall, there was no evidence of a trend in live birth prevalence over time (adjusted for the 
presence of ECAs) (p=0.986) (Table 5.16 and Table 5.20). However, the live birth prevalence 
of AVA/S decreased significantly by 3% per year (RR=0.97, 95% CI: 0.95-0.99), the live 
birth prevalence of CoA decreased significantly by 2% per year (RR=0.98, 95% CI: 0.97-
0.99) and the live birth prevalence of ToF increased significantly by 3% per year (RR=1.03, 
95% CI: 1.01-1.04). 
Table 5.20 Trends in the live birth prevalence of CHD over time, by CHD subtype 
Subtype RR (95% CI) P-value 
SV 0.96 (0.92-1.01) 0.083 
HLH 1.00 (0.98-1.02) 0.795 
EA 0.99 (0.95-1.02) 0.412 
HRH 0.99 (0.97-1.01) 0.353 
CAT 1.00 (0.97-1.04) 0.889 
AVSD 1.01 (0.99-1.02) 0.366 
AVA/S¥ 0.97 (0.95-0.99) <0.001 
TGV 1.00 (0.98-1.01) 0.915 
ToF 1.03 (1.01-1.04) 0.001 
TAPVR 0.99 (0.96-1.02) 0.371 
IAA 1.00 (0.96-1.05) 0.885 
CoA 0.98 (0.97-0.99) 0.002 
DORV 1.01 (0.97-1.04) 0.736 
MVA 0.98 (0.95-1.01) 0.160 
VSD† 1.03 (0.99-1.08) 0.113 
ASD† 1.01 (0.96-1.07) 0.640 
PVS† 1.00 (0.99-1.02) 0.707 
PDA† 1.08 (1.02-1.14) 0.013 
Other† 0.97 (0.95-0.99) 0.008 
All subtypes 1.00 (1.00-1.00) 0.986 
*Relative risks (RRs) were estimated using multilevel Poisson regression models with a random intercept (for 
register), adjusted for presence of structural and chromosomal extra-cardiac anomalies. 
†The RRs for these subtypes were estimated using Poisson regression with a random slope and random intercept 
¥ The RR for this subtype was estimated using Poisson regression with a random intercept and an over-
dispersion term.
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5.3.14.2 Interaction between year of delivery and the presence of ECAs 
Overall, there was an interaction between year of delivery and the presence of ECAs 
(p<0.001). The trends were therefore modelled separately for isolated cases, cases with 
structural ECAs and cases with chromosomal/ genetic ECAs. The trend over time in CHD 
with chromosomal ECAs decreased very slightly over time, whereas the prevalence of 
isolated CHD and CHD with structural ECAs remained stable (Table 5.21). There were no 
significant trends over time in the prevalence of isolated CHD (p=0.505), CHD with structural 
ECAs (p=0.729) and CHD with chromosomal/ genetic ECAs (p=0.239). 
There was an interaction between year of delivery and the presence of ECAs in cases of VSD 
(p<0.001). The trends in VSD were therefore modelled separately for cases with isolated 
VSD, VSD with structural ECAs and VSD with chromosomal/ genetic ECAs. The live birth 
prevalence of isolated VSD increased by 2% per year, whereas the live birth prevalence of 
VSD with structural ECAs and the live birth prevalence of VSD with chromosomal/ genetic 
VSD, increased by 1% per year. However, none of these trends reached statistical significance 
(Table 5.21). 
 
Table 5.21 Trends in live birth prevalence according to the presence of ECAs 
Subtype Isolated CHD CHD with structural 
ECAs 
CHD with chromosomal/ 
genetic ECAs 



















5.3.15 Heterogeneity in live birth prevalence between registers 
5.3.15.1 All CHD adjusted for the presence of ECAs 
Overall, there was significant heterogeneity in live birth prevalence between registers (LR test 
for random intercept: p<0.001). As shown in Table 5.22, the live birth prevalence of all CHD 
was greatest in the CARIS, followed by NorCAS. CAROBB, EMSYCAR, SWCAR and 
WANDA had broadly similar live birth prevalence rates.  
There was also significant heterogeneity in live birth prevalence between registers for every 
CHD subtype (LR test: p<0.001 for each CHD subtype). Figure 5.6 shows the percentage of 
the prevalence contributed by each register. Here, it appears that there is a greater degree of 
variation among the milder CHD subtypes than the more severe ones, particularly among 
isolated cases of CHD. For many subtypes, CARIS and NorCAS account for the largest 
proportions of cases. 
 
Table 5.22 Live birth prevalence by register 
Register Prevalence per 10,000 live births (95% CI) 







CARIS 73.2 (70.6-75.8) 14.9 (13.8-16.1) 13.1 (12-14.2) 113.2 (110-116.4) 
CAROBB 23.5 (21.7-25.4) 4.3 (3.5-5.2) 6.4 (5.5-7.5) 43.0 (40.5-45.6) 
EMSYCAR 26.8 (25.7-27.9) 3.9 (3.5-4.4) 5.3 (4.8-5.8) 43.8 (42.4-45.2) 
NorCAS 68.8 (66.9-70.9) 4.7 (4.2-5.2) 10.3 (9.6-11.1) 94.1 (91.7-96.4) 
SWCAR 31.3 (29.6-33.2) 6.2 (5.5-7.1) 7.9 (7-8.9) 53.9 (51.6-56.3) 
WANDA 19.6 (18.4-20.9) 3.1 (2.6-3.6) 7.3 (6.5-8.1) 40.6 (38.8-42.5) 
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5.3.16 Heterogeneity in trends in live birth prevalence between registers 
5.3.16.1 All CHD adjusted for the presence of ECAs 
Overall, there was variation in trends in live birth prevalence between registers (p<0.001). 
However, variation in trends over time between registers was observed in only the milder 
CHD subtypes:  SD, ASD, PDA and “other” CHD subtypes (all p<0.001). As shown in 
Figure 5.7 A, trends in live birth prevalence over time in all CHD subtypes combined were 
similar in the areas covered by NorCAS, EMSYCAR, CAROBB and WANDA, with a slight 
increase in prevalence over time. Trends in CHD prevalence in the area covered by SWCAR 
also increased slightly over time, but with a steeper gradient. Alternatively, trends in live birth 
prevalence over time in the area covered by CARIS appeared to decrease. For cases of VSD, 
the trends in the registers mirrored those of trends in all CHD subtypes combined. For cases 
of ASD and PDA, all registers had very similar (slightly increasing) trends in total birth 
prevalence over time, with the exception of CARIS, which showed a decreasing trend in total 
birth prevalence (Figure 5.7 C and D). For cases with “Other” CHD subtypes, the prevalence 
decreased slightly for all registers except SWCAR, where the prevalence appeared to increase 
slightly over time (Figure 5.7). 
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Figure 5.7 Live birth prevalence of CHD over time, by register and subtype 
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5.3.17 Prenatal diagnosis 
5.3.17.1 Isolated CHD 
Excluding cases notified to CAROBB, EMSYCAR and SWCAR (see section 5.2.3.4), there 
were 8,956 (98.2%) cases of isolated CHD with data on prenatal diagnosis. Of these, 3,225 
were CHD subtypes that are possible to prenatally diagnose. Overall, 935 (30.0%) cases had a 
prenatal diagnosis (of any congenital anomaly). There was substantial variation in prenatal 
diagnosis by subtype (Table 5.23). For example, 72.4% of cases with HLH had a prenatal 
diagnosis compared to just 5.9% of cases with IAA. 




RR of prenatal diagnosis  
(95% CI); p-value 
SV 42 (64.6) 1.06 (1.00-1.12); p=0.035 
HLH 270 (72.4) 1.05 (1.02-1.07); p<0.001 
EA 33 (47.8) 1.06 (0.99-1.14); p=0.087 
HRH 124 (52.8) 1.08 (1.04-1.12); p<0.001 
CAT 26 (41.3) 1.07 (0.99-1.15); p=0.104 
AVSD 71 (33.3) 1.07 (1.02-1.12); p=0.006 
AVA/S 26 (8.8) 1.05 (0.97-1.13); p=0.220 
TGV 82 (18.1) 1.15 (1.10-1.21); p<0.001 
ToF 51 (14.6) 1.21 (1.12-1.30); p<0.001 
IAA 2 (5.9) 0.95 (0.74-1.21); p=0.665 
CoA 67 (14.1) 1.09 (1.04-1.15); p<0.001 
DORV 37 (48.7) 1.05 (0.99-1.12); p=0.130 
Other 104 (19.8) 1.03 (0.98-1.07); p=0.237 
All subtypes 935 (30.0%) 1.07 (1.06-1.09); p<0.001 
TAPVR, MVA, VSD, ASD, and PVS were not included as they are very difficult to diagnose prenatally. PDA 
was excluded because the ductus arteriosus is always open prenatally.
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5.3.18 Trends in prenatal diagnosis 
5.3.18.1 Isolated CHD 
Overall, there was a significant 7% increase in prenatal diagnosis rates per year (RR=1.07, 
95% CI: 1.06-1.09; p<0.001). As shown in Table 5.23, there was a significant increase in the 
prenatal diagnosis rate of HLH (5% per year, p<0.001), HRH (8% per year, p<0.001), TGV 
(15% per year, p<0.001), ToF (21% per year, p<0.001) and CoA (9% per year, p<0.001). 
5.3.19 Heterogeneity in prenatal diagnosis between registers 
5.3.19.1 Isolated CHD 
Overall, there was significant variation in prenatal diagnosis rates between registers (LR test 
for random intercept: p<0.001). However, variation in prenatal diagnosis rates between 
registers was only evident in the “Other” CHD subtype (p<0.001). Indeed, prenatal diagnosis 
rates for CHD of severe and moderate severity are comparable between registers (Figure 5.8).  
5.3.20 Heterogeneity in trends in prenatal diagnosis between registers 
5.3.20.1 Isolated CHD 
The trends in prenatal diagnosis rates over time, shown in Figure 5.8, do not vary 
substantially by register for severe, moderate or mild CHD. Indeed, the addition of a random 
slope into the regression models did not improve model fit for any of the CHD subtypes. 
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Figure 5.8 Graph showing percentage of prenatally diagnosed cases of isolated CHD over time, by register 
and CHD severity 
 
Trends in prenatal diagnosis rates are not presented for cases with mild CHD as these cases are very difficult to 
diagnose prenatally.
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5.3.21 Association between prenatal diagnosis and maternal age 
5.3.21.1 Isolated CHD 
Considering all CHD subtypes combined, there was no association between prenatal diagnosis 
rates and maternal age at delivery (p=0.493) (Table 5.24). It was not possible to examine the 
association between prenatal diagnosis rates and maternal age in individual subtypes, due to 
low sample size. However, it was possible to examine this association in the severity 
categories. Here, there were no significant associations between maternal age and prenatal 
diagnosis rates in cases with CHD of severe and moderate severity (p=0.789 and p=0.502, 
respectively) (Table 5.24). 





RR of prenatal 
diagnosis (95% CI)ф 
P-value 
Severe <20 1.28 (0.92-1.78) 0.789 
20-24 1.07 (0.82-1.41)  
25-29 1 (Reference category)  
30-34 1.10 (0.84-1.44)  
35-40 1.03 (0.76-1.40)  
≥40 0.96 (0.54-1.71)  
Moderate <20 1.09 (0.76-1.56) 0.502 
20-24 0.78 (0.58-1.06)  
25-29 1 (Reference category)  
30-34 0.88 (0.66-1.16)  
35-40 0.95 (0.68-1.33)  
≥40 0.77 (0.41-1.43)  
All 
subtypes 
<20 1.19 (0.95-1.50) 0.493 
20-24 0.97 (0.81-1.17)  
25-29 1 (reference category)  
30-34 0.95 (0.79-1.14)  
35-40 1.08 (0.87-1.32)  
≥40 0.96 (0.65-1.40)  
† CAROBB, EMSYCAR and SWCAR were excluded due to missing prenatal diagnosis data 
Ф Adjusted for year of birth and estimated using a multilevel Poisson model with a random intercept. 
‡Isolated cases included only. 
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5.3.22 Pregnancy outcomes 
5.3.22.1 All CHD 
Overall, 0.8% of cases occurred in late miscarriages, 1.9% in stillbirths, 11.6% in TOPFAs 
and 85.7% in live births. As shown in Figure 5.9, there was variation in pregnancy outcomes 
between CHD subtypes. There was significant variation in pregnancy outcomes according to 
the presence of ECAs (Chi-square test: p<0.001). Specifically, cases of isolated CHD tended 
to occur more frequently in live births than cases of CHD with structural ECAs, 
chromosomal/ genetic ECAs and teratogenic syndromes. Pregnancy outcomes are discussed 
below in more detail, according to the presence of ECAs. 
5.3.22.2 Isolated CHD 
Altogether, 58 (0.4%) isolated cases occurred in late miscarriages, 144 (1.1%) in stillbirths, 
687 (5.2%) in TOPFAs and 12,625 (96.0%) in live births. These proportions varied according 
to subtype, with just 51.8% of cases with HLH occurring in live births compared to 99.1% of 
cases with VSD. 
5.3.22.3 CHD with structural ECAs 
Of the cases with CHD and structural ECAs, 38 (1.6%) were late miscarriages, 87 (3.6%) 
were stillbirths, 497 (20.8%) were TOPFAs and 1,768 (74.0%) were live born. Again there 
was variation in pregnancy outcomes according to CHD subtype (Table 5.25). For example, 
just 28 (37.3%) cases of HLH were live born whereas 97.9% of cases with PDA were live 
born. 
5.3.22.4 CHD with chromosomal/ genetic ECAs 
Of the cases of CHD with chromosomal/ genetic ECAs, 66 (1.7%) were late miscarriages, 140 
(3.7%) were stillbirths, 1,100 (29.0%) were TOPFAs and 2,488 (65.6%) were live born. 
Pregnancy outcomes differed according to CHD subtype (Table 5.25). For example, 27 
(27.3%) HLH cases were live born compared to 68 (100%) cases with PVS. 
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Table 5.25 Pregnancy outcomes for CHD cases, by CHD subtype and ECAs 
CHD 
subtype 
Isolated CHD  CHD with Structural ECAs CHD with Chromosomal/ Genetic ECAs 
LB                 LM                SB              TOPFA LB                 LM                SB              TOPFA LB                 LM                SB              TOPFA 
SV 71 (67.6) 0 (0) 1 (1.0) 33 (31.4) 12 (54.5) 1 (4.5) 0 (0) 9 (40.9) 10 (50) 2 (10) 0 (0) 8 (40) 
HLH 367 (51.8) 7 (1.0) 25 (3.5) 309 (43.6) 28 (37.3) 0 (0) 4 (5.3) 43 (57.3) 27 (27.3) 3 (3) 4 (4) 65 (65.7) 
EA 96 (76.2) 3 (2.4) 12 (9.5) 15 (11.9) 9 (60) 1 (6.7) 1 (6.7) 4 (26.7) 12 (92.3) 0 (0) 1 (7.7) 0 (0) 
HRH 308 (77.8) 1 (0.3) 10 (2.5) 77 (19.4) 33 (45.2) 3 (4.1) 8 (11) 29 (39.7) 62 (60.8) 1 (1) 2 (2) 37 (36.3) 
CAT 86 (81.1) 2 (1.9) 1 (0.9) 17 (16) 24 (50) 2 (4.2) 3 (6.3) 19 (39.6) 32 (48.5) 3 (4.5) 2 (3) 29 (43.9) 
AVSD 295 (87.3) 5 (1.5) 6 (1.8) 32 (9.5) 66 (59.5) 2 (1.8) 4 (3.6) 39 (35.1) 498 (64.3) 7 (0.9) 42 (5.4) 227 (29.3) 
AVA/S 400 (96.6) 0 (0) 3 (0.7) 11 (2.7) 26 (78.8) 1 (3) 1 (3) 5 (15.2) 35 (74.5) 0 (0) 0 (0) 12 (25.5) 
TGV 759 (95) 2 (0.3) 9 (1.1) 29 (3.6) 44 (81.5) 2 (3.7) 0 (0) 8 (14.8) 28 (57.1) 2 (4.1) 1 (2) 18 (36.7) 
ToF 562 (93.4) 0 (0) 7 (1.2) 33 (5.5) 135 (74.2) 3 (1.6) 6 (3.3) 38 (20.9) 172 (71.4) 4 (1.7) 6 (2.5) 59 (24.5) 
TAPVR 155 (99.4) 0 (0) 0 (0) 1 (0.6) 24 (96) 0 (0) 0 (0) 1 (4) 10 (100) 0 (0) 0 (0) 0 (0) 
CoA 46 (92) 1 (2.0) 1 (2) 2 (4) 9 (90) 0 (0) 0 (0) 1 (10) 32 (66.7) 2 (4.2) 2 (4.2) 12 (25) 
IAA 739 (98.7) 1 (0.1) 3 (0.4) 6 (0.8) 95 (83.3) 0 (0) 5 (4.4) 14 (12.3) 99 (66.9) 6 (4.1) 3 (2) 40 (27) 
DORV 106 (79.7) 3 (2.3) 1 (0.8) 23 (17.3) 28 (63.6) 2 (4.5) 1 (2.3) 13 (29.5) 28 (43.1) 0 (0) 3 (4.6) 34 (52.3) 
MVA 146 (97.3) 1 (0.7) 0 (0) 3 (2) 14 (100) 0 (0) 0 (0) 0 (0) 13 (72.2) 0 (0) 1 (5.6) 4 (22.2) 
VSD 5020 (99.1) 11 (0.2) 16 (0.3) 20 (0.4) 504 (82.5) 8 (1.3) 14 (2.3) 85 (13.9) 712 (68.1) 15 (1.4) 37 (3.5) 281 (26.9) 
ASD 1334 (98) 9 (0.7) 15 (1.1) 3 (0.2) 336 (82.6) 3 (0.7) 11 (2.7) 57 (14) 388 (86.8) 2 (0.4) 11 (2.5) 46 (10.3) 
PVS 811 (99.3) 1 (0.1) 1 (0.1) 4 (0.5) 51 (92.7) 0 (0) 0 (0) 4 (7.3) 68 (100) 0 (0) 0 (0) 0 (0) 
PDA 370 (100) 0 (0) 0 (0) 0 (0) 93 (97.9) 0 (0) 2 (2.1) 0 (0) 67 (100) 0 (0) 0 (0) 0 (0) 
Other 954 (89.4) 11 (1.0) 33 (3.1) 69 (6.5) 237 (59) 10 (2.5) 27 (6.7) 128 (31.8) 195 (41.8) 19 (4.1) 25 (5.4) 228 (48.8) 
All 
subtypes 12625 (96) 58 (0.4) 144 (1.1) 687 (5.2) 1768 (74) 38 (1.6) 87 (3.6) 497 (20.8) 2488 (65.6) 66 (1.7) 140 (3.7) 1100 (29) 
ECA=ECAs, LB= Live birth, LM= Late miscarriage, SB= Stillbirth, TOPFA= Termination of pregnancy for fetal anomalies 
 
137 
5.3.23 Termination of pregnancy for fetal anomaly 
5.3.23.1 All CHD 
Overall, 2,292 (11.6%) cases of CHD occurred in TOPFA, of which 93 (4.3%) occurred <13 
weeks gestational age, 392 (18.2%) between 14-18 weeks, 1,461 (68.0%) between 19-23 
weeks, 181 (8.4%) between 24-29 weeks and 22 (1.0%) occurred ≥30 weeks (Table 5.25). As 
shown in Figure 5.10 A, these proportions varied by CHD subtype. Additionally, TOPFA 
rates varied according to the presence of ECAs (Chi-square test: p<0.001); cases of CHD with 
structural ECAs or chromosomal/ genetic ECAs tended to be terminated earlier than isolated 
cases. TOPFA rates according to the presence of ECAs are described in more detail below. 
5.3.23.2 Isolated CHD 
As shown in Table 5.25, 687 (5.1%) cases of isolated CHD occurred in TOPFA. Among 
isolated cases of CHD that resulted in TOPFA, 10 (1.5%) occurred at <13 weeks gestational 
age, 35 (5.4%) occurred between 14-18 weeks, 545 (83.5%) occurred between 19-23 weeks, 
56 (8.6%) between 24-29 weeks and seven (1.1%) occurred at ≥30 weeks. These proportions 
varied by CHD subtype (Figure 5.10 B). 
5.3.23.3 CHD with structural ECAs 
As shown in Table 5.25, 497 (20.8%) cases of CHD with structural ECAs occurred in 
TOPFA. Of these, 21 (4.5%) occurred <13 weeks gestational age, 91 (19.6%) between 14-18 
weeks, 309 (66.5%) between 19-23 weeks, 38 (8.2%) between 24-29 weeks and six (1.3%) 
occurred ≥30 weeks. These proportions varied by CHD subtype (Figure 5.10 C). 
5.3.23.4 CHD with chromosomal/ genetic ECAs 
As shown in Table 5.25, 1,100 (29.0%) cases of CHD with chromosomal/ genetic ECAs 
resulted in TOPFA. Of these, 62 (6.1%) occurred <13 weeks gestational age, 265 (25.9%) 
between 14-18 weeks, 602 (58.8%) between 19-23 weeks, 85 (8.3%) between 24-29 weeks 












5.3.24 Trends in termination rates 
5.3.24.1 All CHD adjusted for the presence of ECAs 
Table 5.26 shows the “risk” for TOPFA per year’s increase in year of delivery, adjusted for 
the presence of ECAs. Overall, the risk of TOPFA increased significantly by 2% per year 
(p=0.001). While there was a significant increase in TOPFA rates for “Other” CHD subtypes 
over time (8% per year, p<0.001), there were no significant trends for the other CHD 
subtypes. However, there was some evidence of an increase in TOPFA rates for EA (17% per 
year, p=0.023), CAT (8% per year, p=0.023) and TGV (3% per year, p=0.010), although these 
did not reach statistical significance after applying the Bonferroni adjustment. 
Table 5.26 RRs of TOPFA per year’s increase in year of delivery, adjusted for ECAs 
CHD subtype RR of TOPFA per year P-value 
SV 1.04 (0.97-1.12) 0.291 
HLH 1.03 (1.00-1.06) 0.074 
EA 1.17 (1.02-1.34) 0.023 
HRH 1.04 (0.99-1.08) 0.099 
CAT 1.08 (1.01-1.16) 0.023 
AVSD 0.98 (0.95-1.01) 0.231 
AVAs 1.04 (0.96-1.13) 0.375 
TGV 1.09 (1.02-1.16) 0.010 
ToF 1.03 (0.99-1.08) 0.130 
IAA 1.09 (0.96-1.24) 0.181 
CoA 0.97 (0.91-1.02) 0.248 
DORV 1.00 (0.94-1.07) 0.955 
PVS 1.18 (0.97-1.43) 0.100 
Other 1.08 (1.05-1.11) <0.001 
All subtypes 1.02 (1.01-1.03) 0.001 
VSD, ASD, TAPVR, MVA and PDA are not included as these subtypes are very rarely diagnosed prenatally. 
OR=Odds ratio, TOPFA=Termination of pregnancy for fetal anomaly
141 
5.3.24.2 Interaction between trends in TOPFA and the presence of ECAs 
Considering all CHD subtypes combined, the interaction between year of delivery and the 
presence of ECAs was statistically significant (p<0.001); in other words trends over time in 
TOPFA rates varied significantly in cases of isolated CHD, CHD with structural ECAs and 
CHD with chromosomal/ genetic ECAs. Therefore, TOPFA rates over time were modelled 
separately in isolated cases of CHD, CHD with structural ECAs and CHD with chromosomal/ 
genetic ECAs. In cases of isolated CHD, the risk of TOPFA increased by 4% per year 
(RR=1.04, 95% CI: 1.02-1.06; p<0.001), in cases of CHD with structural ECAs, the risk of 
TOPFA increased by 3% per year (RR=1.03, 95% CI: 1.02-1.06; p<0.001) and in cases of 
CHD with chromosomal/ genetic ECAs, the risk of TOPFA increased by 1% per year 
(RR=1.01, 95% CI: 1.00-1.02; p=0.033). 
There were no significant interactions between year of delivery and the presence of ECAs in 
any of the CHD subtypes. That is, there was no evidence that trends in TOPFA rates over 
time varied according to the presence of ECAs. 
5.3.25 Trends in terminations in prenatally diagnosed cases only 
5.3.25.1 Isolated CHD 
Among prenatally diagnosed cases of CHD, the risk of TOPFA decreased by 3% per year, 
although this did not quite reach statistical significance (p=0.031). Among prenatally 
diagnosed cases only, there was some evidence that the risk of TOPFA decreased by 33% per 
year in cases of DORV (p=0.011) (Table 5.27).
142 
Table 5.27 Trends in TOPFA rates over time in isolated cases of CHD, by prenatal diagnosis 
CHD 
subtype 
Prenatally diagnosed and 
prenatally undiagnosed cases Prenatally diagnosed cases* 



















p= 0.385 1.000 
HLH 
1.04 (1.01-1.07); 




p= 0.357 1.000 
EA 
1.13 (0.98-1.3);  




p= 0.183 0.132 
HRH 
1.06 (1.01-1.11); 




p= 0.231 1.000 
CAT 
1.03 (0.93-1.15); 




p= 0.834 1.000 
AVSD 
1.00 (0.92-1.09); 




p= 0.053 0.065 
AVA/S 
1.03 (0.92-1.14); 




p= 0.817 1.000 
TGV 
1.15 (1.04-1.26); 




p= 0.985 1.000 
ToF 
1.09 (1-1.19); 




p= 0.188 1.000 
IAA 
1.13 (0.76-1.67); 
p= 0.549 0.474 
1/2 







p= 0.746 1.000 
DORV 





p= 0.011 0.053 
Other 
1.06 (1-1.13);  















TAPVR, MVA, VSD, ASD, and PVS were not included as they are very difficult to diagnose prenatally. PDA 
was excluded because the ductus arteriosus is always open prenatally. There were too few cases of IAA to 
examine TOPFA rates in prenatally diagnosed cases only. 
OR=Odds ratio, TOPFA=Termination of pregnancy for fetal anomaly 
*Analysis carried out on cases notified to CARIS, NorCAS and WANDA
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5.3.26 Heterogeneity in termination rates between registers 
5.3.26.1 All CHD adjusted for the presence of ECAs 
There was significant variation in TOPFA rates between registers (significance of random 
intercept: p<0.001). There was no significant difference in TOPFA rates between registers for 
any of the CHD subtypes. However, in cases of EA and TAPVR, the random intercept almost 
reached statistical significance (significance of random intercept: p=0.036 and p=0.035, 
respectively). EA resulted in TOPFA in 4.6% of cases notified to CARIS, 0% of cases 
notified to CAROBB, 13.5% of cases notified to EMSYCAR, 7.7% of cases notified to 
NorCAS, 0% of cases notified to SWCAR and 33.3% of cases notified to WANDA. TAPVR 
resulted in TOPFA in just one case, which was notified to CARIS. 
5.3.27 Association between maternal age and total birth prevalence 
5.3.27.1 All CHD adjusted for ECAs 
Considering all CHD subtypes, there was a significant association between the total birth 
prevalence of CHD and maternal age at delivery (adjusted for the presence of ECAs) 
(p<0.001). Specifically, the risk of CHD increased as maternal age increased (Table 5.28). 
The total birth prevalence was 86.6 per 10,000 total births in mothers aged <20 and 123.1 per 
10,000 total births in mothers aged ≥40. 
VSD, ASD and AVSD were significantly associated with maternal age at delivery (after 
adjustment for the presence of ECAs) (p<0.001 for each). Specifically, the risk of VSD, ASD 
and AVSD increased with increasing maternal age, with mothers aged 40 and over at 80%, 
126% and 443% significant increased risk compared to mothers aged between 25 and 29, 
respectively (Table 5.27). There was some evidence that the prevalence of HRH was 
associated with maternal age at delivery (p=0.033), although the association did not quite 
reach statistical significance. Here there appeared to be a U-shaped association between the 
total birth prevalence of HRH and maternal age at delivery. 
As shown in Table 5.28, adjusting the models for year of delivery had little impact on the 
association with maternal age at delivery.
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Table 5.28 Prevalence and RR of CHD according to maternal age, by CHD subtype 





(95% CI)*†  P-value 
Adjusted RR 
(95% CI)† ‡ P-value 
SV <20 8 0.6 (0.2-1.1) 0.83 (0.38-1.82) 0.195 0.84 (0.38-1.83) 0.174 
 20-24 22 0.6 (0.4-0.9) 0.91 (0.52-1.59)  0.92 (0.53-1.61)  
 25-29 31 0.6 (0.4-0.9) 1 (Ref category)  1 (Ref category)  
 20-34 14 0.3 (0.2-0.5) 0.47 (0.25-0.91)  0.48 (0.25-0.92)  
 35-39 17 0.7 (0.4-1.1) 1.21 (0.66-2.23)  1.27 (0.69-2.35)  
 ≥40 3 0.7 (0.1-1.9) 1.17 (0.36-3.84)  1.25 (0.38-4.12)  
HLH <20 47 3.4 (2.5-4.5) 1.31 (0.93-1.83) 0.363 1.31 (0.93-1.83) 0.357 
 20-24 101 2.9 (2.4-3.5) 1.10 (0.85-1.44)  1.10 (0.85-1.43)  
 25-29 125 2.6 (2.2-3.1) 1 (Ref category)  1 (Ref category)  
 20-34 114 2.5 (2-3) 0.93 (0.72-1.2)  0.93 (0.72-1.2)  
 35-39 59 2.4 (1.8-3.2) 0.92 (0.67-1.26)  0.91 (0.66-1.25)  
 ≥40 11 2.2 (1-4) 0.83 (0.44-1.58)  0.83 (0.43-1.57)  
EA <20 9 0.4 (0.2-0.9) 0.68 (0.28-1.63) 0.566 0.68 (0.28-1.63) 0.565 
 20-24 15 0.4 (0.2-0.7) 0.68 (0.36-1.26)  0.68 (0.36-1.26)  
 25-29 30 0.6 (0.4-0.9) 1 (Ref category)  1 (Ref category)  
 20-34 17 0.4 (0.2-0.6) 0.58 (0.32-1.06)  0.58 (0.32-1.06)  
 35-39 13 0.6 (0.3-1) 0.89 (0.46-1.7)  0.88 (0.46-1.7)  
 ≥40 0 0 (0-0.8)     
HRH <20 38 2.7 (1.9-3.7) 1.56 (1.06-2.29) 0.033 1.56 (1.06-2.31) 0.028 
 20-24 95 2.6 (2.1-3.2) 1.5 (1.1-2.03)  1.51 (1.11-2.05)  
 25-29 82 1.7 (1.3-2.1) 1 (Ref category)  1 (Ref category)  
 20-34 81 1.7 (1.3-2.1) 1.02 (0.74-1.41)  1.03 (0.75-1.42)  
 35-39 50 1.9 (1.4-2.5) 1.22 (0.84-1.78)  1.25 (0.86-1.82)  
 ≥40 11 2.4 (1.2-4.3) 1.61 (0.86-3.03)  1.67 (0.89-3.15)  
CAT <20 15 1.1 (0.6-1.8) 1.23 (0.68-2.24) 0.067 1.23 (0.68-2.23) 0.080 
 20-24 21 0.6 (0.4-0.9) 0.67 (0.39-1.16)  0.67 (0.39-1.15)  
 25-29 44 0.8 (0.6-1.1) 1 (Ref category)  1 (Ref category)  
 20-34 31 0.7 (0.5-1) 0.86 (0.54-1.38)  0.85 (0.53-1.37)  
 35-39 28 1.1 (0.7-1.7) 1.49 (0.9-2.45)  1.45 (0.88-2.39)  
 ≥40 6 1.3 (0.5-2.9) 1.77 (0.75-4.2)  1.71 (0.72-4.06)  
AVSD <20 69 4.9 (3.8-6.2) 1.41 (1.06-1.87) <0.001 1.41 (1.06-1.87) <0.001 
 20-24 142 3.9 (3.3-4.7) 1.14 (0.91-1.44)  1.15 (0.91-1.44)  
 25-29 159 3.3 (2.8-3.9) 1 (Ref category)  1 (Ref category)  
 20-34 180 3.9 (3.3-4.5) 1.22 (0.98-1.52)  1.22 (0.98-1.52)  
 35-39 156 6.4 (5.4-7.5) 2.12 (1.69-2.66)  2.12 (1.69-2.66)  
 ≥40 76 16 (12.5-20.1) 5.43 (4.11-7.18)  5.45 (4.12-7.21)  
AVA/S <20 32 2.3 (1.6-3.2) 0.84 (0.57-1.24) 0.093 0.85 (0.58-1.25) 0.147 
 20-24 85 2.4 (1.9-3) 0.88 (0.67-1.16)  0.89 (0.68-1.18)  
 25-29 129 2.7 (2.2-3.2) 1 (Ref category)  1 (Ref category)  
 20-34 103 2.2 (1.8-2.6) 0.84 (0.64-1.09)  0.85 (0.65-1.11)  
 35-39 34 1.4 (0.9-1.9) 0.54 (0.37-0.81)  0.57 (0.38-0.84)  
 ≥40 12 2.2 (1-4) 0.91 (0.48-1.73)  0.97 (0.51-1.86)  
TGV <20 39 2.7 (1.9-3.7) 0.84 (0.59-1.2) 0.828 0.84 (0.59-1.2) 0.822 
 20-24 107 3.1 (2.5-3.7) 0.96 (0.75-1.22)  0.95 (0.74-1.22)  
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(95% CI)*†  P-value 
Adjusted RR 
(95% CI)† ‡ P-value 
 25-29 156 3.2 (2.7-3.8) 1 (Ref category)  1 (Ref category)  
 20-34 142 3.0 (2.6-3.6) 0.96 (0.76-1.21)  0.96 (0.76-1.21)  
 35-39 64 2.7 (2-3.4) 0.87 (0.64-1.17)  0.86 (0.64-1.16)  
 ≥40 17 3.5 (2-5.7) 1.17 (0.7-1.96)  1.15 (0.69-1.93)  
ToF <20 51 3.6 (2.7-4.7) 0.99 (0.72-1.36) 0.087 0.98 (0.71-1.35) 0.143 
 20-24 142 4.1 (3.4-4.8) 1.16 (0.92-1.45)  1.14 (0.91-1.43)  
 25-29 168 3.5 (2.9-4) 1 (Ref category)  1 (Ref category)  
 20-34 155 3.1 (2.6-3.7) 0.95 (0.75-1.18)  0.94 (0.75-1.17)  
 35-39 99 4 (3.2-4.9) 1.25 (0.97-1.62)  1.22 (0.94-1.57)  
 ≥40 23 4.8 (3-7.3) 1.58 (1.01-2.46)  1.51 (0.96-2.36)  
TAPVR <20 14 1 (0.5-1.7) 1.34 (0.72-2.5) 0.735 1.34 (0.72-2.5) 0.735 
 20-24 32 0.9 (0.6-1.3) 1.25 (0.77-2.02)  1.25 (0.77-2.02)  
 25-29 36 0.7 (0.5-1) 1 (Ref category)  1 (Ref category)  
 20-34 29 0.6 (0.4-0.9) 0.89 (0.54-1.47)  0.89 (0.54-1.47)  
 35-39 15 0.6 (0.3-1) 0.92 (0.49-1.73)  0.93 (0.49-1.73)  
 ≥40 3 0.7 (0.1-1.9) 1.03 (0.32-3.37)  1.03 (0.32-3.38)  
IAA <20 7 0.5 (0.2-1) 0.79 (0.34-1.8) 0.645 0.79 (0.34-1.8) 0.645 
 20-24 14 0.4 (0.2-0.7) 0.64 (0.34-1.21)  0.64 (0.34-1.21)  
 25-29 29 0.6 (0.4-0.9) 1 (Ref category)  1 (Ref category)  
 20-34 18 0.4 (0.2-0.6) 0.66 (0.37-1.19)  0.66 (0.37-1.19)  
 35-39 10 0.4 (0.2-0.8) 0.75 (0.36-1.54)  0.75 (0.36-1.54)  
 ≥40 1 0.2 (0-1.2) 0.38 (0.05-2.82)  0.38 (0.05-2.82)  
CoA <20 56 4 (3-5.2) 1.13 (0.84-1.54) 0.084 1.14 (0.84-1.55) 0.052 
 20-24 125 3.5 (2.9-4.2) 1 (0.79-1.27)  1.01 (0.8-1.28)  
 25-29 167 3.4 (2.9-4) 1 (Ref category)  1 (Ref category)  
 20-34 174 3.5 (3-4.1) 1.07 (0.86-1.34)  1.08 (0.87-1.35)  
 35-39 105 4.1 (3.4-5.1) 1.29 (1-1.67)  1.32 (1.02-1.71)  
 ≥40 28 5.2 (3.4-7.8) 1.71 (1.11-2.63)  1.77 (1.15-2.72)  
DORV <20 18 1.3 (0.8-2) 1.86 (1.04-3.29) 0.209 1.86 (1.05-3.31) 0.227 
 20-24 31 0.9 (0.6-1.2) 1.23 (0.75-2.02)  1.23 (0.75-2.01)  
 25-29 34 0.7 (0.5-1) 1 (Ref category)  1 (Ref category)  
 20-34 39 0.8 (0.6-1.1) 1.12 (0.7-1.8)  1.11 (0.69-1.78)  
 35-39 22 0.9 (0.6-1.4) 1.3 (0.75-2.25)  1.26 (0.73-2.18)  
 ≥40 7 1.5 (0.6-3.2) 2.21 (0.98-4.99)  2.11 (0.93-4.78)  
MVA <20 16 1.1 (0.7-1.9) 1.63 (0.89-2.98) 0.469 1.64 (0.9-3) 0.457 
 20-24 33 0.9 (0.6-1.3) 1.35 (0.82-2.21)  1.36 (0.83-2.23)  
 25-29 33 0.7 (0.5-0.9) 1 (Ref category)  1 (Ref category)  
 20-34 42 0.9 (0.6-1.2) 1.37 (0.85-2.2)  1.39 (0.86-2.23)  
 35-39 19 0.8 (0.5-1.2) 1.31 (0.73-2.35)  1.36 (0.76-2.45)  
 ≥40 1 0.2 (0-1.2) 0.38 (0.05-2.76)  0.4 (0.05-2.92)  
VSD <20 468 32.2 (29.3-35.3) 1.02 (0.92-1.14) <0.001 1.02 (0.92-1.14) <0.001 
 20-24 1090 30.5 (28.7-32.4) 0.99 (0.92-1.08)  0.99 (0.92-1.08)  
 25-29 1436 29.4 (27.9-31) 1 (-)  1 (Ref category)  
 20-34 1421 29.8 (28.2-31.4) 1.08 (1-1.17)  1.08 (1-1.17)  
 35-39 779 31.8 (29.5-34.2) 1.21 (1.11-1.32)  1.21 (1.11-1.32)  
146 





(95% CI)*†  P-value 
Adjusted RR 
(95% CI)† ‡ P-value 
 ≥40 229 46.4 (40.3-53) 1.8 (1.55-2.08)  1.79 (1.55-2.08)  
ASD <20 138 9.6 (8.1-11.4) 0.96 (0.79-1.17) <0.001 0.96 (0.79-1.17) <0.001 
 20-24 391 10.7 (9.7-11.9) 1.13 (0.99-1.3)  1.13 (0.99-1.3)  
 25-29 446 9.1 (8.3-10) 1 (Ref category)  1 (Ref category)  
 20-34 401 8.3 (7.5-9.2) 0.97 (0.84-1.11)  0.97 (0.84-1.11)  
 35-39 277 11.5 (10.1-13) 1.41 (1.21-1.65)  1.41 (1.21-1.65)  
 ≥40 85 17.7 (14.1-22) 2.26 (1.78-2.86)  2.26 (1.78-2.86)  
PVS <20 67 4.7 (3.6-5.9) 0.94 (0.72-1.25) 0.167 0.94 (0.71-1.25) 0.199 
 20-24 160 4.5 (3.8-5.2) 0.94 (0.76-1.16)  0.94 (0.76-1.15)  
 25-29 227 4.5 (3.9-5.2) 1 (Ref category)  1 (Ref category)  
 20-34 205 4.2 (3.6-4.8) 1 (0.82-1.21)  0.99 (0.82-1.21)  
 35-39 116 4.8 (3.9-5.8) 1.24 (0.99-1.57)  1.23 (0.98-1.55)  
 ≥40 26 5 (3.2-7.5) 1.37 (0.89-2.11)  1.35 (0.88-2.08)  
PDA <20 39 2.7 (1.9-3.7) 1.4 (0.95-2.06) 0.248 1.4 (0.95-2.06) 0.248 
 20-24 77 2.2 (1.7-2.8) 1.18 (0.86-1.61)  1.18 (0.86-1.61)  
 25-29 83 1.8 (1.4-2.2) 1 (Ref category)  1 (Ref category)  
 20-34 108 2.4 (2-2.9) 1.39 (1.04-1.85)  1.39 (1.04-1.85)  
 35-39 47 2 (1.4-2.6) 1.17 (0.81-1.68)  1.17 (0.81-1.68)  
 ≥40 12 2.6 (1.4-4.6) 1.56 (0.85-2.86)  1.56 (0.85-2.85)  
Other <20 111 7.8 (6.4-9.4) 1.03 (0.83-1.28) 0.153 1.03 (0.83-1.28) 0.151 
 20-24 246 6.9 (6-7.8) 0.91 (0.77-1.07)  0.91 (0.77-1.07)  
 25-29 373 7.5 (6.7-8.3) 1 (Ref category)  1 (Ref category)  
 20-34 346 7.4 (6.6-8.2) 0.98 (0.84-1.14)  0.98 (0.84-1.14)  
 35-39 190 7.8 (6.7-9) 1.03 (0.86-1.23)  1.03 (0.86-1.23)  
 ≥40 49 10.5 (7.7-13.9) 1.4 (1.04-1.9)  1.4 (1.04-1.9)  
All  <20 1241 86.6 (81.8-91.6) 1.06 (0.99-1.13) <0.001 1.05 (0.99-1.13) <0.001 
subtypes 20-24 2929 81.9 (79-85) 1.02 (0.97-1.07)  1.02 (0.97-1.07)  
 25-29 3788 77.5 (75-80.1) 1 (Ref category)  1 (Ref category)  
 20-34 3620 75.8 (73.3-78.4) 1.03 (0.99-1.08)  1.03 (0.98-1.08)  
 35-39 2100 85.9 (82.1-89.7) 1.22 (1.16-1.29)  1.21 (1.14-1.28)  
 ≥40 600 123.1 (113.2-
133.7) 
1.81 (1.65-1.98)  1.78 (1.63-1.95)  
*Adjusted for ECAs 
‡Adjusted for ECAs and year of delivery 
†Cases notified to CAROBB (all years), EMSYCAR (all years), and SWCAR for 2010 were excluded from this 
analysis due to missing maternal age data. 
Maternal age was missing in 187 (1.9%) isolated cases, 10 (0.6%) cases with structural ECAs and 24 (1.0%) 
cases with chromosomal/ genetic ECAs.
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5.3.27.2 Interaction between maternal age and the presence of ECAs 
There was a significant interaction between maternal age and the presence of ECAs 
(p<0.001). Therefore, the association with maternal age was modelled separately for isolated 
CHD, CHD with structural ECAs and CHD with chromosomal/ genetic ECAs. As shown in 
Table 5.29, there was no association between maternal age and the prevalence of isolated 
CHD (p=0.103). There was a significant association between maternal age and the prevalence 
of CHD with structural ECAs (p<0.001). The association appeared to be U-shaped, with 
mothers under 20 and aged 35 and over at increased risk (Table 5.27). There was also a 
significant association between maternal age and the prevalence of CHD with chromosomal/ 
genetic ECAs (p<0.001), where the risk of CHD increased linearly with increasing age (Table 
5.27). 
There was a significant interaction between maternal age and the presence of ECAs in cases 
of AVSD (p<0.001), VSD (p<0.001) and ASD (p<0.001). There was some evidence of an 
association between maternal age and the presence of ECAs in cases of ToF (p=0.016), 
although this did not quite reach statistical significance. Table 5.28 shows the RRs of CHD 
according to maternal age in cases of AVSD, ToF, ASD, and VSD modelled separately 
according to the presence of ECAs. 
In isolated cases of AVSD, there was no statistically significant association between 
prevalence and maternal age at delivery (p=0.103). However, the risk of AVSD appeared to 
decrease linearly with increasing maternal age at delivery. For example, compared to cases 
born to mothers aged 25-29, the risk of AVSD was 74% greater in cases born to mothers aged 
<20 (RR=1.74, 95% CI: 1.11-2.74). In cases of AVSD with structural ECAs, the association 
between prevalence and maternal age did not reach statistical significance (p=0.061), but a U-
shaped association was observed (Table 5.28). There was a significant association between 
maternal age and prevalence in cases of AVSD with chromosomal/ genetic ECAs (p<0.001) 
(Table 5.28). Mothers of increased maternal age were at increased risk of AVSD, for 
example, mothers aged 40 and over were eight times significantly more likely to have a 
pregnancy associated with AVSD (Table 5.29). 
In cases with ToF, there was no significant association with maternal age in isolated cases 
(p=0.462) or cases with structural ECAs (p=0.178), but there was an association with 
maternal age in cases with chromosomal/ genetic ECAs (p<0.001). Increased maternal age 
was associated with an increased risk of ToF (Table 5.29). 
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For cases of VSD and ASD, there were no significant associations with maternal age in 
isolated cases (p= 0.485 and p=0.025, respectively) or in cases with structural ECAs (p=0.085 
and p=0.028, respectively), but there was a significant association in cases with chromosomal/ 
genetic ECAs (p<0.001 and p<0.001); increasing maternal age was associated with an 
increased risk of VSD and ASD (Table 5.29).
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Age Isolated CHD CHD with structural 
ECAs 
CHD with chromosomal 
ECAs 
RR (95% CI) P-
value 
RR (95% CI) P-
value 
RR (95% CI) P-value 
AVSD <20 1.74 (1.11-2.74) 0.103 2.99 (1.15-7.80) 0.061 1.08 (0.72-1.62) <0.001 
 20-24 1.18 (0.80-1.73)  2.69 (1.21-6.00)  0.99 (0.72-1.35)  
 25-29 1 (Ref category)  1 (Ref category)  1 (Ref category)  
 20-34 0.98 (0.66-1.44)  1.61 (0.70-3.74)  1.31 (1.00-1.73)  
 35-39 0.83 (0.49-1.38)  2.07 (0.81-5.26)  2.84 (2.16-3.74)  
 ≥40 0.86 (0.31-2.37)  4.69 (1.43-15.37)  8.07 (5.86-11.1)  
ToF <20 0.84 (0.55-1.28) 0.463 2.19 (1.11-4.31) 0.178 0.73 (0.34-1.58) <0.001 
 20-24 1.10 (0.83-1.46)  1.46 (0.81-2.63)  1.17 (0.72-1.89)  
 25-29 1 (Ref category)  1 (Ref category)  1 (Ref category)  
 20-34 0.82 (0.62-1.10)  1.32 (0.74-2.34)  1.07 (0.67-1.72)  
 35-39 0.90 (0.63-1.29)  1.65 (0.86-3.18)  2.07 (1.27-3.37)  
 ≥40 0.74 (0.35-1.60)  2.66 (1.00-7.09)  3.52 (1.74-7.12)  
VSD <20 1.00 (0.88-1.12) 0.485 1.47 (1.05-2.07) 0.085 0.83 (0.58-1.19) <0.001 
 20-24 1.01 (0.92-1.10)  1.10 (0.83-1.46)  0.8 (0.62-1.05)  
 25-29 1 (Ref category)  1 (Ref category)  1.06 (0.84-1.34)  
 20-34 1.08 (0.99-1.17)  1.03 (0.79-1.35)  2.68 (2.15-3.34)  
 35-39 1.01 (0.90-1.12)  1.20 (0.87-1.64)  7.39 (5.7-9.59)  
 ≥40 1.03 (0.84-1.27)  1.75 (1.06-2.89)    
ASD <20 0.86 (0.67-1.09) 0.025 1.47 (0.97-2.23) 0.028 0.84 (0.5-1.41) <0.001 
 20-24 1.13 (0.95-1.34)  1.37 (0.98-1.91)  0.88 (0.6-1.28)  
 25-29 1 (Ref category)  1 (Ref category)  1 (Ref category)  
 20-34 0.90 (0.75-1.06)  0.91 (0.65-1.29)  1.26 (0.91-1.74)  
 35-39 1.13 (0.92-1.38)  1.45 (1.00-2.10)  2.47 (1.77-3.45)  
 ≥40 1.34 (0.93-1.93)  1.72 (0.91-3.26)  6.55 (4.39-9.78)  
All <20 0.99 (0.92-1.07) 0.976 1.52 (1.27-1.82)   <0.001 1.04 (0.87-1.23) <0.001 
Sub-
types 
20-24 1.00 (0.95-1.06)  1.27 (1.1-1.47)  0.93 (0.82-1.06)  
25-29 1 (Ref category) 1 (Ref category) 1 (Ref category) 
20-34 0.99 (0.94-1.05)  1.04 (0.9-1.2)  1.18 (1.05-1.32)  
 35-39 1.00 (0.94-1.07)  1.23 (1.04-1.45)  2.18 (1.94-2.47)  
 ≥40 1.04 (0.91-1.19)  1.47 (1.1-1.96)  5.63 (4.85-6.53)  
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5.4 Discussion 
This is the largest and most comprehensive study to examine the epidemiology of CHD in the 
UK, according to CHD subtype. Using data from six BINOCARs, I found a total birth 
prevalence of 65 per 10,000 total births and a live birth prevalence of 56 per 10,000 live 
births. Over time, the total birth prevalence and the live birth prevalence of ToF increased, 
whereas the prevalence of AVA/S and CoA decreased. Trends were not observed in any other 
CHD subtype. The prevalence of all CHD subtypes varied between the registers. CHD 
occurred in isolation in the majority of cases (68% of total birth cases and 75% of live born 
cases). Isolated cases of CHD were rarely prenatally diagnosed (30%), although the more 
severe subtypes were diagnosed more frequently than the milder subtypes. Prenatal diagnosis 
rates for HLH, HRH, TGV, ToF and CoA increased over the study period. This increase in 
prenatal diagnosis rates appeared to account for an increase in TOPFA rates over the study 
period. Maternal age at delivery was associated with the prevalence of ToF, AVSD, VSD and 
ASD but only in cases with chromosomal/ genetic ECAs. 
5.4.1 Strengths 
The primary strength of this study is the use of population-based data derived from 
established, high-quality, CARs. Standard methods of identifying and classifying cases across 
all registers and the use of multiple sources of notifications ensure high case ascertainment. 
Moreover, all registers use the same ICD coding system, resulting in consistent coding across 
the registers. Accurate diagnoses are achieved by the review of complex cases by paediatric 
pathologists and clinical geneticists and, where relevant, diagnoses are confirmed via post 
mortem. 
Using data from six CARs covering a birth population of three million, I was able to examine 
the epidemiology of CHD according to CHD subtype. I was also able to examine CHD 
according to the presence of ECAs, which not only have very different aetiologies but are also 
diverse in terms of outcome, characteristics and interventions. Due to the richness of the data, 
I was able to investigate characteristics of cases with CHD including: standardised birth 
weight, gestational age, sex, maternal age, prenatal diagnosis and pregnancy outcomes. I was 
also able to examine trends in prevalence, TOPFA rates and prenatal diagnosis rates, which 
are important factors in determining the number of children living with CHD. 
A further strength is that I was able to examine all pregnancy outcomes, including late 
miscarriages, stillbirths and TOPFAs. Therefore, I could report on pregnancy outcomes, 
which may be useful for parents when a diagnosis is made during the prenatal period. 
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Additionally, the fact that the study was not restricted to live births meant that my trends in 
total birth prevalence are not likely to be confounded by changing trends in TOPFA or fetal 
death. 
The multilevel methods utilised to analyse trends in prevalence, TOPFA rates and prenatal 
diagnosis rates enable more accurate estimates of standard error to be calculated compared to 
a single level analysis of the nested data. The random effects limit the potential for 
confounding due to registers contributing data from different time periods [127]. I was also 
able to examine trends in prevalence adjusted for maternal age, which may have been a 
confounding factor, given that the proportion of births to mothers of advanced maternal age 
increased from 12% in 1998 to 19% in 2010. 
5.4.2 Limitations 
This study also has some limitations. Firstly, LR tests were used to assess the fit of models 
after the inclusion of a random intercept, a random slope and to test the presence of over-
dispersion. However, in random effect models, the LR test is known to be conservative. 
Therefore the p-values provided for the LR test represent the upper bound of the significance 
level [128]. This should not have impacted the interpretation of the results given that the p-
values for heterogeneity were highly significant. 
To account for multiple testing, I applied a Bonferroni adjustment and classified p<0.003 as 
statistically significant, as opposed to the more commonly used nominal significance level of 
p<0.05. This adjustment limited the possibility of type I errors (i.e. false positives), but as a 
result may have increased the possibility of type II errors (i.e. false negatives). This may have 
been particularly problematic given that many of the subtypes occurred infrequently, and 
therefore the power may have been low for some analyses. However, in the results section, I 
also highlighted the results that were significant at the p<0.05 level. 
Additionally, there was a high level of maternal age data missing and so analyses on maternal 
age was restricted to cases notified to four BINOCARs. After adjustment for maternal age, I 
found that the association between CHD prevalence and year of birth did not alter. Due to the 
models being fitted to two slightly different data sets, this should perhaps be interpreted with 
caution. However, refitting the unadjusted models to the subset of the data, showed very 
similar RRs to the unadjusted models fitted to the full data set. This suggests that the subset of 
data was representative of the full set of data. 
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Similarly, data on prenatal diagnosis was used from three registers only. Given the small 
numbers for certain subtypes combined with the rarity of prenatal diagnosis, it was possible 
that the study did not have the power to detect trends in diagnosis rates over time for all 
subtypes. Additionally, I was only able to examine prenatal diagnosis of isolated CHD 
because the BINOCARs do not specifically record which anomaly was prenatally diagnosed. 
Heterogeneity in prevalence estimates between registers will have been caused by differences 
in ascertainment as opposed to real variation. For example, close relations between paediatric 
cardiology departments with NorCAS and CARIS, may have caused increased ascertainment 
of CHD cases by these registers. This is evident in the high level of ascertainment of mild 
cases specifically. Other registers rely more heavily on cardiac databases which have greater 
focus on cases that were admitted for catheterization, investigation or surgery. This is likely to 
have impacted on the ascertainment of CHD of milder severity (in particular on VSDs that 
close spontaneously), but would have had little impact on CHD of moderate or severe 
severity, which are more likely to require medical intervention. The ascertainment of the less 
severe forms of mild CHD by NorCAS and CARIS may explain why I identified a suggestion 
of a decreasing trend post-2005 in these two registers only, if the milder cases tended to be 
diagnosed later in life and were, therefore, not captured in the data despite being born during 
the study period. As discussed by Hoffman et al, it is likely that the under ascertained cases of 
VSDs are milder forms of the CHD subtype and arguably, these cases are not clinically 
significant [129]. Differences in ascertainment may also have been caused by the observed 
variation in prenatal diagnosis rates. Alternatively, heterogeneity in prevalence may be linked 
to differences in study populations. For example, as discussed in Chapter 4, the populations 
covered by the six BINOCAR were diverse in terms of maternal ethnicity, smoking status, 
maternal BMI and maternal diabetes which may be risk factors for certain CHD [4, 5, 80, 96, 
97, 108, 130, 131]. All data notified to the BINOCAR are routinely collected in the clinical 
setting and, therefore, these variables were not complete enough to include in my analysis. 
I modelled trends in the prevalence of CHD linearly, as most other studies have done [55, 57, 
60, 62]. An alternative approach would have been to model the trends non-linearly using 
piecewise regression (splines). Piecewise regression can be used to model trends in several 
sections, which must join at pre-specified time-points called knots. Had I used this approach 
however, my results for severe and moderate subtypes would have remained unchanged. For 
CHD overall and for the mild CHD subtypes however, I would not have found similar trends 
prior to 2004 but significant decreases thereafter. This decrease in prevalence is likely caused 
by the cases delivered at the end of the study period having a smaller window for diagnosis. 
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For this reason, modelling this plateau may actually be more misleading than merely 
modelling the trend linearly. The other disadvantage of using piecewise regression, is that it is 
heavily influenced by the natural fluctuations in yearly prevalence, which always occur due to 
CHD being a rare event. 
5.4.3 Summary and comparison to other studies 
5.4.3.1 Sex distribution 
There was an even distribution of male and female cases. This is consistent with 18 studies 
identified in the literature review detailed in Chapter 3, where 46-54% cases were male. 
However, Tennant et al’s meta-analysis of five studies showed a 70% increased risk of CHD 
in males compared to females. I found that the more severe subtypes tended to have a male 
preponderance, so perhaps the studies discussed by Tennant et al had lower ascertainment of 
the milder CHD subtypes. Lary and Paulozzi hypothesise that sex differences in congenital 
anomalies that originate within the first eight weeks may be related to variation in 
susceptibility to teratogens or to X or Y linked genes that influence morphogenesis [132]. 
5.4.3.2 Prenatal diagnosis 
There was a significant increase in the rate of prenatal diagnosis over the study period. While 
the trend was only significant among cases of HLH, HRH, TGV, ToF and CoA, prenatal 
diagnosis rates increased in all subtypes with the exception of IAA. Few studies have reported 
on trends in prenatal diagnosis of CHD, but those that have reported improvements over time 
in the North of England (1985-2004, using a subset of my data), France (1983-2000) and the 
USA (1990-1994) [133-135]. This is likely to have resulted from improvements in diagnostic 
technologies over time (e.g. fetal echocardiography) but in the UK, may also be related to the 
recent implementation of the FASP guidelines, which state that all pregnant women should 
have their pregnancies prenatally screened for “severe” CHD [136]. 
I found a prenatal diagnosis rate of 30% amongst isolated cases of CHD. This exceeds Ailes 
et al’s prenatal diagnosis rate of 15% (among “non-syndromic” cases of CHD) in the USA 
(1998-2005) [126]. However, Ailes et al included cases of TAPVR, VSD, ASD and PVS, 
which I excluded as prenatal diagnosis is uncommon in these subtypes. My prenatal diagnosis 
rate also exceeds Bull et al’s rate of 23.4% in the UK (1993-1995), despite Bull et al 
examining “complex” cases of CHD only (defined as those requiring intervention or resulting 
in death in the first year of life). Bull et al’s lower rate is likely related to the earlier study 
period [137]. Compared to my study, Khoshnood et al reported a substantially greater prenatal 
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diagnosis rate of 40%, among isolated cases of CHD (excluding VSDs) born in Paris (2005-
2008) [73]. This higher rate is likely due to Khoshnood et al’s more recent study period. 
Indeed, between 2005-2008 my prenatal diagnosis rate increased to 36.7%. 
When considering all CHD subtypes combined, I identified significant heterogeneity in 
prenatal diagnosis rates between registers. However, this variation was restricted to “Other” 
CHD subtypes. After excluding these cases, there was no longer significant variation in 
prenatal diagnosis rates. The “Other” CHD subtype is a very heterogeneous group, and 
therefore variation in the prenatal diagnosis of these anomalies may be related to differences 
in coding between registers. For example, some registers may not record exactly the same set 
of anomalies given that there is no specific EUROCAT criteria for this group [138]. 
In my study, there was no association between prenatal diagnosis and maternal age at 
delivery. Conversely, in Ailes et al’s study, women aged <30 were significantly more likely to 
have a prenatal diagnosis than women aged ≥30 (RR=1.50). However the effect size 
decreased after adjustment for CHD complexity, presence of ECAs, year of delivery, family 
history of CHD, gestational age, plurality, ethnicity, maternal education, BMI, pre-gestational 
diabetes, hypertension, fertility treatments, previous pregnancy loss, pregnancy intention and 
trimester of first prenatal visit (aRR=1.13). Given that advanced maternal age is a risk factor 
for certain congenital anomalies [105, 139, 140], these women tend to be scanned more 
frequently and perhaps more likely to be offered fetal echocardiography, which may explain 
the increased prenatal diagnosis rates. Perhaps the difference in my results compared to the 
study by Ailes et al is related to inclusion criteria. For example, Ailes et al included cases with 
ECAs whereas these were excluded in my analyses of prenatal diagnosis. Had I included these 
cases, I would have identified significantly greater prenatal diagnosis rates among mothers 
aged ≥30 compared to <30. 
5.4.3.3 TOPFA rates 
There was an increasing trend in the proportion of isolated CHD cases that resulted in 
TOPFA. Given that the trend was not present amongst prenatally diagnosed cases only, this 
suggests that the trend in TOPFA rates was driven my improvements in prenatal diagnosis. 
While the trend did not reach statistical significance in the individual subtypes, TOPFA rates 
increased over time in all subtypes, with the exceptions of AVSD, CoA and DORV. While 
there was an increase in prenatal diagnosis rates for AVSD, there was no increase in TOPFA 
for these cases. Indeed, among prenatally diagnosed cases of AVSD, TOPFA rates actually 
decreased, although this did not quite reach statistical significance. Potentially, improvements 
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in the prognosis of children with this CHD subtype resulted in fewer women considering 
TOPFA. 
Khoshnood et al reported that TOPFA rates for CHD increased in Paris between 1983-1994, 
but stabilised between 1995-2000 [133]. In my study, the trend in TOPFA appeared steeper 
prior to 2000 but still increased at a lower rate thereafter. Given that the trend in prenatal 
diagnosis increased steadily over the study period, the stabilisation of the TOPFA rate is 
perhaps due to other factors that impact upon women’s decision to terminate, such as 
improved prognosis. 
5.4.3.4 Total birth prevalence of CHD 
I found that the total birth prevalence of CHD in England and Wales was 65 per 10,000 total 
births. In Chapter 3, 12 studies were identified that had reported the total birth prevalence of 
all CHD. Here, the prevalence ranged between 30.1 to 213.4 per 10,000 total births, meaning 
my prevalence rate is at the lower end of the spectrum. However, in my study, the prevalence 
of CHD varied by register, with the prevalence rates associated with CARIS (112.3 per 
10,000 total births) and NorCAS (93.5 per 10,000 total birth), being more comparable to the 
previous studies. The ascertainment of the milder subtypes, which are difficult to diagnose, is 
likely to be a large contributing factor to the variation in prevalence. Additionally, in my 
study, cases are coded according to the EUROCAT guidelines, which has a strict definition of 
CHD. For example, the EUROCAT does not class cases of PDA< 37 weeks gestational age, 
heart murmurs and heart block as CHD, which were included in some of the other studies. 
As shown in Table 5.30, the prevalence estimates of the individual CHD subtypes in my study 
are generally comparable to those reported elsewhere. With the exceptions of SV, HRH and 
PDA, all of my prevalence estimates fall within the range of those reported elsewhere. The 
prevalence of SV is slightly lower in my study than in eight previous studies. This is likely a 
result of differences in coding systems. For example, some studies may have coded cases with 
HRH as SV, given that this subtype was not analysed separately [1, 53, 56, 66, 76, 79]. 
Indeed, the study with the greatest prevalence of SV (prevalence=2.6 per 10,000), actually 
defined the condition as “common ventricle” [79]. The variation in the prevalence of PDA is 
also likely due to coding, given that all studies had different criteria for excluding PDA in 
preterm infants. For example, Yang et al excluded PDA if it closed during the first 14 days of 
life (prevalence= 15.7), whereas Johnson et al excluded PDA if it was “associated with 
prematurity”, but provided no definition of prematurity (prevalence=44.2) [56, 79]. In my 
study, the prevalence of HRH was substantially higher than in previous studies because I 
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classed TA, PVA and HRH as HRH. Had the other studies combined the subtypes in this 
manner, then similar prevalence rates would have been observed. 
 
Table 5.30 Total birth prevalence in the current study and previous population-based studies (as discussed 
in Chapter 3) 





SV 0.6-2.6 0.5 (0.4-0.6) 
HLH 0.5-3.0 2.9 (2.7-3.1) 
EA 0.2-1.1 0.5 (0.4-0.6) 
HRH 0.3 1.9 (1.7-2) 
TA 0.4-0.7  
PVA 0.3-1.1  
CAT 0.4-2.8 0.7 (0.6-0.8) 
AVSD 0.9-6.2 4.0 (3.8-4.3) 
AVA/S 0.3-3.2 1.6 (1.5-1.8) 
TGV 2.0-8.3 3.0 (2.8-3.2) 
ToF 2.6-6.5 3.4 (3.2-3.6) 
TAPVR 0.2-1.1 0.6 (0.5-0.7) 
IAA 0.4-0.8 0.4 (0.3-0.4) 
CoA 1.3-4.9 3.3 (3.1-3.5) 
DORV 0.2-1.8 0.8 (0.7-0.9) 
MVA 1.6* 0.6 (0.5-0.7) 
VSD 6.6-53.9 22.2 (21.6-22.7) 
ASD 0.1-35.1 7.3 (7-7.6) 
PVS 0.8-9.7 3.1 (2.9-3.3) 
PDA 6.5-44.2 1.8 (1.6-1.9) 
 
*Only one study reported the prevalence of MVA
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5.4.3.5 Live birth prevalence 
While there is substantial variation in prevalence estimates between studies, my estimates 
generally fall in the middle of the range for most of the CHD subtypes (Table 5.31). This is 
likely due to more inclusive definitions of S ; for example, in Wu et al’s study, TA is classed 
as SV (SV prevalence=0.8, TA prevalence =0.5). Similar issues with coding are also likely to 
have influenced the prevalence of HRH, which is also composite group of subtypes and has a 
lower prevalence in my study. In my study, the live birth prevalence of VSD was comparable 
to six studies [1, 56, 58, 61, 62, 86], but around half that reported in a three studies [55, 68, 
76]. However, these estimates were more comparable to the prevalence of VSD in the areas 
covered by CARIS and NorCAS (prevalence = 39.9 and 39.1 per 10,000 live births, 
respectively). As discussed in Chapter 3, large VSDs tend to be well ascertained, but small 
VSDs are not because they are very difficult to diagnose. Therefore, heterogeneity in 
prevalence is related to the maximum age at diagnosis and the method of ascertainment of 
cases.
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Table 5.31 Live birth prevalence in the current study and previous population-based studies (as discussed 
in Chapter 3) 





SV 0.8-1.5 0.3 (0.2-0.4) 
HLH 0-2.3 1.4 (1.3-1.5) 
EA 0.2-1.3 0.4 (0.3-0.5) 
HRH 0.2-0.6 1.3 (1.2-1.5) 
TA 0.2-0.9 - 
PVA 0.3-1.3 - 
CAT 0.2-1.0 0.5 (0.4-0.6) 
AVSD 0.8-4.1 2.8 (2.7-3) 
AVA/S 0.2-4.8 1.5 (1.4-1.7) 
TGV 0.2-6.3 2.8 (2.6-2.9) 
ToF 1.9-5.5 2.9 (2.7-3.1) 
TAPVR 0.3-1.6 0.6 (0.5-0.7) 
IAA 0.1-0.8 0.3 (0.2-0.4) 
CoA 1.8-4.4 3.1 (2.9-3.3) 
DORV 0.4-2.3 0.5 (0.5-0.6) 
MVA 1.5* 0.6 (0.5-0.7) 
VSD 15.6-71.3 20.6 (20.1-21.2) 
ASD 2.0-32.3 6.8 (6.5-7.1) 
PVS 1.9-13.2 3.1 (2.9-3.3) 
PDA 0.9-20.1 1.8 (1.6-1.9) 
 
*MVA prevalence was reported in a single study
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5.4.3.6 Trends in the prevalence of CHD 
I found no evidence of a trend over time in the total birth prevalence of CHD. While three 
previous studies reported no evidence of trends in prevalence rates in Russia (1973-88, 28,511 
total births), in Italy (1999-2008, 191,171 total births) and in the UK (1960-69, 163,692 total 
births), these were relatively small studies [64, 72, 74]. Several larger studies have conversely 
reported increasing trends in the prevalence of CHD in the USA (1968-2005, 1,301,143 total 
births) and in Canada (1979-93, 593,042 total births) [79, 80]. Additionally, Khoshnood et al 
reported an increasing trend in Europe up to the year 2000 (7,299,116 total births), and a decrease 
thereafter [52]. Leirgul et al also reported an increasing trend between 1994-2005 and decreasing 
trend between 2005-09 in Norway (954,413 total births) [141]. While overall I did not identify an 
increasing trend however, in five of the six BINOCAR registers the prevalence appeared to 
increase slightly over the study period. Indeed the trend may not have been apparent due to the 
slight decreasing trend in cases notified to CARIS, which is one of the larger registers. While all 
of the registers use the same coding system, methods of ascertainment vary slightly between 
register. For example, cases notified to CARIS are classed as: confirmed, suspected or probable 
[142]. Confirmed cases are those based on cytogenetics, post mortem or clinical reports on live 
births; those classed as suspected cases are those picked up prenatally but not yet confirmed 
clinically or those with inpatient data but with non-specific codes; probable cases are those with 
impatient data and specific codes. Only probable and confirmed cases contribute to the 
prevalence rates for CARIS. Cases with inpatient data but non-specific codes are followed up and 
verified with paediatric case notes. Possibly these cases take longer to ascertain and therefore 
cases born towards the end of the study period are less likely to have been confirmed yet, which 
could contribute towards the decreasing trend. Alternatively, the population in Wales may differ 
slightly from that of England. Perhaps smoking rates or maternal age distribution have not 
followed the same patterns as England. 
For the individual subtypes, I identified a small increasing trend in the prevalence of ToF. While 
the risk of ToF increased by just 3% per year, this equates to an excess of approximately 16 cases 
per year in England and Wales. As discussed in the literature review in Chapter 3, Pradat et al 
reported an increasing trend in the total birth prevalence of ToF in Sweden (1981-92) and 
Johnson et al reported an increasing prevalence of ToF in Canada (1979-1988) [53, 79]. 
Additional studies that did not meet the inclusion criteria for the literature review have also 
reported increasing trends in ToF prevalence. For example, Botto et al reported a doubling in the 
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total birth prevalence of ToF in 1995-1997 compared to 1968-1972 in Metropolitan Atlanta. 
Grech et al reported an increasing trend in ToF in Malta (1980-94), but did not perform a formal 
statistical test [143]. Conversely, Francannett et al did not identify any increasing trends in ToF in 
their study of five registers (Australia, New South Wales 1981-1984; Central Eastern France 
1983-1989; Italy (IMER) 1982-1989, Sweden 1981-1986 and France, Strasbourg 1979-1985), 
although the increasing trend was of borderline statistical significance in the register with the 
longest period of follow-up (France, Strasbourg) [144]. Although these trends may be related to 
improved ascertainment over time, there is some evidence that ART is a risk factor for ToF 
[145]. Therefore, if uptake of ART increased over time, this may explain some of the increase in 
prevalence. 
I also identified a significant decreasing trend in the prevalence of AVA/S and CoA. The trend in 
AVA/S was also observed by Wu et al, although this was amongst live births and may have been 
confounded by increasing rates of TOPFA [55]. Conversely, Pradat et al reported an increasing 
trend in the prevalence of aortic stenosis in Sweden (1981-92), although did not include cases of 
aortic atresia as I did in my study [53]. No other studies have identified a decreasing trend in the 
prevalence of CoA. Without further research it is not possible to assess whether these decreases 
in CoA and A A/S are “real” or chance findings. 
Several population-based studies have reported an increasing trend in the prevalence of VSD and 
ASD [53, 57, 79, 130, 131, 146]. Additionally, Khoshnood et al reported that the prevalence of 
mild CHD (classed as VSD, ASD and PVS), increased until 2000 and decreased thereafter [52]. 
Several authors hypothesise that increasing trends are related to improved ascertainment over the 
study period as opposed to real increases. Diagnoses of septal defects are likely to have improved 
due to improved echocardiography equipment, lower waiting times for outpatient clinic 
appointments, a greater number of paediatricians with expertise performing scans, and lower 
thresholds for referral. Increasing trends may also have been related to the changing age 
distribution over time, with older mothers perhaps being more at risk of a pregnancy affected by 
septal defects [80]. Similarly, research shows that CHD is also more common in the offspring of 
women with pre-gestational diabetes, which is becoming more prevalent over time [5, 147]. In 
my study, I did not identify an overall increasing trend in the prevalence of VSD or ASD. 
However, in five of the six BINOCARs there was some indication of a slight increase over time. 
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5.4.3.7 Maternal age 
I found an association between maternal age at delivery and the prevalence of ToF, AVSD, ASD 
and VSD. However, the association reached statistical significance in cases that occurred with 
chromosomal/ genetic ECAs only. This is unsurprising given the known association between 
advanced maternal age and chromosomal anomalies. Indeed, it is likely that maternal age is a risk 
factor for a chromosomal anomaly which is directly responsible for the development of the CHD, 
as opposed to maternal age being a risk factor for ToF, AVSD, ASD and VSD directly. Although 
the overall association with maternal age was not significant amongst isolated cases of AVSD, 
the prevalence was significantly greater amongst mothers aged <20 compared to 25-29. There 
was also some evidence of an association with the prevalence of HRH, although this did not 
reach statistical significance at the p<0.002 level. Here there was a U-shaped association between 
HRH prevalence and maternal age, which was not restricted to cases with chromosomal/ genetic 
ECAs.  
Other studies have shown that increased maternal age is a risk factor for AVSD (occurring with 
chromosomal/ genetic ECAs) and (non-chromosomal) VSD, ASD, CoA and TGV. For example, 
Forrester et al reported a 25 and 29% significant increased risk of (non-chromosomal) VSD and 
ASD respectively, in cases with mothers aged ≥35 compared to <35, although they did not adjust 
for year of birth [76]. Miller et al have shown that compared to women aged 25-29, women aged 
35 and over are at 20, 36, 54 and 65% significant increased risk of a pregnancy associated with 
(non-chromosomal) VSD, ASD, CoA or TGV, respectively, after adjustment for year of delivery 
[80]. Given that these studies examined multiple subtypes it is possible that some of these 
associations were identified by chance. Indeed, Long et al did not report an association between 
(non-chromosomal) TGV prevalence and maternal age, although prevalence increased linearly 
over the maternal age categories [148]. On the other hand, cases born to mothers of advanced 
maternal age may have been subjected to more screening prenatally and postnatally, meaning the 
increased risk may be related to ascertainment bias. Additionally, the populations described by 
Forrester et al, Miller et al and Long et al are more ethnically diverse than the population covered 
by the BINOCAR, so this may have had an impact if an interaction exists between maternal age 
and ethnicity. Lastly, Long et al also reported that women aged ≥35 were 45% significantly more 
likely to have a pregnancy associated with (non-chromosomal) ToF compared to women aged 25-
29. While I did not find an overall association with maternal age and ToF prevalence, I did find a 
significant 58% increased risk in women aged ≥40 compared to those aged 25-29
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 Chapter 6. Congenital heart disease in twins: what are the risks? 
6.1 Introduction 
Research consistently suggests that there is an increased risk of congenital anomalies in 
multiple compared to singleton pregnancies [113, 149-151]. Most of these studies combine 
twins and higher order births [149, 151], or examine twins only [113]. However, one study 
has shown that the risk of congenital anomaly increases with increasing number of fetuses 
within the multiple birth [150]. There is also some evidence that the risk amongst twins that 
share a placenta, monochorionic (MC) twins, exceeds that of twins that do not share a 
placenta, dichorionic (DC) twins [113]. The risk of CHD amongst twins and multiples is less 
well researched. While several case-series have investigated the prevalence of CHD in twins 
[152-155], few studies have compared the rate to singletons [113, 151, 156]. Of those that 
have, the risk of CHD was significantly increased by between 47-63% in twins [113, 151, 
156]. Even fewer studies have examined the risk of CHD according to chorionicity. In 
Glinianaia et al’s study, there was a 30% and 50% increased risk of CHD in MC and DC 
twins compared to singletons, but this only reached significance in DC twins [113]. Herskind 
et al examined the RR in twins compared to singletons according to zygosity, which can act 
as a proxy for chorionicity given that all DZ twins are DC and approximately two thirds of 
MZ twins are MC [157]. Herskind et al reported significant increased risks of 35 and 30% in 
MZ and DZ twins, respectively [156]. No studies have separately examined the risk of CHD 
in higher order births, likely due to low case numbers. 
6.1.1 Aim 
The aim of this study was to examine the epidemiology of twins and higher order births born 
with CHD in the North of England between 1998-2010, using high quality population-based 
registers (see Appendix A for the publication corresponding to this chapter). 
6.1.1.1 Objectives 
1. To describe pregnancy outcomes, gestational age at delivery, standardised birth weight, 
prenatal diagnosis and maternal age distribution in twins versus singletons with CHD. 









6.2.1 Case inclusion 
Cases of CHD notified to the NorCAS between 1st January 1998-31st December 2010 were 
included in this study. Information on chorionicity was obtained from the NorSTAMP (see 
Chapter 4). 
Cases of CHD known to occur with ECAs are likely to have different aetiologies than cases 
with isolated CHD. For example, CHD occurring with chromosomal or genetic ECAs may be 
a result of the chromosomal anomaly, perhaps caused by chromosomal aneuploidy [45]. 
These cases are likely to have different risk factors, such as increased maternal age, which has 
been associated with an increased risk of chromosomal anomalies [158, 159]. Analysis was 
carried out on cases of isolated CHD only, to investigate the purest possible association 
between CHD and plurality. 
6.2.2 Case coding 
Twins were coded as MC or DC. Due to small case numbers, it was not possible to analyse 
the association between plurality and CHD according to CHD subtype. However, it was 
possible to analyse groups of CHD subtypes, which were classified according to CHD 
severity. 
6.2.3 Data 
Data on the annual number of live and stillbirths born to mothers residing in the North of 
England (combined and by maternal age) was provided by the ONS. Data on the annual 
number of twin and higher order multiple live and stillbirths (combined and by maternal age) 
were provided by the NorSTAMP. The annual numbers of singleton births (combined and by 
maternal age) were calculated by subtracting the annual number of multiple births (provided 
by the NorSTAMP) from the annual number of all births (provided by the ONS). Maternal 
age data was missing for 248 (2.1%) twin pregnancies and were excluded from the 
denominator for analysis of maternal age. 
Table 6.1 shows the variables included in the analysis.  Year of delivery was classed as a 
continuous variable and all other variables were treated as categorical. By performing a fetal 
growth formula to calculate birth weight at 40 weeks gestation (according to a regional birth 
weight reference)[125], birth weight was standardised for gestational age at delivery, sex and 
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plurality. Due to missing data, it was not possible to calculate birth weight in 50 (1.7%) 
singletons and one (0.7%) twin, so these cases were excluded from this analysis. Gestational 
age was missing in 43 (1.5%) singletons and one twin (0.7%), so these cases were excluded 
form analysis for this variable. 
Information on the exact timing of prenatal diagnosis was not available, so prenatal diagnosis 
was simply categorised as “diagnosed” or “not diagnosed”. Prenatal diagnosis refers to the 
diagnosis of any congenital anomaly. Prenatal diagnosis was missing in 1,256 (31.6%) 
singletons, 62 (33.2%) twins and in three (37.5%) triplets. These cases were therefore 
excluded from the analysis of prenatal diagnosis.
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Table 6.1 Description of variables used in analysis 
Variable Classification 
Year of delivery (years) Continuous variable 
Gestational age at delivery 
(weeks) 
Extreme preterm (20-27 weeks) 
Very preterm (28-31 weeks) 
Moderately preterm (32-36 weeks) 
Term (37-41 weeks) 
Post-term (≥41 weeks) 
Sex Male (reference category) 
Female 







CHD with structural ECAs 
CHD with chromosomal/ genetic ECAs 
Prenatal diagnosis Prenatally diagnosed (any congenital anomaly) 
Not prenatally diagnosed (any congenital anomaly) 
Standardised birth weight (SD 
from the mean) 
Low birth weight: SD<-1  
Average birth weight: -1 ≤ SD ≥1 
High birth weight: SD>1 
Plurality Singleton 
Twin 
Higher order multiple 
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6.2.4 Statistical analysis 
Descriptive statistics were produced for gestational age at delivery, standardised birth weight, 
maternal age at delivery, sex and the presence of ECAs. χ2 or Fisher’s exact tests were 
performed to assess the association between plurality and pregnancy outcomes, sex and the 
presence of ECAs. Mann-Whitney tests were used to assess the associations between plurality 
and gestational age at delivery and standardised birth weight (both categorical variables). 
Total birth prevalence was calculated as the number of cases (in live births, late miscarriages, 
stillbirths or TOPFA) per 10,000 live and stillbirths (total births). Analysis was completed 
separately for twins and higher order multiple births as these cases are not necessarily 
homogenous in terms of prevalence, gestational age at delivery, birthweight and maternal age 
at delivery [149]. Additionally, the RR of congenital anomalies in higher order multiples 
compared to singletons is likely to exceed the RR of CHD in twins compared to singletons. 
From a counselling point of view and a public health perspective, it was therefore more 
appropriate to separate the twins and higher order pregnancies. 
The unadjusted RR of isolated CHD in twins compared to singletons was estimated using 
Poisson regression models with log of the total births as the offset and plurality (classed as 
singleton or twin) as an explanatory variable. Adjusted RRs were estimated by refitting the 
models to include year of delivery (as a continuous variable) and maternal age (categorised as 
<20, 20-29, 30-34 and ≥35). The interaction between year of delivery and plurality was 
investigated by refitting the model with a cross product term. The unadjusted RR of CHD per 
years increase in year of delivery were also estimated using Poisson regression. The 
unadjusted RR of CHD associated with maternal age was similarly estimated. 
Analyses were completed for all twins, according to chorionicity and CHD severity. The RR 
of CHD in higher order pregnancies compared to singletons was not estimated due to low case 
numbers. 





Between 1998-2010, there were 399,414 singleton pregnancies, 6,101 twin pregnancies and 
161 higher order multiple pregnancies that resulted in (at least one) live or stillbirth. This 
equated to 11,871 twin total births, given that only one twin was live born or stillborn in 331 
pregnancies, and 497 higher order births. Of the twin births, 4,359 pregnancies (8,605 births) 
(72.5%) were DC and 1,170 pregnancies (2,317 births) (19.5%) were MC, leaving 542 
pregnancies (949 births) (8.0%) with unknown chronicity. The proportion of twin pregnancies 
increased from 2.6% in 1998 to 2.9% in 2010, although this did not quite reach statistical 
significance (test for trend: p=0.069). The proportion of higher order pregnancies decreased 
significantly from 0.03% in 1998 to 0.02% in 2010 (test for trend: p=0.004). 
There were 4,160 cases of CHD notified to NorCAS between 1998-2010: 3,965 singletons, 
187 twins and eight triplets. Of the 187 twins with CHD, 114 (61.0%) were DC twins, 60 
(32.1%) were MC twins and 13 (7.0%) had unknown chorionicity. 
6.3.1 Extra-cardiac anomalies 
Of the singletons with CHD, 700 (17.7%) occurred with chromosomal/ genetic ECAs and 281 
(7.1%) occurred with structural ECAs. Of the twins with a CHD, 15 cases (8.0%) occurred 
with chromosomal/ genetic ECAs and 18 (9.6%) occurred with structural ECAs. Twins with 
CHD were at significant decreased risk of chromosomal/ genetic ECAs compared to 
singletons (RR=0.45, 0.28-0.740; p<0.001). The risk of structural ECAs was not significantly 
different in twins compared to singletons (RR=1.22, 95% CI: 0.77-1.91; p=0.399).  
Of the triplets with CHD, one (12.5%) occurred with chromosomal/ genetic ECAs, one 
occurred with structural ECAs (12.5%). Cases with ECAs were excluded from further 
analysis, leaving 2,984 singletons, 154 twins and six triplets with isolated CHD. 
6.3.2 CHD severity and concordance 
Of the singletons with isolated CHD, 132 (4.4%) had severe CHD, 721 (23.9%) had moderate 
CHD, 1,967 (65.9%) had mild CHD and 173 (5.8%) were of unclassified severity. Of the 
twins, seven (4.5%) had severe CHD, 31 (20.1%) had moderate CHD, 106 (68.8%) had mild 
CHD and 10 (6.5%) were of unclassified severity. Of the triplets, one (16.7%) had moderate 
CHD, four (66.7%) had mild CHD and one had CHD of unclassified severity. The 
distribution of the severity categories in twins according to chorionicity is shown in Table 6.2. 
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There were eight sets of twins with concordant CHD (four sets with the same subtype), of 
which six sets were DC and two were MC twins. None of the triplets were concordant. 
6.3.3 Pregnancy outcomes 
Pregnancy outcomes varied significantly in twins compared to singletons (Fisher’s exact test: 
p=0.255). As shown in Figure 6.1, live births and stillbirths were more common in twins than 
singletons. TOPFAs and late miscarriages were more common in singletons. All six triplets 
were live births. 
There was no evidence of an association between pregnancy outcomes and chorionicity in 
twins (Fisher’s exact test: p=0.281). Of the DC twins with CHD, 109 (95.6%) were live 
births, three (2.6%) were stillbirths and two (1.8%) were TOPFAs. Of the MC twins with 
CHD, 55 (91.7%) were live births, one (1.7%) was a stillbirth and four (6.7%) were TOPFAs.  
Figure 6.1 Pregnancy outcomes in cases of CHD, by plurality 
 
 
6.3.4 Gestational age at delivery 
Among live born cases, the distribution of gestational age at delivery was significantly 
different in twins compared to singletons (Mann-Whitney test: p<0.001). A greater proportion 
of twins were born preterm compared to singletons (Figure 6.2). An even greater proportion 
of triplets were delivered preterm (Figure 6.2), although no formal statistical test was 
performed due to low case numbers. 
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There was a significant difference in the distribution of gestational age at delivery according 
to chorionicity in twins (Mann-Whitney test: p=0.004). Of the DC twins with CHD, four 
(4.2%) were extremely preterm, 13 (13.7%) were very preterm, 44 (46.3%) were moderately 
preterm, and 34 (35.8%) were term. Of the MC twins with CHD, two (4.4%) were extremely 
preterm, 10 (22.2%) were very preterm, 29 (64.4%) were moderately preterm and 4 (8.9%) 
were term. 
Figure 6.2 Gestational age at delivery in live born cases of CHD, by plurality 
 
Gestational age at delivery was missing for 43 (1.5%) of singletons and 1 (0.7%) twin, so these cases were 
excluded from this analysis. 
 
6.3.5 Standardised birthweight 
Among live born cases of CHD, there was some evidence that the distribution of standardised 
birth weight varied between twins and singletons, although this did not quite reach statistical 
significance (p=0.053). Indeed, twins were more likely to have low standardised birth weight 
compared to singletons (37.5% vs 29.6%) (Figure 6.3). All three triplets were of average 
standardised birth weight. 
Among twins, there was no significant difference in the distribution of standardised birth 
weight according to chorionicity (Mann-Whitney test: p=0.104). In DC twins with CHD, 25 
(26.3%) cases were low birth weight, 55 (58.9%) were average birth weight and 15 (15.6%) 
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were high birth weight. Of the MC twins with CHD, 20 (44.4%) were low birth weight, 18 
(40.0%) were average birth weight and seven (15.6%) were high birth weight. 
Figure 6.3 Standardised birth weight in live born cases of CHD, by plurality 
 
Standardised birthweight was missing for 50 (1.7%) singletons and one (0.7%) twins and was excluded from this 
analysis 
 
6.3.6 Prenatal diagnosis 
There were 1,256 (31.6%) singletons, 62 (33.2%) twins and three (50.0%) triplets with 
missing prenatal diagnosis data. Excluding these cases, 880 (32.4%) singleton cases, 38 
(30.4%) twin cases and one (20.0%) triplet case had a prenatal diagnosis (of any congenital 
anomaly). There was no significant difference in the proportion of singleton compared to twin 
cases that were prenatally diagnosed (χ2 test: p=0.642). 
There was no significant difference in the prenatal diagnosis rates between DC and MC twins 
(Fisher’s exact test=1.00). There was a prenatal diagnosis (of any congenital anomaly) in 23 
(31.5%) DC twins with CHD and in 14 (31.1%) MC twins with CHD. 
6.3.7 Birth prevalence and pregnancy risk 
There were 2,984 cases of isolated CHD amongst singletons, giving a prevalence of 74.7 per 
10,000 total births (Table 6.2); 0.7% of singleton pregnancies were associated with CHD. 
There were 154 twins with CHD, giving a prevalence of 129.7 per 10,000 total births; in 2.5% 
of twin pregnancies, at least one twin was affected by isolated CHD. There were six higher 
order multiples with CHD, giving a prevalence of 120.7 (95% CI: 44.4-260.9) per 10,000 
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total births; in 3.7% of higher order pregnancies, at least one fetus was affected by isolated 
CHD. 
Of the 154 twins with CHD, 96 (62.4%) occurred in DC pregnancies and 47 (30.5%) occurred 
in MC pregnancies, giving prevalence rates of 111.6 and 202.8 per 10,000 total births, 
respectively (Table 6.2). Specifically, at least one twin was affected by isolated CHD in 2.2% 
of DC twin pregnancies and 4.0% of MC twin pregnancies. The prevalence of severe, 
moderate and mild CHD are shown in Table 6.2 according to chorionicity. At least one twin 
was affected by severe, moderate and mild CHD in twin pregnancies 0.1%, 0.5% and 1.7% of 
twin pregnancies, respectively.  
 
Table 6.2 Prevalence of CHD in twins and singletons, according to CHD severity and chorionicity 
CHD 
severity 
Twins  Singletons 
 
 
N (% of 2,984), 
prevalence per 




N (% of 154), 
prevalence per 
10,000 total births 
(95% CI) 
Dichorionic Twins 
N (% of 96), 
prevalence per 




N (% of 47),  
prevalence per 











































6.3.8 Maternal age 
Amongst singletons, the risk of CHD was not associated with maternal age (p=0.528). 
Amongst twins, the association between CHD and maternal age was of borderline statistical 
significance (p=0.070), with mothers aged <20 having a 93% increased risk of a pregnancy 
associated with CHD than mothers aged 20-29 (Table 6.3). Of the triplets with CHD, three 
(37.5%) were born to mothers aged 20-29, two (25.0%) to mothers aged 34-35 and three 
(37.5%) to mothers aged ≥35. Due to low case numbers, it was not possible to test the 
association with maternal age in higher order multiple births 
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Amongst DC twins, there was no significant association between maternal age and CHD 
(p=0.412) (Table 6.3). Amongst MC twins, there was a significant association between 
maternal age and CHD (p=0.012), with mothers aged<20 being at 237% increased risk of a 
pregnancy associated with CHD compared to mothers aged 20-29 (Table 6.3).
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Table 6.3 Relative risk of CHD according to maternal age and year of delivery 






































































*29 (0.7%) singletons had missing maternal age data and were excluded. Maternal age data was missing in 2.1% 
of twins without CHD so these were excluded from the denominator. 
RR=Relative Risk 
 
6.3.9 Temporal trends 
The risk of CHD amongst singletons decreased significantly by 2% per year (p<0.001) (Table 
6.3). There was no evidence of a trend in CHD prevalence over time in twins (any 
chorionicity) (p=0.954) or in DC twins (p=0.091). In MC twins, the risk of CHD increased 
significantly by 8% per year (p=0.036) (Table 6.3). Due to low case numbers, it was not 
possible to analyse temporal trends in the prevalence of CHD in higher order multiple births. 
6.3.10 Relative risk of CHD in twins compared to singletons 
Twins were at 73% significant increased risk of CHD compared to singletons (p<0.001) 
(Table 6.4). There was an 78%, 46% and 81% increased risk of severe, moderate and mild 
CHD in twins (any chorionicity) compared to singletons (p=0.135, p=0.037 and p<0.001 
respectively) (Table 6.4), although this only reached statistical significance in cases of 
moderate and mild CHD. 
MC twins were at 82% significant increased risk of CHD compared to DC twins (RR=1.82, 
95% CI, 1.29-2.57; p<0.001). Compared to singletons, DC twins were at 49% significant 
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increased risk of CHD (p<0.001) and MC twins were at 172% significant increased risk of 
CHD (p<0.001) (Table 6.4). DC twins were at 41%, 63% and 49% increased risk of severe, 
moderate and mild CHD respectively (Table 6.4), although this did not reach statistical 
significance for severe CHD (p=0.501, p=0.016 and p=0.002, respectively). MC twins were at 
292% significant increased risk of severe CHD (p=0.020) and 207% significant increased risk 
of mild CHD (p<0.001). There was no significant effect amongst cases of moderate CHD 
(p=0.637) (Table 6.4). 
The adjustment for year of delivery and maternal age at delivery had little impact on the RR 
of CHD in twins compared to singletons (Table 6.4). 
When considering all twins (any chorionicity), the interaction between year of delivery and 
plurality was non-significant (p=0.446), meaning there was no evidence that the RR in twins 
compared to singletons altered over the study period. Similarly, the interaction between year 
of delivery and plurality was not statistically significant amongst DC twins (p=0.521). 
Amongst MC twins there was a significant interaction between year of delivery and plurality 
(p=0.012), with the RR of CHD in MC twins compared to singletons increasing over the 
study period (interaction term: RR=1.11, 95% CI:1.02-1.20).
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Table 6.4 Relative risk of CHD in twins versus singletons, according to CHD severity and chorionicity 
CHD 
Severity 
Twins (any chorionicity) 
RR (95% CI); p-value 
Dichorionic Twins 
RR (95% CI); p-value 
Monochorionic Twins 
RR (95% CI); p-value 
















































































*Adjusted for year of delivery and maternal age. Maternal age was missing in 29 (0.7%) singleton cases and so 
these cases were excluded. Maternal age data was missing in 2.1% of twins without CHD so these were excluded 




In this population-based study, there was a 73% increased risk of CHD in twins compared to 
singletons. MC twins were at 172% and DC twins were at 49% increased risk of CHD compared 
to singletons. The risk did not vary substantially by severity, except for MC twins, where the risk 
of severe CHD had the largest effect size. I did not examine the RR of CHD in triplets, but the 
prevalence exceeded that of singletons and twins. 
This is one of few studies to examine the RR of CHD in twins compared to singletons. The 
primary strength of this study is the use of population-based data derived from an established, 
high-quality, CAR. Multiple sources notify the register of cases which ensures high case 
ascertainment. Accurate diagnoses are achieved by the review of complex cases by paediatric 
pathologists and clinical geneticists and, where relevant, diagnoses are confirmed via post 
mortem. Additionally, by linking to a population-based register of multiple pregnancies, I was 
able to estimate the RR of CHD according to chorionicity, which very few studies have been able 
to do [113, 156]. Data on chorionicity is unlikely to be misclassified, given that the final 
diagnosis of like-sex twins is based on placental examination and histology.  
A further strength is that cases of CHD occurring in TOPFAs, late miscarriages and stillbirths 
were included. TOPFA are less frequent in twin compared to singleton pregnancies, so had they 
been excluded, the RR of CHD associated with twins may have been overestimated [160]. 
Stillbirth is more common in twin compared to singleton pregnancies; the exclusion of stillbirths 
could have had the opposite effect and diluted the RR of CHD [160]. 
I also examined the RR of CHD in twins versus singletons adjusted for some confounding 
factors. I adjusted for year of delivery, which is a potential confounder given that the twinning 
rate has increased slightly over the study period. Maternal age may have been a confounding 
factor due to the known association between increased maternal age and multiple pregnancy 
[161] and the increased risk of CHD with increased maternal age, which is reported in some, but 
not all studies of singletons [53, 59, 76, 80]. 
This study has some limitations. Firstly, the sample size was small meaning non-significant 
results should be interpreted with caution as they could have resulted from type II errors. 
Additionally, I was only able to examine severity categories as opposed to subtypes, which may 
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have different RRs. As NorSTAMP requires parental consent, chorionicity data was not available 
for all twins. However, choronicity data was missing for just 7% of cases and 8% of the 
denominator. Moreover, eight sets of twins with CHD were from the same pregnancy. This 
violates one of the assumptions of Poisson regression, which specifies that all observations 
should be independent. However, after excluding eight cases (one out of each twin pair), the RR 
reduced only slightly (unadjusted RR=1.63, 95% CI: 1.38-1.93; p<0.001, RR=1.40, 95% CI: 
1.14-1.73; p=0.002 and RR=2.60, 95% CI: 1.94-3.49; p<0.001 for all twins (any chorionicty), 
DC twins and MC twins, respectively). I did not have data on zygosity as this is not recorded on 
the NorSTAMP. However, chorionicity can be used to make inference on zygosity given that all 
MC twins are monozygotic and the majority (~90%) of DC twins are dizygotic [155]. Lastly I 
was not able to investigate the risk associated with ART as the NorCAS and NorSTAMP and did 
not record this information at the time of the study. 
My 73% significant increased risk of CHD in twins compared to singletons is slightly greater 
than that reported elsewhere [113, 151, 156]. Mastroiacovo et al reported an increased risk of 
51% in Europe and Latin America (1978-1995), Glinianaia et al reported an increased risk of 
47% in the North of England (using a subset of the present data, 1998-2002) and Herskind et al 
reported an increased risk of 63% in Denmark (1977-2001)[113, 151, 156]. In my study, the RR 
of CHD in MC twins increased significantly over the study period, so I may have found a greater 
RR than other studies due to my more recent study period. The increase in risk may be a result of 
increased screening of MC twins, given that the increased risk of congenital anomaly in MC 
twins has become more widely known over time. In the UK, the National Institute for Health and 
Care Excellence (NICE) guidelines were updated in 2011 to recommend at least nine antenatal 
scans for MC twin pregnancy[162]. However, in my analysis of prenatal diagnosis, there was no 
significant difference in the prenatal diagnosis of MC compared to DC cases of CHD. However, 
the data on prenatal diagnosis was incomplete and was likely not to be missing completely at 
random, which may have introduced some bias. While MC twin births account for just 0.6% of 
all births, on a population level (England and Wales) this amounts to an excess of approximately 
seven cases per year. 
I identified a greater risk of CHD in MC twins compared to DC twins. Conversely, in the study 
by Glinianaia et al, there was no significant difference in the RR by chorionicity, but just nine 
cases in MC twins were examined [113]. Herskind et al estimated the RR of CHD according to 
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zygosity, finding no significant difference in risk [156]. However, bias may have been incurred 
due to missing zygosity information. Indeed, in their cases with missing zygosity, the RR of CHD 
was greater than that of all twins (RR=2.41, 95% CI: 2.07-2.80). Had a higher proportion of MZ 
twins had missing zygosisty, this could partly explain why monozygotic twins were not at 
increased risk. Alternatively, given that one third of MZ twins are DC, it is likely the effect size is 
deflated due to mixing of chorionicity types [156]. Lastly, Herskind et al included only live 
births, which may have impacted on their results given that TOPFAs are more common in 
singleton pregnancies [156, 160]. 
I found a significant increased risk of moderate and mild CHD in twins (any chorionicity) 
compared to singletons. While the risk of severe CHD was increased, it did not reach statistical 
significance, likely due to low sample size. The RR was statistically significant amongst MC 
twins, due to the larger effect size. Several studies have examined the RR of CHD in multiples 
compared to singletons by CHD subtype [150, 151, 163]. Significant increased risks have been 
reported for VSD, ASD, SV, ToF, AVSD and CoA, although the effect sizes vary by study. 
Herskind et al uniquely examined subtypes separately according to zygosity, but could only 
examine VSD in MZ twins due to low sample size, finding a 73% increased risk compared to 
singletons. 
The aetiology of the increased risk of CHD in multiple births is unresolved. Twin to twin 
transfusion in MC twins was identified as an important risk factor for CHD [155, 164]. However, 
this doesn’t explain why there would be an increased risk in DC twins. Others hypothesise that 
placental vascular anastomoses between the MZ co-twins’ circulations may lead to fluctuations in 
blood flow during fetal heart development, causing CHD [165, 166]. Potentially, this 
anastomoses is even more severe in triplets, which would explain the even greater prevalence. 
Alternatively, MZ twinning itself is hypothesized to be part of a morphogenic anomaly which 
leads to a congenital anomaly [167]. Given that all MC twins are MZ and around 10% of DC 
twins are MZ, this might explain why there was an increased risk in both MC and DC twins and 
why the effect size was greater in MC twins. However, previous research also found an increased 
risk amongst DZ twins [163]. Perhaps the increased risk in DC twins could be related to the use 
of ART, which can result in twin pregnancy and has been linked to an increased CHD prevalence 
[168]. However, a systematic review of four studies that compared twins conceived by ART 
compared to naturally conceived twins found that there was no increased risk of congenital 
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anomaly [169]. Additionally, NICE guidelines have recently changed to state that just one 




 Chapter 7.  Long-term survival and risk factors for mortality among 
individuals with congenital heart disease: A systematic review and meta-
analysis 
7.1 Introduction 
As discussed in Chapter 1, during the first year of life, babies with severe CHD require 
complex surgeries to enable survival. With advances in medical, surgical and intensive care 
interventions, an estimated 83% of babies with CHD now survive infancy [171]. Whilst one 
year survival estimates have been described [1, 20, 60, 62, 172-174], long-term survival 
estimates are not as well researched. 
A systematic review on the long-term prognosis of CHD was published in 2008 [175]. 
However, this revolved around hospital-based studies that ascertained cases post-surgically or 
in adulthood, so estimates were not representative of all individuals with CHD [175]. 
7.1.1 Aim 
To conduct a systematic review and meta-analysis of population-based studies that reported 
long-term survival of children born with CHD. The aim was to accurately assess and quantify 




7.2.1 Inclusion criteria 
Population-based, original studies were included if they: 1) ascertained all individuals born 
with CHD within a pre-defined geo-political area; 2) reported survival estimates (or the 
number of cases born and the number/proportion alive) at age ≥5 years; 3) reported survival 
estimates for all CHD (in humans) combined or a single CHD subtype including: VSD, PVS, 
ASD, AVA/S, AVSD, CoA, CAT, PVA (with VSD or with intact ventricular septum (IVS)), 
ToF, TAPVR, TGV, TA, SV, HLH and EA; 4) were available from the British library or 
internet, written in the English language. 
7.2.2 Exclusion criteria 
Articles were excluded if: cases were not followed from birth (e.g. follow-up began in 
adulthood or after surgical correction); cases were not born in well-defined regions (i.e. 
hospital-based studies); survival was not estimated as a proportion of those born with CHD 
(e.g. age-specific population mortality rates); survival was only reported for certain subtype 
groups (e.g. “severe” CHD). Where multiple articles reported on the same dataset, the most 
recent (in terms of birth years included) or the largest study was included. Both articles were 
included if they reported survival for different CHD subtypes or ages. 
7.2.3 Search strategy 
I conducted comprehensive literature searches of MEDLINE, EMBASE and Scopus from 
their inception (1946, 1974 and 1996, respectively) to June 2015 inclusive. MeSH-terms and 
key word searches were entered systematically into the databases (Table 7.1). 
After systematic searches of each database, the citations were extracted and titles and 
abstracts were screened according to the inclusion criteria and full articles were retrieved for 
all relevant citations. Reference lists of included articles were searched and key journals such 
as “Congenital Heart Disease”, “Birth Defects Research”, “Circulation”, “Heart” and 
“Cardiology in the Young” were searched using keywords.
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Table 7.1 Medline, Embase and Scopus search terms 
 Medline Embase Scopus 
1 exp Heart Defects, 
Congenital/ep, mo or 
(((congenital) and 
(heart or cardiac or 
cardiovascular)).ti,ab) 
exp congenital heart 




(heart or cardiac or 
cardiovascular)).ti,ab) 
TITLE-ABS-KEY 
((congenital) and (heart or 
cardiac or cardiovascular))  
2 survival analysis/ or 
kaplan-meier estimate/ 
or proportional hazards 
models/or mortality/ or 
child mortality/ or fatal 
outcome/ or infant 
mortality/ or mortality, 
premature/ or survival 
rate/ or ((surviv$ or 
death$ or mortalit$ or 
fatalit$ or die$).ti,ab) 
survival/ or life 
expectancy/ or long 
term survival/ or 
overall survival/ or 
short term survival/ or 
survival prediction/ or 
survival rate/ or 
survival time/ or 
Mortality/ or 
childhood mortality/ or 
premature mortality/or 
((surviv$ or death$ or 
mortalit$ or fatalit$ or 
die$).ti,ab) 
TITLE-ABS-KEY 
(surviv$ or death$ or 
mortalit$ or fatalit$ or 
die$)  
3 Epidemiologic studies/ 
or Exp cohort studies/ 
or (cohort adj (study or 
studies)).tw. or Cohort 
analy$.tw. or (Follow 
up adj (study or 
studies)).tw. or 
(observational adj 
(study or studies)).tw. 




Longitudinal study/ or 
Retrospective study/ or 
Prospective study/  or 
Cohort analysis/ or 
(Cohort adj (study or 
studies)).mp. or 
(follow up adj (study 
or studies)).tw. or  
(observational adj 
(study or studies)).tw. 
or (epidemiologic$ adj 





“ ongitudinal stud$” or 
“Retrospective stud$” or 
“Prospective stud$”  or 
“Cohort analys$” or 
“Cohort stud$” or “follow 
up stud$” or “follow-up 
stud$”  “observational 
stud$” or “epidemiologic$ 
stud$” or “population-
based”) 
4 1 and 2 and 3 1 and 2 and 3 (LIMIT-
TO(EXACTKEYWORD, 
"Human") 
5 4 not (case study.mp or 
exp Case Reports/ or 
exp Clinical Trials as 
Topic or clinical 
trial.mp) 
4 not (case study.mp or 
exp Case Report/ or 
exp controlled clinical 





6 Limit 5 to humans Limit 5 to humans  
7 Limit 6 to English 
language 
 





7.2.4 Data extraction 
I performed the literature searches, citation screening and reviewed the full papers. One of my 
supervisors, Prof Judith Rankin, screened 10% of the titles and all abstracts to confirm 
decisions on inclusion, and extracted data on all included papers. There were no discrepancies 
in terms of article inclusion between reviewers. 
Study characteristics including study design, quality, sources of data, risk factors for mortality 
(log-rank tests, crude hazard ratios (HRs) and adjusted hazard ratios (aHRs)) were extracted 
from each article (using the data extraction form in Appendix C). 
Kaplan-Meier survival estimates and corresponding 95% confidence intervals (CIs) were 
obtained from each included study at age one, five, 10 etc. Where 95% CIs were not reported, 
the number of cases born, and the proportion survived, were used to estimate 95% binomial 
CIs, assuming no cases were censored. Survival estimates for all CHD subtypes combined, 
and for each CHD subtype, were extracted. Where survival estimates were presented only 
graphically, these were extracted using Plot Digitizer software [176, 177]. 
Authors were contacted and asked to provide further survival estimates or confidence 
intervals where they were not reported in the manuscript. Additionally, authors were 
contacted when it was not clear whether cases with ECAs were included or excluded. 
7.2.5 Statistical analysis 
Where there were at least three studies reporting survival, pooled estimates of survival were 
calculated using a meta-analysis with random effects. Weighting to each articles was allocated 
using the inverse of the variance. To stabilise the variance and adjust the study weights, a 
simplified double arcsine transformation was performed on the survival estimates and 95% 
CIs [178]. This approach also restricts the estimates to be ≤ 100%. Cochrane’s Q test and the 
I2 statistic was used to test for heterogeneity in survival estimates between articles, with I2> 
50% indicating substantial heterogeneity [51]. Random effects meta-regression was 
performed for all CHD subtypes combined in order to assess year of delivery as a source of 
heterogeneity. Here the year the study commenced in was used as an explanatory variable. 
The adjusted R-squared value was used to estimate the proportion of between article variation 
accounted for by the year of study commencement. A “bubble plot” was used to present the 
fitted meta-regression model. Here bubbles represent each article, with sizes dependent on the 
precision of the survival estimates. Publication bias was assessed via Egger’s test [179]. 
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Analysis was performed in Stata 13 and p<0.05 was considered statistically significant. 
7.2.6 Quality assessment 
Quality appraisal was based on four of Hayden et al’s six domains, developed to assess 
potential bias in systematic reviews of prognostic studies [180]. The domains used included: 
study ascertainment, study attrition, outcome ascertainment and analysis. The domains 
relating to confounding and prognostic factors were not relevant to this review because the 
primary aim was to investigate unadjusted survival estimates.  
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Figure 7.1 shows a PRISMA diagram for the flow of articles through the review. Of 7,839 
identified articles, 15 met the inclusion criteria [67, 86, 116, 181-192]. 
Figure 7.1 PRISMA flowchart 
 
7.3.1 Study characteristics 
Study characteristics are shown in Table 7.2. All the included studies were conducted in high 
income, western populations, with 10 set in Europe (three in the UK [116, 181, 186], one in 
Sweden [183], one in Norway [187], one in Belgium [189], one in Bohemia [86], three in 
Denmark [67, 184, 185]) and five in the USA (two in Texas [182, 190], one in Metropolitan 
Atlanta [188], two in New York State [191, 192]). Although several of the articles reported 
survival on subsets of the same population, all were included as survival was reported for 
different CHD subtypes. The oldest article included cases born between 1973-1997 [183] and 
the most recent articles between 1983-2006 [185, 191]. Of the 15 included articles, eight 
included cases with ECAs, with approximately 20% of cases occurring with other congenital 
anomalies in each article [67, 184-187, 189, 191, 192]. Four articles excluded cases with 
trisomy 13 and 18 but included cases with all other ECAs [182, 183, 188, 190]. Two articles 
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reported survival for isolated cases of CHD (i.e. CHD with no ECAs) [116, 181] and one 
study did not state whether or not cases with ECAs were included [86]. Prevalence estimates 
were reported by most studies and ranged from 3.7 to 10.2 per 1000 live births, when 
considering all CHD as a composite group [67, 103]. 
7.3.2 Survival estimates 
Five articles reported survival to age five [181, 182, 184, 189, 190], three to age 10 [186-188], 
two to age 15 [86, 183], one to age 20 [116], three to age 25 [67, 191, 192] and one to age 30 
[185]. 
For all CHD (as a composite group), pooled one year survival from six articles was 87.0% 
(95% CI: 82.1-91.2), pooled five year survival from eight articles was 85.4% (95% CI: 79.4-
90.5) and pooled 10 year survival from four articles was 81.4% (95% CI: 73.8-87.9) (Figure 
7.2). It was not possible to pool estimates beyond 10 years as there were too few articles. 
However, Figure 7.3 shows the survival estimates plotted over increasing age, up to age 25. 
Here the fitted meta-regression shows that survival decreases very gradually with increasing 
age over 25 years. There was no evidence of publication bias according to Egger’s tests 
(p=0.748 for one year, p=0.237 for five years and p=0.601 for 10 years). There was 
significant heterogeneity between articles for one year survival (I2=99.0%, p<0.001), five year 
survival (I2=99.6%, p<0.001) and 10 year survival (I2=99.5%, p<0.001). Meta-regression 
showed that more recent study period was significantly associated with increased one, five 
and 10 year survival (p=0.047, p=0.013 and p=0.046) (Figure 7.4). According to the adjusted 
R2 values, study period accounted for 50.9%, 62.8% and 87.0% of the between article 
variance for one, five and 10 year survival. However, after adjustment for study period, there 
remained substantial residual heterogeneity attributable to between-study heterogeneity 
(I2=98.2% for survival at age one, I2= 98.4% at age five and I2=93.7% at age 10). 
Table 7.3 shows the survival estimates and pooled survival estimates for individuals with 
CHD, by subtype. Pooled one year survival was lowest for individuals with HLH (18.5%, 
95% CI: 2.8-43.5) and greatest for individuals with VSD (95.5%, 95% CI: 89.0-99.2). There 
was significant heterogeneity in survival estimates between articles for all CHD subtypes, 
with the exception of ToF (I2=37.9%, p=0.169). Heterogeneity between estimates for SV was 
of borderline statistical significance (I2=65.0%, p=0.057). Pooled five year survival varied by 
subtype, with survival for HLH being 14.4% (95% CI: 2.8-32.8) and survival for VSD being 
96.3% (95% CI: 93.7-98.2). With the exception of ToF (I2=0.0%, p=0.612) and SV 
(I2=26.9%, p=0.250), there was significant heterogeneity in survival estimates between 
193 
articles (Table 7.3). It was possible to calculate pooled 15 year survival estimates for AVA/S, 
AVSD, CAT and CoA, but not for any other CHD subtypes. There were too few studies to 
calculate pooled survival beyond age 15, although in the few studies that had reported 
survival into adulthood, survival was still very gradually declining.
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Figure 7.2 Forest plot for all CHD at ages one, five and 10 
195 
Figure 7.3 Bubble plot of survival estimates for all CHD at ages one to 25 
196 
Figure 7.4 Bubble plots showing the association between study period and survival for all CHD 
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Table 7.3 Survival estimates at age one to 25 
Subtype Article N Survival Estimates (95% CI) 



















Dastgiri et al[181] 1,069 78.4 (75.8-80.8)* 74.7 (73.8-75.5)†      
Tennant et al [116] 4,281 92.3 (91.5-93.1) 91.1 (90.2–91.9) 90.8 (89.9–91.6) 90.3 (89.3–91.2) 89.5 (88.4–90.6)  
Jackson et al [186] 1,543 86.1 (84.3-87.8)* 82.0 (81.0-83.0) 80.4 (79.5-81.7)†    
Meberg et al [187] 360 91.4 (88.0-94.1)* 88.9 (85.2-91.9)*     
Moons et al [189] 921 96.0 (94.5-97.2)* 95.6 (94.0-96.8)*     
Olsen et al [67] 6,646 80 (79-81) 76 (75-77)* 75 (74-76)   72 (70-73) 
Samanek et al [86] 5,030 80.0 (78.9-81.1) 77.8 (76.6-79.0) 77.4 (76.2-78.5) 77.1 (75.9-78.3)   
Nembhard et al 
[190] 
19,530  90.7 (90.2-91.1)*     
Pooled estimate (95% CI), 























 Tennant et al[116] 1,805 99.2 (98.7-99.5) 99.1 (98.6–99.5) 99·1 (98·5–99·4) 99·1 (98·5–99·4) 98.3 (96.6–99.1)  
Moons et al[189] 303  99.3 (97.6-99.9)*      
Nembhard et al 
[190] 
10,382  93.9 (93.5-94.4)*     
Olsen et al [67] 1,559 94 (93-95)  90 (89-91.7)    
Samanek et al [86] 2,092 91.1 (89.8-92.3)*   89.4 (88.0-90.7)   
Garne [184] 195  96.9 (93.4, 98.9)*     
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 
95.5 (89.0-99.2)  
99.0%, p<0.001 
 
96.3 (93.7-98.2)  
97.1%, p<0.001 
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Subtype Article N Survival Estimates (95% CI) 


















Tennant et al [116] 382 98.7 (96.8-99.5) 98.1 (96.1-99.1) 98.1 (96.1-99.1) 98.1 (96.1-99.1) 98.1 (96.1-99.1)  
Garne [184] 33  97.0 (84.2-99.9)*     
Nembhard et al [190] 1170  91.6 (89.9-93.1)*     
Samanek et al [86] 292 96.2 (94.0-98.5) 95.6 (93.1-98.0) 95.6 (93.1-98.0) 95.6 (93.1-98.0)   
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 
 95.6 (91.1-98.6) 
89.6%, p<0.001 
 













Tennant et al [116] 365 97.3 (95.0-98.5) 97·0 (94·6–98·3) 97·0 (94·6–98·3) 96·3 (93·3–98·0) 96.3 (93.3–98.0)  
Moons et al [189] 162  99.4 (96.6-100.0)*     
Nembhard et al [190] 9164  89.9 (89.3-90.5)*     
Olsen et al [67] 361 93 (90-95.3)  91 (88-95.6)   84 (72-91) 
Samanek et al [86] 436 94.0 (92.4-96.3)  92.9 (90.1- 
95.1)* 
92.9 (90.1- 95.1)*   
Garne [184] 78  98.7 (93.1, 100.0)*     
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 




94.0 (89.9-97.1)  
81.6%, p=0.004 


















s Tennant et al [116] 171 92.4 (87.3-95.5) 91.2 (85.9-94.6) 91.2 (85.9-94.6) 89.3 (83.2-3.3) 89.3 (83.2-3.3)  
Garne [184] 24  87.5 (67.6, 97.3)*     
Moons et al [189] 36  100.0 (90.3-100.0)*      
Nembhard et al [190] 560  79.1 (75.5-82.4)*     
Samanek [86] 391 90.3 (87.3-93.3)   88.4 (85.1-91.7)   
Wang et al [191] 877 78.8 (75.9-81.4) 76.6 (73.6–79.3)  74.1 (71.0–77.0)  73.4 (70.1–
76.4) 
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 












Subtype Article N Survival Estimates (95% CI) 



















Tennant et al [116] 94 84.0 (74.9-90.1) 80·9 (71·3–87·5) 79.7 (70.1–86.6) 79.7 (70.1–86.6) 79.7 (70.1–86.6)  
Frid et al [183] 502 77.1 (73.2-80.7)* 66.5 (62.2-70.7)* 64.3 (59.9-68.5)* 63.1 (58.8-67.4)*   
Miller et al [188] 338 69.9 (61.8-76.0) 60.4 (52.3-67.5) 57.9 (49.7-65.3)    
Moons et al [189] 37  91.9 (78.1-98.3)*     
Nembhard et al 
[190] 
853  72.1 (69.0-75.1)*     
Olsen et al [67] 354 75 (70-79)  65 (59-70)   59 (51-65) 
Samanek et al [86] 201 62.2 (55.4-69.0) 54.7 (47.7-61.8) 54.2 (47.1-61.2) 54.2 (47.1-61.2)   
Wang et al [191] 1,004 68.4 (65.5-71.2) 62.8 (59.7–65.7)  59.5 (56.3–62.6) 58.1 (56.5-61.4) 56.6 (52.8–
60.2) 
Garne [184] 20  50 (27.2-72.8)*     
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 




64.0 (57.2-70.5)  
81.4%, p<0.001 
















Tennant et al [116] 189 91.5 (86.6–94.7) 91.5 (86.6–94.7) 90.9 (85.8–94.3) 90·9 (85·8–94·3) 89.6 (83.7–93.5)  
Moons et al [189] 46  91.3 (79.2-97.6)*     
Nembhard et al 
[190] 
1145  78.6 (76.1-80.9)     
Olsen et al [67] 334 84 (79-87)  82 (77-85)   78 (61-82) 
Samanek et al [86] 266 68.0 (62.3-73.8) 65.4 (59.6-71.3) 65.0 (59.2-70.9) 65.0 (59.2-70.8)   
Garne [184] 12  58.3 (27.7-84.8)*     
Wang et al [191] 2,529 79.4 (77.8-81.0) 77.0 (75.4–78.6)  76.0 (74.3–77.7)  75.2 (73.3-
77.0) 
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 




56.2 (36.3-75.1)  
87.3%, p<0.001 








Article N Survival Estimates (95% CI) 
















Tennant et al [116] 36 36.1 (21.0–51.4) 36.1 (21.0–51.4) 36.1 (21.0–51.4)    
Moons et al [189] 7  85.7 (42.1-99.6)*      
Nembhard et al 
[190] 
160  56.9 (48.8-64.7)*     
Olsen et al [67] 78 45 (34-55) 45 (34-55) 45 (34-55) 45 (34-55) 45 (34-55) 45(34-55) 
Samanek et al [86] 55 12.7 (3.7-21.7) 10.5 (4.1-22.2)* 7.3 (0-15.4) 7.3 (0-15.4)   
Garne [184] 7  14.3 (0.4, 57.9)*     
Wang et al [191] 460 64.8 (60.2-69.0) 60.8 (56.1–65.1)  59.2 (54.4–63.6)  55.2 (49.5–
60.5) 
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 
39.2 (17.5-63.4)  
93.3%, p<0.001 
42.4 (25.0-61.0)  
92.6%, p<0.001 
28.5 (9.6-52.6)  
87.3%, p<0.001 





















Idorn et al [185] 75 41.7 (30.1-53.3)* 37.5 (26.4-49.2)* 35.3 (24.0-46.5)* 37.5 (26.4-49.2)* 35.3 (24.0-46.5)* 37.5 (26.4-
49.2)* Fixler et al [182] 118 59.3 (49.9-67.6) 55.7 (45.8–64.4)     
Moons et al [189] 6  83.3 (36.5-99.1)*     
Samanek et al [86] 53 18.9 (8.1-29.6) 7.6 (0.3-14.8) 7.6 (0.3-14.8) 7.6 (0.3-14.8)   
Pooled estimate (95% CI), 









































) Moons et al [189] 6 67 (19-96)* 50 (11.8-88.2)*     




Article N Survival Estimates (95% CI) 











Tennant et al [116] 190 90.5 (85.4-93.9) 83·7 (77·6–88·2) 83·1 (76·9–87·7) 83.1 (76.9–87.7) 80.8 (72.8–86.6)  
Wang et al [192] 1,739      86.9 (85.3-
88.4) 
Moons et al [189] 52 83 (70-92)* 82.7 (69.7-91.8)*     
Nembhard et al 
[190] 
766  79.1 (76.1-81.9)*     
Olsen et al [67] 381 83 (79-87)  70 (65-74)   67 (58-74) 
Garne [184] 7  82.6 (61.2-95.0)*     
Wang et al [191] 2,843 85.7 (84.3-86.9) 80.5 (79.0–81.9)     
Samanek et al [86] 169 84.6 (79.0-90.2)  76.6 (70.1-83.2) 76.6 (70.1-83.2)   
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 
































 Tennant et al [116] 54 72.2 (58.2-82.2) 72.2 (58.2-82.2) 72.2 (58.2-82.2) 72.2 (58.2-82.2) 72.2 (58.2-82.2)  
Garne [184] 5  20 (0.5-71.6)*     
Samanek et al [86] 40 52.5 (36.7-8.23) 50.0 (34.2-65.8) 50.0 (34.2-65.8) 50.0 (34.2-65.8)   
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 
 53.7 (30-76.6) 
76.6%, p=0.014 
 






















Tennant et al [116] 189 82.5 (76.3-87.3) 81·0 (74.6–85.9) 80.3 (73.8–85.3) 78·4 (71.6–83.9) 74.1 (64.4–81.5)  
Wang et al [192] 1,840      74.5 (72.4-
76.4) 
Wang et al [191] 2,622 75.7 (74.1-77.3) 70.8 (69.0–72.5)     
Moons et al [189] 29  100.0 (88.1-100.0)*     
Olsen et al [67] 461 74 (70-78)  62 (38-67)   50 (41–59) 
Samanek et al [86] 271 61.6 (56.7-67.5) 56.5 (50.3-62.4)* 53.9 (46.8-60.9) 53.9 (46.8-60.9)   
Garne [184] 21  76.2 (52.8, 91.8)*     




Article N Survival Estimates (95% CI) 
1 year 5 years 10 years 15 year s 20 years 25 years 
Pooled estimate (95% CI), 



















Tennant et al [116] 24 83.3 (61.5-93.4) 66.7 (44.3–81.7) 62.5 (40.3–78.4) 62.5 (40.3–78.4)   
Idorn et al [185] 106 68.0 (58.2-76.7)* 61.7 (51.4-70.6)* 60.5 (50.4-69.7)* 57.4 (47.6-67.1)* 57.4 (47.6-67.1)* 57.4 (47.6-
67.1)* 
Fixler et al [182] 67 76.1 (64.0-84.6) 74.6 (62.4–83.4)     
Moons et al [189] 4 100 (39.8-100.0)* 100 (39.8-100.0)*     
Samanek et al [86] 39 46.2 (30.2-62.1)  35.9 (20.5-51.3) 35.9 (20.5-51.3)   
Pooled estimate (95% CI), 





53.1 (36.5-69.2),  
72.4%, p=0.027 
















Tennant et al [116] 73 4.1 (1.1-10.5) 2.9 (0.5-8.9)     
Wang et al [192]       35.6 (32.6-
38.7) 
Wang et al [191] 1315 40.1 (37.47-42.7) 34.1 (31.5-36.6)     
Idorn et al [185] 252 12.5 (8.9-17.5)* 10.4 (6.9-14.8)* 10.4 (6.9-14.8)* 8.8 (5.6-12.9)*   
Fixler et al [182] 311 41.8 (36.3-69.9) 38.0 (32.6-43.5)     
Moons et al [189] 10 50 (18.7-81.3)* 40.0 (12.2-73.8)*     
Samanek et al [86] 172 0 (0.0-2.1)* 0 (0.0-2.1)* 0 (0.0-2.1)* 0 (0.0-2.1)*   
Pooled estimate (95% CI), 












Article N Survival Estimates (95% CI) 












Tennant et al [116] 31 83.9 (65.5-93.0) 74.2 (55.0–86.2) 74.2 (55.0–86.2) 64.5 (43.1-80.0)   
Fixler et al [182] 286 64.7 (58.8-69.9) 56.1 (49.9-61.7)     
Garne [184] 16  56.3 (29.9- 80.2)*     
Moons et al [189] 9 56 (21-86)* 55.6 (21.2-86.3)*     
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 


















Tennant et al [116] 55 67.3 (53.2-78.0) 58.0 (43.8-69.7) 58.0 (43.8-69.7) 54.6 (39.7-67.2) 54.6 (39.7-67.2)  
Garne [184] 5  60.0 (14.7-94.7)*     
Moons et al [189] 3  100 (29.2-100.0)*     
Nembhard et al [190] 160  68.8 (61.0-75.8)*     
Samanek et al [86] 22 67.9 (50.2-86.5) 64.3 (46.2-82.4) 64.3(46.2-82.4) 64.3(46.2-82.4)   
Pooled estimate (95% CI), 
Heterogeneity I2 & p-value 
 64.8 (55.5-73.6) 
25.5%, p=0.255 
 
    
* Indicates that 95% CIs were not reported in the study, but 95% binomial exact 95% CIs were calculated by the authors.  
† 95% CIs obtained from author 
TG  in Fixler et al’s study relates to dextro-TGV only  
VSD=ventricular septal defect 
IVS= intact ventricular septum 
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7.3.3 Quality assessment 
Quality assessment is shown in Table 7.4. All articles satisfied the study ascertainment 
domain because by definition, population-based studies are representative of the population. 
The attrition domain was satisfied by a third of articles, due to studies failing to report the 
proportion of untraced cases. However, many of the articles classed unmatched cases as alive 
and so it is possible that all cases were traced. The outcome ascertainment domain was 
satisfied by 93.3% of studies and the analysis domain by 80%. Studies that did not satisfy the 
analysis domain were those that did not perform survival analysis and instead reported the 
proportion alive, which does not account for case censorship. This may have slightly inflated 
the survival in these studies. 
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Table 7.4 Quality assessment 
Domain Quality items, potential 
bias 















The study population is 
adequately described for 
key characteristics (i.e CHD 





 9 (60%) 
Ascertainment is adequately 
described, including: 
method of ascertainment, 
included birth years, study 
location 
[67, 86, 116, 
181-192] 
 15 (100%) 
Inclusion and exclusion 
criteria are adequately 
described (i.e ICD codes 




 12 (80%) 
There is adequate 
ascertainment. 
[67, 86, 116, 
181-192] 
 15 (100%) 
POTENTIAL BIAS: The 
study sample represents 
the population of interest 
on key characteristics 
sufficient to limit potential 
bias to the results. 
[67, 86, 116, 
181-192] 












The proportion of traced 
cases is stated and adequate 







Reasons for untraced cases 
are provided 







Untraced cases are 
adequately described for 
key characteristics (i.e CHD 
subtype) 







There are no important 
differences between key 
characteristics and 





Domain Quality items, potential 
bias 
Yes Not stated Number 
of studies, 
% 
outcomes in participants 
who were traced and 
untraced. 
POTENTIAL BIAS: 
Untraced cases are not 
associated with key 
characteristics (i.e., the 
study data adequately 
represent the sample), 
sufficient to limit potential 
bias. 





















Frequency of outcome is 
recorded 
[116, 181-192]  13 
(86.7%) 
The method of 
ascertainment of deaths is 
valid and reliable to limit 
misclassification bias 




POTENTIAL BIAS: The 
outcome of interest is 
adequately measured in 
study participants to 
sufficiently limit potential 
bias. 










There is sufficient 
presentation of results (i.e 
number of cases and 95% 
CIs). 
[67, 86, 116, 




The analysis is adequate for 
the design of the study. 
[67, 86, 116, 
181, 182, 185, 
186, 188-192] 
 12 (80%) 
Results are not selectively 
reported 
[67, 86, 116, 
181-192] 
 15 (100%) 
POTENTIAL BIAS:  The 
statistical analysis is 
appropriate for the design 
of the study, limiting 
potential for presentation 
of invalid results. 
[67, 86, 116, 
181, 182, 185, 
186, 188-192] 
 12 (80%) 
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7.3.4 Risk factors for mortality 
Crude and adjusted hazard ratios are shown in Table 7.5. 
Considering all CHD subtypes as a composite group, three studies showed that the risk of 
mortality significantly decreased with more recent year of delivery [67, 184, 191]. The risk of 
mortality also decreased with increasing year of delivery among cases of SV physiology [182, 
185], AVSD [183, 188], TGA [192], CoA [192], HLH [192] and ToF [192]. 
Considering all CHD subtypes combined, two studies reported twice the proportion of deaths 
amongst children born preterm compared to term [184, 190]. Two articles also reported 
increased risks of mortality among children with UV physiology who were born preterm, with 
a greater effect amongst those born severely preterm [182, 185]. There was no significant 
association between survival and preterm delivery in children with AVSD [188]. 
Considering children with all CHD subtypes combined, two studies reported that low 
birthweight was associated with increased mortality, with the risk being greater amongst 
preterm cases [190, 191]. Two studies reported a significant increased risk of mortality 
amongst low birth weight babies with UV physiology [182, 185]. In both articles, the effect 
was greater in extremely low birth weight babies, although this only reached significance in 
one study [182]. There was no evidence of an association between mortality and birthweight 
in cases of AVSD [188]. Among cases of TGV, ToF, HLH and CoA, low birth weight was 
associated with increased risk of mortality, with greater effect sizes among preterm cases 
[192]. 
Considering all CHD subtypes, five studies reported an increased risk of mortality amongst 
cases with ECAs compared to isolated cases of CHD [67, 184, 190, 191]. Two further studies 
reported similar increased risks of mortality in cases with UV physiology with ECAs 
compared to isolated cases [182, 185]. Wang et al reported increased risks of mortality in 
children with CoA, TGV and ToF and ECAs, but not amongst cases with HLH. Frid et al 
reported no significant difference in mortality rates between cases of AVSD with ECAs 
compared to those with isolated AVSD [183]. Miller et al reported a significant increased risk 
of mortality amongst cases of AVSD with two non-chromosomal ECAs (compared to isolated 
AVSD), but not amongst cases with just one non-chromosomal ECA [188]. 
Frid et al reported that children with isolated AVSD who underwent surgical intervention, 
were at increased odds of mortality at age five. The effect size increased with more recent 
year of delivery (OR=0.97 in 1973-77 and OR=0.02 in 1993-97) [183], however, confidence 
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intervals were not reported, so it was not possible to assess whether the association reached 
statistical significance. Garne et al did not formally assess the risk of mortality associated with 
surgical intervention (in all cases of CHD combined), but commented that surgery was not 
performed in the majority of deaths [184]. 
One article examined the association between mortality and socioeconomic status, among 
children with AVSD, finding no significant association (p=0.506) [188]. However, survival 
decreased linearly over the four categories of socioeconomic status (0-4.9% in 
poverty=62.3% survival, 5.0%-9.9% in poverty=60.4% survival, 10-19.9% in poverty= 57.9% 
survival and ≥20% in poverty= 56.9%). There were also no significant associations between 
mortality and maternal education in any of the studies of all CHD, UV physiology, TGV, 
ToF, HLH and CoA [182, 190, 192]. However, there was a linear decrease in mortality with 
increasing maternal education in each study. 
Considering all CHD subtypes, Nembhard et al reported that the risk of mortality was 
significantly increased in males [190]. Females with UV physiology were at 27% significant 
increased risk of mortality, the association was no longer significant after adjustment for 
confounders [182]. Idorn et al also reported no significant association between infant sex and 
mortality among individuals with UV physiology [185]. Females with TGV were at 16% 
significant increased risk of mortality after adjustment for potential confounders [192]. There 
were no significant associations reported between infant sex and mortality amongst cases of 
AVSD [188], ToF [192], HLH [192] and CoA [192]. 
Considering all CHD subtypes, Nembhard reported improved survival amongst children born 
in urban compared to rural areas [190]. For children with TGV, HLH and CoA, Wang et al 
did not find a significant association although the risk of mortality was lower amongst those 
born in the city [192]. Idorn et al reported no association between mortality and being born in 
tertiary centres (compared to “Other” place of birth) in children with U  physiology [185]. 
Wang et al was the only study to report on plurality as a risk factor for mortality, finding no 
significant association after adjustment for potential confounders [191]. 
Six articles examined maternal age at delivery as a risk factor for mortality [182, 185, 188, 
190-192]. In two studies, there was no evidence of an association in individuals with UV 
physiology, but both studies reported elevated risk amongst mothers aged under 20 [182, 
185]. In children with AVSD, there was no significant association between mortality and 
maternal age, but mortality rates were greater with maternal age<29 [188]. Considering all 
CHD subtypes combined, Wang et al and Nembhard et al reported a linear decrease in the risk 
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of mortality with increasing maternal age, although Wang et al reported that the effect was 
only significant amongst mothers aged ≥35 (aHR= 0.88) [191]. There were no significant 
associations with maternal age among children with CoA, HLH and ToF, although maternal 
age ≥35 appeared protective among children with TGV [192]. 
Two studies examined paternal age as a risk factor for mortality and found no significant 
association, one in children with UV physiology and the other with children with AVSD [185, 
188]. 
Considering all CHD subtypes combined, one study investigated the association between 
parity and mortality, finding that multiparous individuals were at  significant increased risk of 
mortality compared to nulliparous individuals, after adjusting for potential confounders 
(aHR= 1.19, 95% CI: 1.10-1.28). 
Five studies investigated the influence of maternal ethnicity as a risk factor for mortality, all 
using non-Hispanic white ethnicity as the reference category [182, 188, 190-192]. Hispanic 
maternal ethnicity was not associated with mortality in all CHD subtypes combined [190, 
191], CAT [190], TGV [190, 192], ToF [190, 192], TA [190], PVS [190], PVA-IVS [190], 
EA [190], HLH [190, 192], AVA/S[190], CoA [192], VSD [190] or ASD [190]. However, 
cases of UV physiology born to Hispanic mothers were at borderline significant increased risk 
of mortality [182]. Non-Hispanic Black ethnicity was not associated with mortality in cases of 
CAT [190], TA [190], PVS [190], EA [190], HLH [190], AVA/S [190], AVSD [188, 190] or 
HLH [190] and CoA [190]. but was associated with an increased risk of mortality in cases of 
UV physiology [182], TGV [190, 192], ToF [190, 192], PVA-IVS[190], VSD [190] and ASD 
[190]. There was conflicting evidence on the association between non-Hispanic Black 
ethnicity and mortality for CoA and all CHD subtypes combined [190, 192].
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Table 7.5 Risk factors for mortality 
Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 
aHR (95% CI) 
Fixler et 
al [182] 
UV physiology Year of delivery 1996-2000 2001-2003 0.60 (0.49-0.73) 0.53 (0.43-0.66) 
Frid et al 
[183] 
AVSD  N/A 1973-77/ 1993-97 63% vs 8%, p=0.003  
Garne[18
4] 
All CHD  1986-93 1994-98 21% vs 13%, p<0.05  
Idorn et al 
[185] 
UVP  1990-99 1977-89 2.04 (1.63-2.55) 2.65 (2.06-3.42) 
   2000-09 0.85 (0.64-1.12) 0.77 (0.57-1.05) 
Miller et 
al [188] 
AVSD  1979-1991 1992-2003  0.59 (0.3-0.98) 
Olsen et 
al[67] 




All CHD  2001-06 1983-88  2.06 (1.83-2.33) 
   1989-94  1.81 (1.61-2.04) 




TGA  2001-06 1983-88  2.87 (2.29-3.59) 
   1989-94  2.22 (1.77-2.77) 
   1995-2000  1.59 (1.25-2.01) 
[192] CoA  2001-06 1983-88  2.65 (2.05-3.43) 
    1989-94  2.09 (1.63-2.70) 
    1995-2000  1.67 (1.29-2.17) 
[192] HLH  2001-06 1983-88  3.41 (2.76-4.20) 
    1989-94  2.74 (2.22-3.39) 
    1995-2000  1.77 (1.41-2.21) 
[192] ToF  2001-06 1983-88  2.58 (1.97-3.37) 
    1989-94  2.23 (1.72-2.91) 
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Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 
aHR (95% CI) 
    1995-2000  1.49 (1.11-2.00) 
Fixler et 
al [182] 
UV physiology Gestational age 37-44 weeks 20-31 weeks 2.80 (1.80-4.34)  
   32-36 weeks 1.69 (1.32-2.18)  
Garne 
[184] 
All CHD  ≥37 weeks <37 weeks 32% vs 15%, p<0.05  
Idorn et al 
[185] 
UV physiology  > 37 weeks <32 weeks 2.34 (1.16-4.73) 0.53 (0.09-2.99) 
  > 37 weeks 32-37 weeks 1.51 (1.10-2.08) 1.68 (1.13-2.51) 
[188] AVSD  ≥37 weeks <37 weeks  1.65 (0.96-2.8) 
Nembhard 
et al [190] 
All CHD  ≥37 weeks <37 weeks 7.6% vs 14.0%  
Miller et 
al [188] 
AVSD Birth weight <2500g 2500g 47.4% vs 38.8%, p=0.197  
Fixler et 
al [182] 
UV physiology  ≥2500g <1500 6.22 (4.00-9.65) 6.27 (3.95-9.96) 
   1500-2499 2.85 (2.22-3.65) 2.08 (1.61-2.70) 
Idorn et al 
[185] 
UV physiology  ≥2500g <1500g 4.15 (1.95-8.84) 6.21 (1.24-31.15) 




All CHD  ≥37 weeks,  <37 weeks, <1500g  2.89 (2.47-3.39 
  2500-3999g <37 weeks, 1500-2499g   1.76 (1.56-1.99) 
   <37 weeks, 2500-3999g  1.22 (1.06-1.41) 
    <37 weeks, ≥4000g  0.56 (0.25-1.25) 
    ≥37 weeks, <1500g   2.23 (1.36-3.66) 
    ≥37 weeks, 1500-2499g  1.74 (1.55-1.94) 
    ≥37 weeks, ≥4000g  0.80 (0.67-0.95) 
[192] CoA  ≥37 weeks,  <37 weeks, <1500g  2.71 (1.91-3.83) 
  2500-3999g <37 weeks, 1500-2499g  2.26 (1.73-2.96) 
   <37 weeks, 2500-3999g  1.39 (0.95-2.04) 
   <37 weeks, ≥4000g  1.22 (0.30-4.94) 
   ≥37 weeks, <1500g  0.79 (0.20-3.20) 
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Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 
aHR (95% CI) 
   ≥37 weeks,  1500-2499g  2.21 (1.70-2.87) 
   ≥37  weeks,  ≥4000g  0.65 (0.43-0.97) 
[192] HLH  ≥37 weeks,  <37 weeks, <1500g  3.55 (2.31-5.46) 
   2500-3999g <37 weeks, 1500-2499g  1.87 (1.46-2.39) 
    <37 weeks, 2500-3999g  1.07 (0.76-1.49) 
    <37 weeks, ≥4000g  0.34 (0.05-2.54) 
    ≥37 weeks, <1500g  2.23 (0.91-5.47) 
    ≥37 weeks, 1500-2499g  1.31 (1.01-1.69) 
    ≥37 weeks, ≥4000g  0.94 (0.70-1.25) 
[192] TGV  ≥37 weeks,  <37 weeks, <1500g  4.97 (3.61-6.84) 
   2500-3999g <37 weeks, 1500-2499g  2.36 (1.84-3.03) 
    <37 weeks, 2500-3999g  1.49 (1.12-1.99) 
    <37 weeks, ≥4000g  0.65 (0.09-4.63) 
    ≥37 weeks, <1500g  2.43 (1.20-4.92) 
    ≥37  weeks, 1500-2499g  1.95 (1.55-2.45) 
    ≥37 weeks, ≥4000g  0.77 (0.55-1.07) 
[192] ToF  ≥37 weeks,  <37 weeks, <1500g  2.77 (2.02-3.80) 
   2500-3999g <37 weeks,  1500-2499g  1.51 (1.16-1.97) 
    <37 weeks,  2500-3999g  1.11 (0.75-1.64) 
    <37 weeks, ≥4000g  - 
    ≥37 weeks, <1500g  1.44 (0.46-4.52) 
    ≥37 weeks, 1500-2499g  1.85 (1.46-2.35) 
    ≥37 weeks,  ≥4000g  0.41 (0.21-0.79) 
Fixler et 
al [182] 
UV physiology ECAs Isolated CHD ECAs 2.32 (1.84-2.9) 1.84 (1.46-2.34) 
Frid et al 
[183] 
AVSD  Isolated CHD Down syndrome 37.7% vs 40.4%, p=0.7  
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Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 
aHR (95% CI) 
Garne 
[184] 
All CHD  Isolated CHD ECAs 13% vs 35%, p<0.05  
Idorn et al 
[185] 
UVP  Isolated CHD ECAs 1.80 (0.35-2.41) 1.95 (1.40-2.71) 
Miller et 
al [188] 
AVSD  Isolated CHD 1 ECA  1.28 (0.6-2.5) 
    2 ECAs  3.32 (1.7-6.3) 
Olsen et 
al [67] 




All CHD  Isolated CHD ECAs  1.37 (1.25-1.51) 
CoA   Down syndrome  2.31 (1.52-3.51) 




HLH  Isolated CHD Down syndrome  1.00 (0.46-2.15) 




TGV  Isolated CHD Down syndrome  1.86 (1.10-3.12) 
   ECAs (not Down syndrome)  1.80 (1.56-2.08) 
[192] ToF  Isolated CHD Down syndrome  2.33 (1.76-3.09) 
    ECAs (not Down syndrome)  2.81 (2.34-3.36) 
Fixler et 
al [182] 
UV physiology Infant sex Male Female 1.27 (1.04-1.55)  
Idorn et al 
[185] 
UV physiology  Male Female 1.14 (0.94-1.38)  




All CHD  Male Female 1.07 (1.00-1.15)  
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Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 




TGV  Female Male  0.84 (0.73-0.97) 
[192] ToF  Female Male  0.90 (0.76-1.06) 
[192] HLH  Female Male  0.97 (0.84-1.12) 
[192] CoA  Female Male  1.00 (0.85-1.18) 
Fixler et 
al [182] 
UV physiology Maternal age 20-29 <20 1.15 (0.87-1.53)  
   ≥40 0.64 (0.32-1.31)  
   30-39 0.93 (0.74-1.17)  
Idorn et al 
[185] 
UV physiology  20-29  >40 1.12 (0.42-3.01)  
   <20 1.05 (0.65-1.69)  
   30-39 0.89 (0.73-1.10)  
Miller et 
al [188] 




All CHD  25-29 <20  1.15 (0.99-1.34) 
   20-24  1.02 (0.91-1.14) 
   30-34  1.03 (0.93-1.14) 




CoA  25-34 <25 years  0.98 (0.80-1.19) 
   ≥35 years  0.84 (0.68-1.03) 
[192] HLH  25-34 <25 years  1.06 (0.90-1.24) 
    ≥35 years  0.99 (0.84-1.17) 
[192] TGV  25-34 <25 years  1.04 (0.88-1.22) 
    ≥35 years  0.84 (0.71-1.00) 
[192] ToF  25-34 <25 years  0.96 (0.79-1.17) 
    ≥35 years  0.96 (0.78-1.19) 
UVP Maternal ethnicity Hispanic 1.19 (0.97-1.47) 1.26 (1.00-1.58) 
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Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 
aHR (95% CI) 
Fixler et 
al [182] 
  Non-hispanic 
White 
NON-HISPANIC black 1.59 (1.15-2.20) 1.41 (1.01-1.97) 
Miller et 
al [188] 
AVSD  Non-hispanic 
White 
Black/African American  0.87 (0.50-1.5) 




All CHD  Non-hispanic 
White 
Asian, Pacific Islander  1.01 (0.83-1.22) 
  Hispanic  1.00 (0.89-1.12) 




TGV  Non-hispanic 
White 
Hispanic  1.20 (0.96-1.49) 
  Non-Hispanic Black  1.31 (1.07-1.60) 
[192] CoA  Non-hispanic 
White 
Hispanic  1.12 (0.86-1.47) 
   Non-Hispanic Black  1.40 (1.10-1.79) 
[192] ToF  Non-hispanic 
White 
Hispanic  1.24 (0.96-1.61) 
   Non-Hispanic Black  1.34 (1.06-1.69) 
Nembhard 
et al [190] 
HLH  Non-hispanic 
White 
Hispanic  0.85 (0.68-1.06) 
  Non-Hispanic Black  0.92 (0.76-1.11) 
[190] CAT  Non-hispanic 
White 
Hispanic  1.76 (0.88-3.49) 
   Non-Hispanic Black  1.88 (0.62-5.66) 
[190] TGV  Non-Hispanic 
White 
Hispanic  1.16 (0.87-1.55) 
   Non-Hispanic Black  2.04 (1.40-2.97) 
[190] ToF  Non-Hispanic 
White 
Hispanic  1.39 (0.92-2.10) 
   Non-Hispanic Black  1.85 (1.09-3.12) 
[190] TA  Non-Hispanic 
White 
Hispanic  0.97 (0.66-1.43) 
   Non-Hispanic Black  1.41 (0.90-2.21) 
[190] PVS  Non-Hispanic 
White 
Hispanic  1.15 (0.68-1.96) 
   Non-Hispanic Black  1.13 (0.57-2.22) 
[190] PVA-IVS  Non-Hispanic 
White 
Hispanic  1.76 (1.06-2.91) 
   Non-Hispanic Black  2.60 (1.32-5.12) 
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Study CHD subtypes Risk factor Reference 
category 
Comparison category HR (95% CI), or % died 
& log-rank test 
aHR (95% CI) 
[190] EA  Non-Hispanic 
White 
Hispanic  1.88 (0.74-4.79) 
   Non-Hispanic Black  1.42 (0.43-4.70) 
[190] HLH  Non-Hispanic 
White 
Hispanic  1.51 (1.13-2.02) 
   Non-Hispanic Black  1.06 (0.67-1.66) 
[190] AVA/S  Non-Hispanic 
White 
Hispanic  0.92 (0.56-1.51) 
   Non-Hispanic Black  1.02 (0.49-2.13) 
[190] CoA  Non-Hispanic 
White 
Hispanic  0.73 (0.53-1.02) 
   Non-Hispanic Black  1.12 (0.71-1.76) 
[190] VSD  Non-Hispanic 
White 
Hispanic  0.96 (0.79-1.18) 
   Non-Hispanic Black  1.56 (1.19-2.03) 
[190] ASD  Non-Hispanic 
White 
Hispanic  0.94 (0.80-1.11) 
   Non-Hispanic Black  1.34 (1.08-1.66) 
[190] AVSD  Non-Hispanic 
White 
Hispanic  0.98 (0.71-1.37) 
   Non-Hispanic Black  1.02 (0.68-1.54) 
[190] All CHD  Non-Hispanic 
White 
Hispanic  0.96 (0.85-1.08) 




In this systematic review and meta-analyses, I found that 87.0% of children born with CHD 
survived to age one, 85.4% to age five and 81.4% to age 10. Few articles reported survival 
beyond age 10, but survival appeared to continue gradually decreasing into adulthood. There was 
substantial variation in survival estimates between articles, some of which was accounted for by 
study period, which positively impacted on survival. Articles consistently showed that less recent 
year of delivery, preterm delivery, presence of ECAs and low birth weight negatively impacted 
on survival. There was some evidence that maternal ethnicity and being born in more rural 
environments negatively influenced survival. There was inconsistent or little evidence 
surrounding socioeconomic status and maternal age as risk factors for mortality. 
The main strength of this systematic review is its restriction to population-based studies. 
Although including hospital-based studies would have increased the amount of data available, 
these studies under-ascertain milder CHD subtypes that do not require major medical 
intervention. Additionally, children with severe CHD may travel to centres with specialist 
expertise. Therefore, the survival estimates reported by hospital-based studies can be 
unrepresentative of the general population of individuals with CHD. The robustness of the 
individual rates to bias was examined using a quality assessment with previously published 
domains and items [180]. While each study failed to satisfy at least one quality item, due to the 
population-based study designs, the potential for bias in each domain remained low. Moreover, 
for all CHD, I did not identify any significant publication bias according to Egger’s test. 
A further strength is the comprehensive nature of my search strategy. Three databases were 
searched for relevant citations along with key journals and reference lists, thus the likelihood of 
missing key studies was limited. Full articles were reviewed by two researchers to ensure they 
fully met the inclusion criteria and that data was extracted correctly. 
There were also several limitations. The maximum follow-up was just 30 years, with five of the 
included studies reporting survival to just five years. The greatest risk of death appeared to occur 
within the first year, but survival continued to decrease over the follow-up, although at a lesser 
rate. A study of CHD related mortality rates between 1999-2006 in the USA showed a high 
mortality rate of 41.5 per 100,000 in infancy, which decreased to 1.38 between ages 1-4 and 
218 
 
stabilised at approximately 0.55 between the ages of 5-65. After age 65 however, the mortality 
rate doubled to 1.10 per 100,000 [193]. 
A further limitation is that longer-term survival estimates may not be representative of children 
born with CHD today. Even in the most recent studies, 25-year survival rates related to 
individuals born in the 1990s; in my meta-regression of one, five and 10 year survival, I showed 
that survival estimates improved over time. 
Given that the primary aim of this systematic review was to identify survival estimates, the 
search strategy may not have included all articles that reported risk factors for long-term CHD 
mortality. However, it is unlikely that studies of risk factors were missed, as all of them should 
also report long-term survival in line with my inclusion criteria. 
All the included articles were performed in high income western populations. Evidence suggests 
that infant mortality rates associated with congenital anomalies are greater in low income 
countries [8]. Therefore, the survival estimates in this review are not likely to be globally 
representative. While I only included articles written in the English language, I did not identify 
any relevant articles written in other languages. 
Most of the included articles included cases with ECAs [67, 86, 181-192]. It is therefore difficult 
to assess how much of the mortality is accounted for by CHD as opposed to the co-occurring 
congenital anomalies. However, cases with ECAs accounted for only 20% of all cases, some of 
which are not likely to be life threatening. Additionally, all articles used all-cause mortality, 
meaning the deaths may not have been directly related to the CHD diagnosis. 
While this review provides an insight into long-term mortality associated with CHD, I have not 
accounted for morbidity. Research suggests that quality of life is lower in those with CHD and 
survivors are subject to morbidities such as endocarditis, cerebrovascular accidents, myocardial 
infarctions and arrhythmias [194-196]. The American Heart Association has also reported that 
children with CHD are at increased risk of developmental disorders [27].  
Using meta-regression, I found more recent study period positively impacted on survival. 
However, despite the adjustment for study period, there was still a high degree of heterogeneity. 
While I adjusted for study period using the year of study commencement, the lengths of the study 
periods varied by article. Therefore, my adjustment for the year of study commencement is not 
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likely to have fully accounted for the changes in survival over time. Study period is likely to have 
had a greater impact than that shown in the meta-regression models. Further heterogeneity is 
likely attributable to a variety of sources. Firstly, case ascertainment is likely a major cause of 
heterogeneity. Olsen et al report lower survival estimates even after accounting for study period, 
but their prevalence of CHD is almost half that of other studies. Given that they included only 
cases diagnosed before age one, it is likely they under-ascertained cases with milder CHD 
subtypes, such as VSD [67]. The data sources used may also have contributed to variation in 
ascertainment, with articles using hospital records as opposed to CARs (which use multiple 
sources for ascertainment), contributing to lower survival estimates, likely due to the milder cases 
being under-ascertained [86]. Additionally, articles that used CARs may have had better 
ascertainment of individuals with ECAs. This is likely to worsen prognosis among these studies 
when compared to say Moons et al, who ascertained cases from a paediatric cardiology register 
[189]. The classification of ECAs is also a source of heterogeneity. Two articles excluded all 
cases with ECAs [116, 181]. Unfortunately too few articles excluded cases with ECAs and so a 
meta-regression could not be performed. 
Variation in study periods is arguably the greatest source of heterogeneity in survival estimates. 
Survival has improved over time due to advances in surgical correction. For example, the Fontan 
operation for repair of SV, HLH and TA and the conduit repair for cases of CAT were introduced 
in the late 1970s and developed across the 1980s-90s [197, 198]. The arterial switch operation for 
treatment of TGV was introduced in 1975 [199], and fully replaced the atrial switch operations in 
the early 1990s resulting in improved long-term survival [200]. Although at first the arterial 
switch operation resulted in greater mortality [201], eventually this led to improved survival 
among cases of TGV [200]. Survival is also likely to have improved over time due to advances in 
prenatal diagnosis. Greater prenatal diagnosis rates may have led to an increase in termination 
(for fetal anomaly) rates. If cases with the more severe subtypes are terminated, this will have 
resulted in better survival. Prenatal diagnosis also allows quicker intervention at birth or even in 
utero, which may also improve survival [202]. Survival is also likely to have improved due to the 
introduction of prostaglandin, which was trialled in neonates with cyanotic CHD in the 1970s 
[203, 204], although was not frequently administered until the 1980s. 
Further research is required to examine survival in non-western countries. Although I aimed to 
examine long-term survival, the longest follow-up was 30 years. Mortality rates suggest that the 
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mortality rates remain stable between age five and 65 [193]. However, after age 65 there is 




 Chapter 8. Survival and risk factors for mortality among individuals with 
congenital heart disease: a data-linkage study 
8.1 Introduction 
In Chapter 7, a systematic review showed that a limited number of population-based studies 
have reported survival of children born with CHD. In particular, there was a paucity of 
information on the survival of children with isolated CHD and beyond the age of five years. 
Research regarding risk factors for mortality is limited. Studies consistently demonstrated that 
less recent year of delivery, preterm delivery, presence of ECAs and low birth weight 
negatively impacted on survival. There was some evidence that maternal ethnicity and being 
born in more rural environments negatively influenced survival. However, there was 
inconsistent or little evidence surrounding socioeconomic status and maternal age as risk 
factors for mortality. Most of the studies examined all CHD subtypes combined. Given that 
the subtypes are diverse in terms of aetiology and severity, this is not particularly informative 
and can be misleading. 
8.1.1 Aim 
The aim of this chapter is to report the long-term survival and risk factors for mortality among 
individuals born with CHD, using high quality population-based register data. 
The original aim was to conduct a national study of long-term survival for individuals born 
with CHD between 1985-2010; involving the linkage of data from six BINOCARs to death 
registrations. The linkage was to be performed by the Health and Social Care Information 
Centre (HSC IC, previously known as the NHS Information Centre) using several patient 
identifiable variables. In 2013, I submitted full ethics applications to the Confidentiality 
Advisory Group (CAG) and the Research Ethics Committee (REC) [205, 206]. Although I 
gained ethical approval from both CAG and REC in November 2013 (CAG 5-08(b) 2013 and 
13/NE/0188, Appendix B), the application could not be progressed by the HSC IC between 
2013-2014 due to their moratorium while they reviewed their policies on patient identifiable 
data. After the moratorium ended, HSC IC would not progress the application because 
Newcastle University did not have an Information Governance (IG) toolkit. I spent several 
months writing a System Level Security Policy, with a member of Newcastle University IT. 
Once this had been approved, the BINCOAR’s CAG approval, (which allows the BINOCARs 
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to collect data without consent) expired and therefore my application with HSC IC was 
further halted until this was fully renewed in April 2015. The HSC IC then reviewed my 
application and requested some further changes. These changes required an update to my 
original CAG approval, which was accepted in September 2015. I am currently waiting for 
final approval from the HSC IC, before the data-linkage can commence. Due to time 
constraints, I had to find an alternative data set to investigate long-term survival of CHD. I 
therefore analysed an existing data set consisting of individuals born between 1985-2003 and 
notified to one BINOCAR (the NorCAS) and linked to death registrations in 2008. Some of 
this data has already been published, although survival was not reported for every CHD 
subtype, cases with multiple CHD subtypes or ECAs were excluded, and there was no 
analysis of risk factors for mortality [116]. 
8.1.1.1 Objectives 
 To produce Kaplan-Meier survival estimates for each CHD subtype at one week, one 
month, one year, five years, 10 years, 15 years and 20 years of age. 
 To examine at what age cases were at greatest risk of mortality, according to CHD 
subtype. 
 Using Cox regression, to describe risk factors for mortality including: the presence of 
ECAs, year of delivery, gestational age at delivery, standardised birth weight, maternal 
age, infant sex, deprivation, prenatal diagnosis, plurality and annual TOPFA rates, 
according to CHD subtype. 
 To predict 30 year survival associated with each CHD subtype. 




8.2.1 Case inclusion 
All live born cases (any plurality) with a final diagnosis of CHD (ICD 9: 745, 746, 7470-
7474) born between 1st January 1985-31st December 2003 and notified to the NorCAS before 
January 2008 were included in this study. 
8.2.2 Data 
The NorCAS (one of the BINOCARs) was linked to the PMS to obtain data on infant deaths. 
Any cases that were not recorded on the PMS were then linked with ONS death registrations. 
Cases were linked to death registrations on 28th January 2008 using “fuzzy” matching of the 
following variables: infant forename and surname, infant sex, last known address and infant’s 
date of birth. Traced cases that were matched to a death registration were classed as dead and 
traced cases that were unmatched to death registrations were classed as alive. Cases were 
classed as traced if they were found on the civil registration system, for example in the form 
of a birth certificate. Untraced cases were further examined on NorCAS records, hospital 
records and through the National Tracing System. Cases that were untraced by PMS, ONS, 
hospital records and the National Tracing System were excluded from the analysis (n=22). 
The variables included in the analysis are shown in Table 8.1. Using a fetal growth formula to 
predict birth weight at 40 weeks gestation (according to regional birth weight references) 
[125], birth weight was standardised for gestational age at delivery, sex and plurality. From 
mothers’ postcode at delivery, the IMD 2004 was calculated (see Chapter 4, section 4.1.1). 
The IMD for the whole of England is ranked from 0 to 32,482. Cases were therefore assigned 
to national tertiles of most, moderately and least deprived. 
There were too few cases of triplets and higher order pregnancies to examine these separately 
from twins. Therefore, plurality was classed as singleton or multiple. 
Information on the exact timing of prenatal diagnosis was not available, so prenatal diagnosis 
was simply categorised as “prenatally diagnosed” or “not prenatally diagnosed”. In this 
chapter, prenatal diagnosis refers to the diagnosis of the specific type of CHD. For example, 




Table 8.1 Description of variables used in analysis 
Variable Classification 
Year of delivery (years) Continuous variable 
Gestational age at delivery 
(weeks) 
Continuous variable 
Annual TOPFA (varies by CHD 
subtype) 
Continuous variable  
Sex Male (reference category) 
Female 




CHD with structural ECAs 
CHD with chromosomal/ genetic ECAs 
Prenatal diagnosis Prenatally diagnosed (subtype specific), 
Not prenatally diagnosed (subtype specific) 
Standardised birth weight (SD 
from the mean) 
SD<-1  




IMD rank Tertile 1 (most deprived, reference category) 
Tertile 2 (moderately deprived) 
Tertile 3 (least deprived) 
 
Statistical analysis 
8.2.2.1 Kaplan-Meier survival estimates 
Kaplan-Meier survival estimates and corresponding 95% CIs were estimated at age one week, 
one month, one year, five years, 10 years, 15 years and 20 years. In order to produce precise 
survival estimates in the tail of the Kaplan-Meier curves, estimates were reported where there 
were at least 10 cases at risk at the beginning of the interval, at least five cases at risk at the 
end of the interval and at least five deaths during the interval [207]. 
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8.2.2.2 Cox regression models 
For each CHD subtype, unadjusted HRs representing the risk of mortality associated with 
year of delivery, gestational age at delivery, standardised birth weight, maternal age at 
delivery, sex, deprivation, prenatal diagnosis, plurality and annual TOPFA rate were 
estimated using univariable Cox regression models [208]. The unadjusted models were fitted 
with three strata for: 1) isolated CHD; 2) CHD with structural ECAs; 3) CHD with 
chromosomal/ genetic ECAs. This was because these groups of CHD are diverse in terms of 
aetiologically, prognosis, and intervention. The strata allows the hazard function to vary 
between strata, but the HR for each risk factor is assumed to be the same in each strata [209]. 
Interactions between the ECAs variable and the other risk factors were examined to ensure 
this was appropriate. In terms of interpretation, the HRs produced in the Cox regression 
models with strata are essentially pooled estimates across the three ECA categories. Where 
there were < 10 cases at risk within a strata, this strata was excluded. 
Adjusted HRs (aHRs) were estimated using multivariable Cox regression models. While a 
formal sample size calculation was not performed (due to this being a secondary analysis on a 
population-based data set), Peduzzi et al’s guideline on the minimum number of events per 
variable entered into the Cox regression was utilised [210]. Here, multivariable analysis was 
performed if, for the CHD subtype in question, the number of cases was 10 times the number 
of variables divided by the probability of a death. As case numbers were limited, only 
variables that were significantly associated with mortality for all CHD subtypes combined 
were included in the multivariable analyses. Hence, multivariable analyses was carried out for 
cases of AVA/S, AVSD, ToF, TGV, VSD and all CHD subtypes combined only. 
Interactions between the risk factors were also tested. However, this was only possible for the 
models for all CHD subtypes combined, due to there being too few cases and therefore not 
enough power to test interactions for the individual CHD subtypes. 
The proportional hazards assumption was checked by examination of the Schoenfield 
residuals and the application of the Grambsch-Therneau test for the linearity of the log(HR) 
[211]. 
Cox-Snell residuals were also examined to investigate model fit. If the model is of a good fit 
to the data, then the cumulative hazard function should have an exponential distribution with a 
HR equal to one [212]. This can be checked by using the Cox-Snell residuals as the analysis 
time and plotting the cumulative hazard function. If this cumulative hazard function follows a 
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45 degree line then the function approximately follows the exponential distribution and the 
model is a good fit to the data [212]. 
Martingale residuals were examined for each continuous explanatory variable in order to 
ensure the linearity of the association [213]. Here a flat Lowess curve of the Martingale 
residuals over the explanatory variable of interest is indicative of a linear association between 
the variable and mortality [214]. 
8.2.2.3 Graphing the hazard function 
The hazard functions were examined in order to assess when the greatest risk of mortality 
occurred. Cox regression produces very unstable estimates of the hazard function. Therefore, 
the hazard functions were produced from Royston-Parmar models, which uniquely model the 
baseline hazard function using cubic splines (i.e. piecewise polynomials joined at pre-
specified time-points called knots) [215]. In this analyses, one knot placed at the 50th 
percentile was sufficient for modelling the baseline hazard. 
All statistical analysis was performed in Stata 13. As all analyses were conducted for each of 
the 20 subtypes, a Bonferroni adjustment was used. Therefore, p<0.003 was considered 
statistically significant. As this is arguably over-conservative, associations significant at the 
p<0.05 level are also discussed and described as having “some evidence of an association”. 
8.2.2.4 Prediction and extrapolation 
From the Cox regression model adjusted for year of delivery only, survival estimates were 
predicted for cases born in the last year of the study period (2003), the last year of the study 
period for the data in Chapters five and six (2010) and the current year (2015). 
Using multivariable Royston-Parmar models (adjusted for the same variables as in the 
multivariable Cox models), baseline survival (i.e. the average risk of death) was extrapolated 
to age 30. The predicted survival curve was compared to the Kaplan-Meier survival curves to 





There were 5,092 live born cases of CHD notified to the NorCAS between 1985-2003, of 
which 5,070 (99.5%) were traced. Of these, 4,181 (82.5%) were isolated CHD, 287 (5.7%) 
occurred with structural ECAs and 602 (11.9%) occurred with chromosomal/ genetic ECAs. 
The frequency of each CHD subtype is shown in Table 8.2. 


















n (% of 5,070) 
SV 34 (0.8) 1 (0.3) 1 (0.2) 36 (0.7) 
HLH 73 (1.7) 2 (0.7) 4 (0.7) 79 (1.6) 
HRH 11 (0.3) 0 (0) 1 (0.2) 12 (0.2) 
EA 24 (0.6) 1 (0.3) 2 (0.3) 27 (0.5) 
TA 27 (0.6) 5 (1.7) 2 (0.3) 34 (0.7) 
PVA 30 (0.7) 4 (1.4) 7 (1.2) 41 (0.8) 
CAT 36 (0.9) 6 (2.1) 10 (1.7) 52 (1.0) 
AVSD 107 (2.6) 20 (7) 137 (22.8) 264 (5.2) 
AVA/S 226 (5.4) 6 (2.1) 15 (2.5) 247 (4.9) 
TGV 202 (4.8) 14 (4.9) 6 (1) 222 (4.4) 
ToF 191 (4.6) 36 (12.6) 44 (7.3) 271 (5.3) 
TAPVR 55 (1.3) 5 (1.7) 4 (0.7) 64 (1.3) 
CoA 216 (5.2) 18 (6.3) 24 (4) 258 (5.1) 
IAA 19 (0.5) 1 (0.3) 13 (2.2) 33 (0.6) 
DORV 14 (0.3) 3 (1) 5 (0.8) 22 (0.4) 
MVA 75 (1.8) 1 (0.3) 4 (0.7) 80 (1.6) 
VSD 1922 (46) 96 (33.6) 164 (27.2) 2,182 (43.0) 
ASD 337 (8.1) 19 (6.6) 66 (11) 422 (8.3) 
PVS 382 (9.1) 16 (5.6) 30 (5) 428 (8.4) 
PDA 11 (0.3) 8 (2.8) 20 (3.3) 39 (0.8) 
Other 189 (4.5) 25 (8.7) 30 (5) 244 (4.8) 
All CHD 4,181 (100) 287 (100.3) 602 (100) 5,070 (100) 
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8.3.1 Survival estimates and mortality rates  
Table 8.3 shows the Kaplan-Meier survival estimates, by CHD subtype. Survival estimates 
are also displayed graphically in Figure 8.16 (red curves). Overall, 85.2% lived to age 20, 
which was significantly lower than survival in the general population (98.9%, 95% CI: 98.9-
99.0; p<0.001) [216]. The rate of mortality was highest during the first week of life, decreased 
steeply until approximately age 6 months and gradually declined thereafter, attenuating 
towards zero (Figure 8.1). 
Survival estimates varied by CHD subtype (Table 8.3): for children with isolated HLH, 
survival was 22.8% at age one month (with no cases surviving beyond age 11), whereas for 
children with isolated ASD, 20 year survival was 94.0%. Twenty year survival for all CHD 
subtypes was significantly lower than that of the general population. For all CHD subtypes, 
the predicted mortality rate was greatest during the first week of life (Figure 8.1). The 
predicted mortality decreased monotonically with increasing age and attenuated towards zero. 
The rate of the decrease in mortality and the age at which the rate started to approach zero 




Table 8.3 Survival estimates up to age 20, by CHD subtype 
Age 
 
Subtype No at risk† % Survival 
(95% CI) 
Subtype No at risk† % Survival 
(95% CI) 
1 week  CHD 4867 96.0 (95.4-96.5) TOF 256 94.5 (91.0-96.6) 
1 month  4756 93.8 (93.1-94.4)  251 92.6 (88.8-95.2) 
1 year  4516 89.1 (88.2-89.9)  231 85.2 (80.4-89.0) 
5 years  4131 87.1 (86.2-88.0)  200 77.1 (71.6-81.7) 
10 years  2910 86.7 (85.7-87.6)  145 76.7 (71.2-81.3) 
15 years  1591 86.0 (85.0-87.0)  84 76.0 (70.3-80.7) 
20 years  515 85.2 (84.1-86.3)  27 74.4 (67.8-79.8) 
1 week  SV 34 94.4 (79.6-98.6) TAPVR 60 93.8 (84.2-97.6) 
1 month  32 88.9 (73.1-95.7)  55 85.9 (74.7-92.4) 
1 year  28 77.8 (60.4-88.2)  45 70.3 (57.5-79.9) 
5 years  24 69.4 (51.7-81.8)  42 70.3 (57.5-79.9) 
10 years  18 66.4 (48.5-79.4)  37 70.3 (57.5-79.9) 
15 years  10 57.7 (38.4-73.0)  24 70.3 (57.5-79.9) 
20 years      70.3 (57.5-79.9) 
1 week  HLH 28 35.4 (25.1-45.9) CoA 246 95.4 (92-97.3) 
1 month  18 22.8 (14.3-32.5)  231 89.5 (85.1-92.7) 
1 year     218 84.5 (79.5-88.4) 
5 years     202 82.2 (76.9-86.3) 
10 years     161 81.7 (76.4-85.9) 
15 years     91 81 (75.6-85.4) 
20 years     30 80.1 (74.3-84.7) 
1 week  HRH 12 83.3 (48.2-95.6) IAA 30 90.9 (74.4-97.0) 
1 month  12 83.3 (48.2-95.6)  30 72.7 (54.1-84.8) 
1 year  10 66.7 (33.7-86)  24 60.6 (42.0-74.9) 
5 years     20 60.6 (42.0-74.9) 
10 years     17 60.6 (42.0-74.9) 
15 years     13 60.6 (42.0-74.9) 
20 years       
1 week  EA 24 88.9 (69.4-96.3) DORV 19 86.4 (63.4-95.4) 
1 month  23 85.2 (65.2-94.2)  18 81.8 (58.5-92.8) 
1 year  21 77.8 (57.1-89.3)  15 68.2 (44.6-83.4) 
5 years  17 70.4 (49.4-83.9)  12 59.1 (36.1-76.2) 
10 years  13 70.4 (49.4-83.9)  10 59.1 (36.1-76.2) 
15 years       
20 years       
1 week  TA 30 88.2 (71.6-95.4) MVA 80 100 (-) 
1 month  27 79.4 (61.6-89.6)  79 98.8 (91.5-99.8) 
1 year  23 67.7 (49.2-80.6)  77 96.3 (88.8-98.8) 
5 years  18 52.9 (35.1-68.0)  73 96.3 (88.8-98.8) 
10 years  12 46.4 (29.0-62.1)  57 96.3 (88.8-98.8) 
15 years     35 96.3 (88.8-98.8) 
20 years       





Subtype No at risk† % Survival 
(95% CI) 
Subtype No at risk† % Survival 
(95% CI) 
1 month  31 75.6 (59.4-86.1)  2142 98.2 (97.5-98.7) 
1 year  24 58.5 (42.1-71.8)  2106 96.5 (95.7-97.2) 
5 years  18 48.3 (32.3-62.6)  1957 96.0 (95.1-96.7) 
10 years  13 48.3 (32.3-62.6)  1308 95.7 (94.7-96.5) 
15 years     656 95.6 (94.6-96.4) 
20 years     189 94.9 (93.5-96.1) 
1 week  CAT 46 88.5 (76.1-94.6) ASD 417 98.8 (97.2-99.5) 
1 month  32 61.5 (47.0-73.2)  416 98.6 (96.9-99.4) 
1 year  17 32.7 (20.5-45.4)  407 96.5 (94.2-97.8) 
5 years  16 32.7 (20.5-45.4)  365 95.2 (92.7-96.9) 
10 years  11 32.7 (20.5-45.4)  225 94.6 (92.0-96.4) 
15 years     119 94.0 (90.9-96.1) 
20 years     43 94.0 (90.9-96.1) 
1 week  AVSD 249 94.3 (90.8-96.5) PVS 425 99.3 (97.8-99.8) 
1 month  238 90.2 (85.9-93.2)  424 99.1 (97.5-99.7) 
1 year  193 73.1 (67.3-78.0)  421 98.4 (96.6-99.2) 
5 years  165 65.9 (59.8-71.3)  388 97.7 (95.7-98.7) 
10 years  124 65.0 (58.9-70.4)  293 97.4 (95.3-98.5) 
15 years  63 64.3 (58.1-69.8)  169 97.0 (94.7-98.3) 
20 years  22 63.0 (56.4-68.9)  56 97.0 (94.7-98.3) 
1 week  AVA/s 240 97.2 (94.2-98.6) PDA 38 97.4 (83.2-99.6) 
1 month  231 93.5 (89.6-96.0)  37 94.9 (81.0-98.7) 
1 year  220 89.1 (84.5-92.4)  33 84.6 (68.9-92.8) 
5 years  205 87.8 (83.1-91.3)  18 84.6 (68.9-92.8) 
10 years  164 87.8 (83.1-91.3)    
15 years  113 85.9 (80.6-89.8)    
20 years  42 85.9 (80.6-89.8)    
1 week  TGV 207 93.2 (89.0-95.9) Other 233 95.5 (92-97.5) 
1 month  195 87.8 (82.8-91.5)  231 94.7 (91.0-96.9) 
1 year  176 79.3 (73.3-84.1)  221 90.6 (86.2-93.6) 
5 years  158 77.5 (71.4-82.4)  205 88.5 (83.8-91.9) 
10 years  111 76.4 (70.2-81.5)  166 88.5 (83.8-91.9) 
15 years  66 74.8 (68.3-80.2)  110 87.9 (83.0-91.5) 
20 years  29 71.4 (63.1-78.1)  46 87.9 (83.0-91.5) 
 
† Where the number at risk was <10 at the start of the interval and/or <5 at the end of the interval, the survival 
estimates are not presented. Survival estimates are not presented for HRH as there were too few cases at risk 





































































































































































It was not possible to plot the hazard functions for cases of HRH, IAA, M A, DOR , PDA or “Other” CHD 
subtypes due to low case numbers. Hazard functions are shown for the first 5 years to better visualise the 













































































































































8.3.2 Risk factors for mortality 
8.3.2.1 Extra-cardiac anomalies 
Survival to age 20 was 89.7% among individuals with isolated CHD, 65.9% among 
individuals with CHD and structural ECAs, and 63.8% among individuals with CHD and 
chromosomal/ genetic ECAs (Table 8.4).The risk of mortality varied significantly according 
to the presence of ECAs (p<0.001). Specifically, there was a 4.15 times greater risk of 
mortality in cases with structural ECAs and a 4.10 greater risk of mortality in cases with 
chromosomal/ genetic ECAs, compared to isolated cases of CHD (Table 8.5) 
There was a significant difference in the unadjusted risk of mortality according to the 
presence of ECAs in cases of AVA/S (p=0.002), ToF (p<0.001), VSD (p<0.001), ASD 
(p<0.001), P S (p<0.001) and “Other” CHD subtypes (p<0.001) (Table 8.5). In the 
multivariable analysis, the risk of mortality varied according to the presence of ECAs in cases 
of ToF (p<0.001), VSD (p<0.001) and all CHD subtypes combined (p<0.001) (Table 8.5). 
The risk of mortality was greater in cases with ECAs than in cases with isolated CHD. 
Generally, the risk of mortality was greater in cases with structural ECAs compared to cases 
with chromosomal/ genetic ECAs, although this was not the case for all CHD subtypes.
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Table 8.4 Kaplan-Meier survival estimates, by CHD subtype and the presence of ECAs 





















CHD 1 week 4,068 97.3 (96.8-97.8) 251 87.8 (83.4-91.1) 548 91.0 (88.5-93.1) 
 1 month 3,991 95.5 (94.8-96.1) 238 83.2 (78.4-87.1) 527 87.5 (84.6-89.9) 
  1 year 3,865 92.4 (91.6-93.2) 205 71.7 (66.1-76.5) 446 74.1 (70.4-77.4) 
  5 years 3,568 91.2 (90.3-92.0) 183 67.5 (61.7-72.6) 380 68.4 (64.5-72.0) 
  10 years 2,519 90.9 (90.0-91.8) 131 66.3 (60.8-71.8) 260 66.7 (62.8-70.4) 
  15 years 1,383 90.5 (89.5-91.3) 68 65.9 (59.9-71.1) 140 65.1 (60.9-68.9) 
  20 years 434 89.7 (88.5-90.7) 32 65.9 (59.9-71.1) 49 63.8 (58.9-67.8) 
SV 1 week 33 97.1 (80.9-99.6)     
  1 month 31 91.2 (75.1-97.1)     
  1 year 28 82.4 (64.9-91.7)     
  5 years 24 73.5 (55.3-85.3)     
  10 years 18 70.3 (51.8-82.8)     
  15 years 10 61.1 (40.8-76.3)     
HLH 1 week 26 35.6 (24.7-46.8)     
  1 month 17 23.3 (13.9-33.2)     
EA 1 week 21 87.5 (66.1-95.8)     
  1 month 20 83.3 (61.5-93.4)     
  1 year 18 75.0 (52.6-87.9)     
  5 years 16 70.8 (48.4-84.9)     
  10 years 12 70.8 (48.4-84.9)     
TA 1 week 25 92.6 (73.5-98.1)     
  1 month 23 85.2 (65.2-94.2)     
  1 year 21 77.8 (57.1-89.3)     
  5 years 17 63.0 (42.1-78.1)     
  10 years 12 59.3 (38.6-75.0)     
PVA 1 week 24 80.0 (60.8-90.5)     
  1 month 23 76.7 (60.8-90.5)     
  1 year 19 63.3 (43.7-77.8)     
  5 years 14 52.5 (33.2-68.6)     
  10 years 10 52.5 (33.2-68.6)     
CAT 1 week 36 91.7 (76.4-97.2)   10 90 (47.3-98.5) 
  1 month 33 66.7 (48.8-79.5)     
  1 year 24 36.1 (21.0-51.4)     
  5 years 13 36.1 (21.0-51.4)     
  10 years 10 36.1 (21.0-51.4)     
AVSD 1 week 104 97.2 (91.6-99.1) 19 95.0 (69.5-99.3) 126 92.0 (86.0-95.5) 
  1 month 97 90.7 (83.3-94.9) 17 85.0 (60.4-94.9) 124 90.5 (84.2-94.4) 
  1 year 88 82.2 (73.6-88.3) 12 60.0 (35.7-77.6) 93 67.9 (59.4-75.0) 
  5 years 78 76.6 (67.4-83.5) 11 55.0 (31.3-73.5) 76 59.1 (50.4-66.8) 
  10 years 58 75.5 (66.2-82.7) 10 55.0 (31.3-73.5) 56 58.2 (49.4-65.9) 
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  15 years 33 75.5 (66.2-82.7)   27 56.7 (47.6-64.7) 
  20 years     12 56.7 (47.6-64.7) 
AVA/S 1 week 220 97.4 (94.2-98.8)   14 93.3 (61.3-99) 
  1 month 214 94.7 (90.8-97.0)   11 86.7 (56.4-96.5) 
  1 year 205 90.7 (86.1-93.8)     
  5 years 190 89.4 (84.6-92.8)     
  10 years 151 89.4 (84.6-92.8)     
  15 years 103 87.2 (81.7-91.0)     
  20 years 40 87.2 (81.7-91.0)     
TGV 1 week 190 94.1 (89.78-96.6) 12 85.7 (53.9-96.2)   
  1 month 179 88.6 (83.4-92.3) 11 78.6 (47.3-92.5)   
  1 year 163 80.7 (74.5-85.5)     
  5 years 145 78.7 (72.4-83.7)     
  10 years 104 78.1 (71.7-83.2)     
  15 years 62 76.4 (69.7-81.8)     
  20 years 25 72.5 (63.4-79.6)     
ToF 1 week 187 97.9 (94.5-99.2) 31 86.11 (69.8-94.0) 38 86.4 (72.1-93.6) 
  1 month 184 96.3 (92.5-98.2) 30 83.3 (66.6-92.1) 37 84.1 (69.5-92.1) 
  1 year 176 92.2 (87.3-95.2) 23 63.9 (46.1-77.2) 32 72.7 (57.0-83.5) 
  5 years 157 85.3 (79.4-89.6) 17 50.0 (32.9-64.9) 26 63.6 (47.7-75.9) 
  10 years 115 84.7 (78.8-89.1) 14 50.0 (32.9-64.9) 16 63.6 (47.7-75.9) 
  15 years 67 84.7 (78.8-89.1)     
  20 years 20 82.5 (74.7-88.1)     
TAPVR 1 week 51 92.7 (81.8-97.2)     
  1 month 48 87.3 (75.2-93.7)     
  1 year 40 72.7 (58.9-82.6)     
  5 years 37 72.7 (58.9-82.6)     
  10 years 33 72.7 (58.9-82.6)     
  15 years 21 72.7 (58.9-82.6)     
CoA 1 week 210 97.2 (93.9-98.7) 14 77.8 (51.0-91.0) 22 91.7 (69.5-97.8) 
  1 month 200 92.6 (88.2-95.4) 11 61.1 (35.3-79.2) 20 83.3 (61.5-97.9) 
  1 year 189 87.5 (82.3-91.3)   18 75.0 (52.6-93.4) 
  5 years 174 85.2 (79.7-89.3)   17 70.8 (48.4-87.9) 
  10 years 141 84.7 (79.1-88.8)   14 70.8 (48.4-84.9) 
  15 years 77 84.7 (79.1-88.8)     
  20 years 25 83.5 (77.4-88.1)     
IAA 1 week 16 84.2 (58.7-94.6)   12 100 
  1 month 12 63.2 (37.9-80.4)   10 92.3 (56.6-98.9) 
  1 year 10 52.6 (28.7-71.9)     
DORV 1 week 13 92.9 (59.1-99)     
  1 month 12 85.7 (53.9-96.2)     
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  1 year 10 71.4 (40.6-88.2)     
MVA 1 week 74 100     
  1 month 73 98.6 (90.7-99.8)     
  1 year 71 97.3 (89.5-99.3)     
  5 years 54 97.3 (89.5-99.3)     
  10 years 33 97.3 (89.5-99.3)     
VSD 1 week 1,917 99.7 (99.4-99.9) 87 91.6 (83.9-95.7) 148 90.2 (84.6-93.9) 
  1 month 1,913 99.5 (99.1-99.8) 85 90.5 (82.6-95.0) 143 87.2 (81.0-91.5) 
  1 year 1,903 99.0 (98.5-99.4) 72 86.3 (77.6-91.8) 121 73.8 (66.3-79.8) 
  5 years 1,778 98.9 (98.3-99.3) 75 84.2 (75.2-90.2) 104 68.9 (61.2-75.4) 
  10 years 1,187 98.8 (98.1-99.2) 52 81.6 (72.1-88.2) 69 68.1 (60.3-74.7) 
  15 years 589 98.8 (98.1-99.2) 25 81.6 (72.1-88.2) 42 67.0 (59.0-73.8) 
  20 years 166 98.0 (96.4-98.9) 11 81.6 (72.1-88.2) 12 67.0 (59.0-73.8) 
ASD 1 week 337 100 18 93.8 (63.2-99.1) 62 93.9 (84.7-97.7) 
  1 month 337 100 17 93.8 (63.2-99.1) 60 93.9 (84.7-97.7) 
  1 year 333 98.8 (96.7-99.6) 14 81.3 (52.3-93.5) 54 90.9 (80.9-95.8) 
  5 years 299 98.2 (96.1-99.2) 12 81.3 (52.3-93.5) 30 86.3 (75.3-92.6) 
  10 years 189 98.2 (96.1-99.2)   11 82.5 (70.5-90.0) 
  15 years 105 98.2 (96.1-99.2)     
  20 years 38 98.2 (96.1-99.2)     
PVS 1 week 380 99.5 (97.8-99.9) 15 93.8 (63.2-99.1) 30 100 
  1 month 379 99.2 (97.5-99.7) 13 93.8 (63.2-99.1) 30 100 
  1 year 378 99.0 (97.2-99.6) 11 81.3 (52.5-93.5) 30 100 
  5 years 249 98.4 (96.5-99.3)   26 96.7 (78.6-99.5) 
  10 years 262 98.4 (96.5-99.3)   20 92.3 (72.1-98.0) 
  15 years 149 98.4 (96.5-99.3)   11 86.5 (62.7-95.6) 
  20 years 47 98.4 (96.5-99.3)     
PDA 1 week 11 100 (-)   19 95 (69.5-99.3) 
 1 month 10 88.9 (43.3-98.4)   19 95 (69.5-99.3) 
 1 year 10 88.9 (43.3-98.4)   19 90 (65.6-97.4) 
 5 years     18 90 (65.6-97.4) 
 10 years     10 85 (60.4-'4.9) 
Other 1 week 186 98.4 (95.1-99.5) 20 80.0 (58.4-91.2) 27 90 (72.1-96.7) 
 1 month 185 97.9 (94.4-99.2) 19 76.0 (54.2-88.4) 25 90 (72.1-96.7) 
 1 year 180 95.7 (91.6-97.8) 16 64.0 (42.2-79.4) 21 83.3 (64.5-92.7) 
 5 years 172 94.7 (90.3-97.1) 12 56 (34.8-72.7) 19 80.0 (60.8-90.5) 
 10 years 136 94.7 (90.3-97.1) 11 80.0 (58.4-91.2) 12 80.0 (60.8-90.5) 
 15 years 95 93.9 (89.1-96.6)     
 20 years 36 93.9 (89.1-96.6)     
† Where the number at risk was <10 at the start of the interval and/or <5 at the end of the interval, the survival 
estimates are not presented. Survival estimates are not presented for HRH as there were too few cases at risk 
even at the first week of survival. 
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Table 8.5 Hazard ratios of the presence of ECAs, according to CHD subtype 
Subtype 








HR (95% CI) P-value HR (95% CI) P-value 
CAT Structural -  -  
 Chromosomal  1.29 (0.55-3.00) 0.507 -  
AVSD Structural  2.11 (0.99-4.49) 0.015 2.05 (0.95-4.44) 0.039 
 Chromosomal  1.90 (1.21-3.00)  1.75 (1.1-2.77)  
AVAs Structural  -  -  
 Chromosomal  3.9 (1.62-9.56) 0.002 3.1 (1.23-7.84) 0.017 
TGV Structural  1.76 (0.70-4.23) 0.209 1.90 (0.70-5.13) 0.271 
 Chromosomal  -  -  
ToF Structural  4.45 (2.50-7.91) <0.001 3.12 (1.61-6.05) <0.001 
 Chromosomal  2.81 (1.53-5.16)  2.93 (1.55-5.5)  
CoA Structural  3.22 (1.43-7.27) 0.005 1.67 (0.67-4.14) 0.267 
 Chromosomal  2.28 (1.05-4.92)  1.75 (0.8-3.81)  
IAA Structural  -  -  
 Chromosomal  0.36 (0.10-1.33) 0.126 -  
DORV Structural  -  -  
 Chromosomal  1.34 (0.26-6.90) 0.730 -  
VSD Structural  15.1 (8.14-27.91) <0.001 7.56 (3.99-14.34) <0.001 
 Chromosomal  29.61 (18.39-47.66)  17.68 (10.71-29.18)  
ASD Structural  18.39 (5.60-60.41) <0.001 -  
 Chromosomal  11.06 (4.15-29.49)  -  
PVS Structural  12.76 (3.19-51.09) 0.001 -  
 Chromosomal  6.40 (1.60-25.59)  -  
PDA Structural  -  -  
 Chromosomal  0.35 (0.08-1.58)  -  
Other Structural  8.77 (3.86-19.93) <0.001 -  
 Chromosomal  3.41 (1.28-9.08)  -  
All  Structural  4.15 (3.23-5.19) <0.001 2.57 (2.04-3.24) <0.001 
CHD Chromosomal  4.10 (3.46-4.85)  3.02 (2.54-3.60)  
 
*Cases with structural ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, CAT, AVA/S, TAPVR, 
IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. Cases with chromosomal/ genetic 
ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV and MVA as there 
were <10 cases at risk in these strata. 
†Adjusted for year of delivery, gestational age at delivery, standardised birth weight, prenatal diagnosis and 
annual TOPFA rate. Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD 
and all CHD subtypes combined, due to low sample sizes.
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8.3.2.2 Year of delivery 
Overall, the unadjusted risk of mortality decreased by 7% per years increase in year of 
delivery (HR=0.93, p<0.001) (Table 8.6). The association remained in the multivariable 
model, but with a slightly stronger effect size (aHR=0.91, p<0.001). 
Of the CHD subtypes, there were no significant associations between year of delivery and 
mortality at the p<0.003 level (Table 8.6). However, there was a suggestion that more recent 
year of delivery was significantly associated with decreased risk of mortality in cases of CAT 
(HR=0.92, p=0.020), AVSD (HR=0.94, p=0.004), TGV (HR=0.93, p=0.004) and ASD (HR= 
0.91, p=0.017). In the multivariable analysis, the effect sizes generally became greater (Table 
8.6).  
To summarise, the risk of mortality significantly decreased over time for all CHD subtypes 
combined. There was some evidence that the risk of mortality decreased over time for cases 
of TA, CAT, AVSD, TGV, ToF, IAA, MVA, ASD and PVS, although the associations did 
not reach the nominal significance level.
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Table 8.6 Hazard ratios for year of delivery, by CHD subtype* 
Subtype 
Univariable models Multivariable models† 
HR (95% CI); p-value) aHR (95% CI); p-value 
SV 0.89 (0.77-1.02); p=0.098 - 
HLH 0.95 (0.90-1.01); p=0.090 - 
HRH 0.99 (0.82-1.20); p=0.953 - 
EA 0.93 (0.80-1.09); p=0.385 - 
TA 0.92 (0.81-1.03); p=0.148 - 
PVA 1.01 (0.94-1.09); p=0.732 - 
CAT 0.92 (0.85-0.98); p=0.015 - 
AVSD 0.94 (0.90-0.98); p=0.004 0.91 (0.86-0.97); p=0.006 
AVA/S 0.95 (0.88-1.02); p=0.141 0.89 (0.78-1.01); p=0.071 
TGV 0.93 (0.88-0.98); p=0.004 0.88 (0.80-0.96); p=0.004 
ToF 0.97 (0.93-1.02); p=0.280 0.91 (0.85-0.99); p=0.020 
TAPVR 1.03 (0.94-1.13); p=0.486 - 
CoA 1.01 (0.95-1.06); p=0.804 1.05 (0.98-1.13); p=0.131 
IAA 0.89 (0.78-1.02); p=0.091 - 
DORV 0.98 (0.85-1.13); p=0.746 - 
MVA 0.88 (0.69-1.12); p=0.306 - 
VSD 0.97 (0.93-1.01); p=0.126 0.93 (0.85-1.02); p=0.135 
ASD 0.91 (0.85-0.98); p=0.017 - 
PVS 0.90 (0.80-1.02); p=0.114 - 
PDA 0.96 (0.84-1.10); p=0.535 - 
Other 0.95 (0.89-1.03); p=0.202 - 
All CHD 0.93 (0.92-0.95); p<0.001 0.91 (0.89-0.93); p<0.001 
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
† Adjusted for gestational age at delivery, standardised birth weight, prenatal diagnosis and annual TOPFA rate. 
Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all CHD subtypes 
combined, due to low sample sizes. 




8.3.2.3 Gestational age at delivery 
Overall, the unadjusted risk of mortality decreased significantly by 12% per weeks increase in 
gestational age at delivery (HR=0.88, p<0.001). The association remained in the multivariable 
model (aHR=0.86, p<0.001) (Table 8.7). 
The unadjusted risk of mortality decreased significantly with increasing gestational age at 
delivery in cases of AVSD (HR=0.85, p<0.001), TGV (HR=0.83, p<0.001), CoA (HR=0.85, 
p<0.001), VSD (HR=0.81, p<0.001) and “Other” CHD subtypes (HR=0.84, p<0.001). There 
was a suggestion that gestational age at delivery was associated with decreased risk of 
mortality amongst cases of HLH (HR=0.90, p=0.006), EA (HR=0.81, p=0.024) and IAA 
(HR=0.81, p=0.045). In general, the effect sizes decreased slightly in the multivariable 
models (Table 8.7). 
To summarise, there was evidence that increased gestational age at delivery was associated 
with improved survival overall and in children with A SD, TG , CoA,  SD, and “Other” 
CHD subtypes. There was also some evidence of an association amongst cases of HLH, TA, 
CAT, IAA and PDA, although these did not reach statistical significance.
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Table 8.7 Hazard ratios for gestational age at delivery, by CHD subtype* 
Subtype 
Univariable models Multivariable models 
HR (95% CI); p-value) aHR (95% CI); p-value 
SV 1.05 (0.85-1.31); p=0.626 - 
HLH 0.90 (0.83-0.97); p=0.006 - 
HRH 0.92 (0.74-1.16); p=0.495 - 
EA 0.81 (0.68-0.97); p=0.024 - 
TA 0.84 (0.68-1.05); p=0.124 - 
PVA 0.85 (0.69-1.05); p=0.129 - 
CAT 0.90 (0.8-1.01); p=0.066 - 
AVSD 0.85 (0.8-0.91); p<0.001 0.84 (0.78-0.9); p<0.001 
AVA/S 0.94 (0.8-1.1); p=0.424 0.92 (0.78-1.09); p=0.347 
TGV 0.83 (0.76-0.9); p<0.001 0.78 (0.71-0.86); p<0.001 
ToF 0.92 (0.83-1.01); p=0.086 0.93 (0.83-1.03); p=0.155 
TAPVR 0.94 (0.73-1.21); p=0.641 - 
CoA 0.85 (0.78-0.92); p<0.001 0.83 (0.76-0.91); p<0.001 
IAA 0.81 (0.66-1); p=0.045 - 
DORV 1.16 (0.84-1.61); p=0.37 - 
MVA 0.79 (0.56-1.1); p=0.154 - 
VSD 0.81 (0.77-0.85); p<0.001 0.79 (0.76-0.83); p<0.001 
ASD 0.99 (0.82-1.2); p=0.920 - 
PVS 0.94 (0.77-1.16); p=0.581 - 
PDA 0.81 (0.61-1.08); p=0.16 - 
Other 0.84 (0.76-0.93); p<0.001 - 
All CHD 0.88 (0.86-0.90); p<0.001 0.86 (0.84-0.88); p<0.001 
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
† Adjusted for year of delivery, standardised birth weight, prenatal diagnosis and annual TOPFA rate. 
Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all CHD subtypes 
combined, due to low sample sizes. 
-Case numbers were too low to estimate hazard ratio
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8.3.2.4 Standardised birth weight 
Overall, the unadjusted risk of mortality was significantly associated with standardised birth 
weight (p<0.001). The risk of mortality increased by 35% in cases with low standardised birth 
weight and decreased by 15% in cases with high standardised birth weight (HR=0.85), 
compared to average standardised birth weight (HR=1.35) (Table 8.8). The association 
remained significant in the multivariable model (p<0.001), although the effect size decreased 
slightly for cases with low birth weight (aHR=1.28) and increased slightly for cases with high 
birth weight (aHR=0.71). 
There were no significant associations between mortality and standardised birth weight in any 
of the CHD subtypes. However, in cases of AVSD and VSD, there was a suggestion of an 
association (at the p<0.05 level, p=0.005 and p=0.036, respectively). Here, low standardised 
birth weight was associated with an increased risk of mortality in cases of AVSD (HR=1.83) 
and VSD (HR=1.51) and high standardised birth weight was associated with a decreased risk 
of mortality in cases of AVSD (HR=0.69) and VSD (HR=0.63). In the multivariable models, 
the association between standardised birth weight and mortality became significant in cases of 
AVSD (p=0.002). Again, cases with low birth weight were at increased risk of mortality and 
cases with higher birth weight were at decreased risk. 
To summarise, there was evidence of an association between standardised birth weight and 
mortality in all CHD subtypes combined and in cases of AVSD. There was some evidence of 








Univariable models Multivariable models 
HR (95% CI); p-
value) 
P-value aHR (95% CI); p-
value 
P-value 
SV Low 1.70 (0.44-6.61) 0.742 -  
 High 1.22 (0.25-5.93)  -  
HLH Low 1.20 (0.68-2.09) 0.413 -  
 High 0.72 (0.38-1.38)  -  
EA Low 3.04 (0.14-66.98) 0.770 -  
 High 0.88 (0.11-7.35)  -  
TA Low 0.82 (0.26-2.64) 0.946 -  
 High 0.98 (0.12-7.9)  -  
PVA Low 1.81 (0.69-4.71) 0.396 -  
 High 0.79 (0.17-3.68)  -  
CAT Low 0.74 (0.36-1.54) 0.510 -  
 High 0.56 (0.18-1.7)  -  
AVSD Low 1.83 (1.2-2.79) 0.005 1.76 (1.15-2.69) 0.002 
 High 0.69 (0.30-1.63)  0.46 (0.19-1.11)  
AVA/S Low 1.22 (0.59-2.52) 0.493 1.42 (0.66-3.06) 0.379 
 High 0.49 (0.11-2.13)  0.52 (0.12-2.33)  
TGV Low 1.03 (0.52-2.04) 0.801 1.01 (0.5-2.05) 0.796 
 High 1.27 (0.62-2.58)  0.78 (0.37-1.65)  
ToF Low 1.10 (0.64-1.88) 0.929 0.98 (0.56-1.74) 0.892 
 High 0.97 (0.4-2.35)  0.81 (0.33-1.99)  
TAPVR Low 0.39 (0.11-1.4) 0.172 -  
 High 0.26 (0.03-1.96)  -  
CoA Low 0.68 (0.34-1.37) 0.294 0.72 (0.36-1.44) 0.396 
 High 1.35 (0.65-2.8)  1.32 (0.62-2.77)  
IAA Low 1.74 (0.47-6.48) 0.682 -  
 High 1.72 (0.31-9.49)  -  
VSD Low 1.51 (0.98-2.33) 0.036 1.28 (0.83-1.97) 0.018 
 High 0.63 (0.30-1.34)  0.42 (0.19-0.91)  
ASD Low 1.74 (0.73-4.14) 0.355 -  
 High 0.79 (0.17-3.62)  -  
PVS Low 4.09 (1.14-14.62) 0.068 -  
 High 0.98 (0.11-8.76)  -  
PDA Low 2.91 (0.48-17.8) 0.248 -  
 High -  -  
Other Low 2.84 (1.20-6.72) 0.050 -  
 High 2.34 (0.83-6.59)  -  
All CHD Low 1.35 (1.15-1.59) <0.001 1.28 (1.08-1.51) <0.001 
 High 0.85 (0.67-1.09)  0.71 (0.56-0.91)  
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
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TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
†Adjusted for year of delivery, gestational age at delivery, prenatal diagnosis and annual TOPFA rates. 
Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all CHD subtypes 
combined, due to low sample sizes. 
-Case numbers were too low to estimate hazard ratio
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8.3.2.5 Maternal age at delivery 
Overall, there was a suggestion of an association between mortality and maternal age at 
delivery, with the risk of mortality decreasing by 2% per years increase in maternal age at 
delivery (HR=0.98, p=0.016). There was no association with maternal age in the multivariable 
model (aHR=1.00, p=0.542) (Table 8.9). 
In the univariable models, there were no statistically significant associations between 
mortality and maternal age in any of the CHD subtypes. However, for the majority of the 
subtypes, the unadjusted risk of mortality appeared to decrease slightly with increasing 
maternal age at delivery (Table 8.9). In the multivariable models, the effect sizes remained 
broadly similar and none of the associations reached statistical significance.  
To summarise, there was evidence of a decreased risk of mortality with increasing maternal 
age, although this was likely caused by confounding. There was no evidence of an association 
when CHD subtypes were considered separately.
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Table 8.9 Hazard ratios for maternal age at delivery, by CHD subtype 
Subtype 
Univariable models Multivariable models 
HR (95% CI); p-value) aHR (95% CI); p-value 
SV 1.02 (0.91-1.14); p=0.724 - 
HLH 1.01 (0.97-1.05); p=0.646 - 
HRH 0.93 (0.77-1.13); p=0.474 - 
EA 1.01 (0.9-1.13); p=0.904 - 
TA 0.93 (0.84-1.02); p=0.120 - 
PVA 1 (0.94-1.06); p=0.895 - 
CAT 1.01 (0.95-1.06); p=0.853 - 
AVSD 1 (0.97-1.03); p=0.934 1.01 (0.98-1.04); p=0.484 
AVA/S 0.99 (0.93-1.05); p=0.698 1.00 (0.93-1.07); p=0.891 
TGV 0.97 (0.92-1.02); p=0.271 0.97 (0.92-1.03); p=0.348 
ToF 1.02 (0.98-1.07); p=0.319 1.03 (0.98-1.07); p=0.284 
TAPVR 1.04 (0.96-1.13); p=0.341 - 
CoA 1.01 (0.96-1.06); p=0.716 1.00 (0.95-1.05); p=0.936 
IAA 1.08 (0.98-1.19); p=0.137 - 
DORV 1.00 (0.88-1.13); p=0.946 - 
MVA 0.79 (0.56-1.11); p=0.169 - 
VSD 0.97 (0.94-1.01); p=0.101 0.99 (0.96-1.02); p=0.602 
ASD 0.97 (0.9-1.04); p=0.342 - 
PVS 0.95 (0.85-1.06); p=0.343 - 
PDA 0.96 (0.84-1.10); p=0.596 - 
Other 0.96 (0.89-1.03); p=0.255 - 
All CHD 0.98 (0.97-1); p=0.016 1.00 (0.98-1.01); p=0.542 
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
† Adjusted for year of delivery, gestational age at delivery, standardised birth weight, prenatal diagnosis and 
annual TOPFA rate. Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD 
and all CHD subtypes combined, due to low sample sizes. 




Overall, there was no evidence that infant sex was associated with mortality (HR=0.98, 
p=0.840). This remained the case in the multivariable model (aHR=1.01, p=0.870) 
In the univariable models, infant sex was not significantly associated with mortality in any of 
the CHD subtypes. However, there was a suggestion that male cases of CoA and TGV were at 
increased risk of mortality compared to female cases (HR=2.41, p=0.003 and HR=1.85, 
p=0.023, respectively) and that male cases of TAPVR were at decreased risk of mortality 
compared to female cases (HR=0.09, p=0.023). In the multivariable analysis, the effect size 
for cases of TGV decreased and the association was no longer significant at the p<0.05 level 
(aHR=1.26, p=0.454). However, the association remained similar for cases of CoA 
(aHR=2.35, p=0.006). 
To summarise, there was some evidence that male cases of TGV and CoA were more likely to 
survive than their female counterparts. There was some evidence that male cases of TAPVR 
were less likely to survive compared to females.
248 
 
Table 8.10 Hazard ratios for male versus female, by CHD subtype 
Subtype 
Univariable models Multivariable models 
HR (95% CI); p-value) aHR (95% CI); p-value 
SV 0.74 (0.2-2.75); p=0.650 - 
HLH 1.09 (0.67-1.78); p=0.718 - 
HRH 1.11 (0.16-7.88); p=0.919 - 
EA 0.96 (0.22-4.31); p=0.960 - 
TA 0.58 (0.2-1.69); p=0.318 - 
PVA 1.55 (0.64-3.76); p=0.328 - 
CAT 0.87 (0.45-1.69); p=0.682 - 
AVSD 0.76 (0.51-1.14); p=0.179 0.91 (0.6-1.4); p=0.681 
AVA/S 1.02 (0.48-2.17); p=0.964 0.98 (0.46-2.11); p=0.968 
TGV 1.85 (1.09-3.15); p=0.023 1.37 (0.78-2.42); p=0.277 
ToF 1.47 (0.9-2.4); p=0.121 1.58 (0.96-2.61); p=0.071 
TAPVR 0.09 (0.01-0.71); p=0.022 - 
CoA 2.41 (1.35-4.29); p=0.003 2.35 (1.28-4.31); p=0.006 
IAA 1.43 (0.45-4.55); p=0.545 - 
DORV 2.4 (0.58-9.83); p=0.225 - 
VSD 0.93 (0.62-1.39); p=0.712 1.13 (0.75-1.71); p=0.548 
ASD 1.26 (0.55-2.91); p=0.581 - 
PVS 1.87 (0.58-6.1); p=0.297 - 
PDA 3.85 (0.73-20.2); p=0.111 - 
Other 1.57 (0.73-3.39); p=0.249 - 
All CHD 0.98 (0.85-1.14); p=0.840 1.07 (0.92-1.24); p=0.402 
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
†Adjusted for year of delivery, gestational age at delivery, standardised birth weight, prenatal diagnosis, annual 
TOPFA rate. Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all 
CHD subtypes combined, due to low sample sizes. 




Overall, there was no evidence that deprivation was associated with the (unadjusted) risk of 
mortality (p=0.208). However, the risk of mortality was lower in the least deprived cases 
(HR=0.82). In the multivariable model, the association remained non-significant (p=0.465) 
and the effect size corresponding to the least deprived decreased slightly (aHR=0.89). 
In both the univariable and multivariable models, there was no evidence of an association 




Table 8.11 HRs for moderate and least deprived compared to most deprived, by CHD subtype 
Subtype 
 Univariable models Multivariable models 
Deprivation 
HR (95% CI) P-value aHR (95% CI) 
P-
value 
SV Moderate 0.42 (0.09-2) 0.064 -  
 Least 4.43 (0.9-21.88)  -  
HLH Moderate 1.25 (0.72-2.17) 0.371 -  
 Least 1.6 (0.8-3.2)  -  
EA Moderate 1.13 (0.19-6.88) 0.636 -  
 Least 2.13 (0.42-10.8)  -  
TA Moderate 0.57 (0.12-2.63) 0.350 -  
 Least 1.98 (0.57-6.84)  -  
PVA Moderate 0.67 (0.25-1.83) 0.581 -  
 Least 0.54 (0.12-2.44)  -  
CAT Moderate 0.82 (0.33-2.02) 0.159 -  
 Least 0.13 (0.02-1.05)  -  
AVSD Moderate 0.73 (0.44-1.2) 0.165 0.97 (0.58-1.63) 0.987 
 Least 0.59 (0.32-1.09)  1.03 (0.54-1.94)  
AVAs Moderate 0.73 (0.31-1.7) 0.413 0.95 (0.39-2.31) 0.494 
 Least 0.47 (0.14-1.58)  0.47 (0.14-1.64)  
TGV Moderate 1.29 (0.67-2.47) 0.695 1.54 (0.79-3) 0.449 
 Least 1.23 (0.62-2.44)  1.19 (0.59-2.38)  
ToF Moderate 1.81 (1.06-3.09) 0.035 1.68 (0.93-3.01) 0.060 
 Least 0.63 (0.25-1.6)  0.56 (0.21-1.44)  
TAPVR Moderate 0.6 (0.2-1.86) 0.563 -  
 Least 0.48 (0.06-3.71)  -  
CoA Moderate 1.12 (0.6-2.09) 0.743 1.21 (0.64-2.26) 0.772 
 Least 0.77 (0.32-1.89)  0.89 (0.35-2.24)  
IAA Moderate 0.61 (0.08-4.93) 0.766 -  
 Least 1.4 (0.36-5.38)  -  
DORV Moderate 0.65 (0.12-3.62) 0.885 -  
 Least -  -  
MVA Least 2.42 (0.15-38.64) 0.533 -  
VSD Moderate 1.05 (0.66-1.68) 0.738 1.13 (0.7-1.84) 0.598 
 Least 0.80 (0.42-1.52)  0.78 (0.4-1.51)  
ASD Moderate 1.75 (0.74-4.12) 0.164 -  
 Least 0.3 (0.04-2.28)  -  
PVS Moderate 2.74 (0.77-9.76) 0.236 -  
 Least 0.74 (0.09-6.15)  -  
PDA Moderate 1.5 (0.12-19.37) 0.313 -  
 Least 5.25 (0.57-48.04)  -  
Other Moderate 1.19 (0.52-2.74) 0.823 -  
 Least 1.35 (0.48-3.82)  -  
All CHD 
Moderate 1.00 (0.84-1.2) 0.208 1.05 (0.88-1.25) 0.465 
Least 0.82 (0.65-1.03)  0.89 (0.71-1.12)  
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*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
HRs were not estimated for HRH due to low case numbers 
† Adjusted for year of delivery, gestational age at delivery, standardised birth weight, prenatal diagnosis and 
annual TOPFA. Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all 
CHD subtypes combined, due to low sample sizes. 
-Case numbers were too low to estimate hazard ratio
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8.3.2.8 Prenatal Diagnosis 
Overall, the unadjusted risk of mortality was almost four times greater in cases that were 
prenatally diagnosed, compared to those that were postnatally diagnosed (HR=3.85, p<0.001). 
In the multivariable model, the effect size increased and the association remained significant 
(aHR=4.65, p<0.001). 
In the univariable models, the risk of mortality was significantly increased in prenatally 
compared to postnatally diagnosed cases of AVA/S (HR=7.91, p<0.001), VSD (HR=4.17, 
p<0.001), PVS (HR=22.51 increased, p<0.001). There was a suggestion that the unadjusted 
risk of mortality was significantly greater in prenatally compared to postnatally diagnosed 
cases of EA (HR=7.43, p=0.010), PVA (HR=4.86, p=0.014), AVSD (HR=1.95, p=0.014), 
ToF (HR=2.25, p=0.020), CoA (HR=2.46, p=0.044) and MVA (HR=51.62, p=0.006). As 
shown in Table 8.12, the associations remained statistically significant in the multivariable 
models, although the effect sizes increased. 
To summarise, prenatally diagnosed cases of AVA/S, VSD and PVS were less likely to 
survive than postnatally diagnosed cases. There was some evidence that prenatally diagnosed 
cases of EA, PVA, AVSD, ToF, CoA and MVA were less likely to survive.
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Table 8.12 Hazard ratios for prenatal diagnosis compared to postnatal diagnosis, by CHD subtype 
Subtype 
Univariable models Multivariable models 
HR (95% CI); p-value) aHR (95% CI); p-value 
SV 1.58 (0.34-7.22); p=0.557 - 
HLH 1.15 (0.67-1.97); p=0.612 - 
HRH 9.49 (0.59-151.82); p=0.112 - 
EA 7.43 (1.61-34.34); p=0.010 - 
TA 1.21 (0.34-4.35); p=0.766 - 
PVA 4.86 (1.72-13.75); p=0.003 - 
CAT 1.75 (0.48-6.43); p=0.397 - 
AVSD 1.95 (1.14-3.32); p=0.014 2.13 (1.13-4.00); p=0.019 
AVA/S 7.91 (2.72-23.01); p<0.001 8.65 (2.81-26.67); p<0.001 
TGV 0.93 (0.36-2.38); p=0.881 0.67 (0.25-1.80); p=0.426 
ToF 2.25 (1.13-4.45); p=0.020 2.83 (1.29-6.2); p=0.010 
TAPVR - - 
CoA 2.46 (1.03-5.89); p=0.044 3.40 (1.34-8.62); p=0.01 
IAA - - 
DORV 0.81 (0.06-11.57); p=0.877 - 
MVA 51.62 (3.1-860.41); p=0.006 - 
VSD 4.17 (2.42-7.19); p<0.001 3.60 (2.06-6.29); p<0.001 
PVS 22.51 (5.62-90.17); p<0.001 - 
Other 1.32 (0.31-5.63); p=0.708 - 
All CHD 3.85 (3.13-4.73); p<0.001 4.65 (3.75-5.76); p<0.001 
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, EA, 
TA, PVA, CAT, AVA/S, TAPVR, IAA, DORV, MVA and PDA as there were <10 cases at risk in these strata. 
Chromosomal/ genetic ECAs were excluded for cases of SV, HLH, HRH, EA, TA, PVA, TGV, TAPVR, DORV 
and MVA as there were <10 cases at risk in these strata. 
† Adjusted for year of delivery, gestational age at delivery, standardised birth weight, and prenatal diagnosis. 
Multivariable models were only fitted to cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all CHD subtypes 
combined, due to low sample sizes. 
HRs not estimated for ASD and PDA as these are not possible to diagnose prenatally. 




Overall, there was no evidence of an association between plurality and mortality (p=0.667). 
However, the risk of mortality was increased in cases from multiple compared to singleton 
pregnancies (HR=1.29). In the multivariable model the association remained non-significant 
(p=0.267), but the effect changed direction, with cases from multiple pregnancies being at 
decreased risk of mortality compared to singletons (aHR=0.81). 
Of the individual CHD subtypes, there was a significant association between plurality and 
mortality in cases of VSD only; cases from multiple pregnancies were at almost four-fold 
increased risk of mortality (aHR=3.54, p=0.001). In the multivariable model, the effect size 
decreased and the association was no longer statistically significant (aHR=1.43, p=0.368). 
Table 8.13 Hazard ratios for cases from multiple compared to singleton pregnancies, by CHD subtype 
Subtype 
Univariable models Multivariable models 
HR (95% CI); p-value) HR (95% CI); p-value 
HLH 1.29 (0.40-4.14); p=0.667 - 
HRH 1.23 (0.13-11.87); p=0.859 - 
CAT 1.51 (0.43-5.31); p=0.523 - 
AVSD 0.42 (0.06-3.05); p=0.394 0.18 (0.03-1.37); p=0.098 
ToF 0.79 (0.25-2.53); p=0.691 0.60 (0.18-1.99); p=0.406 
TAPVR 2.83 (0.57-13.99); p=0.201 - 
CoA 1.73 (0.53-5.63); p=0.362 0.53 (0.13-2.21); p=0.381 
VSD 3.54 (1.71-7.33); p=0.001 1.43 (0.66-3.11); p=0.368 
ASD 0.78 (0.10-5.94); p=0.813 - 
PDA 1.37 (0.95-1.97); p=0.096 - 
All CHD 1.29 (0.40-4.14); p=0.667 0.81 (0.55-1.18); p=0.267 
 
† Adjusted for year of delivery, gestational age at delivery, standardised birth weight, prenatal diagnosis and 
annual TOPFA rate. Multivariable models were only fitted to cases of AVSD, ToF, CoA, VSD and all CHD 
subtypes combined, due to low sample sizes. 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, HRH, CAT, 
TAPVR, and PDA as there were <10 cases at risk in these strata. Chromosomal/ genetic ECAs were excluded for 
cases of HLH, HRH and TAPVR as there were <10 cases at risk in these strata. 
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8.3.2.10 Annual TOPFA rate 
Overall, the unadjusted risk of mortality significantly decreased with increasing annual 
TOPFA rate (p<0.001). Specifically for every percentage increase in TOPFA, the risk of 
mortality decreased by 15% (HR=0.85). In the multivariable model however, the effect size 
diminished and the association was not statistically significant (aHR=1.01, p=0.737). 
There were no statistically significant associations between mortality and annual TOPFA rate 
for any of the individual CHD subtypes (Table 8.14). This remained the case in the 
multivariable models. 
To summarise, when considering all CHD subtypes combined, the risk of mortality 
significantly increased with increasing annual TOPFA rate, but this was likely caused by 
confounding. There were no significant associations between annual TOPFA rate and 
mortality in the individual CHD subtypes. 
Table 8.14 Hazard ratios for annual TOPFA rate, by CHD subtype 
Subtype 
Univariable models Multivariable models 
HR (95% CI); p-value) HR (95% CI); p-value 
SV 0.95 (0.9-1.01); p=0.117 - 
HLH 0.99 (0.98-1); p=0.028 - 
TA 1.01 (0.99-1.04); p=0.331 - 
PVA 1 (0.96-1.04); p=0.935 - 
CAT 0.98 (0.94-1.01); p=0.208 - 
AVSD 0.99 (0.96-1.02); p=0.523 1.01 (0.83-1.24); p=0.892 
AVA/S 1.01 (0.89-1.16); p=0.824 1.28 (0.85-1.92); p=0.234 
TGV 0.82 (0.66-1.01); p=0.066 1.19 (0.88-1.6); p=0.258 
ToF 1.00 (0.95-1.06); p=0.937 1.18 (0.94-1.47); p=0.155 
CoA 0.95 (0.87-1.05); p=0.321 0.6 (0.44-0.83); p=0.002 
VSD 1.02 (0.64-1.62); p=0.932 0.99 (0.83-1.18); p=0.919 
PVS 1.32 (0.75-2.3); p=0.335 - 
All CHD 0.85 (0.81-0.9); p<0.001 1.01 (0.94-1.09); p=0.737 
 
*Hazard ratios were estimated using Cox regression with three strata (isolated CHD, CHD with structural ECAs 
and CHD with chromosomal/ genetic ECAs). Structural ECAs were excluded for cases of SV, HLH, TA, PVA, 
CAT and AVA/S as there were <10 cases at risk in these strata. Chromosomal/ genetic ECAs were excluded for 
cases of SV, HLH, TA, PVA and TGV as there were <10 cases at risk in these strata. 
† Adjusted for year of delivery, gestational age at delivery, standardised birth weight, and prenatal diagnosis. 
Multivariable models were estimated for cases of AVSD, AVA/S, TGV, ToF, CoA, VSD and all subtypes 




8.3.3 Sensitivity analysis 
8.3.3.1 ECAs as strata 
In this chapter, separate strata were fitted to isolated CHD, CHD with structural ECAs and 
CHD with chromosomal/ genetic ECAs. This approach was used to account for variation in 
survival between these categories, and variation in the baseline hazards. As shown in Figure 
8.2, the proportional hazard assumption would have been violated had the presence of ECAs 
been simply incorporated into the models as explanatory variables. Specifically, cases with 
chromosomal ECAs appeared to have a slightly different survival curve over age, compared 
to isolated cases and cases with chromosomal/ genetic ECAs. Although the baseline hazards 
can vary between strata, the association with the explanatory variables is assumed to be the 
same. Therefore, interaction between ECAs and the explanatory variables were investigated. 
There were significant interactions between year of delivery and the presence of ECAs 
(p=0.001). The risk of mortality decreased with increasing year of delivery for isolated CHD, 
CHD with structural ECAs and CHD with chromosomal/ genetic ECAs. However, the effect 
size was smaller in isolated cases compared to cases with ECAs (Figure 8.3). 
Overall, there was a significant interaction between prenatal diagnosis and the presence of 
ECAs (p<0.001). As shown in Figure 8.4, the impact of prenatal diagnosis on mortality was 
greater in cases of CHD with structural ECAs, compared to cases of CHD with chromosomal/ 
genetic ECAs. 
There were no significant interactions between ECAs and gestational age at delivery, 




Figure 8.2 Log-log plot of survival for all CHD subtypes combined 
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Figure 8.4 Margins for prenatal diagnosis according to the presence of ECAs 
 
8.3.3.2 Interactions between risk factors 
Overall, there was a significant interaction between gestational age at delivery and year of 
delivery (p<0.001). As shown in Figure 8.5, the risk of mortality for extremely preterm cases 
of CHD increased slightly over the study period but, decreased for all other gestational ages. 
There was also a significant interaction between prenatal diagnosis and year of delivery 
(p=0.003). As shown in Figure 8.6, the decrease in mortality over the study period was very 
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Figure 8.5 Margins depicting the interaction between year of delivery and gestational age at delivery, for 
all CHD 
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8.3.3.3 Proportional hazards assumption 
For the univariable models of year of delivery, gestational age at delivery, standardised birth 
weight, maternal age, sex, prenatal diagnosis and annual TOPFA rate the proportional hazards 
assumption was satisfied for all CHD subtypes (according to Therneau-Grambsch tests). 
However, using p<0.05 as the nominal significance level, there was evidence that some of the 
univariable models did not satisfy the proportional hazards assumption for certain subtypes 
(Table 8.15). The Schoenfield residuals were plotted against age (survival time) for these 
models (Figure 8.7). Here, standardised birth weight had a slightly greater impact on survival 
under age five for children born with AVA/S, TAPVR and VSD although the change in effect 
was relatively small. The effect of maternal age on survival of individuals with AVSD and all 
CHD combined was relatively stable with increasing age, with perhaps some evidence that 
maternal age had a slightly greater impact within the first five years of life. The effect of sex 
on survival of children with TGV and CoA was slightly lower within the first year of life, but 
remained stable thereafter. In cases of AVA/S, the effect of deprivation became less 
pronounced with increasing age. However, this effect is likely due to low case numbers of 
AVA/S at older ages. 
With the exception of AVA/S, all of the multivariable models satisfied the proportional 
hazards assumption, on the basis of the Therneau-Grambsch tests (Table 8.16). But, using 
p<0.05 as the nominal significance level, there was evidence that the multivariable model for 
CAT did not satisfy the proportional hazards assumption. For both subtypes, the issue with 
proportionality was caused by standardised birth weight; the proportional hazards assumption 
was violated by the high birth weight babies (compared to the average birth weight babies) 




Table 8.15 Univariable models that did not satisfy the proportional hazard assumption at the p<0.05 level 
Variable CHD subtype Therneau Grambsch test of 
proportional hazards: p-
value 
Standardised birth weight AVA/S 0.034 
 TAPVR 0.039 
 VSD 0.017 
Maternal age AVSD 0.017 
 All CHD 0.022 
Sex TGV 0.032 
 CoA 0.016 
Deprivation AVA/S 0.043 
 
Table 8.16 Test of proportional hazards assumption for all multivariable models, by CHD subtype 













Figure 8.7 Schoenfield residuals plotted against age for univariable models 
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8.3.3.4 Model fit 
Considering all CHD subtypes combined, the multivariable model fitted the data well for the 
smaller values of the Cox-Snell residuals (Figure 8.9). However, for older ages, the 
cumulative hazard function decreases and becomes lower than one, and the distribution does 
not follow the exponential function. This is perhaps unsurprising given that the CHD subtypes 
that comprise this composite group are very diverse.  
For the individual subtypes, the multivariable models fit the data reasonably well (Figure 8.9). 
At older ages, the cumulative hazards functions deviate from the 45 degree line somewhat for 
AVA/S and TGV. However, this is expected due to high case censoring and low sample sizes 
in the tail of the data. 
Figure 8.9 Cox Snell residuals plotted against the cumulative hazard, by CHD subtype 
 
Cox Snell residuals were predicted from the multivariable models adjusted for year of delivery, gestational age at 
delivery, standardised birth weight, prenatal diagnosis and annual TOPFA rate. The blue line represents the 
cumulative hazard function. If the models are a good fit to the data, the hazard functions will have an exponential 
function with a hazard rate of one, graphically this means the hazard function will follow the forty five degree 












































































8.3.3.5 Linearity of continuous variables 
The Lowess of the Martingale residuals is linear over maternal age at delivery overall and for 
the individual CHD subtypes (Figure 8.10 and Figure 8.11). The Lowess of the Martingale 
residuals over year of delivery is also linear overall and for each CHD subtype (Figure 8.13 
and Figure 8.12). This suggests that the associations between mortality and maternal age at 
delivery, and mortality and year of delivery, are linear. Therefore, these variables can be 
modelled as a continuous explanatory variables.  
The Lowess of the Martingale residuals over gestational age at delivery is linear for all CHD 
subtypes combined (Figure 8.15). For the majority of CHD subtypes, the Lowess is linear, 
meaning gestational age at delivery can be modelled as a continuous explanatory variable. 
However for SV, EA and PVA there is some evidence of non-linearity at the higher 
gestational ages of delivery. This is likely due to the low frequency of these subtypes, 
combined with the rarity of a gestational age at delivery >40 weeks. 
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Figure 8.11 Martingale residuals for maternal age at delivery, by CHD subtype 
 






























































































































































































































































































































































































Figure 8.13 Martingale residuals for year of delivery, for all CHD 
 




















































































































































































































Figure 8.15 Martingale residuals for gestational age at delivery, for all CHD 
 
8.3.4 Predicting survival 
8.3.4.1 Predicting survival for cases born in or after 2003 
The predicted 20 year survival of children born with isolated CHD (any subtype) in 2003 was 
96.0% (Table 8.17). This was substantially higher than the Kaplan-Meier estimate of 89.7%, 
which was calculated for all cases regardless of year of delivery. With the exception of CoA 
and DORV, the 20 year survival estimates for children born in 2003 were greater than those 
produced using Kaplan-Meier estimates (Table 8.17). Indeed, survival of children with ASD 
(99.3%) and PVS (99.8%) exceeded that of the predicted survival of the general UK 
population born in 2003 (99.2%) [216]. 
Assuming the improvements in survival increased at the same rate as in the existing data, the 
predicted 20 year survival of children born with CHD (any subtype) in 2010 and 2015 was 
98.0% and 98.7%, respectively. The predicted survival estimates for cases born in 2010 and 
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Table 8.17 Predicted survival to age 20 for cases born in 2003 and 2010 
CHD 
subtype 
Delivered in 2003 
Survival (95% CI) 
Delivered in 2010 
Survival (95% CI) 
Delivered in 2015 
Survival (95% CI) 
SV 88.9 (46.2-98.2) 95.0 (42.8-99.7) 97.2 (40-99.9) 
HLH* 8.9 (1.1-27.7) 16.7 (0.9-50.9) 23.7 (0.7-65.7) 
HRH 65.3 (3.2-94.8) 66.4 (0-98.4) 67.2 (0-99.4) 
EA 84.4 (32.9-97.4) 89.7 (15.4-99.4) 92.5 (6.3-99.8) 
TA 95.0 (57.6-99.5) 98.6 (63-100) 99.4 (66.3-100) 
PVA* 45.7 (12-74.9) 46.2 (2.8-84.6) 46.5 (0.5-89.6) 
CAT 72.6 (31-91.6) 86.5 (36.9-97.9) 92.1 (40.9-99.2) 
AVSD 82.2 (61.4-92.4) 86.8 (56.2-96.6) 89.4 (51.8-98.1) 
AVA/S 93.1 (82.3-97.4) 95.3 (80.4-99) 96.5 (78.8-99.5) 
TGV 85.7 (73-92.7) 90.7 (75.4-96.7) 93.2 (76.8-98.2) 
ToF 93.8 (83.9-97.7) 96.9 (86.3-99.3) 98.1 (87.7-99.7) 
CoA 62.9 (28.9-84.1) 54 (4.7-88.3) 47 (0.3-90.9) 
TAPVR 86.4 (72.9-93.5) 88.1 (65.4-96.3) 89.2 (58.9-97.6) 
IAA* 91.2 (37.7-99.1) 97.4 (38.2-99.9) 98.9 (38.1-100) 
DORV 23.7 (0-80.1) 3.3 (0-86.7) 0.2 (0-90.5) 
MVA 98.2 (60.8-99.9) 98.7 (8.2-100) 98.9 (0-100) 
VSD 99.1 (97.5-99.7) 99.5 (97.5-99.9) 99.6 (97.4-99.9) 
ASD 99.3 (96.1-99.9) 99.7 (95.2-100) 99.8 (94.4-100) 
PVS 99.8 (97.1-100) 99.9 (97.1-100) 100 (97-100) 
PDA 78.9 (6.6-98) 86.4 (0.5-99.6) 90.2 (0-99.9) 
Other 97.5 (87.5-99.5) 98.6 (84.4-99.9) 99.1 (81.6-100) 
All CHD 96.0 (94.9-96.9) 98.0 (97-98.6) 98.7 (98-99.2) 
 
*Eleven year survival was estimated for HLH, survival for children with PVA and IAA was estimated up to age 
19 and 6 months. 
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8.3.4.2 Predicting 30 year survival 
Figure 8.16, shows the baseline survival curves at the average prognostic index for all isolated 
cases, according to CHD subtype. The predicted survival curves fit the raw data, depicted by the 
Kaplan-Meier curves, reasonably well. For all CHD subtypes combined, predicted survival over-
estimated the Kaplan-Meier survival estimates. However, even at 20 years where the difference 
was greatest, the discrepancy is only 3% (predicted survival estimate: 89.7% (95% CI: 88.5-90.7) 
and Kaplan-Meier survival estimate: 92.8% (95% CI: 91.8-93.6)). Predicted survival was also 
over-estimated for cases of TA, TGV, AVSD and VSD, although here the predicted 95% 
confidence intervals overlapped the Kaplan-Meier 95% confidence intervals. 
For all CHD subtypes, predicted 30 year survival was lower than predicted 20 year survival 
(Table 8.18). However, the decrease in predicted survival was relatively minimal. 
Table 8.18 Predicted 30 year survival of isolated CHD, by CHD subtype 
CHD subtype Predicted 20 year 
survival (95% CI)  
Predicted 30 year 
survival (95% CI) 
SV 68.8 (46.1-85.0) 66.0 (42.1-83.8) 
HLH 1.7 (0.4-7.0) 1.5 (0.3-6.9) 
EA 70.2 (48.2-85.7) 69.1 (46.5-85.1) 
TA 71.3 (41.6-89.7) 68.0 (37.1-88.4) 
PVA 44.9 (26.7-64.5) 42.2 (23.8-63.0) 
CAT 21.7 (10.3-40.2) 21.0 (9.5-40.1) 
AVSD 89.9 (76.4-96.1) 89.4 (75.4-95.9) 
TGV 79.0 (71.9-84.7) 78.3 (70.9-84.2) 
ToF 85.9 (79.2-90.7) 85.0 (77.6-90.2) 
TAPVR 73.5 (58.9-84.4) 72.6 (57.4-83.9) 
CoA 85.4 (79.6-89.8) 85.1 (79.1-89.6) 
VSD 99.5 (99.0-99.7) 99.5 (98.9-99.7) 
ASD - - 
PVS 98.9 (96.6-99.6) 98.8 (96.4-99.6) 
Other 94.1 (88.9-96.8) 93.9 (88.9-96.8) 
All CHD 92.8 (91.8-93.6) 92.6 (91.6-93.5) 
There were not enough cases of HRH, AVA/S, IAA, DORV, MVA and PDA to predict 30 year survival. It was not 
possible to extrapolate 30 year survival for cases of ASD, due to low frequency of deaths. 
270 
 

















































































The predicted survival (and 95% CIs): is the baseline survival curve from Royston-Parmar regression (adjusted for 
year of delivery, gestational age at delivery, standardised birth weight, prenatal diagnosis and annual TOPFA rate), 




















































































In this chapter, Kaplan-Meier survival estimates for 20 year survival were calculated for each 
CHD subtype (where possible). Hazard functions were examined to crudely estimate when 
children with CHD were at greatest risk of mortality. Several risk factors for mortality were 
analysed according to CHD subtype. Prediction methods were used to estimate 20 year survival 
for cases born at the end of the study period and for cases born after the study period. Thirty year 
survival was also estimated for cases born in the study period. 
In total, 89.7% of children born with isolated CHD were alive at age 20. Survival varied 
substantially according to CHD subtype, with no cases of HLH surviving past the age of 11 but 
98.2% of children with isolated ASD surviving to age 20. With the exception of isolated VSD, 
ASD and PVS, 20 year survival for children with CHD was significantly lower than that of the 
general population. 
Overall, the predicted mortality rate was greatest during the first week of life. The mortality rate 
decreased steeply within the first year of life and stabilised thereafter. Predicted mortality rates 
varied considerably by CHD subtype, but were always highest during the first week of life. 
Considering all CHD subtypes combined, more recent year of delivery, increased gestational age 
at delivery, high standardised birth weight and increased annual TOPFA rate all significantly 
decreased the risk of mortality. The presence of structural or chromosomal ECAs, low 
standardised birth weight and prenatal diagnosis of CHD increased the risk of mortality. There 
was some evidence that increased maternal age decreased the risk of mortality, although this did 
not reach statistical significance at the Bonferroni adjusted level of α=0.003 and was likely 
caused by confounding. The risk factors of mortality varied according to CHD subtype. Increased 
gestational age at delivery was significantly associated with decreased risk of mortality in cases 
of A SD, TG , CoA,  SD and “Other” CHD subtypes; low standardised birth weight was 
associated with a significant increased risk of mortality in cases of AVSD; prenatal compared to 
postnatal diagnosis was significantly associated with increased risk of mortality in cases of 
AVA/S, VSD and PVS; year of delivery, maternal age at delivery, infant sex, deprivation and 
annual TOPFA rates were not significantly associated with mortality in any of the CHD subtypes. 
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The predicted 20 year survival of children with CHD (any subtype) was 96.0% for cases born in 
2003, 98.0% for cases born in 2010 and 98.7 for cases born in 2015. The predicted 20 year 
survival for children born from 2003 onwards with ASD and PVS met that of the general UK 
population. The predicted 30 year survival of children born with CHD was 92.6% (based on cases 
being born at the average year of delivery, 1995). 
8.4.2 Strengths 
This study has a variety of different strengths. Firstly, this is one of few population-based studies 
to report the long-term survival of children born with CHD. Compared to most studies on long-
term survival, this study had a large sample size, therefore, risk factors for mortality could quite 
uniquely be examined for most of the individual CHD subtypes. Additionally, data was 
ascertained from a high-quality population-based register which is notified of cases from multiple 
sources, to ensure high case ascertainment. The NorCAS is cross-validated with the Freeman 
hospital cardiac database annually. Accurate diagnoses are achieved by the review of complex 
cases by paediatric pathologists and clinical geneticists and, where relevant, diagnoses are 
confirmed via post mortem. Cases are included on the NorCAS if they are diagnosed before age 
12 (16 before 2001), meaning even mild cases of VSD which are difficult to diagnose are 
included. Only 17 (0.4%) cases were untraced, reducing the possible incursion of bias. The 
majority of the untraced cases were VSD (10, 58.8%) or PVS (3, 17.7%). Given that these two 
subtypes were some of the most common, the proportion untraced was very small and thus not 
likely to have impacted on the survival estimates. 
A further strength is that the assumptions of each Cox regression model were thoroughly 
checked. All models were robust in that they all satisfied the Cox proportional hazards 
assumption (using Therneau-Grambsch tests with p<0.003 classed as statistically significant). 
The multivariable models for the individual subtypes were all of good fit to the data, as indicated 
by the Cox-Snell residuals. However, the multivariable model for all CHD subtypes combined 
was not a good fit to the data for older ages. However, given that CHD subtypes are very diverse 
in terms of survival and risk factors of survival, this is not surprising. A further strength is that 
survival estimates were not reported where there were less than 10 cases at risk at the start of the 
interval. Therefore only precise, reliable estimates were presented. To decrease the risk of type I 
errors incurred by multiple testing, a Bonferroni adjustment was used and p<0.003 was classed as 
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statistically significant. But, as discussed in the limitations section, associations significant at the 
p<0.05 level were also highlighted. 
8.4.3 Limitations 
This study also has a number of limitations. Firstly, survival estimates have previously been 
reported from this data set for isolated CHD [116]. However, in this study, a more developed 
coding system was used for cases of CHD. Furthermore, the previous study reported survival 
estimates relating to isolated cases of CHD only and also did not investigate risk factors of 
survival of children born with CHD, which are novelly included in this study. 
Despite this being one of the largest population-based studies of CHD survival, with 5,092 cases 
of CHD, only 657 (13.2%) were born 20 years prior to the date of data matching (28th January, 
2008). Therefore, 20 year survival estimates could not be reported for all CHD subtypes, due to 
low sample size. The low proportion of cases at risk between ages five and 20 may also have 
impacted the validity of the risk factors at the older ages, particularly for the rarer subtypes where 
the number of deaths were few. Although the proportional hazards assumption was satisfied for 
all subtypes, suggesting HRs were equal at say, age 20 and at age one, this was analysed by 
testing the linearity of the Schoenfield residuals over the analysis time. Given that the 
Schoenfield residuals are only estimated when there is an event, this may not have been a robust 
test for some CHD subtypes. While I am confident that the risk factors are reliable for survival to 
age five, where deaths are common, risk factors of survival up to age 20 still require validation in 
a larger data set. 
Additionally, the 20 year Kaplan-Meier estimates relate to survival of cases born between 1985-
1988. Due to medical and surgical advances, 20 year survival for cases born today is greater than 
survival of cases born in the 1980s. This issue was tackled by predicting the survival of cases 
born in 2010 (after the study period ended) using Cox regression. This approach is somewhat 
limited in that survival is assumed to have increased at the same rate between 2003-2015 as it did 
between 1985-2003. Therefore, the Kaplan-Meier estimates should be interpreted as the lower 
bound of survival and the predicted survival estimates should be interpreted with caution. 
A further limitation is that only cases born prior to 2003 were included. Ideally, cases born up to 
2010 would have been analysed, to increase the sample size and allow estimation of 30 year 
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survival. While the original aim for this chapter was to link death registrations to data on cases 
born between 1985-2010 and notified to six BINOCARs, this was not possible. However, 
survival was extrapolated in order to provide an estimate of 30 year survival. 
While this is one of the larger studies to examine risk factors of CHD survival, there are still 
issues with small sample size for certain subtypes. Therefore, care should be taken when 
interpreting non-significant associations as these could have resulted from type I errors. For risk 
factors such as year of delivery, there were no significant associations in any of the individual 
CHD subtypes. However, almost all of the HRs showed that the mortality rates decreased over 
time. Indeed, the associations almost reach statistical significance at the p<0.003 level for two of 
the CHD subtypes (e.g. AVSD and TGV, both p=0.004). It was for this reason that both 
significant associations at the p<0.003 (Bonferroni adjusted level of significant) level and at the 
p<0.05 level were discussed. Moreover, due to low sample size, multivariable models were fitted 
to cases of AVSD, AVA/S, CoA, ToF, TGV, VSD and all CHD subtypes combined only. 
In this study, the presence of ECAs, year of delivery, gestational age at delivery, standardised 
birth weight, maternal age at delivery, infant sex, deprivation, prenatal diagnosis and annual 
TOPFA rate were examined as possible risk factors for mortality. However, there are many more 
risk factors that it was not possible to examine. In previous population-based studies, ethnicity, 
parity and place of delivery were significantly associated with mortality in children with CHD 
(see Chapter 7). The data notified to NorCAS is that routinely collected in the clinical setting and 
therefore variables such as ethnicity and parity are poorly recorded and therefore these variables 
could not be analysed in this chapter. Additionally, surgical and medical interventions are not 
recorded on the NorCAS. Type of intervention is likely to have influenced survival. In particular, 
for cases of HLH, survival may be improved with palliative surgery (the three staged Fontan 
procedure) but many parents still opt for comfort care, resulting in certain death [217]. Moreover, 
it has been reported that younger age at surgical intervention positively influences survival in 
children with ASD, AVSD, ToF and HLH [20, 218-221], although a small study found no such 
association in cases of ToF AVA/S and CoA [222]. Additionally the NorCAS does not hold 
clinical information on morbidities such as sepsis or hypertension, which increase the risk of 
mortality in children with CHD [20]. 
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A further limitation is that there was no information available on cause of death. Therefore, it is 
possible that the mortalities were not related to a cardiac event. However, 20 year survival 
estimates for children with CHD were compared to 20 year survival estimates for the general 
population of the UK (98.9%). Given that cause of death was not known, mortality among cases 
with ECAs may not be a result of a cardiac event. However, this issue was overcome by reporting 
survival estimates separately for cases with ECAs and isolated cases. But in the more severe 
CHD subtypes, the effect of other congenital anomalies is likely to be over-powered by the 
lethality of the CHD. 
As discussed in Chapter 1, there are several classification systems used to code CHD into 
subtypes. The NorCAS uses the ICD classification system, which codes CHD into subtypes 
based on aetiology. This is clearly useful from an epidemiological perspective. However, the ICD 
coding system does not provide information on the severity of the CHD, which may vary within 
subtype. For example, the ICD classification system does not provide detail on the size of a VSD. 
Such information is important given that larger VSDs have poorer prognoses and are more likely 
to require surgical intervention [223]. The survival estimates presented for VSDs may therefore 
be overly optimistic for large VSDs, yet pessimistic for smaller VSDs. However, given the 
paucity of data on the long-term survival of CHD, particularly isolated CHD, the survival 
estimates presented in this chapter are still valuable for clinicians counselling parents when their 
child is diagnosed with a CHD. Had the subtypes been sub-classified there may have been too 
few cases in each sub-category to analyse meaningfully. 
Lastly, I have examined long-term mortality without taking into account morbidity. Several 
studies have shown that CHD survivors have at increased risk of endocarditis, cerebrovascular 
events, myocardial infarctions and arrhythmias [194-196]. This information is also important for 
parents when a diagnosis of CHD is made. 
8.4.4 Comparison to previous studies 
In this study, 89.7% of children with isolated CHD survived to age 20. As shown in Chapter 7, 
only one other population-based study reported survival of isolated CHD beyond age 10. This 
study by Olsen et al reported that just 73% of cases survived until age 25 (73% at age 10) [67]. 
Olsen et al reported a prevalence of 3.7 per 1000 live births, compared to 7.6 per 1000 in this 
study. Therefore, it is likely that Olsen et al had a low case ascertainment. If the milder CHD 
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subtypes were under-ascertained, which is likely given their cases had to be ascertained before 
age one, this explains why Olsen et al reported a lower survival estimate than in the current study. 
In my study, cases with CHD and ECAs were at four-fold increased risk of mortality compared to 
isolated cases (all CHD subtypes combined). Olsen et al, Wang et al and Knowles et al similarly 
reported that children with ECAs were at increased risk of mortality, but with much lower effect 
sizes (HR=1.33, HR=1.37 and HR=1.56) [67, 191]. Given that I identified the greatest effect 
sizes in cases of VSD, ASD and PVS, Olsen et al are likely to have reported lower effect sizes 
due to their under-ascertainment of mild CHD subtypes [67]. Similarly, Wang et al did not 
include cases of VSD, ASD or PVS, and Knowles et al included only those cases that required 
intervention, so may have under-ascertained these cases with these subtypes [191]. Compared to 
cases with isolated AVSD, I found a two-fold increased risk among cases with structural ECAs 
(HR=2.09). Miller et al similarly found that children with AVSD were at 28% increased risk of 
mortality (HR=1.28) when there was one structural ECA and three-fold increased risk when there 
was two or more structural ECAs (HR=3.32)[188]. Pooling these results would have produced a 
comparable HR to that presented in my study. I found that cases of AVSD with chromosomal/ 
genetic ECAs were at almost two-fold increased risk of mortality (HR=1.91). Similarly, Frid et al 
reported that cases of AVSD with Down syndrome were at increased risk of mortality (OR=1.26) 
[183]. While Frid et al reported a lower effect size than in my study, this is likely because they 
examined Down syndrome only as opposed to all chromosomal/ genetic ECAs. Conversely, 
Miller et al reported no significant difference in the risk of mortality among cases with Down 
syndrome compared to those without [188]. This may be because they used “cases without Down 
syndrome” as their reference category which is likely to have contained cases with structural 
ECAs. Therefore, the difference between the two categories would have been less pronounced. 
No other population-based studies have examined the effect of ECAs on the long-term survival of 
children born with CHD. 
In this study, 20 year survival estimates for children with CHD (all subtypes combined) improved 
significantly over time (HR=0.91), from 85% in 1985-1990 to 95.3% in 1998-2003. This finding 
reflects that of several population-based studies [67, 117, 171, 191]. Olsen et al reported that one 
year survival improved from 72% in 1977-1986 to 87% in 1997-2005 (OR=0.42) [67]. Garne et 
al reported that survival improved from 79% in 1986-1993 to 87% in 1994-1998 [117]. Wang et 
al also reported improvements in 25 year survival over time, with a two-fold increased risk of 
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death in cases (with severe/moderate CHD) born in 1983-1988 compared to 2001-2006 
(HR=2.06) [191]. Oster et al reported an almost three-fold increased risk of one year mortality in 
cases (with severe/moderate CHD) born 1979-1993 compared to 1994-2005 (HR=2.65)[171]. 
Considering the CHD subtypes individually, I found no significant associations with year of 
delivery (at the p<0.003 level). However, the decreasing trends in mortality over time almost 
reached statistical significance in cases of AVSD, CAT, TGV, VSD, ASD and PVS. Although 
the trends were not significant, the risk of mortality decreased over time in all CHD subtypes, 
with the exception of PVA. Among cases of AVSD, Frid et al observed a significant decrease in 
post-operative mortality over time but no significant change in non-operated cases [183]. 
Potentially the improved survival in cases of AVSD is related to advances in surgical techniques. 
Miller et al did not find any significant trend in mortality of children with AVSD, but did report 
lower survival estimates in 1979-1991 (55.6%) compared to 1992-2003 (72.6%) [188]. Fixler et 
al reported a 47% significant decrease in the combined mortality of corrected TGV, HLH, SV, 
PVA (with intact ventricular septum) and TA from 1996-2000 compared to 2001-2003 [182]. 
Perhaps categorising the years of delivery into just two groups and combining the subtypes 
provided enough power to detect a significant difference over time. 
In this study, greater gestational age at delivery was associated with improved survival for all 
subtypes combined and for A SD, TG , CoA,  SD and “Other” CHD subtypes. Survival was 
shown to improve with increased gestational age for most CHD subtypes, although this did not 
reach statistical significance, possibly due to low power. Knowles et al reported an increased risk 
of mortality in preterm compared to term cases (HR=1.43) [20]. Miller et al reported improved 
survival in term cases compared to preterm cases of AVSD (63.5% versus 46.1%, respectively) 
[188]. For cases of corrected TGV, HLH, SV, PVA and TA combined, Fixler et al similarly 
reported a decreased risk of mortality in term cases compared to very preterm cases (20-31 
weeks: HR=2.80) and moderately preterm cases (32-36 weeks: HR=1.69) [182].  
In this study, high standardised birth weight was associated with improved survival for all CHD 
subtypes combined. Wang et al and Oster et al similarly reported that increased birth weight 
improved survival (in severe/moderate cases combined) [171, 191]. Fixler et al reported that 
greater birth weight improved survival for combined cases of corrected TGV, HLH, SV, PVA 
and TA [182]. I found some evidence that standardised birth weight was associated with 
improved survival in cases of  SD and “Other” CHD subtypes, but no other CHD subtype. 
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However, despite not reaching statistical significance, high birth weight improved long-term 
survival for all CHD subtypes, with the exceptions of S , TG , CoA, IAA, and “Other” CHD 
subtypes. Similarly, low birth weight was indicative of poorer survival in all subtypes except TA, 
CAT, TAPVR, and CoA. 
There was some evidence that increased maternal age was associated with improved long-term 
survival of all CHD subtypes combined. A similar association between maternal age and survival 
has also been reported by two population-based studies, which examined severe/moderate CHD 
combined [171, 191]. Wang et al reported a decreased risk of mortality in cases born to mothers 
aged >35 compared to 30-34 (HR=0.88) [191]. Oster et al reported that maternal age ≥30 was 
associated with an decreased risk of one-year mortality compared to mothers aged <30 
(HR=0.77) [171]. In my study, the effect was not present in the multivariable model, likely due to 
confounding. If some of the subtypes with a better prognosis were more prevalent amongst older 
mothers, this may explained why I found an association between maternal age and survival when 
all CHD subtypes were combined but not for individual CHD subtypes. 
In this study, there were no significant associations between infant sex and mortality. Conversely, 
Wang et al and Fixler et al found borderline significant increases in survival amongst females 
compared to males (HR=1.07 and HR=1.27) [182, 191]. Additionally, Knowles et al also 
reported a significant increased risk of mortality among female cases (HR=1.25) [20]. However, 
all three studies examined composite groups of subtypes and therefore this may be because the 
more severe subtypes occurred less often in females [20, 182, 191]. 
I found little evidence of an association between deprivation and survival. However, amongst all 
CHD subtypes, survival was decreased in the least compared to most deprived tertiles. Amongst 
cases with AVSD, Miller et al did not find a significant association between socioeconomic status 
and survival, however, survival decreased linearly with decreasing level of deprivation [188]. The 
association with deprivation may still exist, perhaps with a small effect size, but requires a larger 
dataset in order to investigate it with more power. 
I established that prenatal diagnosis was associated with an increased risk of mortality in all CHD 
subtypes combined, and in cases of PVA, AVA/S, VSD and PVS. I also found some evidence of 
the association in cases of EA, AVSD, ToF, CoA and MVA, although these did not quite reach 
the significance at the Bonferroni adjusted level. While the direction of this effect may be 
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surprising, it has been previously reported in the population-based setting. Oster et al reported an 
increased risk of one-year mortality in cases (severe/moderate CHD subtypes combined) 
diagnosed before compared to after the first day of life (HR=0.54) [171]. A further study by Oster 
et al showed that the effect was present among cases of “critical CHD”, (a composite group of 
HLH, TA, CAT, TAPVR, PV, ToF, TGV, IAA, CoA, EA, SV and DORV) but not amongst cases 
of “non-critical CHD” ( SD, ASD, PVS, AVA/S) [224]. A meta-analysis of eight small hospital-
based studies showed an increased risk of preoperative mortality among prenatally diagnosed 
cases of “critical” CHD. However, prenatally diagnosed cases were more likely to be “high risk” 
and to opt for comfort care. Excluding these cases, prenatal diagnosis positively impacted 
survival, but only if the cases were diagnosed in a specialist centre. Additionally, hospital-based 
studies have previously reported an increased risk of post-operative mortality in prenatally 
diagnosed cases of PVA and TGV [225, 226]. Four studies have conversely reported no 
significant association between prenatal diagnosis and post-operative survival in cases of HLH 
[227-229], TGV[228] and all CHD (combined) [230]. However, three of these small studies were 
underpowered and actually, survival was lower in prenatally diagnosed cases [228-230]. A 
further hospital-based study conversely reported greater survival amongst prenatally diagnosed 
cases of CoA. However, this study excluded cases that were diagnosed after one month of age, 
citing that these cases were too difficult to diagnose prenatally [231]. 
8.4.5 Potential mechanisms 
Survival of children born with CHD improved over the study period. This improvement is related 
to a host of factors. Firstly, many surgical interventions were developed over the study period. 
For example, the Fontan staged operation for repair of SV, HLH and TA and the conduit repair 
for cases of CAT were introduced in the late 1970s and developed across the 1980s-90s [197, 
198]. In the UK however, intervention amongst cases of HLH was introduced in the early 1990s 
[232]. Similarly, the arterial switch operation was introduced in 1975 [199], and fully replaced 
the atrial switch operations (i.e. the Mustard or Senning procedures) in the early 1990s [200]. 
Although at first the arterial switch operation resulted in greater mortality [201], eventually this 
led to improved survival among cases of TGV [200]. Prior to the development of the Fontan 
operation, there was no alternative intervention. Therefore, the survival rates for HLH in 
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particular improved as this anomaly is incompatible with life if left untreated. But even more 
recently, around 58% of parents elected not to intervene surgically in cases with HLH [233]. 
Prostaglandin was first trialled in neonates with cyanotic CHD in the 1970s [203, 204], although 
was not frequently administered until the 1980s. Crucially, prostaglandin prevents the closure of 
the ductus, which otherwise occurs within the first few days of life, thus allowing oxygenated and 
deoxygenated blood to mix in circulation [204]. While this is not a permanent solution for 
cyanotic CHDs, it improves pulmonary circulation and prevents acidosis occurring, enabling 
children to remain stable prior to surgical intervention and thus more likely to survive [204]. The 
increased administration of prostaglandin in children with cyanotic CHDs is likely to have 
improved survival estimates over time. 
Increased gestational age at delivery and high standardised birth weight were associated with 
improved long-term survival for all CHD subtypes combined. Cardiac operative mortality has 
been shown to increase in infants with low birth weight and low gestational age at delivery [234]. 
Furthermore, among children with CHD, low gestational age at delivery also poses an increased 
risk of necrotising entercolitis, which could be another explanation for the increased risk of 
mortality [235]. Of course, in non-anomalous individuals, the risk of mortality increases as 
gestational age and birth weight decreases [236, 237]. Potentially, gestational age was a larger 
contributor to mortality than CHD among the cases delivered extremely preterm, particularly 
among the milder CHD subtypes. I found that, over the study period, the risk of mortality 
decreased, except in extremely preterm cases. This could suggest that improvement in survival 
due to advances in surgical intervention have not impacted upon extremely preterm cases, 
perhaps because they do not live long enough to undergo intervention. 
In this study, prenatally diagnosed cases of CHD were at greater risk of mortality. Even within 
the same CHD subtype, there is a spectrum of disease severity. Therefore, this paradoxical 
finding is likely due to the most severe versions of a subtype being prenatally diagnosed [238]. 
Additionally, compared to postnatally diagnosed cases, prenatally diagnosed cases tend to have a 
lower birth weight, lower gestational age at delivery, lower APGAR score, ECAs and multiple 
CHD subtypes [227, 230, 238, 239]. While prenatal diagnosis increased the risk of mortality, 
studies have shown that prenatally diagnosed cases of HLH are less likely to have early 
neurologic morbidities and more likely to be stable in the pre-operative period [227-229]. Indeed, 
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Tworetzky reported that prenatally diagnosed cases of HLH were less likely to experience 
preoperative acidosis, tricuspid regurgitation and ventricular dysfunction [229]. Bonnet el al also 
reported that acidosis and multi-organ failure were less common amongst prenatally diagnosed 
cases of TGV [226]. Escobar-Diaz et al similarly reported a lower rate of acidosis in prenatally 
diagnosed cases of TGV, although this did not reach statistical significance due to low power 
[239]. Some of the benefit may be due to the earlier administration of prostaglandins [227].
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 Chapter 9. Future prevalence of CHD 
9.1 Introduction 
As shown in Chapter 7 and 8, survival for individuals with CHD has improved over time. 
This has led to an increase in the population of people living with CHD in the UK [240], and 
elsewhere [241, 242]. Due to the ongoing medical surveillance, reinvestigation and often 
reoperation of affected individuals, UK hospital admission rates have therefore risen [26]. 
Given this increasing need for health services for individuals born with CHD, future 
prevalence estimates and case numbers could aid health service planning. 
Trends in the live birth prevalence of CHD in England and Wales were modelled in Chapter 
3, using the yearly prevalence of cases notified to six BINOCARs. However, past trends 
could be more accurately modelled using the monthly prevalence of CHD, due to the 
increased number of data points. Furthermore, there is some evidence of seasonality in the 
prevalence of CHD [243-249], although this has not been shown in all studies [70, 250]. 
Seasonality, if it exists, should be accounted for in the estimation of future trends. 
The aim of this study was to model trends in the live birth prevalence of CHD in the North of 





9.2.1 Case inclusion and data 
Data on the monthly number of live births (any plurality) in the population between 1998-
2013 were obtained from PHE. All live born cases (singletons and multiples) with a final 
diagnosis of CHD notified to the NorCAS between 1st January 1998 and 31st December 2010 
were included in this study. In this chapter, month of birth for each case of CHD was 
available. The other five BINOCAR registers were not able to provide data on month of 
delivery and so cases notified to NorCAS only are included in this chapter. Case data was 
available until 2010 only. 
9.2.2 Statistical analysis 
Analysis was performed for all CHD subtypes combined and for each CHD subtype. Analysis 
was also performed for all CHD regardless of plurality to maximise case numbers. Analysis 
corresponds to all cases of CHD (including cases with ECAs) as there were too few monthly 
case numbers to examine prevalence separately for isolated cases and cases with ECAs. 
Additionally, for the purpose of estimating future health service requirements for individuals 
with CHD, modelling the prevalence of all CHD was appropriate. 
Wavelet analysis and harmonic regression were performed to analyse trends in the number of 
live births (in the general population) and in CHD prevalence. These models were then 
extrapolated to estimate the future number of live births and the future prevalence of CHD. 
Both of these figures were then used to estimate the number of live born cases of CHD 
delivered between 2011 and 2020. 
9.2.3 Wavelet analysis 
Seasonality in the number of live births and the prevalence of CHD (per 10,000 live births) 
was analysed using wavelet analysis. Wavelet analysis decomposes the time series of CHD 
prevalence and estimates how seasonality changes over time. Graphs of the Wavelet power 
spectrum were produced, where a high wavelet power level occurring at the same period at 
each age being indicative of seasonality. A random pattern in the wavelet spectrum indicated 
that there was little evidence of seasonality [251]. More information on the precise formulae 
used to estimate wavelets can be found in Rosch and Schmidbauer’s guide using R [252]. 
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9.2.4 Harmonic regression 
The number of live births (in the general population) and the prevalence of CHD (per 10,000 
live births) over time were modelled using linear regression. In time series data, there is often 
autocorrelation between observations (i.e. correlation between data as a function of time, 
perhaps relating to an unobserved variable), which causes non-constant variance. This non-
constant variance violates the assumption of ordinary least squares regression. An alternative 
is to model the data using generalised least squares (GLS) regression, which accounts for 
variation in error terms [253]. The number of live births and CHD prevalence (per 10,000 live 
births) were used as the outcome variables in GLS models. The disadvantage of this method 
over the Poisson regression used in Chapter 4, is that it is not possible to use an offset term to 
account for the size of the denominator. However, given that this chapter includes only one 
BINOCAR, the denominator population is similar for each time point and so this should not 
cause bias. 
The GLS models were fitted with Sine and Cosine terms in order to model seasonality over 
time. For the model of CHD prevalence, p represents the period (i.e. 12 months): 
𝐶𝐻𝐷 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 =  𝛽1 cos ( 
2 𝜋 𝑡𝑖𝑚𝑒 
𝑝
) +  𝛽2 𝑠𝑖𝑛 ( 
2 𝜋 𝑡𝑖𝑚𝑒 
𝑝
) +  𝛽3 𝑡𝑖𝑚𝑒  
These functions provide linear transformations of time that range between -1 and 1, in relation 
to the period p. The coefficient for time (i.e. β3), can be interpreted as the trend in CHD 
prevalence over time, after adjusting for seasonal variation in prevalence. If the addition of 
linear splines improved the fit of the model (assessed using a LR test), then these were also 
included. The location of the knots were chosen based on examining time series plots for 
points of inflection. 
These models were used to predict the number of live births or birth prevalence up to 2020. 
Using the predicted number of live births and the predicted prevalence, case numbers were 
also estimated up to 2020. Sin and Cos terms were removed from the models where they did 
not improve fit. 
When examining the trends in CHD subtypes, a Bonferroni correction was used in order to 
reduce the possibility of type II errors relating to multiple testing. Therefore, p<0.003 was 




9.3.1 Live births 
Between 1998-2013, there were 409,875 live births in the North of England. The number of 
births per month ranged between 2,162 and 2,964. As shown in Figure 9.1 (the blue line 
representing “actual births”), the number of live births decreased between 1998-2001, 
increased between 2002-2010 and decreased slightly between 2010-2013. In Figure 9.1, there 
was also evidence of seasonality in the number of live births, indicated by the repetitive 
pattern in the monthly live births.  
Wavelet analysis showed that the seasonality in live births was constant between 1998-2013, 
as indicated by high wavelet power (shown in red) occurring at the same time each year 
(Figure 9.2). 
Using harmonic regression, the Sin term significantly improved the fit of the model (p<0.001) 
and the Cos term almost reach statistical significance (p=0.054), which implies seasonality in 
the live births. Linear splines, with knots at December 2001 and December 2009, improved 
the fit of the model and were therefore included in the harmonic regression model. 
Accounting for seasonality, the number of live births decreased by an average of six births per 
month (95% CI: 4-7; p<0.001) between 1998-2001, increased by five births per month (95% 
CI: 4.-5; p<0.001) between 2002-2009 and decreased by four births per month (95% CI: 2-5; 
p<0.001) between 2010-2013. Using this model, the number of annual live births were 
estimated until 2020 (Figure 9.1, red line representing the modelled live births). 
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Figure 9.1 Number of live births over time, actual and modelled 
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9.3.2 Birth prevalence of CHD 
There were 3,682 live born cases of CHD notified to NorCAS between 1998-2010. The live 
birth prevalence of CHD over time is shown in Figure 9.3 (actual prevalence represented by 
the blue line), by CHD subtype. 
The wavelet power spectrum plots show little evidence of seasonality for all CHD subtypes 
combined and for each CHD subtype (Figure 9.4). Cos and Sin terms did not significantly 
improve the fit of the regression models for any of the CHD subtypes (at the p<0.003 level), 
although there was a suggestion of seasonality in the live birth prevalence of HRH (Cos: 
p=0.012), ToF (Sin: p=0.010), CoA (Cos: p=0.042) and ASD (Cos: p=0.009) (Table 9.1). 
The prevalence of all CHD subtypes (combined) decreased over time, but did not reach 
statistical significance at the p<0.003 level (coef= -0.09, p=0.022) (Table 9.1). The prevalence 
of PDA increased significantly over time (coef= 0.02 (per month), p<0.001), the prevalence 
of VSD and MVA decreased significantly over time (coef= -0.08, p=0.001 and coef= -0.08, 
p=0.002, respectively). There was some evidence that the prevalence of ASD decreased over 
time (-0.02, p=0.041). There was no evidence of trends in any of the other CHD subtypes. 
Splines did not improve the model fit for any of the models and so were not included.  
Using the regression models, the prevalence of CHD was estimated for each month until 2020 
(Figure 9.3, red line). The predicted monthly case numbers are also shown in Figure 9.5. The 
predicted number of cases born per year between 2016 to 2020 are shown in Table 9.2, 
according to CHD subtype. 
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Table 9.1 Harmonic regression models of CHD live birth prevalence, by CHD subtype 




Time of delivery (months) Coef 
(95% CI); p-value 
SV 0.533 0.191 0 (0-0); p=0.943 
HLH 0.562 0.062 0.01 (0-0.01); p=0.092 
EA 0.716 0.785 0 (0-0); p=0.661 
HRH 0.012 0.315 0 (-0.01-0.01); p=0.85 
CAT 0.091 0.063 0 (0-0.01); p=0.179 
AVSD 0.989 0.700 0 (-0.02-0.01); p=0.822 
AVAS 0.266 0.345 -0.01 (-0.02-0); p=0.058 
TGV 0.350 0.828 0 (-0.01-0.01); p=0.954 
ToF 0.684 0.010 0.01 (-0.01-0.02); p=0.332 
TAPVR 0.487 0.182 0 (0-0.01); p=0.233 
IAA 0.349 0.043 0 (-0.01-0); p=0.622 
CoA 0.042 0.137 0 (-0.01-0.02); p=0.434 
DORV 0.087 0.663 0 (0-0.01); p=0.164 
MVA 0.585 0.722 -0.01 (-0.02-0); p=0.002 
VSD 0.814 0.671 -0.08 (-0.12--0.03); p=0.001 
ASD 0.009 0.519 -0.02 (-0.05-0); p=0.041 
PVS 0.865 0.947 0 (-0.02-0.02); p=0.929 
PDA 0.105 0.656 0.02 (0.01-0.03); p<0.001 
Other 0.530 0.599 -0.01 (-0.02-0); p=0.175 
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Table 9.2 Yearly projected number of cases (95% CI) in the North of England, born 2016-2020 
CHD 
subtype 
2016 2017 2018 2019 2020 
SV 1 (0-2) 1 (0-2) 1 (0-2) 1 (0-2) 1 (0-3) 
HLH 5 (2-8) 5 (2-9) 6 (2-9) 6 (2-9) 6 (2-10) 
EA 1 (0-2) 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 
HRH 4 (1-8) 4 (0-8) 4 (0-8) 4 (0-8) 4 (0-8) 
CAT 3 (1-6) 4 (1-6) 4 (1-6) 4 (1-6) 4 (1-6) 
AVSD 12 (7-18) 12 (6-18) 12 (5-18) 11 (5-18) 11 (4-18) 
AVA/s 4 (0-9) 4 (0-8) 3 (0-8) 3 (0-8) 2 (0-8) 
TGV 12 (7-17) 12 (6-18) 12 (6-18) 11 (5-18) 11 (5-18) 
ToF 17 (10-23) 17 (10-23) 17 (10-24) 17 (9-24) 16 (9-24) 
TAPVR 5 (2-7) 5 (2-8) 5 (2-8) 5 (2-8) 5 (1-9) 
IAA 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 
CoA 14 (9-19) 14 (8-19) 14 (8-19) 14 (8-20) 13 (7-20) 
DORV 2 (1-4) 2 (1-4) 2 (0-4) 2 (0-4) 3 (0-5) 
MVA 0 (0-2) 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1) 
VSD 94 (75-113) 90 (70-110) 86 (64-107) 81 (59-104) 77 (53-101) 
ASD 25 (16-35) 24 (14-34) 23 (12-33) 21 (10-33) 20 (8-32) 
PVS 20 (13-28) 20 (12-28) 20 (11-28) 19 (10-28) 19 (10-29) 
PDA 15 (12-19) 16 (12-19) 16 (12-20) 17 (13-21) 17 (13-22) 
Other 7 (1-13) 7 (0-13) 6 (0-13) 6 (0-13) 5 (0-13) 




In this chapter, the future prevalence of CHD in the North of England was estimated until 2020. 
The estimated live birth prevalence of CHD remained relatively stable, with a predicted 
prevalence of 72.3 per 10,000 live births in 2016, falling to 67.8 per 10,000 live births in 2020. 
After accounting for seasonality in live births, this equated to 242 cases born to mothers residing 
in the North of England in 2016, decreasing slightly to 214 cases in 2020. 
9.4.2 Strengths 
There were several strengths to the analysis performed in this chapter. Firstly, I had access to 
monthly number of live births. Therefore, it was possible to examine and therefore rule out, 
seasonality in the live birth prevalence of CHD. This also meant I could model the prevalence of 
CHD as opposed to the raw counts; this approach may have erroneously shown that there was 
seasonality in CHD, due to the seasonality in the live births. 
Additionally, I modelled the data using GLS regression, which allows for unequal variance. 
While OLS regression would not have caused biased estimates, it would have given equal weight 
to all observations, regardless of the error structure [253]. 
9.4.3 Limitations 
There were several limitations to this study. Firstly, it was only possible to estimate future 
prevalence for a small area of the UK, using one BINOCAR. In Chapter 5, I showed that there 
was substantial variation in the prevalence of CHD between BINOCARs. However, much of this 
heterogeneity was likely caused by case ascertainment as opposed to real differences. The 
NorCAS is the longest established BINOCAR, with the second greatest prevalence (after 
CARIS). Therefore, the prevalence in this chapter arguably represents a truer estimate when 
compared to the other BINOCARs. The ONS estimate that there will be 4.0 million births in the 
UK between 2012-2017 and 4.1 million between 2017-2022 [254]; using my modelled 
prevalence, this would equate to 30,032 and 27,939 cases of CHD respectively. For more 
accurate estimates, the model needs to be extended to cover more regions of the UK. The model 
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needs to be further refined to include information on CHD risk factors, such as maternal age, 
BMI, diabetes, smoking and ethnicity [4, 80, 96, 97]. I was not able to account for these factors 
as I did not have the population births categorised according to these variables. These variables 
may fluctuate over time which could lead to fluctuations in birth prevalence that were not 
described by my models. Refining the model would lead to more accurate future estimates, which 
would be important for health care planning. This information could be used to inform health 
economics research, which would assess the funds required to treat individuals born with CHD. 
The model predictions are flawed in that they assume that the future prevalence follow the same 
trends as the past (or observed) trends in prevalence. Due to low case numbers, it was not feasible 
to predict the prevalence of singletons and multiples separately. In Chapter 7, I showed that 
trends in prevalence did not vary in singletons compared to twins overall. However, I showed that 
the prevalence among MC twins specifically, increased by 8% per year. MC twins account for a 
small proportion of births (0.6%), meaning the increase of 8% per year accounts for an additional 
seven cases of CHD per year in England and Wales (approximately). 
9.4.4 Comparison to previous studies 
In this chapter, I found no evidence of seasonality in the prevalence of CHD. Several studies have 
previously examined seasonality of CHD, with  uteijin et al’s largest and most recent study 
finding no evidence of seasonality between 2000-2008 in Europe [250]. Smaller studies found a 
slightly increased prevalence of CHD in the summer months [58, 70, 243, 244, 246-249]. 
Specifically, seasonality was reported for cases of VSD [58, 243], EA [58], ASD [58, 243], HLH 
[245], PVS, AVA/S [58] and CoA [58]. But where Luteijin et al used harmonic regression to 
examine seasonality, many of the other studies more crudely compared the proportion of cases in 
the summer and winter months [243, 244, 247]. One study that employed several techniques for 
examining seasonality, reported different findings using each [58]. The aetiology of seasonality 
in congenital anomalies is still under debate, but is hypothesised to be related to environmental 
teratogens, such as air pollution, influenza outbreaks, maternal fever, vaccinations and the use of 
pesticides [250, 255]. 
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 Chapter 10. Discussion 
The overall aim of this thesis was to examine survival and risk factors for mortality among 
individuals with CHD. In the discussion below, I will briefly outline the main findings from 
each of the chapters that make up this thesis. The findings of each chapter have already been 
compared to previous studies in the respective chapter discussions, so in the summaries of 
each chapter I will briefly put the results into context of the most relevant literature. I will 
then outline the implications of these findings for policy and practice in the UK and discuss 
areas of future research. 
10.1 Summary and context of findings 
I began this thesis with a review of the international literature on the birth prevalence of CHD. 
I found that globally, the birth prevalence of CHD ranged between 30-213 per 10,000 total 
births, varying substantially between studies. In the larger studies, there was evidence that the 
prevalence of CHD had increased over time [53, 57, 60, 79, 80]. However, increasing trends 
in these studies were driven by septal defects, which have become easier to diagnose over 
time due to developments in ultrasound technologies and echocardiography [256]. However, 
several studies also reported an increase in the prevalence of ToF [53, 60, 79]. A possible 
cause for this increase is the rise in women undergoing ART [257], as ART has recently been 
shown to increase the risk of ToF [145, 168]. Trends for other CHD subtypes were more 
conflicting. There was some evidence that advanced maternal age was associated with an 
increased risk of non-chromosomal CHD, although this was driven by septal defects and CoA 
[53, 59, 76, 80]. While there is increasing evidence of a genetic aetiology for some CHD 
subtypes [45], in many countries, women of advanced maternal age are likely to undergo 
more prenatal screening during pregnancy [258, 259] and thus case ascertainment is a 
possible cause. Alternatively, the association may have been confounded by maternal obesity, 
which is correlated with maternal age and is now a known risk factor for septal defects [4]. 
Few recent studies reported on CHD birth prevalence and trends in birth prevalence in the 
UK, which is important given the current reconfiguration of paediatric cardiology services 
[24]. 
The analysis of data from six BINOCARs, showed that the singleton birth prevalence of CHD 
was 65 per 10,000 births between 1991-2010, in England and Wales. I did not find any 
evidence of trends in CHD (all subtypes combined) or in septal defects, as several studies did 
in my literature review [53, 57, 60, 79, 80]. However, there was a suggestion of an increasing 
trend in CHD in five of the BINOCARs; but not in the largest register (CARIS). My more 
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recent study period may have been a factor for the discrepancy with the previously published 
literature. Consistent with several studies [53, 60, 79], I identified a small increasing trend in 
ToF of 3% per year. I also found small decreasing trends in the prevalence of CoA (2% per 
year) and AVA/S (3% per year). Risk factors have not been described for CoA and AVA/S so 
it is difficult to assess why these decreases occurred and whether they are real or result from 
chance findings. Increased maternal age at delivery was associated with an increased risk of 
CHD, although this was restricted to cases with structural or chromosomal/ genetic ECAs as 
opposed to isolated cases. Of the individual subtypes, maternal age was associated with ToF, 
AVSD, VSD and ASD, but again, among cases with chromosomal/ genetic ECAs only. 
Therefore, the link with maternal age is likely caused by the co-occurring congenital anomaly 
as opposed to the CHD itself. However, this contradicts several of the studies in my literature 
review, which found an association with maternal age in isolated cases [53, 59, 76, 80]. 
Potentially, this difference could relate to the coding systems used and the definitions of 
ECAs. But notably, a study that did not fit the inclusion criteria for my review also reported 
that the association with maternal age at delivery was restricted to syndromic cases only 
[260]. I found that isolated cases of CHD were rarely prenatally diagnosed (30% of cases). 
However, prenatal diagnosis rates were much higher for the more severe CHD subtypes and 
increased over the study period. This increase accounted for an increase in TOPFA over the 
study period. 
My analysis of CHD in twins and higher order multiples showed that the prevalence in higher 
order multiples was 120.7 per 10,000 total births and in twins was 129.7 per 10,000. This 
equated to a 73% increased risk in twins compared to singletons, which is similar to that 
described in previous studies [113, 151, 156]. Uniquely, I found that the risk in MC twins 
exceeded that of DC twins, by around 80%. One hypothesised cause is that placental vascular 
anastomoses between co-twins’ circulations, leads to fluctuations in blood flow during fetal 
heart development [165, 166]. Potentially, there are confounders such as the use of ART, 
maternal BMI and folic acid uptake, which may have contributed to the increased risk, but I 
was unable to investigate these factors. The prevalence of CHD in MC twins increased over 
time. It is possible that this is a real increasing trend, perhaps caused by increased uptake of 
ART, which reportedly increases the risk of MZ twinning [261]. Alternatively, this trend may 
have been caused by changes in the NICE guidelines, to allow increased prenatal screening 
among MC twins [162]. 
My systematic review and meta-analysis of the long-term survival of individuals born with 
CHD, identified 15 studies that had previously examined long-term survival [67, 86, 116, 
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181-192]. However, the maximum follow-up was 25 years [191, 192] and five of the articles 
reported five-year survival only [181, 182, 186, 187, 189]. Additionally, all studies were 
based on population from high income countries. Pooled one year survival was 87.0%, pooled 
five-year survival was 85.4% and pooled 10-year survival was 81.4%. Survival beyond age 10 
was not reported by enough articles to calculate a pooled estimate. Survival varied by CHD 
subtype, with pooled five year survival being greatest for individuals with VSD (96.3%) and 
lowest for individuals with HLH (14.4%). Studies consistently showed that less recent year of 
delivery [67, 184, 191, 192], preterm delivery [182, 184, 185, 190], presence of ECAs and 
low birth weight [182, 185, 192] negatively impacted on survival. There was some evidence 
that non-White ethnicity negatively impacted on survival [182, 192]. Associations between 
mortality and socioeconomic status were non-significant although there did appear to be a 
linear increase in mortality with increasing deprivation [182, 190, 192]. Therefore, it is likely 
that the effect size of this association is small and the studies were not large enough to 
identify a significant difference. 
My analysis of data from one BINOCAR linked to death registrations showed that one year 
survival was 89.1%, five year survival was 87.1%, 10 year survival was 86.7% and twenty 
year survival was 85.2%. Survival in my study was therefore similar to the pooled survival 
described in my systematic review. However, some of the data I analysed in my survival 
chapter also contributed to one of the articles included in my systematic review [116]. 
Consistent with my systematic review, I found more recent year of delivery, increased 
gestational age at delivery and high standardised birth weight decreased the risk of mortality. 
The presence of ECAs increased the risk of mortality. In terms of mechanisms, year of 
delivery positively impacted survival in the UK due to the improvements in surgical 
interventions, such as the introduction of the Fontan staged operation, the arterial switch 
operation and the conduit repair [197, 198] [232] [200]. The administration of new medical 
interventions, such as prostaglandin, also improved survival [203, 204]. Increased gestational 
age and birth weight were also protective, due to the decreased chances of co-morbidities such 
as necrotising entercolitis developing [235]. Cases with ECAs had a worse prognosis, likely 
due to the co-occurring congenital anomaly as opposed to the CHD. Perhaps the co-occurring 
anomaly meant that the individual was not stable enough to undergo intervention for CHD. 
There was some evidence that increased maternal age decreased the risk of mortality, 
although this did not quite reach statistical significance and was likely caused by 
confounding, given that there were more mothers of advanced maternal age in the more recent 
study years. As in my review, I did not find a significant association between deprivation and 
mortality. But overall, mortality decreased linearly with decreasing deprivation. I also found 
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that increased annual TOPFA rate decreased the risk of mortality and prenatal diagnosis 
increased the risk of mortality likely because prenatal diagnosis is a marker for greater CHD 
severity. There were less statistically significant risk factors for mortality when considering 
CHD subtypes individually, which in part might be due to low power. 
The last phase of my thesis was to predict the future survival and birth prevalence of CHD in 
the North of England. The predicted 20-year survival of children with CHD was 98.7% for 
cases born in 2015, although this varied by CHD subtype. The predicted prevalence of CHD 
was 74.0 per 10,000 live births in 2015 and 68.8 per 10,000 live births in 2020, which equated 
to 235 and 201 cases, respectively. 
10.2 Strengths of the thesis 
In this thesis, I used population-based register data to examine the epidemiology of CHD. 
This approach has several advantages over alternative study-designs, such as hospital-based 
studies. Firstly, data is collected from multiple sources and therefore ascertainment, even of 
mild CHD subtypes, is high. All cases are confirmed by echocardiography, catheterisation or 
post-mortem to ensure that there are no false positives. Cases notified to NorCAS and CARIS 
are cross-validated with regional cardiac databases within local paediatric cardiology units, to 
ensure case completeness. 
Given that the BINOCARs collect data on a small core set of variables, data is typically very 
complete for these variables. The BINOCARs receive notifications from prenatal ultrasound, 
fetal medicine and cytogenetic laboratories and are therefore able to collect data on cases that 
occur in TOPFAs, late miscarriages and stillbirths. This meant that I could estimate trends in 
prevalence over time regardless of changes in TOPFA and fetal death rates. Due to the 
population-based design of the registers, all cases are ascertained regardless of whether they 
survived until medical intervention or until a certain age. Indeed, NorCAS and CARIS 
include cases diagnosed up to age 12. This means that cases of CHD are included regardless 
of where they are on the spectrum of severity. Therefore, the statistics produced in this thesis 
are representative of all individuals with CHD. Additionally, cases born to mothers who 
reside in the areas covered by the registers but are born elsewhere are recorded on the CARs, 
again ensuring complete case ascertainment. 
An advantage of using the NorCAS register was that it is linked to the NorSTAMP. This 
meant that I could examine the risk of CHD in multiple compared to singleton pregnancies, 
and uniquely, whether the risk was moderated by chorionicity. Using the NorCAS, I was also 
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able to access the month of birth and the monthly denominator data, which meant I could 
analyse trends after accounting for seasonality in live births in the general population. 
Another strength of my analyses is that I had enough data to examine the prevalence and 
survival of CHD according to CHD subtype. This is vital given that the subtypes are so 
diverse in terms of aetiology, prognosis and health service provision. Additionally, analysing 
risk factors for prevalence and survival on CHD as a composite group can cause bias. For 
example, investigating the association between CHD survival and say, maternal age, could 
show that young maternal age is protective if the milder subtypes (with the best prognosis) are 
those associated with older maternal age. 
10.3 Limitations of the thesis 
There are several limitations to using population-based register data. For example, the data 
recorded on the CARs is that routinely recorded in the clinical setting and, therefore, not all 
variables of interest are available for analysis. For example, given the association between 
congenital anomalies and maternal BMI [4], it would have been interesting to examine this 
variable as a risk factor for increased prevalence and for survival. While some of the registers 
record BMI, it isn’t one of the core variables. Additionally, information on ethnicity and 
smoking status is poorly recorded on the registers as this is not documented well in the 
clinical setting. Using information from clinical notes, the registers collect information on 
folic acid uptake. However, this is very incomplete and therefore could not be analysed. 
According to a recent systematic review, prenatal uptake of folic acid decreases the risk of 
CHD [262]. However, there are currently no UK studies on this. Furthermore, the 
BINOCARs do not record data on maternal medications or alcohol uptake which may 
increase the risk of CHD and potentially influence survival [43]. 
Another disadvantage is that the registers are not currently allowed to hold data on ART. This 
would have been interesting to examine as a risk factor for CHD, particularly as a risk factor 
for ToF, which increased over time in my study and in several others [53, 60, 79]. Moreover, 
it would have been interesting to see how this contributed to the increased risk of CHD in 
twins. Although I found the highest risk in MC as opposed to DC twins, there is increasing 
evidence that MZ twins are more common after ART [261]. MZ twinning may have become 
more common given the recent changes in the NICE guidelines, stating that one embryo 
should be implanted in the first round of IVF (in women aged <40) and two if the first round 
is not successful (or if the woman is aged 40-42) [170]. Previously, up to three embryos could 
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be implanted, which would have increased the chances of DZ twins or higher order 
pregnancies. 
A further disadvantage of using register data is the detail of the case coding. The BINOCARs 
code all cases using the ICD coding system, meaning it is not possible to distinguish the 
severity of individuals with the same subtype. Hospital-based studies are likely to have access 
to more clinical information which would enable cases to be coded more sensitively, with a 
coding system such as the ISC which better accounts for severity (see Chapter 1). However, 
given the small case numbers it is also of benefit to code the subtypes more crudely in order 
to increase statistical power. A further issue in this thesis was the coding of cases with HRH. 
Changes between the ICD nine and ICD 10 classification systems meant that a new code was 
developed for cases of HRH. Because of this, there was an artificial increase in the prevalence 
of HRH. HRH is technically a secondary anomaly, which results from CHD subtypes such as 
PVA and TA. The easiest way to deal with this change would have been to code all cases of 
HRH according to their primary anomaly. Unfortunately, the primary anomaly was not 
detailed in 60% of HRH cases and therefore HRH had to be treated as a composite group of 
TA and PVA. While these subtypes are similar in terms of aetiology and treatment, it would 
have been more useful, in terms of prevalence and birth outcomes, to examine them 
separately. Fortunately this was not an issue in the survival chapter (Chapter 8) as none of 
these cases were initially coded under ICD 10 due to the earlier study period. 
A major limitation of this work is that I was not able to analyse the impact of medical/ 
surgical intervention on survival. The type of intervention may impact survival. For example, 
the Fontan operation for HLH is associated with 47-85% perioperative survival, whereas 
comfort care results in certain death [217]. Combining all cases of HLH as I have remains 
informative in terms of health care planning, but may not be useful for parents who want to 
know post-operative survival of a child with HLH. Additionally, I was not able to examine 
the impact of morbidities such as sepsis or hypertension, which have been shown to increase 
the risk of mortality [20]. 
There is no universally adopted coding system for cases with multiple CHD subtypes. As 
described in Chapter 1, there are several methods that have previously been used. In this 
thesis, I used a hierarchy based on that by Khoshnood et al, which favours the CHD subtype 
of greatest aetiological severity [52]. Different approaches will have produced slightly 
different results in terms of prevalence and survival. For example, if like Wang et al [191], I 
had allowed each case to contribute to each of the relevant CHD subtypes, then my 
prevalence rates would have been greater for the milder CHD subtypes. Additionally, survival 
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would have been poorer for the milder subtypes if these cases co-occurred with severe 
subtypes. 
A further study limitation is that survival analysis was performed on data from just one 
BINOCAR (the NorCAS), for cases born between 1985-2003. I had originally intended to 
link data from the six BINOCARs to death registrations, for cases born between 1985-2010. 
The data linkage was to be completed by the Health and Social Care Information centre (HSC 
IC). Unfortunately, at the time of my application, the HSC IC went through a moratorium 
while they addressed their practises relating to patient identifiable data. As a result, my 
application is still waiting to be approved by the HSC IC. The NorCAS data I analysed in 
Chapter 8 was a pre-existing data-set, which is why only cases born prior to 2003 were 
included. Had I successfully obtained the data from the six BINOCARS, this would have been 
a much larger data set. Therefore, I could have produced survival estimates to 20 years for the 
rarer CHD subtypes, such as SV or HLH. Additionally, with this larger dataset I would have 
had greater power to investigate risk factors for mortality. In the current analysis, 
multivariable analysis is carried out for only the more common CHD subtypes due to low 
power. Furthermore, risk factors such as standardised birth weight and annual TOPFA rate, 
were statistically significant when all CHD was considered as a composite group, but not for 
individual subtypes. While it is possible that the associations did not exist for the individual 
subtypes, it is likely that there were some type II errors caused by low power. In particular, it 
would have been interesting to examine the association between mortality and deprivation, 
which appears to have a small effect size.  
10.4 Implications for practice 
The information provided in this thesis has several implications for clinical practice. Firstly, I 
found that the total and live birth prevalence of CHD and most of its subtypes has remained 
stable over time amongst singletons. In 2015, the predicted live birth prevalence of CHD is 
74.0 per 10,000 (235 cases in the North of England), falling to 68.8 per 10,000 (201 cases in 
the North of England) in 2020. This information is important for health service planning. 
However, I also identified an increase in the prevalence of CHD amongst MC twins, of 8% 
per year. While MC twin births account for just 0.6% of all births, on a population level 
(England and Wales) this amounts to an excess of approximately seven cases per year. 
Additionally, while I found a small increasing trend (3% per year) in the live birth of ToF, 
this equates to an excess of approximately 16 cases per year in England and Wales. While 
these numbers are relatively low, the diagnosis of CHD in pregnancy has a massive emotional 
impact on parents, and given the complex surgeries required for individuals with CHD, a 
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small increase in cases numbers can have large implications in terms of staff, facilities and 
costs.  
Compared to singletons, I found a 49% increased risk of CHD in DC twins and a three-fold 
increased risk in MC twins. Women with twin pregnancies should be counselled on the risk of 
having a baby with CHD. This research emphasises the importance of the increased fetal 
cardiology assessment of women with twin pregnancies. While this was recently introduced 
in the NICE guidelines for MC twins, there is currently no such guideline for DC twins (see 
Chapter 1). 
In the UK, there is little evidence that women of advanced maternal age are at increased risk 
of CHD. Therefore, in line with current guidelines (Chapter 1), these women do not need to 
be referred for fetal echocardiography scans unless other congenital anomalies are suspected. 
Among individuals with CHD, the greatest mortality rate was observed within the first few 
weeks of life. However, after infancy, there remains a gradual decrease in survival which 
exceeds that of the general population. This information is important for clinicians when 
counselling parents who have had a prenatal diagnosis, and can aid decision making in terms 
of whether to continue with the pregnancy. However, the estimated survival for an individual 
with a prenatally diagnosed CHD was lower than for individuals without a prenatal diagnosis, 
because the prenatal diagnosis usually occurs for fetuses with the most severe form of a CHD 
subtype. The information is also important for parents who have child diagnosed prenatally, 
in order to help manage their expectations. 
Long-term survival has been consistently improving for individuals with CHD. This has led to 
an emerging population of adults living with CHD. Given that these individuals require long-
term follow-up and sometimes reoperation, this information is important for health service 
planning. 
10.5 Further research 
There are several areas of future research that have been highlighted in this thesis. Firstly, a 
larger population-based study is required to examine the association between deprivation and 
long-term survival in individuals with CHD. While my study, along with several others, did 
not find a significant association with deprivation [182, 188, 190-192], this is possibly due to 
low power, given that a linear association with a small effect size was observed. A larger 
study is required before deprivation can be ruled out as a risk factor for long-term survival. 
Even if the effect size is small, on a population-based level it might be quite important, 
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particularly if it is a modifiable risk factor. The association with deprivation, if it exists, may 
be related to uptake of prenatal screening, TOPFA rates, access to health care and time until 
surgery. A larger study would also be required to properly investigate risk factors for 
mortality for individual CHD subtypes. In my analysis, many of my univariable models were 
underpowered for individual subtypes and I did not have the power to perform multivariable 
regression for all CHD subtypes.  
Further research regarding ART as a risk factor for CHD, particularly ToF, is required. 
Indeed, the increased risk of CHD in twins may be confounded by ART. Currently, it is not 
possible to link data on ART to CAR data in the UK, but this has been done in other 
populations [145, 168]. However, even these studies are flawed in that the control group 
(those without CHD), were those with congenital anomalies that were not hypothesised to be 
related to ART. 
I was not able to examine the impact of ethnicity on survival. Previous studies have shown 
that non-White ethnicity is associated with improved prognosis [182, 188, 190-192]. 
However, all of these studies are based on populations in the USA. If this association exists, 
further research is required to assess whether it is a real difference or a product of 
confounding. Ethnicity may be acting as a proxy for deprivation, access to healthcare or 
uptake of screening, for example. 
This thesis focuses on mortality among individuals with CHD. However, there remains a 
paucity of information regarding the quality of life and long-term morbidities among 
individuals with CHD. This information would be important for parents when a diagnosis of 
CHD is made prenatally. 
Given that few population-based studies have examined surgical interventions or co-
morbidities as predictors of CHD, this could be an important area of future research. This 
would bring together the richness of hospital-based data and the complete case ascertainment 
of population-based studies. In particular, it would be interesting to investigate how type and 
timing of surgical intervention impacts long-term survival. This information could also be 
used to examine the average ‘cost’ per case of CHD. Additionally, further research is required 
to examine the association between case volume and survival. A recent systematic review, 
which was conducted in order to inform the NHS review of CHD services, found some 
evidence that low case volume was associated with poorer prognosis [263]. However, the 
results varied between studies and were not hypothesised to be “directly causal” and no UK 
studies were identified [263]. 
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While I have modelled and extrapolated the birth prevalence of CHD, it would be useful to 
predict the population prevalence of CHD, i.e. the number of individuals currently living with 
CHD. Given that these individuals require lifetime follow-up and often reoperation, this 
would be beneficial in terms of health service planning.
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Appendix C) Data extraction form 
Study Title: 
 




Included CHD subtypes (ICD codes where possible): 
 
How were cases with multiple CHD subtypes coded? 
 
Were cases with extra-cardiac anomalies included, if so what was the percentage? 
 
What was the maximum age limit at diagnosis? 
 
How many cases of CHD were there? 
 
How were cases ascertained? 
 
What was the source of information on deaths? 
 
Are survival estimates reported? 
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How are survival estimates reported (e.g. numerically or graphically)? 
 
Survival estimates and 95% CIs 












       
       
       
       
       
       
       
       
       
       
       
       





Quality items, potential bias Yes Not stated 
The study population is adequately described for key 
characteristics (i.e. CHD subtype frequency, sex distribution, 
and ethnicity). 
  
Ascertainment is adequately described, including: method of 
ascertainment, included birth years, study location 
  
Inclusion and exclusion criteria are adequately described (i.e. 
ICD codes stated and inclusion of extra-cardiac anomalies. 
  
There is adequate ascertainment.   
POTENTIAL BIAS: The study sample represents the 
population of interest on key characteristics sufficient to 
limit potential bias to the results. 
  
The proportion of traced cases is stated and adequate   
Reasons for untraced cases are provided   
Untraced cases are adequately described for key characteristics 
(i.e. CHD subtype) 
  
There are no important differences between key characteristics 
and outcomes in participants who were traced and untraced. 
  
POTENTIAL BIAS: Untraced cases are not associated with 
key characteristics (i.e., the study data adequately 
represent the sample), sufficient to limit potential bias. 
  
Frequency of outcome is recorded   
The method of ascertainment of deaths is valid and reliable to 
limit misclassification bias 
  
POTENTIAL BIAS: The outcome of interest is adequately 
measured in study participants to sufficiently limit 
potential bias. 
  
There is sufficient presentation of results (i.e. number of cases 
and 95% CIs). 
  
The analysis is adequate for the design of the study.   
Results are not selectively reported   
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Quality items, potential bias Yes Not stated 
POTENTIAL BIAS: The statistical analysis is appropriate 
for the design of the study, limiting potential for 
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